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Peptide isosteres are important tools for the understanding of peptide function and for the 
development of drugs.  (E)-Alkene peptide isosteres are particularly useful due to their close 
geometric match of the amide bond structure.  We developed a method for the generation of a 
small library of (E)-alkene peptide isosteres on solid support via cuprate mediated SN2? ring 
opening of allylic BUS-aziridines.  We also studied the selectivity for the opening of these 
aziridines in the solution phase. 
Halenaquinone is a marine natural product that was first isolated in 1983 from the Pacific 
sponge Xestosongia exigua. We realized the synthesis of a thiophene-containing analog, thio-
halenaquinone.  The key steps include an alkynyl ketone-benzocylcobutane Diels-Alder reaction 
to construct the naphthalene subunit, a Heck cyclization to form the quaternary carbon, and a 
ring closing metathesis to install the final ring.  This compound showed an IC90 ~5 ?M against 
Pfnek-1 and an analog that had an IC90 ~3 ?M.  Based on these results we designed and 
synthesized a simplified analog that showed an IC90 ~4 ?M.  This compound was selected to 
move on to animal testing and the synthesis was optimized for the preparation of  and 200 mg of 
the lead structure. 
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1.0  SYNTHESIS OF (E)-ALKENE PEPTIDE ISOSTERES VIA AZIRIDINE 
RING OPENING 
1.1 INTRODUCTION 
Peptides are important intermediates of biochemical pathways and have a vast array of 
biological activities. They act as hormones, neurotransmitters, growth factors and enzyme 
substrates.1 Though peptides are at the heart of many biological processes, they are rarely 
utilized as therapeutic agents due to their poor pharmacokinetic profile, poor 
bioavailability, low absorption, short life time, and their immunogenic effects.2 Attempts 
to address these shortcomings have led to the development of peptidomimetics. 
Designing peptidomimetics involves the selection of a lead peptide, followed by 
modifications to the backbone and/or side chains in an attempt to improve the affinity and 
potency for the target of interest while also improving the pharmacokinetic profile.3-7   
For example the Perlmutter group has illustrated this point through the incorporation of a 
?-amino acid residue into a known EP24.15 inhibitor (Figure 1).8  The inhibitor 
maintained activity while eliminating  degradation by EP24.11. 
 
 2 
HO2C N
H
H
N
N
H
H
N
Ph
O
O
Ph
O
CO2H
HO2C N
H
H
N
H
N
Ph
O O
Ph
H
N
O
CO2H
1
IC50 0.2 ?M
Degrdn by EP24.11 100%
2
IC50 2.8 ?M
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Figure 1. An example of peptidomimetics improving stablity. 
 
Peptidomimetics were originally defined by Farmer9,10 as potentially novel 
scaffolds designed to replace the entire peptide backbone while retaining the istosteric 
topography of the enzyme-bound peptide conformation. As work in this area has 
increased, the term peptidomimetic is used frequently to describe numerous structural 
types.11 This has expanded the definition to any molecule designed to perform the 
function of a peptide.12 Peptidomimetics are now being grouped into three structural 
classifications.11 Type-I mimetics contain isosteric backbone modifications, but otherwise 
map onto the lead structure atom for atom.  Type-II mimetics are non-peptide small 
molecules that bind to peptide receptors. Type-III mimetics are seemingly unrelated to 
the original peptide, but possess the proper functionality on a novel scaffold displayed 
correctly in space to serve as a topographical mimic. HIV-protease inhibitors 313,14 and 
4
15 are examples of type-I peptidomimetics, which contain isosteric amide bond 
replacements such as epoxide, ketomethyl, and hydroxy-ethylene units (Figure 2). 
Another example of this class of mimetics is 516,17 which inhibits the formation of 
catalytically active heterodimeric (R1/R2) enzyme in herpes simplex virus (Figure 2).  
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Figure 2.  Examples of Type I peptidomimetics.  
 
The HIV-1 protease inhibitor 6,18 angiotensin II antagonist 719 and 
farnesyltransferase inhibitor 8,20,21 are examples of type-III mimetics. While none of 
these compounds contain peptide-like structures, their functionality allows for interaction 
with target enzymes (Figure 3).  Peptides containing conformationally restricted amino 
acid units, some heterocycles and natural products are also deemed peptidomimetics 
because they act at the same site or receptor as a peptide.22 Though the term 
peptidomimetic is very broad, mimetics regardless of structure have been important in the 
development and understanding of peptide function and drug discovery.  
N N
HO OH
O
H2N NH2
6
CN4H
N
N
Cl
CH2OHn-Bu N
Cl
N
Br
O
N
O
NH2
7 8  
 Figure 3.  Examples of Type III peptidomimetics. 
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1.1.1 Amide Bond Replacement 
Amides are rigid, polar, normally planar, and usually the nitrogen hydrogen and carbonyl 
group are positioned in a nearly trans-orientation.23 The conformation of a peptide is 
defined by the dihedral angles of the backbone, ? and ? (Figure 4). The angle ? refers to 
the torsion angle between the amino group and the ?-carbon, while ? refers to the torsion 
angle between the ?-carbon and the carbonyl group.24 While these angles are free to 
change by the rotation of a single bond, the steric interactions between the substituents on 
the ?-carbon and N-atoms limit the rotational freedom.  As a consequence, the 
conformations available to a peptide, based on the rotation of these angles, are decreased 
as the steric bulk at the ?-carbon increases.25 
?
?? ?N
O
O
N
H
H
R H
i-1
i
i
i+1
 
 Figure 4.  Bond angle designations in linear peptides. 
 
The amide bond is the most common linkage in the peptide backbone and thus has 
become one of the most frequent sites of modification when developing peptidomimetics. 
Since peptides are prevalent in many biological pathways, nature has developed a myriad 
of enzymes that effectively cleave peptides into their amino acid building blocks.  
Enzymes have evolved to catalyze the proteolytic cleavage of peptide bonds between 
natural and some unnatural amino acid sequences. Since the amide bond is a major site of 
peptide degradation, replacement of this bond should improve the stability toward 
proteolytic cleavage.26 
 5 
N
O
R
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OH
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[ hydroxyethylamino]
O
[ cis or trans
  epoxide ]
P
O
OH
[ phosphinate ]
N
N
N
N
[ 1,4 tetrazole ]
N
[ 1,2 pyrole ]
O
[ sugars or
carbohydrates]  
 Figure 5.  Examples of amide bond replacements. 
 
Pseudopeptides have been developed with numerous replacements for the amide 
bond (Figure 5).23 The development of effective mimetics requires consideration of the 
mimetic’s ability to simulate the steric, electronic, conformational and solvation 
properties of the amide bond.  While no isosteric replacement maintains all of the 
properties of the original amide bond, each group has unique properties that allow for its 
use as a mimetic.  
Retro-inverso (? [NHCO]) isosteres maintain the amide bond structure, but invert 
the position of nitrogen and carbonyl carbon.  This allows for the conservation of the side 
chain topology, but protects against enzymatic cleavage.27,28 The partial retro-inverso 
amide 9 shows both increased inhibition of tumor metastasis as well as greater metabolic 
stability and selectivity when compared to the Arg-Gly-Asp-Ser sequence 10 found in 
many metastasis inhibitors.29,30  
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H2N N
H
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H
OH
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HN NH2
O
O
CO2H
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O
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H
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H
N
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 Figure 6.  Example of retro-inverso isostere and parent structure. 
 
The reduced amide and ketomethylene groups remove one of the atoms of the 
amide bond.  A reduced amide (?[CH2NH]) allows for rotation of the ? angle and 
imparts greater stability toward enzymatic degradation because the amine becomes 
protonated at physiological pH.   The ketomethylene isostere (?[COCH2]) retains the 
ability to accept a hydrogen bond, but lacks the rigidity of the parent amide.31 This group 
is resistant to proteolytic cleavage since a carbon-carbon bond must be cleaved instead of 
a carbon-nitrogen bond.  The ketomethylene isostere has shown biological activity and 
has been used in the development of thrombin inhibitors.32   
 Hydroxyethylene and (E)-alkene isosteres change multiple aspects of the amide 
bond, yet are still effective mimetics.  Hydroxyethylene (?[CH(OH)CH2]) isosteres, such 
as 4 (Figure 2), were developed from the statin segment of pepstatin-A, a naturally 
occurring aspartyl protease inhibitor discovered by Umezawa.23,33 This isosteric 
replacement is mainly used as a transition state mimetic for the tetrahedral intermediate 
formed in the proteolytic cleavage.  The (E)-alkene (?[(E)-CH=CH]) is the best isosteric 
mimetic to approximate the rigidity, bond angle and bond length of the amide bond.34-39 
This isosteric replacement has been used in the development of various peptide analogues 
that show biological activity such as enkephalin mimics, inhibitors of ACE, HIV-1 
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protease, protein kinase,40-42 and reactive oxygen generation.43-45  Additionally these 
compounds have been introduced into polypeptide sequences to examine their effect on 
protein structure and function.46,47 The (E)-alkene isostere Leu ?[E-CH=CH]Gly-Val-
Phe-OCH3 11 was shown to be a competitive inhibitor of human amniotic renin and more 
potent than the analogous renin substrate 12 without the isosteric replacment.48 
 
H2N N
H
H
N OMe
O
O
O
O
H2N
H
N OMe
O
O
O
11 12  
 Figure 7.  Example of (E)-alkene isostere (11) and parent structure (12). 
1.1.2 (E)-Alkene Peptide Isosteres 
Molecules containing (E)-alkene isosteres can display potent biological activity.36,43-45,49,50 
These findings suggest that this isostere is well suited to mimic the amide bond.  The (E)-
alkene isosteric replacement not only removes the hydrolyzable amide bond, but 
effectively mimics its rigidity, bond length (Ci(?)-Ci-1(?)) and bond angles (Figure 8).26 
Additional, methyl- and CF3-substituted alkenes have been shown to promote ?-turn 
formation.51 The CF3-substituted olefins have also been shown to more closely reproduce 
the dipole moment of the amide when compared to other olefinic amide bond 
replacements.51 The promise of (E)-alkene isosteres has led to the development of 
synthetic methodology which focuses on rearrangements, metathesis and SN2? additions. 
 
 8 
N
H
H
N
O
O
H
N
d = 3.8 Å
H
N
O
H
N
d = 3.9 Å  
 Figure 8.  Distances between the ?-carbon of residue i and the carbonyl group of 
 residue i+1 in peptides and (E)-alkene isosteres. 
 
Etzkorn et al. were able to access Ser-trans-Pro mimetics through an Ireland- 
Claisen rearrangement (Scheme 1).52   Addition of the lithiate of 1-iodo-cyclopentene to 
the easily prepared Weinreb amide of N-Boc-O-benzyl-L-serine afforded compound 14. 
Luche reduction of the ketone gave the alcohol 15 in a 4:1 mixture a diastereomers. The 
desired (S,R)-isomer was acetylated to yield 16 the Ireland-Claisen precursor.  Upon 
treatment with LDA, TMSCl and pyridine, 16 underwent the rearrangement to yield 17 as 
the major diastereomer.   Cleavage and oxidation of the hydroxy acid followed by 
removal of the benzyl group yielded the Boc-Ser-Pro-OH isostere 18. 
 
BocHN
O
BnO
BocHN
OH
BnO
N
O
BocHN
O
BnO
BocHN
O
BnO
O
OTBS
BocHN
BnO
O
OH
HO
BocHN
HO
CO2H
13 14 15
16 17
18
1-iodo-cycopentene
s-BuLi, THF, -78 °C
CeCl3, NaBH4
THF/MeOH
Cl
O
OTBS
pyr., THF
1. LDA, pyr., 
   TMSCl, THF
2. TBAF, THF
1. i. Pb(OAc)4, CHCl3/EtOAc
    ii. CrO3, H2SO4, acetone
2. Na, NH3, THF
 
 Scheme 1.  Etzkorn’s synthesis of a Ser-trans-Pro mimetic. 
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Liskamp and Bol were able to construct Phe ?[(E)-CH2=CH2)Gly mimetics by 
employing a [2.3] Still-Wittig approach (Scheme 2).53 Reduction of Tr-Phe-OMe 19 to 
the corresponding aldehyde followed by vinyl addition yielded the allylic alcohol 20. 
Alkylation with tributyltinmethyl iodine gave the Still-Wittig precursor 21. Upon 
treatment with n-BuLi, the rearrangement took place to afford 22. Trityl deprotection 
followed by coupling to N-Cbz-Phe-OH and oxidation yielded Cbz-Phe-Phe?[(E)- 
CH2=CH2)Gly-OH 23. 
  
TrHN
OMe
O
TrHN
OH
TrHN
O
SnBu3
TrHN OH Cbz-Phe-HN OH
O
19 20 21
22
23
1. i. Dibal
    ii. Swern Ox.
2. VinylMgBr
KH, Bu3SnCH2I
THF
n-BuLi, hexanes 
-100 °C
1. TFA/DCM, Dowex OH-
2. isobutyl chloroformate,
    NMM, Cbz-Phe-OH
3. Jones Ox.  
Scheme 2. Liskamp and Bol’s synthesis of Phe ?[(E)-CH2=CH2)Gly mimetics. 
 
Wai et al. utilized an Overman rearrangement to install trisubstituted (E)-alkene 
isosteres (Scheme 3).54 An Evans aldol reaction between oxazolidinone 24 and aldehydes 
25a-c followed by acetimidate formation led to compounds 29-31.  Heating in xylenes 
afforded the rearrangement products 32-34. Treatment with LiOH and Boc2O gave the 
unnatural ?[(E)-C(CH3)=CH) pseudopeptides 35a-c.  
Olefin metathesis has been employed by Miller et al. to synthesize various 
dipeptide isosteres (Table 1).55 The treatment of allylic amines 36a-c with 3-methyl 
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butenoate and Grubbs catalyst yielded peptide isosteres 37a-c in moderate yield.  Though 
the amines were racemic in these examples, the use of the enantiomerically pure amine 
36d derived from N-Boc-Pro yielded 37d in 85% and 80% ee.  Though this method uses 
readily available starting materials, the need to use the amines in excess is a major 
limitation. 
 
H
N Xc
R
R1 n-Pr
O
O
N O
O
Bn
XcR
OOH
n-PrR1
XcR
OO
n-Pr
CX3
HN
R1
O
X3C
BocHN OH
R
R1 n-Pr
O
25a  R=Et
25b  R=i-Pr
R
25c
N O
O
Bn
26 R=Et, R1=Me, Y= OMe
27 R=i-Pr, R1=Me, Y= Xc
28 R=R1=(CH2)4  Y=Xc
29 R=Et, R1=Me, Y= OMe, X=Cl
30 R=i-Pr, R1=Me, Y= Xc, X=F
31 R=R1=(CH2)4  Y=Xc, X=Cl
32 R=Et, R1=Me, Y= OMe, X=Cl
33 R=i-Pr, R1=Me, Y= Xc, X=F
34 R=R1=(CH2)4  Y=Xc, X=Cl
35a R=Et, R1=Me
35b R=i-Pr, R1=Me
35c R=R1=(CH2)4
24 Xc=
n-Bu2BOTf, DCM, Et3N
-78 °C to 0 °C, then 25a
LiOH, CH2N2
Cl3CCN, or F3CCN, DBU, DCM
Xylene, reflux
i. LiOH, THF/MeOH/H2O
ii. Et3N, Boc2O, Dioxane/H2O
CHO
CHO
 
 Scheme 3. Wai's synthesis of (E)-alkene isosteres. 
 
A popular way to construct (E)-alkene isosteres is via SN2?-additions to displace 
aziridines, activated alcohols, and carbamates.  The initial work on SN2?-aziridine ring 
opening was carried out independently by Wipf and Fritch26 and Ibuka et al. (Scheme 
4).26,56   Starting from either N-Boc-threonine methyl ester 38 or the free anime 42, 
aziridines 40 and 44 were accessible. Activation of alcohol 38 followed by reduction of 
the ester and treatment with base afforded aziridine 39.  Aziridine 43 was constructed by 
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treatment with tosyl chloride followed by reduction of the ester and treatment with base.  
Upon oxidation of alcohol and olefination, alkenylaziridines 40 and 44 were reacted with 
various cuprates.  Treatment of 40 with MeLi, CuCN and BF3•OEt2 led to the (E)-alkene 
41 in 68% yield.  Aziridine 44 was subjected to MeLi or BuLi, CuCN and BF3•OEt2 
conditions and yielded the corresponding isosteres 45a-b in 74% and 86%, respectively.  
 
 Table 1. Olefin metathesis to form (E)-alkene peptide isosteres. 
BocHN BocHN OMe
O
N
Boc
BocHN
Ph
BocHN
BocHN OMe
O
BocHN OMe
O
Ph
N
Boc
OMe
O
Entry                      Amine          Amine  Equiv.                Product               Yield [%]    E/Z ratio
1
3 60 >10:1
2
3 67 >10:1
3 2 31 >10:1
4 5 83
BocHN
R
3-Methyl butenoate
CH2Cl2, Reflux
BocHN OMe
OR
36a-d 37a-d
36a
36b
36c
36d
37a
37b
37c
37d
Grubbs II
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O
OMe
OH
NH2 H
OH
N
Ts
H
H
N
Ts
H OMe
O
O
OMe
OH
NHBoc H
OH
N
Boc
H
H
N
Boc
H OEt
O
BocHN
CO2Et
TsHN
CO2Me
R
45a,b  R = Me, Bu
38 39
40
41
42
43 44
1. MsCl, (i-Pr)2NEt, 
    DCM
2. LiBH4, Et2O
3. K2CO3, MeCN
1. SO3•pyridine, Et3N
    DMSO
2. Ph3PCHCO2Et, DCM
MeLi, CuCN
BF3•OEt2, THF
1. TsCl, py.
2. NaBH4, LiCl
    THF, EtOH
1. Dess-Martin, DCM
2. Ph3PCHCO2Me, 
    DCM
i. MeLi, CuCN
   BF3•OEt2, THF
ii. BuLi, CuCN
    BF3•OEt3, THF  
Scheme 4. Wipf's method for synthesizing (E)-aalkene peptide isosteres. 
 
The Wipf group continued to be active in this area of research in 1997, Wipf and 
Henninger reported the first synthesis of (E)-alkene peptide isosteres via SN2?-aziridine 
opening on solid support (Scheme 5).57 The initial step was the synthesis of a novel resin-
bound Horner Wadsworth-Emmons reagent 47, which was accessed by EDCI coupling of 
acid 46 with Wang Resin.  Treatment of the resin with KOt-Bu followed by addition of 
48 yielded the resin-bound aziridine 49.  Upon exposure to a variety of cuprates, 49 
underwent ring opening, which led to 50a-e.  Acidic cleavage, followed by esterification 
with TMS-Cl, MeOH yielded 51a-e in 74-55% yield. This methodology could be applied 
to iterative solid phase peptide synthesis or to the development of combinatorial libraries.  
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(EtO)2P(O) CO2H (EtO)2P(O) CO2
CO2
H
N
Ns
H NsHN
CO2
R
NsHN
CO2Me
R
46 47
49
O
H
N
Ns
H
48
50
Wang Resin, EDCI
DMAP, DCM
t-BuOK, THF
RLi, CuCN,
THF
1. TFA, DCM
2. TMSCl, THF
51a-e, R = Me, Bu, i-Bu, Ph(CH2)2, Et  
Scheme 5. SN2'-Opening of allylic aziridines with cuprates on solid support. 
 
 In 1998, Wipf et. al. were able to synthesize both methyl- and CF3-substituted 
alkene isosteres and show that they promote ?-turn formation (Scheme 6).51 Starting from 
the epoxyalcohol 52, epoxide 53 was accessed via Swern oxidation, followed by Wittig 
olefination.  The epoxide was treated with NaN3, then the resulting azide was reduced 
with Ph3P and cyclized to form 54 in 13% yield.  The aziridine was subsequently Boc-
protected, and exposed to Me2Zn, CuCN and LiCl. The resulting (E)-alkene isostere was 
treated with MeNH2, which yielded the amide 55 in 33% yield.  A similar synthetic route 
was initially purposed for the synthesis of the CF3-analogue, 56 was converted to 57 via a 
carbonylation, DCC coupling of the acid and Reformatsky addition-elimination.  The 
desired (Z)-olefin isomer was isolated, subjected to Sharpless dihydroxylation, followed 
by Ph3P-promoted epoxide formation. Reduction of the benzyl ester followed by Wittig 
olefination yielded 58.  Treatment with NaN3 and Ph3P afforded the amino alcohol, but 
the desired ring closure did not occur. Boc-protection of the amine and subsequent 
mesylation of the alcohol gave 59.  Treatment with MeMgBr, CuCN, LiCl and ZnCl2 
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facilitated an anti-SN2?-displacement of the mesylate, and treatment with LiAl(NHMe)4 
gave 60 in 65% yield.  
The Fujii group has developed SN2?-addition chemistry to yield a wide array of 
alkene peptidomimetics.  Early work in the group focused on the ability to access both 
(L,L) and (L,D) dipeptide mimetics from the same starting material (Scheme 7).58-60 
Treatment of aziridine 61 with IZn(CH2)2CO2R
3, CuCN and LiCl afforded the (L,L) 
dipeptide isostere 63.  Exposure of 66 to the same reagents gave the (L,D)-diastereomer 
64.  Treatment of 59 with HCl afforded the opened aziridine 62, which upon treatment 
with cuprate underwent an anti-SN2?-displacement of the chloride to yield 64.   The same 
procedure can be used to access 63 from 66.  This allows a single aziridine to yield either 
diastereomer of the isostere selectively. 
 
OH
O
1. Oxalyl chloride,
    Et3N, DMSO
2. Ph3PCHCO2Me
N
H
OMe
O
BocHN
CONHMe
CF3CCCl3
CO2Bn
CF3 CF3
O
OMe
O
CO2Me
NHBoc
MsO CF3
BocHN
CONHMe
CF3
O
OMe
O
52 53 54
55
56 57 58
59 60
1. NaN3, NH4Cl,
    MeOH
2. Ph3P, MeCN
1. Boc2O, Et3N
2. Me2Zn, LiCl, 
    CuCN, THF
3. MeNH2, NaCN
    MeOH
1. Zn, CuCl, CO2
2. BnOH, DCC, THF
3. Zn, CuCl, MeCHO
    TFAA, 4 Å MS, THF
1. AD-mix a
2. Ph3P, DIAD
3. DIBAL
4. Ph3PCHCO2Me
1. NaN3, MeOH
2. Ph3P, THF, H2O
3. Boc2O, Et3N
4. MsCl, Et3N, DCM
1. MeMgCl, CuCN
    LiCl, ZnCl2, THF
2. LiAl(NHMe)4, THF
 
Scheme 6. Synthesis of trisubstituted (E)-alkene peptide isosteres. 
 15
 
4 M HCl
Dioxane
R2
CO2Me
NHR1
Cl
R1= Ts,   R2= Me
R1= Mts, R2= i-Pr
R1= Mts, R2= Bn
R2
CO2Me
NHR1
CO2R
3
R2
CO2Me
NHR1
CO2R
3
R2
CO2Me
NHR1
Cl
R3=Me or Bn R
3=Me or Bn
61 62
63
64
65 66
R2
N
R1
CO2Me
R2
N
R1 CO2Me
4 M HCl
Dioxane
CO2R
3
IZn
CuCN, LiCl
CO2R
3
IZn
CuCN, LiCl
CO2R
3
IZn
CuCN, LiCl
CO2R
3
IZn
CuCN, LiCl
 
Scheme 7.  Fujii's (E)-alkene synthesis. 
 
Fujii and co-workers were also able to access systems similar to 62 and 65 
without using an aziridine as an intermediate (Scheme 8).61-63 Alcohol 67 was obtained in 
a few steps from N-Boc-Phe-OMe, and subsequent protection of the alcohol with Ac2O 
yielded 68.  Conversion of the olefin to the ketone via ozonolysis, followed by Wittig 
olefination and removal of the acetate group yielded 69.  Mesylation of the alcohol 
followed by treatment with iPrMgCl, CuCN, BF3•OEt2 afforded the trisubstituted olefin 
71.  
In 2002, the Fujii group investigated the SN2?-openings of oxazolidinones 
(Scheme 9).61,64 Alcohols 72a-b were oxidized to the corresponding ketone, followed by 
treatment with MeMgCl to yield a mixture of 73 and 74.  Treating the desired isomer 73 
with NaH and Boc2O afforded oxazolidinone 75.  Ozonolysis followed by olefination 
yielded the allylic oxazolidinone 76.  The dipeptide isosteres 77 were produced upon 
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exposure of 76 to iPrMgCl, CuCN and LiCl.  This method afforded access to both tri- and 
tetrasubstituted alkenes of biological interest. 
 
Bn
OH
BocNH
Bn
OH
CO2tBu
BocNH
Bn
OAc
BocNH
Bn
OMs
CO2tBu
BocNH
Bn
CO2tBu
BocNH
67 68 69
70 71
Ac2O, py.
1. O3 then DMS
2. Ph3CHCO2t-Bu
3. Na2CO3, MeOH
MsCl, Et3N iPrMgCl, CuCN
BF3•OEt3, HMPA
 
Scheme 8.  Fujii's SN2'-displacement of allylic mesylate to form (E)-alkene. 
 
Bn
OH
BocHN R
Bn
BocHN R
HO
Bn
BocHN R
OH
Bn
CO2t-Bu
RBocHN
BocN O
O
Bn
R
BocN O
O
Bn
R CO2t-Bu
73 a, b R = H, Me 74 a, b R = H, Me
75 a, b R = H, Me
76 a, b R = H, Me 77 a, b R = H, Me
1. Oxalyl Chloride, 
    iPr2NEt, DMSO
2. MeMgCl, CeCl3
1. NaH
2. Boc2O
1. O3 then DMS
2. (EtO)2P(O)CH2CO2t-Bu
    LiCl, iPr2NEt
iPrMgCl, CuCN
LiCl, BF3•OEt2
72 a, b R = H, Me
 
Scheme 9. SN2'-Opening of an oxazolidinone to form an (E)-alkene peptide 
 isostere. 
 
The Fujii group has published an interesting route to trisubstitued (E)-alkene 
peptide isosteres via a palladium-catalyzed carbonylation (Scheme 10).65  Treatment of 
phenylalanine with CDI followed by the lithium enolate of ethyl acetate gave 79.  
Exposure to base and trapping with Tf2O afforded enol trifalte 80.  This compound was 
converted to the 81 via treatment of alkylcuprates.  Reduction with DiBAL and treatment 
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with methyl chloroformate yielded allylic carbonate 82.  Upon exposure to catalytic 
palladium in MeOH under and atmosphere of CO, 82 underwent convertion to the desired 
dipeptide isostere 83.   
Wipf and co-workers were able to access (E)-alkene peptide utilizing the 
hydrozirconation-imine addition methodology developed in their group.38  Treatment of 
alkyne 84 with Cp2ZrHCl, followed by transmetaltion to Me2Zn and addition to N-Boc-
isovaleraldimine afford 85 as a mixture of diastereomers.  Upon silyl removal and 
protection of the resulting alcohol as the acetate, the diastereomers were separated.  
Deprotection of the alcohol and subsequent oxidation to the acid gave 87.  This building 
block was used in the synthesis of (E)-alkene peptide isostere containing analogs of the 
cyclic peptide Gramicidin S. 
 
CO2HBn
NHBoc
i. CDI
ii. CH2=C(OLi)OEt Bn
NHBoc
O
CO2Et Tf2O, iPr2NH Bn
NHBoc
CO2Et
OTf
Bn
NHBoc
CO2Et
R
R2CuLi
R = Bu, Me
i. DiBAL, BF3•OEt2
ii. ClCO2Me, py. DMAP Bn
NHBoc
R
OCO2Me
Pd2(dba)3•CHCl3, Ph3P
MeOH, CO
78 79 80
81 a, b, R = Bu, Me 82 a, b R = Bu, Me
Bn
NHBoc
R
CO2Me
83 a, b R = Bu, Me  
Scheme 10.  Palladium-catalyzed carbonylation approach to (E)-alkene peptide 
 isosteres. 
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OTBDPS
Ph
Cp2ZrHCl, Me2Zn 
then
N-Boc-isovaleraldimine
N
H
Boc
Ph
OTBDPS
1. TBAF
2. Ac2O, Et3N,
    DMAP
N
H
Boc
Ph
OAc
1. K2CO3, MeOH
2. Dess-Martin periodinane
3. NaClO2, NaH2PO4
   2-methyl-2-butene
N
H
Boc CO2H
Ph
84 85
86
87  
Scheme 11.  Imine addition route to (E)-alkene peptide isosteres. 
 
The Kelly group has developed a route to (E)-alkene peptide isosteres that allows 
for the generation of gram quantities of material for the incorporation into polypeptides 
(Scheme 12).46  Wittig olefination of aminoaldehyde 88 afforded the eneyne in good 
yield and high enantiomeric excess.  Hydroboration of the alkyne followed by oxidation 
gave 90, which was converted to imide 92.   Alkylation followed by cleavage of the 
auxillary gave dipeptide isostere 93. 
These methods offer a variety of routes for the synthesis of (E)-alkene 
peptidomimetics. As such, a large variety of mimetics incorporating both natural and 
unnatural side chains can be developed. This allows for an increase in our understanding 
of peptide interaction with enzymes or receptors and may be used in the development of 
pharmaceuticals. 
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Ph3PCH2C=CTMS
nBuLi
BocHN
H
O
Ph
88
BocHN
Ph
TMS
i. cyclohexene, BH3
ii. H2O2
BocHN
Ph
O
OH
1. tBuCOCl
2.
HN O
O
Ph
nBuLI
BocHN
Ph
O
N O
O
Ph
89
90
91
92
1. LDA, BnBr
2. LiOH, H2O2 BocHN
Ph
O
OH
Ph
93  
Scheme 12. Kelly method for the synthesis of (E)-alkene peptide isosteres. 
1.1.3 The mechanism of copper-mediated SN2? reactions 
The SN2? reaction is formally defined as a bimolecular nucleophilic substitution with 
allylic rearrangement.  This reaction has been known since the 1920’s, but until the last 
25 years it has seen little synthetic use due to the formation of mixtures of regio- and 
stereoisomers.  Useful chemistry66,67 was developed once it was found that allylic acetates 
underwent more selective SN2? reaction in the presence of organocuprates.68,69 
 SN2? reactions of allylic halides and organometalic reagents, in the absence of 
copper, typically favor addition when the approaching nucleophile is syn to the leaving 
halide.70 In the presence of a copper source, the addition follows exclusively an anti-
pathway, where the nucleophile and leaving group are on opposite sides of the olefin.  
Corey proposed a possible explanation for this change in selectiviy in which the copper 
coordinates with the olefin and the departing halide (Figure 9).71 The filled d10 orbital of 
copper was able to simultaneously interact with the ?* orbital of the carbon-carbon 
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double bond and the ?* orbital of the C-X bond (Figure 9, eq 1).  This interaction not only 
serves to activate both the olefin for attack and the halide for displacement, but also 
delivers the nucleophile to the side opposite the leaving group, yielding high anti-
selectivity.  A similar mechanism has been proposed by Marshall for the anti-SN2? 
opening of vinylepoxides (Figure 9, eq 2).72 As in the previous example, the copper 
interacts with the antibonding orbitals of the olefin and the epoxide allowing the 
nucleophile to add in an anti-fashion.   
 
Cu
d (Cu)
?* (C__X)
?* (C=C)
R
L
LnRCu
X
94
95
Cu
d (Cu)
?* (C__O)
?* (C=C)
R
L
LnRCu
O O
96
97
eq 1
eq 2
 
Figure 9.  Interaction of Cu d10-orbitals with the anti-bonding orbitals of an 
 allylic  halide  or epoxide. 
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1.2 SYNTHESIS OF (E)-ALKENE PEPTIDE ISOSTERES IN SOLUTION 
AND ON SOLID SUPPORT VIA CUPRATE MEDIATED SN2?  REACTIONS 
1.2.1 L-685,458: Lead Compound for Library Synthesis 
?-Secretase is responsible for the cleavage of the amyloid ?-protein precursor (APP) 
affording the carboxyl terminal amyloid ?-protein (A?), the major constituent of the 
protein plaques associated with Alzheimer’s Disease (AD).73 These plaques are formed, 
in part, due to the highly lipophilic character of the A? protein and activate an 
inflammatory process that initiates the clinical onset and progression of AD.74-78   While 
considered essential to the understanding of the etiology of AD, the ?-secretase protease 
is yet to be well characterized and much of its function is still not clear.  New insight to 
elucidate the ?-secretase behavior was gained by the development of inhibitors.79-82  
L-685,458 (Figure 10) is a specific ?-secretase inhibitor possessing a 
hydroxyethylene dipeptide isostere, suggesting that it serves as a transition state analog 
within the catalytic site of an aspargyl protease.83 Due to the potency and selectivity L-
685,458 exhibits over other protease inhibitors, it seems to be a good model for the 
synthesis of peptidomimetics of the type of 98 (Figure 11).  We envisioned the 
replacement of the central amide bond with either a di- or trisubstituted (E)-alkene 
peptidomimetic, installed via the SN2?-aziridine ring opening.  By replacing this bond, we 
hoped to construct a molecule that had improved stability toward proteolytic cleavage, 
but retained the biological activity of the lead structure.   
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NH2N
H
H
N
H
NO
O
O
OO
OH
L-685,458  
Figure 10. Structure of L-685,458. 
1.2.2 Retrosynthetic analysis for a library based on L-685,458 
Retrosynthetically, the removal of the nitrogen protecting group and coupling 
with ?-hydroxy carboxylic acids would yield mimetics 98. The resin-bound aziridine 99 
would arise from the coupling of aziridines of type 100 with polystyrene resins loaded 
with various amino acids.  The required aziridines would be synthesized using an aza-
Darzens approach starting from imine 101.  
 
NH2N
H O
O
N
H R2 R3
Bn R1
R
OH
O
H
N
BUS
Bn
R2
O
OH N
S
Bn
H
N
N
H
R1
O
O
N
R2BUS
Bn
98 99
100 101
O
 
Figure 11. Retrosynthetic analysis of the isostere library. 
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1.2.3 Synthesis of allylic aziridines 
The synthesis of the required allylic aziridines began with the condensation of t-
butylsulfinamide84-86 with phenylacetaldehyde in the presence of PPTS and MgSO4 to 
give imine 101 in 89% yield (Scheme 13). Treatment of methyl-2-bromopropionate with 
LHMDS at –78 °C followed by the addition of 101 afforded an N-sulfinyl aziridine 
which upon exposure to m-CPBA yielded 103 and 104 in 52% combined yield.87 Using 
the same procedure with methyl-bromoacetate yielded 105 in 23% yield.  A crystal 
structure of the aziridine intermediate 106, before m-CPBA oxidation, confirmed the 
relative and absolute configuration of the azirdination step (Figure 12).87   
 
S
NH2
O
phenylacetaldedhyde
PPTS, DCM
            86%
S
N
O
Bn
101
1. BrCH2CO2Me, LHMDS, 
    THF -78 °C
2. m-CPBA, DCM
     23% (2 steps)
H
N
BUS
Bn
CO2Me
H
N
BUS
Bn
CO2Me
1. Br(Me)CHCO2Me
    LHMDS, THF -78 °C
2. m-CPBA, DCM
     52%  (2 steps)
H
N
BUS
Bn
H
CO2Me 103
104
105
102
 
Scheme 13. Synthesis of di- and trisubstituted aziridines 
 
The BUS-group is not a typical nitrogen protecting group88 and furthermore it has 
not been demonstrated to be an activating group for allylic aziridines for SN2?-
displacement.  A tosyl group would be better suited to both the addition chemistry and 
subsequent removal, but formation of the imine is difficult due to isomerization during 
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the reaction.87,89  Cleavage of the sulfoxide followed by protection of the free nitrogen as 
a tosyl amide would offer an alternative method for introduction of the tosyl function.  
The deprotection of the aziridine 106 with acid or under nucleophilic conditions did not 
afford the desired material (Table 2). 
 
H
N
S
Bn
CO2Me
106
O
 
Figure 12. X-ray crystal structure of aziridine 106. 
 
Table 2. Attempted deprotection of aziridine 106. 
Conditions
106 107
H
N
H
Bn
CO2Me
H
N
S
Bn
CO2Me
O
 
Entry Conditions Temp Time (h) Result 
1 HCl, MeOH r.t. 0.5 dec. 
2 5 equiv TFA, 1:1 Acetone/H2O r.t. 1 dec. 
3 MeMgBr, THF -78 °C 3 dec. + ester addition 
 
To study the reactivity of BUS-activated allylic aziridines, several model systems 
were constructed (Scheme 14). Treatment of 103 with DiBAL at –78 °C followed by 
Wittig olefination conditions yielded the ?,?-unsaturated methyl ester 108 in 70% yield.  
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Treatment of the same aldehyde intermediate with trimethylsilyl diethylphosphonoacetate 
yielded the ?,?-unsaturated acid 109 in 60% yield.  This acid was then coupled to L-Phe-
OMe with DEPBT to afford in 96% the ?,?-unsaturated amide 110.  Similarly, aziridine 
105 was treated with DiBAL at –78 °C, followed by treatment with either methyl 
diethylphosphonoacetate or trimethylsilyl diethylphosphonoacetate to yield the ?,?-
unsaturated methyl ester 111 or acid 112 in 57% and 52%, respectively.  When acid 112 
was coupled to L-Phe-OMe, 113 was isolated in 45% yield.   
 
H
CO2H
N
BUS
Bn
H
H
N
BUS
Bn
CO2H
H
N
BUS
Bn
CO2Me
H
CO2Me
N
BUS
Bn
H
H
N
BUS
Bn
H
N
H
O
CO2Me
Bn
H
N
BUS
Bn
H
N CO2Me
O Bn
103
DiBAL, DCM, -78 °C  then
MeO2CCHPPh3Br
               70%
1. DiBAL, DCM, -78 °C  
2.(EtO)2P(O)CH2CO2TMS
    n-BuLi, Et2O/THF (3:1)
               60% (2 steps)
Phe-OMe•HCl, DIPEA
DEPBT, DMF
               96%
1. DiBAL, DCM, -78 °C  
2. (EtO)2P(O)CH2CO2Me
    n-BuLi, Et2O/THF (3:1)
          52% (2 steps)
1. DiBAL, DCM, -78 °C  
2.(EtO)2P(O)CH2CO2TMS
    n-BuLi, Et2O/THF (3:1)
               57% (2 steps)
Phe-OMe•HCl, DIPEA
DEPBT, DMF
               45%
103
108
109 110
105
111
105
112
113  
Scheme 14. Synthesis of allylic aziridines from 103 and 105. 
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1.2.4 SN2?-Opening of allylic Bus-protected aziridines in solution phase 
With these compounds in hand, it was possible to test the ability of the BUS group to 
activate aziridines for SN2?-reactions.  Treatment of 108 with Me2Zn, CuCN and LiCl led 
to formation of 114a/115b as an inseparable 12:1 mixture of isomers in 77% combined 
yield (Table 3, Entry 1). Treatment of this mixture with DiBAL at 0 °C led to alcohol 116 
in 68%.  Treatment with i-PrMgCl, i-BuMgCl, or phenethylMgCl and CuCN gave 
product ratios ranging from 3:1 to 9:1 by NMR and isolated yields from 55-73% (Table 
3, Entries 2-4). The relative configuration of these products was confirmed by x-ray 
analysis of ester 114c (Figure 12) and alcohol 116 (Figure 14), both showing the (L,D)-
dipeptide isostere as the major isomer. 
 
Table 3. SN2?-Ring opening of 108 with various cuprate reagents 
H
N
BUS
Bn
CO2Me
Conditions
HN
CO2Me
Bn
RBUS
CO2MeR
HN
BUS
108 114a-d 115a-d  
Entry Conditionsa R Ratiob (114/115) Yieldc,d 
1 Me2Zn, CuCN, 2 equiv LiCl Me 12:1 77% 
2 i-PrMgCl, CuCN i-Pr 9:1 55% 
3 i-BuMgCl, CuCN i-Bu 4.9:1 73% 
4 PhenethylMgCl, CuCN Phenethyl 3:1 61% 
a3 equiv reagents, -20 °C, THF, 3 h. bDetermined by NMR. cMixture of isomers. dIsolated 
yield. 
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DiBAL, DCM, 0 °C
           67%
114a/115a 116
HN
CO2Me
Bn
BUS
HN
Bn
BUS
OH
 
Scheme 15.  Reduction of ester mixture 114a/115a. 
 
 
Figure 13.  X-ray crystal structure of 114c. 
 
 
Figure 14. X-ray crystal structure of 116. 
 
The addition of a benzyl group to these substrates proved to be more difficult than the 
addition of alkyl groups (Table 4).  Attempts to achieve high yielding reactions with short 
reaction times met with limited success.  The treatment of 108 with Bn2Zn, CuCN and 
LiCl or BnMgCl and CuBr•DMS at –78 °C for 3 or 8 h, respectively, gave no reaction 
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(Table 4, Entry 1 and 9). Treatment with BnMgCl and CuCN at –78 oC to –20 o C led to 
only the formation of the reduced compound 114f (Table 4, Entry 2).  The addition of 
LiCl to this reaction afforded a mixture of 114f and the desired compound 114e in 55% 
and 34% yield respectively (Table 4, Entry 3).  When ZnCl2 was added to the above 
mixture, the reaction became more sluggish and required 18 h and warming from either 0 
oC or –20 oC to room temperature to go to completion, but the desired product was 
isolated in 80% yield as a single isomer (Table 4, Entry 4 and 5). Once conditions were 
found that afforded the product in good yield, attempts were made to shorten the reaction 
time to allow a more straightforward application of this procedure to solid phase 
synthesis.  Allowing the reaction to warm up more quickly did not afford shorter reaction 
times (Table 4, Entry 6-8).  
The key transformation for the library synthesis was the SN2?-opening of 
aziridines coupled to amino acids.  No compounds similar to 110 have been extensively 
studied in this type of reaction.  Treating 110 to the standard SN2?-addition conditions led 
to the formation of 117a, b and d in good yields in isomer ratios of 9:1 to 3:1 (Table 5, 
Entries 1, 2 and 4).  Since these results were similar to those obtained for the reaction of 
108 under identical conditions, the additional steric bulk and stereocenter did not greatly 
affect the selectivity of the reaction in most cases. Unexpectedly, the treatment of 110 
with i-BuMgCl and CuCN gave a reversal of selectivity affording 118c as the major 
isomer in a 3:1 ratio in 66% yield.  The structure of the major compounds was assigned 
by comparision to the spectra of compounds 114a-d and 115c.  Though these reactions 
provide a moderate to high yield, they were slow and did not go to completion after 3 h.  
This could be due to the steric bulk of the amino acid side chain, deprotonation of the 
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amide and electronic repulsion of the nucleophile, or complexation of the rate-
accelerating Lewis acid to the backbone amides. 
 
Table 4. Addition of a benzyl substituent to 108 via SN2?-ring opening. 
H
N
BUS
Bn
CO2Me
Conditions
HN
CO2Me
Bn
RBUS
114e R= Bn
114f R= H108  
Entrya BnMgCl 
(eq) 
CuX (eq) LiCl 
(eq) 
ZnCl2 
(eq) 
Temp Time 
(h) 
Product 
1 Bn2Zn (3) CuCN (3) 6 - -78 °C 3 108 
2 BnMgCl (3) CuCN (3) - - -78 °C to -20 °C 3 114f 
3 BnMgCl 
(10) 
CuCN (10) 20 - 0 °C to r.t. 18 114f (55%)b, 
114e (34%)b 
4 BnMgCl 
(10) 
CuCN (10) 20 10 -20 °C to r.t. 18 114e (80%)b 
5 BnMgCl 
(10) 
CuCN (10) 20 10 0 °C to r.t. 18 114e (80%)b 
6 BnMgCl 
(10) 
CuCN (10) 20 10 0 °C to r.t. 1 108:114e 
(10:1)c 
7 BnMgCl 
(10) 
CuCN (10) 20 10 0 °C to r.t. 3 108:114e 
(10:1)c 
8 BnMgCl 
(10) 
CuCN (10) 20 10 0 °C to r.t. 6 108:114e 
(3.4:1)c 
9 BnMgCl 
(10) 
CuBr•DMS 
(10) 
20 - -78 °C 8 108 
a All reaction run on 0.028 mmol scale. b Isolated yield. c Ratio determined by NMR. 
 
After extensive investigation of the 2,3-trans-aziridine, focus shifted to the 
reaction of the 2,3-cis-aziridines. Ring opening of 111 afforded compounds 119a-d as 
single isomers in high yields of 100-72%. Similarly, the SN2?-reaction of 113 yielded 120 
in 61% as a single isomer (Scheme 16).  As in the reactions of 110, the selectivity of the 
addition was not affected by the incorporation of the phenylalanine residue, but the 
reaction rate was decreased. 
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Table 5. SN2?-Ring opening of 110 with various cuprate reagents. 
OMe
N
H O
O
HN
Bn
Bn
BUS
R
+ConditionsH
N
BUS
Bn
H
N CO2Me
O Bn
OMe
N
H O
O
HN
Bn Bn
RBUS
110 117a-d 118a-d  
Entry Conditions R Ratiob (117/118) Yieldc,d 
1 Me2Zn, CuCN, 2 eq LiCl Me 9:1 100% 
2 i-PrMgCl, CuCN i-Pr 3:1 84% 
3 i-BuMgCl, CuCN i-Bu 1:3 66% 
4 PhenethylMgCl, CuCN Phenethyl 7:1 67% 
a 3 eq of reagent, -20 °C, THF, 3 h. b Determined by NMR. c Mixture of isomers.  
d Isolated yiled. 
 
Table 6. SN2?-Ring opening of 111 with various cuprate reagents. 
Conditions
HN
CO2Me
Bn
RBUS
H
CO2Me
N
BUS
Bn
H
111 1119a-d  
Entry Conditions R Yieldc,d 
1 Me2Zn, CuCN, 2 eq LiCl Me 100% 
2 i-PrMgCl, CuCN i-Pr 84% 
3 i-BuMgCl, CuCN i-Bu 66% 
4 PhenethylMgCl, CuCN Phenethyl 67% 
a 3 eq of reagent, -20 °C, THF, 3 h. b Determined by NMR. c Mixture of isomers.  d Isolated yield. 
 
H
N
BUS
Bn
H
N
H
O
CO2Me
Bn
OMe
N
H O
O
HN
Bn Bn
Bus
113 120
Me2Zn, CuCN, LiCl
THF, -20 °C
             61%
 
Scheme 16. SN2?-Ring opening of 113. 
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1.2.5 Determination of the minor isomer generated by addition to 2,3-trans allylic 
aziridines 
The origin of the minor isomer formed when the 2,3-trans-aziridines 108 and 110 
were subjected to SN2?-ring opening was investigated. Initially, the structure of the minor 
isomer was not known, but there were two reasonable possible assignments.  For 
example, an epimer at the newly formed stereocenter could arise from a syn-SN2?-
reaction.  Another possiblily was the generation of a (Z)-olefin, which could arise from 
the reaction of the allylic aziridine in a different conformation.   
To examine the possibility of a syn-addition pathway, the product of this reaction 
was independently synthesized (Scheme 17). Treatment of 104 with DiBAL at –78 °C 
and then exposure to methyl diethylphosphonacetate yielded 121 in 69%.  Treatment with 
Me2Zn, CuCN, LiCl or i-BuMgCl and CuCN provided the (L,L) dipeptide isostere 122a-
b as single diastereomers in 97% and 70% yield, respectively. Comparison of 1H NMR of 
122a-b to those of the mixtures of 114a/115a and 114c/115c showed that the 
characteristic signal at 5.57 ppm for the minor isomer was not present.  This 
demonstrated that the minor isomer was not generated from reaction of 108 via syn-SN2?-
addition. 
The other possibility would be the reaction of the aziridine 108 from two different 
ground state conformations.  The extended conformation 123 (Figure 15), where the 
enone points away from the aziridine, undergoes anti- SN2?-addition, leading to the major 
product 114a. The other conformation could be generated by rotation of a single bond to 
place the enone beneath the aziridine shown for 124.  Anti-SN2?-addition to this 
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conformation would yield the (Z)-alkene 114a. The energetic difference between these 
conformations has been calculated for the simpler N-methylsulfonyl-trans-2-methyl-3-
vinyl aziridine to be 3.4 kcal/mol.90   This energy difference was not sufficient to totally 
eliminate the higher energy conformation, so it was possible to generate the (Z)-alkene in 
this manner.  Single crystal x-ray analysis of 118c confirmed the structure of the minor 
isomer generated in this progress as the (Z)-alkene  (Figure 16).  
 
HN
CO2Me
Bn
RBUS
122a R=Me
122b R=i-Bu
H
CO2Me
N
BUS
Bn
H
N
BUS
Bn
CO2Me
1. DiBAL, DCM, -78 °C  
2. (EtO)2P(O)CH2CO2Me
    n-BuLi, Et2O/THF (3:1)
          69% (2 steps)
i. Me2Zn, CuCN, LiCl
THF, -20 °C; 97% 
ii. i-BuMgCl, CuCN
THF, -20 °C; 70%104 121
 
Scheme 17. Synthesis of the epimer of 114a and 114c. 
 
N
MeBn
MeO2C
H
BUS
MeCuL
MeCuL
anti-SN2'
syn-SN2'
HN
CO2Me
Bn
BUS
N
MeBn
BUS
MeO2C
MeCuL anti-SN2'
MeCuLsyn-SN2'
CO2Me
HN
BUS
123
124
114a
115a  
Figure 15.  Possible reactive conformations of 108 and the resulting addition 
 products. 
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Figure 16.  X-ray crystal structure of 118c. 
1.2.6 Attempted deprotection of the BUS amide 
The final aspect of BUS-group chemistry to be investigated was its removal from allylic 
amines, but this transformation proved to be problematic. Treatment of 114a/115a under 
the standard BUS-deprotection conditions91 (TFA/anisole or trific acid/anisole Table 7, 
Entries 1 and 2) led to decomposition, presumably via cleavage of the carbon-nitrogen 
bond.  Treatment with LAH92 or Red-Al93,94, which is known to cleave sulfonamides, led 
to the isolation of alcohol 116 but no cleavage of the BUS-group. Although the BUS-
group could not be removed, it was decided to transfer this procedure to solid phase and 
investigate the opportunities for library development using these substrates. 
 
Table 7.  Attempted deprotection of the BUS-amide 
HN
CO2Me
Bn
BUS
Conditions
H2N
CO2Me
Bn
114a/115a 125  
Entry Conditions Temp Time (h) Result 
1 TFA, anisole r.t. 16 dec. 
2 Triflic acid, anisole r.t. 3 dec. 
3 LAH 0 °C to r.t. 48 116 
4 Red-Al 0 °C to r.t. 48 116 
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1.2.7 The synthesis of a library on solid support 
The goal in this phase of the project was the synthesis of a library of analogs 
based on compound L-685,458.  We wished to exploit the chemistry developed in the 
group47  to effect SN2?-aziridine opening on solid support. The three points of diversity 
that could be introduced would arise from the coupling of various amino acids, the 
addition of different cuprates and from variation of the structure of aziridines 109 and 
112 bound to the solid support (Figure 17).  The BUS-group on the nitrogen of 126 
would help to mimic the Boc-group found on the parent peptide.  By replacing the central 
amide bond, we hoped increase the metabolitic stability of the peptide. To help facilitate  
 
NH2N
H
H
N
H
NO
O
O
OO
OH
L-685,458
NH2N
H O
O
N
H R2 R3
Bn R1O2
S
Amino AcidsCuprates
Aziridines
126  
Figure 17.  The structures L-685,458 and (E)-alkene analog 126. 
 
this work,  we would carry out all solid-phase reactions using a New Brunswick 
Scientific Bohdan Mini Block, which was designed to agitate and filter the resins used in 
parallel reactions.  This instrument consisted of three components: a) an orbital shaker; b) 
a reaction block and c) a fritted reaction tube (Figure 18 a, b, c). Up to 48 fritted test 
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tubes could be placed in a single block allowing for up to 96 reactions to be conducted 
when both blocks were used.  The top of the reaction block was fitted with a septum that 
sealed the reaction tubes.   This unit was used to support the reaction vessels and filter 
excess solvent or reagent from the reaction tube.  The block has a built in valve that may 
be closed to ensure none of the reaction mixture escaped from the tube and could be 
easily opened to empty the vessel at the end of the reaction. Figure 19c shows the 3 mL 
fritted reaction tube.  The resins were placed in the fritted tube, where all the reactions, 
washings, and drying were performed without transfer to different vessels. 
 
A                                                    B                                           C
 
Figure 18. The three components of the Bohdan Mini Block system. 
 
The library synthesis would begin with the Fmoc deprotection of polystyrene 
Rink resin 127 to unmask the free amine; this amine would then be coupled to the amino 
acids and subsequently deprotected to yield 128a-d.  The aziridine would then be coupled 
to the resin bound amino acid to yield 129a-d and 130a-d. At this point, cuprates would 
be added to open the aziridine, followed by acidic cleavage to yield 132a-x (Scheme 18).  
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Amino Acid
1. DMF/piperidine (8:2), 10 min
2. Fmoc-D-or L-Phe or Fmoc-D-or L-Leu
    DIPEA, DEPBT, DMF, 3 h
3. DMF/piperidine (8:2), 10 min
128a-d
109, TFFA, DIPEA
DMF, 3 h
112, TFFA, DIPEA
DMF, 3 h
R2Zn, CuCN, LiCl
THF, -20 °C, 3 h
R2Zn, CuCN, LiCl
THF, -20 °C, 3 h
DCM/TFA (7:3), 10 min
DCM/TFA (7:3), 10 min
 
Scheme 18. Synthesis of tri-peptide isosteres on solid support. 
 
Based on our previous results on solid-supported aziridine opening,57 coupled 
with the results from the solution phase studies of 108, 110, 111, and 113,  it was 
anticipated that this sequence would afford the library members in good yield with high 
purities.  While the solution phase data seemed to suggest that this process would be 
effective on solid phase, the initial data suggested otherwise.  The library was made under 
the conditions shown in Scheme 18 but the results were disappointing (Table 8). While 
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the reactions proceeded as expected, the addition of the methyl group gave variable 
results. The methyl additions worked to form 132a, d, g, j effectively, but not 132m, p, s, 
v (Table 8).  Based on solution phase data, these two aziridines react similarly, so this 
result was problematic. A possible reason for these variable results was the cooling 
system of the Bohdan blocks.  The recirculating chiller used was unable to reach and 
maintain the desired –20 °C within the reaction block. This not only led to higher than 
desired temperatures, but uneven cooling within the reaction block.  Changing the 
cooling system from a recirculation chiller to a simple dry ice 1:1 ethylene gycol/water 
bath allowed for a more uniform temperature throughout the reaction block and could 
easily be maintained at the desired –20 °C. A resynthesis of half the library that gave 
poor results before led to improved conversion (Table 8, Trial 2).   
As this work progressed, it became necessary to modify the solid support that was 
used, since the original Argo-Gel resin was no longer available.  The switch was made to 
Nova-Biochem Rink Resin, which was also a polystyrene support, but had a higher 
loading capacity of 0.62 mmol/g.  With this resin in hand, the methyl and ethyl additions 
to 129a-d were repeated and afforded similar yields ensuring there was no difference in 
reactivity (Table 9).  
After establishing that this new resin performed well for this application, an 
attempt was made to synthesize a library with methyl, ethyl, and benzyl substituents 
(Table 10).  The benzyl additions were conducted under conditions similar to Table 4, 
Entry 4, except that the temperature was kept at –20 °C for 12 h, then increase to 0 °C for 
6 h. Though these reactions were conducted under similar conditions as the successful 
solution phase experiments, no product was observed.  The yields from the methyl and 
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ethyl additions were comparable to those in Table 9.  The purity of the material directly 
after cleavage from the resin was determined for the successful conversions. The purities 
were found to be low to moderate and work was begun to improve this aspect of the 
methodology. 
 
Table 8. Summary of yields of (E)-alkene peptide library members (Scheme 18). 
Entry Amino 
Acid 
R2 R3 Trial 1 
yielda 
Trial 2 
yielda 
Entry Amino 
Acid 
R2 R3 Trial 1 
Yielda 
Trial 2 
Yielda 
132a L-Phe Me Me 40% 17%  132m L-Phe H Me traceb NDc 
132b L-Phe Me Et 49%a 27%  132n L-Phe H Et 31% NDc 
132c L-Phe Me Ph traceb NDc 132o L-Phe H Ph n.d. NDc 
132d D-Phe Me Me 46% 36%  132p D-Phe H Me traceb NDc 
132e D-Phe Me Et 51% 29%  132q D-Phe H Et 42%  NDc 
132f D-Phe Me Ph traceb NDc 132r D-Phe H Ph n.d. NDc 
132g L-Leu Me Me 54%  34%  132s L-Leu H Me traceb NDc 
132h L-Leu Me Et 44%  28%  132t L-Leu H Et 37%  NDc 
132i L-Leu Me Ph traceb NDc 132u L-Leu H Ph n.d. NDc 
132j D-Leu Me Me 13%  28%  132v D-Leu H Me traceb NDc 
132k D-Leu Me Et 53%  30% 132w D-Leu H Et 53%  NDc 
132l D-Leu Me Ph traceb NDc 132x D-Leu H Ph n.d. NDc 
aIsolated yield bDetermined by LCMS, UV detection 210 nm cND = Not determined 
 
Table 9. Test of Nova-Biochem Rink resin using methyl and ethyl additions  
 (Scheme 18). 
Entry Amino Acid R2 R3 Yielda 
132a L-Phe Me Me 40% 
132b L-Phe Me Et 32% 
132d D-Phe Me Me 29% 
132e D-Phe Me Et 36% 
132g L-Leu Me Me 34% 
132h L-Leu Me Et 28% 
132j D-Leu Me Me 24% 
132k D-Leu Me Et 30% 
a Isolated yield 
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The reactions that were effective in solution phase did not always translate to the solid 
phase.  The reaction of the Grignard-derived cuprates, i-PrMgCl, i-BuMgCl or 
phenethylMgCl and CuCN with 129a gave unexpectedly poor results. Product formation 
was observed in low yield when using i-PrMgCl and CuCN, but no product was observed 
with i-BuMgCl or phenethylMgCl and CuCN.  To insure that the poor reactiviy was not 
simply due to a poor quality of the reagent, the additions to 108, 110, and 129a were 
conducted using the same batch of cuprate reagent.  The additions to 108 and 110 went as 
in previous attemps (Table 3, Entries 3 and 4, Table 5, Entries 3 and 4), but no reaction 
was observed with the resin bound aziridine.   The reaction of 110 in the presence of the 
resin-bound aziridine 129a went to completion, but again no addition to the resin-bound 
aziridine was observed.   These results would indicate that these reagents are not well 
suited for use in solid phase reactions using the current reaction block technique. 
 
Table 10.  Summary of yields and purities of (E)-alkene peptide library members  
(Scheme 18). 
Entry Amino 
Acid 
R2 R3 Puritya Yieldb Entry Amino 
Acid 
R2 R3 Puritya Yieldb 
132a L-Phe Me Me ND 40% 132m L-Phe H Me 60% 29% 
132b L-Phe Me Et 50% 32% 132n L-Phe H Et 68% 17% 
132y L-Phe Me Bn - - 132cc L-Phe H Bn - - 
132d D-Phe Me Me ND 36% 132p D-Phe H Me 66% 26% 
132e D-Phe Me Et 55% 29% 132q D-Phe H Et 61% 30% 
132z D-Phe Me Bn - - 132dd D-Phe H Bn - - 
132g L-Leu Me Me ND 36% 132s L-Leu H Me 54% 30% 
132h L-Leu Me Et 37% 39% 132t L-Leu H Et 55% 36% 
132aa L-Leu Me Bn - - 132ee L-Leu H Bn - - 
132j D-Leu Me Me 47% 24% 132v D-Leu H Me 55% 36% 
132k D-Leu Me Et 55% 30% 132w D-Leu H Et 60% 26% 
132bb D-Leu Me Bn - - 132ff D-Leu H Bn - - 
aIsolated yield bDetermined by LCMS, UV detection at 210 nm cND = Not determined 
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After establishing which reactions were successful on solid phase, the sequence 
was futher. The easiest and most important step to investigate was the initial coupling, 
since a poor yield in this step would perpetuate itself through the synthesis. In addition to 
investigating yield, a second rink resin developed by Polymer Labs was introduced to see 
if it offered any advantage over the Nova-Biochem resin.  N-Cbz-Phe was coupled to 
each resin, under a variety of conditions; the resin was dried over night, and then cleaved.  
The standard conditions used in the previous library trials, 1.5 equiv of DEPBT and 
amino acid, led to product in 60% and 34% yield (Table 11, Entries 1 and 4) after 
cleavage. An increased amount of DEPBT and amino acid proved the yield of isolated 
product with both resins, but the yields using the Polymer Labs resins were not as high 
for the Nova-Biochem resin.  
 
Table 11. Optimization studies of the initial coupling reaction using Cbz-Phe-OH. 
NH2
1. Conditions
2. 30% TFA/CH2Cl2 CbzHN
O
NH2
133 134  
Entry Resin Conditionsa Yieldb 
1 Nova-BioChem Rink Amide 1.5 equiv DEPBT, Cbz-N-Phe-OH 60% 
2 Nova-BioChem Rink Amide 5.0 equiv DEPBT, Cbz-N-Phe-OH 65% 
3 Nova-BioChem Rink Amide 10.0 equiv DEPBT, Cbz-N-Phe-OH 73% 
4 Polymer Labs Rink 1.5 equiv DEPBT, Cbz-N-Phe-OH 34% 
5 Polymer Labs Rink 5.0 equiv DEPBT, Cbz-N-Phe-OH 52% 
6 Polymer Labs Rink 10.0 equiv DEPBT, Cbz-N-Phe-OH 56% 
aAn equimolar amount of DIPEA was added to the reagents in a solution of DMF, 3 h, 
rt. bIsolated yield. 
 
After investigating the resin loading, the focus then shifted to the final cleavage 
step from the resin.  The original conditions for this cleavage, 30% TFA in 
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dichloromethane at room temperature, are rather harsh. The amount of TFA was 
decreased as well as the temperature in hopes of affording material with increased purity 
after cleavage from the solid support.  While cooling the reaction increased the purity 
from 50 to 71% (Table 12, Entries 1 and 2), changing the amount of TFA had little effect 
(Table 12, Entries 2-4).  The best purity was obtained when 20% TFA in 
dichloromethane at 0 °C was used (Table 12). 
 
Table 12. Optimization studies for compound cleavage from the resin. 
H
N
N
H O
O
N
H
BUS
Bn Bn
NH2N
H O
O
N
H
BUS
Bn Bn
Conditions
131a 132a  
Entry Resin Conditions Temp. Puritya 
1 Nova-BioChem Rink Amide 7:3 TFA:CH2Cl2 r.t. 50% 
2 Nova-BioChem Rink Amide 7:3 TFA:CH2Cl2 0 °C 71% 
3 Nova-BioChem Rink Amide 8:2 TFA:CH2Cl2 0 °C 78% 
4 Nova-BioChem Rink Amide 9:1 TFA:CH2Cl2 0 °C 76% 
aBefore column chromatography determined by HPLC, UV detection at 210 nm. 
 
After investigating the first and last steps on solid phase, different resins and 
applying some observations from the solution phase reactions, the conditions for the 
synthesis of the library were modified.   The coupling of amino acids to the resin changed 
from a single reaction with 1.5 equiv of amino acid and DEPBT to the reaction being 
conducted twice with 5 equiv of the reagents. The reaction time in the coupling of the 
aziridines 109 and 112 to the solid-supported amino acid was extended to 6 h from 3.  
Finally, since observations of the solution phase reactions that generated compounds 
117a-d and 120 had shown that 3 h were not sufficient for the reaction to reach 
completion, the reaction time on solid phase was increased to 6 h. These new conditions 
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were then applied to the synthesis of the methyl- and ethyl-substituted members of the 
library.  However, the yields were not increased by using these new conditions but were 
significantly worse.  Due to the decreased yield, the purities were not determined, but 
based on comparison of the crude 1H NMR of these samples with those from Table 10, 
they were comparable. 
The major difference between the optimization experiments and the library 
synthesis was the number of operations.  While it ass trivial to focus on four to six 
reactions simultaneously, it became increasingly difficult to give the same individual care 
to 16-24 separate reactions.  Although some aspects of the chemistry were operationally 
simple and required little care, such as washes and coupling reactions, others such as the 
cuprate additions and work-up procedures became more challenging when increasing the 
number of reactions.  These difficulties may help to explain why small optimization 
studies showed improved results, but when the knowledge gathered from these studies 
was applied to a large number of reactions, the process did not improve.  
1.3 CONCLUSION 
We were able to demonstrate the SN2?-ring opening of BUS-activated aziridines with 
organocuprate reagents on solid phase. The study of the reactivity of these aziridines has 
shown the BUS-activation follows a pattern similar to the nosyl- or tosyl-activated 
hetereocycles, but leds to a decreased rate and diastereoselectivity. This methodology 
was used in the solid phase preparation of a small combinatorial library based on L-
 43
685,458.  Members of this library were obtained in yields between 20-50% with an 
average purity before final chromatographic purification of 56%. 
1.4 EXPERIMENTAL SECTION 
 
General:  All moisture-sensitive reactions were performed under an atmosphere of N2.  
Glassware was flame dried prior to use.  THF and Et2O were dried by distillation over 
Na/benzophenone.   CH2Cl2 was dried by distillation over NaH.  Unless otherwise stated, 
solvents and reagents were used as received.  Analytical thin layer chromatography was 
performed on pre-coated silica gel 60 F-254 plates (particle size 0.040-0.055 mm, 230-
400 mesh) and visualization was accomplished with a 254 nm UV light or by staining 
with an anisaldehyde solution (7.5mL of p-anisaldehyde, 25 mL of concentrated H2SO4 
and 7.5 mL of glacial acetic acid in 675 mL of 95% ethanol) or KMnO4 solution (1.5 g of 
KMnO4, 10 g of potassium carbonate and 2.5 mL of 5% aqueous NaOH in 150 mL of 
H2O).  Flash chromatography on SiO2 was used to separate and purify the crude reaction 
mixtures.  NMR spectra were recorded at 300 MHz/75 MHz (1H NMR/13C NMR) at 21 
oC in CDCl3 unless otherwise noted.  Chemical shifts (?) are reported as follows: 
chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, qn=quintet, 
dd=doublet of doublet, ddd= doublet of doublet of doublet, dt=doublet of triplet, 
dq=doublet of quartet, m=multiplet, b=broad).  LC/MS analyses used a Hewlett Packard 
Series 1100 MSD. Semi-prepative HPLC was performed on a Varian 215 delivery system 
in conjuntion with a Varian ProStar 325 UV detector using a Rainin Instrument company 
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dynamax 60 Å C-18 column (No. 3-211-C). Chiral HPLC analysis was performed on a 
Dynamax SD-200 delivery system in conjunction with a Dynamax UV-1 absorbance 
detector.  A Chiralcel OD (0.46 cm x 25 cm) or AD-H (0.46 cm x 25 cm) column was 
used for analytical separation.  Infrared spectra were measured on a Nicolet AVATAR 
360 FTIR E.S.P. spectrometer. Mass spectra were obtained on a double focusing 
instrument. Optical rotations were measured on a Perkin-Elmer 241 polarimeter at 25 oC.  
 
S
O
N
Bn 
 (SS)-(-)-N-(Benzyl)-t-butylsulfinamide (101).   To a solution of 10.9 g (89.9 mmol) of t-
butylsulfinamide in 168 mL of CH2Cl2 was added 54.1 g (450 mmol) of MgSO4, 11.0 mL 
(98.9 mmol) of distilled phenylacetaldehyde, and 1.13 g (4.49 mmol) of PPTS at room 
temperature.  The reaction mixture was stirred for 48 h, filtered through a pad of celite 
and concentrated in vacuo.  The resulting residue was purified by chromatography on 
SiO2 (10-20% EtOAc/Hexanes) to yield 16.9 g (84%) of 101 as an orange oil: [?]D25 
+19.8 (c 0.96, CHCl3); IR (neat) 3086, 3062, 3029, 2960, 2925, 2867, 1620, 1602, 1496, 
1474, 1454, 1363, 1181, 1089 cm-1; 1H NMR ?  8.14 (t, 1 H, J =  5.2 Hz), 7.35-7.24 (m, 5 
H), 3.86 (d of AB, 1 H, J = 17.0, 5.28 Hz), 3.82 (d of AB, 1 H, J = 15.3, 5.15 Hz), 1.20 
(s, 9 H); 13C NMR ? 167.4, 134.8, 129.2, 128.8, 127.1, 56.8, 42.6, 22.4; MS (EI) m/z (rel 
intensity) 167 ([M-C4H8]
+, 32), 153 (7), 118 (5), 117 (10), 105 (12), 104 (27), 91 (22), 77 
(10), 65 (7), 57 (100); HRMS (EI) Calcd for C8H9NOS (M-C4H8) 167.0404, found 
167.0406.  
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(3S)-Benzyl-(2R)-methyl-1-(2-methylpropane-2-sulfonyl)-aziridine-2-carboxylic acid 
methyl ester (103).  To a solution of 1.59 g (5.18 mmol) of 106 in 60 mL in CH2Cl2 at 0 
oC was added 1.34 g (7.77 mmol) of m-CPBA.  The reaction mixture was stirred for 3 h, 
gradually warmed to room temperature, quenched with 10 mL 10% NaHSO3, and 
extracted with CH2Cl2 (3x).  The combined organic layers were washed with saturated 
aqueous NaHCO3, dried (MgSO4), filtered, and concentrated in vacuo.  The residue was 
purified by chromatography on SiO2 (30% EtOAc/Hexane) to yield 1.07 g (63%) of 103 
in 87% ee (determined by HPLC) as an off white solid: Mp 62.8-65.7 oC; [?]D25 –8.8 (c 
1.1, CHCl3); IR (KBr) 3459, 2984, 1740, 1630, 1497, 1455, 1311, 1160, 1127, 1075, 
1015, 950, 891 cm-1; 1H NMR ? 7.35-7.25 (m, 5 H), 4.05 (dd, 1 H, J = 7.8, 5.8 Hz), 3.77 
(s, 3 H), 3.04 (dd, 1 H, J = 15.2, 5.7), 2.80 (dd, 1 H, J = 15.2, 7.8 Hz), 1.66 (s, 3 H), 1.42 
(s, 9 H); 13C NMR ? 168.8, 136.6, 128.9, 128.7, 127.0, 60.3, 53.1, 50.7, 48.8, 34.2, 23.9, 
15.4; MS (ES) m/z (rel intensity) 348.1 ([M+23Na]+, 100), 228.1 (20) ; HRMS (ES) Calcd 
for C16H23NO4NaS (M+
23Na) 348.1245, found 348.1235.  
 
N
Bn CO2Me
S OO
 
(3S)-Benzyl-(2S)-methyl-1-(2-methylpropane-2-sulfonyl)-aziridine-2-carboxylic acid 
methyl ester (104).  Isolated as a colorless oil in 259 mg (15% yield) as the minor 
diastereomer from the reaction yielding 103: [?]D25 –26 (c 0.90, CHCl3); IR (neat) 3054, 
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2987, 1747, 1639, 1421, 1311, 1265, 1129, 896 cm-1; 1H NMR ? 7.37-7.25 (m, 3 H), 
7.18-7.14 (m, 2 H), 3.78 (s, 3 H), 3.17 (dd, 1 H, J = 8.4, 4.9 Hz), 3.01 (dd, 1 H, J = 14.9, 
4.9 Hz), 2.81 (dd, 1 H, J = 14.9, 8,4 Hz), 1.88 (s, 3 H), 1.47 (s 9 H); 13C NMR ? 168.8, 
136.5, 128.8, 128.7, 127.0, 60.5, 52.8, 51.3, 50.9, 34.4, 23.9, 17.3; MS (EI) m/z (rel 
intensity) 266 ([M-C2H3O2]
+, 22), 205 (5), 204 (32), 174 (6), 147 (9), 146 (59), 145 (27), 
144 (74), 135 (30), 121 (5), 118 (16), 114 (21), 104 (33), 103 (47); HRMS (EI) Calcd for 
C14H20NO2S (M-C2H3O2) 266.1214, found 266.1227.  
 
N
S
Bn CO2Me
O O
 
(3S)-Benzyl-1-(2-methylpropane-2-sulfonyl)-aziridine-(2S)-carboxylic acid methyl 
ester (105). To a solution of 10.5 mL (49.5 mmol) of HMDS in 500 mL of THF cooled 
to 0 oC was added 31.0 mL (49.5 mmol) of a 1.6 M solution of n-BuLi in hexanes. The 
reaction mixture was stirred for 1 h, cooled to –78 oC and treated with 1.60 mL (49.5 
mmol) of methylbromoacetate via syringe pump over 1 h. A solution of 5.00 g (22.4 
mmol) of 101 in 25 mL of THF was cooled to –78 oC and added via canula over 30 min.  
The resulting mixture was stirred for 7 h at –78 oC, quenched with 100 ml H2O, extracted 
with EtOAc (3x), dried (MgSO4), filtered, and concentrated in vacuo.  The residue was 
redissolved in 140 mL of CH2Cl2, cooled to 0 
oC, and 6.76 g (39.2 mmol) of m-CPBA 
was added. The reaction mixture was stirred for 2 h, warmed gradually to room 
temperature, quenched with 100 mL of a 10% aqueous solution of NaHSO3, and 
extracted with CH2Cl2 (3x).  The combined organic layers were washed with saturated 
aqueous NaHCO3, dried (MgSO4), filtered, and concentrated in vacuo.  The residue was 
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purified by chromatography on SiO2 (100% CH2Cl2) to yield 1.63 g (23%) of 105 in 99% 
ee as a yellow solid:  Mp 54.1-62.8 oC; [?]D25 –7.9 (c 1.3, CHCl3); IR (KBr) 2993, 1743, 
1602, 1438, 1305, 1234, 1129, 1039 cm-1; 1H NMR ? 7.36-7.18 (m 5 H), 3.80 (s 3 H), 
3.44 (d, 1 H, J = 7.2 Hz), 3.26 (ddd, 1 H, 13.2, 7.3, 6.0 Hz), 3.12 (dd, 1 H, J = 14.7, 5.8 
Hz), 2.93 (dd, 1 H, J = 14.7, 7.4 Hz), 1.48 (s, 9 H); 13C NMR ? 166.5, 136.4, 128.7, 
128.7, 127.0, 59.9, 52.6, 43.2, 41.3, 33.2, 23.9; MS (ES) m/z (rel intensity) 334.1 
([M+23Na]+, 100), 215.1 (6), 214.1 (78); HRMS (ES) Calcd for C15H21NO4NaS (M+
23Na)  
334.1089, found 334.1097. 
 
Bn
CO2MeN
S
O
 
(3S)-Benzyl-(2R)-methyl-1-(2-methylpropane-2-(S)-sulfinyl)-aziridine-2-carboxylic 
acid methyl ester (106).  To a solution of 2.1 mL (9.9 mmol) of HMDS in 32 mL of 
THF was added at 0 oC 6.2 mL (9.9 mmol) of a 1.6 M solution of n-BuLi in hexanes. The 
reaction mixture was stirred for 1 h, cooled to –78 oC, treated dropwise with 1.1 mL (9.9 
mmol) of methyl bromopropinate and stirred for 2 h.  A solution of 1.0 g (4.5 mmol) of 
101 in 5 mL of THF was cooled to –78 oC and added via canula over the course of 30 
min.  The resulting mixture was stirred for 3 h, quenched with 10 mL H2O, extracted with 
EtOAc (3x), dried (MgSO4), filtered, and concentrated in vacuo.  The residue was 
purified by chromatography on SiO2 (20% EtOAc/Hexanes) to yield 0.82 g (59%) of 106 
as a pale yellow oil: [?]D25 93 (c 0.55, CHCl3); IR (neat) 2952, 1731, 1496, 1455, 1272, 
1200, 1160, 1087, 1029, 980, 936 cm-1; 1H NMR ? 7.35-7.15 (m, 5 H), 3.78 (s, 3 H), 3.53 
(dd, 1 H, J = 7.5, 5.9 Hz), 2.93 (dd, 1 H, J = 15.0, 5.9 Hz), 2.80 (dd, 1 H, J = 14.9, 7.4 
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Hz), 1.58 (s, 3 H), 1.24 (s 9 H); 13C NMR ? 170.6, 137.6, 129.0, 128.9, 127.0, 56.9, 53.3, 
49.2, 45.9, 34.7, 22.3, 16.5; MS (ES) m/z (rel intensity) 332.2 ([M+23Na]+, 100), 227.2 
(31), 213.2 (23); HRMS (ES) Calcd for C16H23NO3NaS (M+
23Na) 332.1296, found 
332.1296. 
 
N
Bn
CO2Me
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3-[(3S)-Benzyl-(2R)-methyl-1-(2-methylpropane-2-sulfonyl)-aziridin-2-yl]-(E)-acrylic 
acid methyl ester (108).  To a solution of 0.20 g (0.61 mmol) of 103 in 4 mL of CH2Cl2 
at –78 oC was added 1.2 mL (1.2 mmol) of a 1 M solution of DiBAL in hexanes.  The 
reaction mixture was stirred for 30 min and quenched with 2 mL of a saturated aqueous 
solution of NH4Cl.  To the resulting solution was added 0.40 g (1.2 mmol) of 
(methoxycarbonylmethyl) triphenylphosphonium bromide.  The reaction mixture was 
stirred, warmed to room temperature for 15 h, filtered through a pad of Celite, diluted 
with H2O and extracted with CH2Cl2 (3x).  The combined organic layers were washed 
with brine, dried (MgSO4), and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (30%EtOAc/Hexane) to yield 0.15 g (70%) of 108 as an off 
white solid: Mp 76.2-77.2 oC (CH2Cl2); [?]D25 –2.3 (c 0.96, CHCl3); IR (KBr) 2975, 2949, 
1719, 1654, 1440, 1301, 1124 cm-1; 1H NMR ? 7.36-7.15 (m, 5 H), 7.11 (d, 1 H J = 15.8 
Hz), 6.09 (d, 1 H, J = 15.8 Hz), 3.73 (s, 3 H), 3.37 (dd, 1 H, J = 8.7, 4.9 Hz), 3.13 (dd, 1 
H, J = 15.1, 4.9 Hz), 2.83 (dd, 1 H, J = 15.1, 8.7), 1.58 (s, 3 H), 1.43 (s, 9 H); 13C NMR ? 
166.0, 146.7, 136.5, 129.1, 128.6, 127.2, 123.5, 60.1, 53.2, 52.0, 51.1, 34.2, 24.1, 16.3; 
MS (ES) m/z (rel intensity) 374.2 ([M+23Na]+, 100), 288.3 (5), 255.2 (8), 254.2 (33), 
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232.2 (18), 200.2 (4); HRMS (ES) Calcd for C18H25NO4NaS (M+
23Na) 374.1402, found 
374.1415. 
 
N
Bn
CO2H
SO O
 
3-[(3S)-Benzyl-(2R)-methyl-1-(2-methylpropane-2-sulfonyl)-aziridin-2-yl]-(E)-acrylic 
acid (109).  To a solution of 1.00 g (3.06 mmol) of 103 in 20 mL of CH2Cl2 at –78 
oC 
was added 6.20 mL (6.20 mmol) of a 1 M solution of DiBAL in hexanes.  The reaction 
mixture was stirred for 30 min, quenched with 4 mL of cold (-78 oC) MeOH, warmed to 
rt, treated with 4 mL of saturated aqueous NH4Cl, extracted with CH2Cl2 (3x), dried 
(MgSO4), and concentrated in vacuo.  The resulting aldehyde was washed with benzene, 
concentrated in vacuo (3x) and dried under high vacuum.  To a solution of 2.04 g (7.60 
mmol) of trimethylsilyl diethylphosphonoacetate in Et2O at 0 
oC was added 4.80 mL 
(7.60 mmol) of a 1.6 M solution of n-BuLi in hexanes.  The ice bath was removed, and 
the reaction mixture was warmed to room temperature, stirred for 1 h, and cooled again 
to 0 oC. A solution of the aldehyde in 6 mL of a 1:1 solution of THF/Et2O was added 
dropwise.  The resulting solution was stirred for 3 h, poured over 20 mL of 2 M aqueous 
NaHSO4, immediately extracted with EtOAc (3x), dried (Na2SO4) and concentrated in 
vacuo.  The residue was purified by chromatography on SiO2 (30%-50%EtOAc/Hexane) 
to yield 630 mg (60%) of 109 as an off white sticky solid: Mp 120.2-124.4 oC (CH2Cl2); 
[?]D25 –21 (c 0.58, CH2Cl2); IR (KBr) 3089, 2984, 2659, 1698, 1310, 1128, 931 cm-1; 1H 
NMR (Acetone-d6) ? 7.33-7.19 (m, 5 H), 7.11 (d, 1 H, J = 15.7 Hz), 6.10 (d, 1 H, J = 
15.7 Hz), 3.34 (dd, 1 H, J = 8.2, 5.3 Hz), 3.19 (dd, 1 H, J = 15.0, 5.3 Hz), 2.97 (dd, 1 H, 
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J = 15.0, 8.2 Hz), 1.61 (s, 3 H), 1.37 (s, 9 H); 13C NMR (Acetone-d6) ? 166.4, 148.0, 
137.9, 129.3, 129.3, 127.3, 123.6, 59.9, 53.9, 51.1, 34.3, 23.9, 16.2; MS (ES) m/z (rel 
intensity) 360.2 ([M+23Na]+, 100), 259.2 (3), 240.2 (13); HRMS (ES) Calcd for 
C17H23NO4SNa (M+
23Na)  360.1245, found 360.1255.  
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2-{3-[(3S)-Benzyl-(2R)-methyl-1-(2-methylpropane-2-sulfonyl)-aziridin-2-yl]-(E)-
acryloylamino}-3-phenyl-(S)-propionic acid methyl ester (110).  To a solution of 0.20 
g (0.59 mmol) of 109 in 12 mL DMF was added 0.53 g (1.8 mmol) of DEPBT, 0.62 mL 
(3.6 mmol) of diisopropyl ethyl amine, and 0.38 mg (1.8 mmol) of L-phenylalanine 
methyl ester•HCl and was stirred for 3 h at room temperature.  The reaction mixture was 
quenched with 10 mL of a saturated aqueous solution of NH4Cl and extracted with Et2O 
(5x). The combined organic layers were washed with brine, dried (MgSO4) and 
concentrated in vacuo.  The resulting residue was purified by chromatography on SiO2 
(30% EtOAc/Hexane) to yield 0.28 g (96%) of 110 as an iridescent foam: [?]D25 49 (c 
0.60, CHCl3); IR (KBr) 3290, 2985, 1746, 1668, 1633, 1538, 1455, 1308, 1205, 1126, 
982, 936, 848 cm-1; 1H NMR ? 7.36-7.09 (m, 10 H), 6.88 (d, 1 H, J = 15.7 Hz), 6.13 (bs, 
1 H), 6.07 (d, 1 H, J = 15.7 Hz), 4.94 (ddd, 1 H, J = 11.8, 6.8, 5.7 Hz), 3.72 (s, 3 H), 3.38 
(dd, 1 H, J = 8.5, 4.9 Hz), 3.13 (dd, 3 H, J = 12.1, 5.6 Hz), 2.83 (dd, 1 H, J = 15.1, 8.6 
Hz), 1.56 (s, 3 H), 1.43 (s, 9 H) ; 13C NMR ? 171.8, 164.4, 142.2, 136.5, 135.8, 129.3, 
128.8, 128.6, 128.5, 127.0, 1267.0, 125.9, 59.8, 53.2, 52.6, 52.3, 51.1, 37.9, 34.1, 24.02, 
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16.3; MS (ES) m/z (rel intensity) 521.6 ([M+23Na]+, 100), 499.6 (83), 467.6 (5), 401.5 (5), 
379.5 (10), 378.5 (17), 377.5 (30), 260.4 (10), 259.3 (22), 198.3 (8), 168.2 (5); HRMS 
(ES) Calcd for C27H34N2O5NaS (M+
23Na) 521.2086, found 521.2067.  
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3-[(3S)-Benzyl-1-(2-methylpropane-2-sulfonyl)-aziridin-(2S)-yl]-(E)-acrylic acid
methyl ester (111).   To a solution of 0.10 g (0.32 mmol) of 105 in 4 mL of CH2Cl2 at –
78 oC was added 0.48 mL (0.48 mmol) of a 1 M  solution of DiBAL in hexanes.  The 
reaction mixture was stirred for 30 min, quenched with 2 mL of cold (-78 oC) MeOH, 
warmed to rt, treated with 2 mL of a saturated aqueous solution of NH4Cl, extracted with 
CH2Cl2 (3x), dried (MgSO4), and concentrated in vacuo.  The resulting aldehyde was 
washed with benzene, concentrated in vacuo (3x) and dried under high vacuum.  To a 
solution of 0.13 g (0.64 mmol) of methyl diethylphosphonoacetate in Et2O at 0 
oC was 
added 0.40 mL (0.64 mmol) of a 1.6 M solution of n-BuLi in hexanes.  The ice bath was 
removed, the reaction mixture was warmed to room temperature, stirred for 1 h, and 
cooled again to 0 oC. A solution of the aldehyde in 0.5 mL of a 1:1 mixture of THF/Et2O 
was added dropwise.  The reaction mixture was stirred for 3 h, quenched with 1 mL of a 
saturated aqueous solution of NH4Cl, extracted with EtOAc (3x), dried (Na2SO4) and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (30% 
EtOAc/Hexanes) to yield 58 mg (52%) of 111 as a white solid:  Mp 101.1-107.4 oC 
(CH2Cl2); [?]D25 –52 (c 0.71, CH2Cl2); IR (KBr) 2985, 1725, 1659, 1440, 1295, 1256, 
1126, 979, 936, 859, 751 cm-1; 1H NMR (Acetone-d6) ? 7.36-7.18 (m, 5 H), 6.89 (dd, 1 H, 
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J = 15.6, 7.2 Hz), 6.34 (dd, 1 H, J = 15.6, 0.8 Hz), 3.73 (s, 3 H), 3.50 (dt, 1 H, J = 7.2, 
0.8 Hz), 3.19 (ddd, 1 H, J = 13.4, 7.2, 6.3 Hz), 3.02 (dd, 1 H, J = 14.7, 6.2 Hz), 2.88 (dd, 
1 H, J = 14.8, 7.2 Hz), 1.39 (s 9 H); 13C NMR (Acetone-d6) ? 165.5, 140.4, 137.6, 129.2, 
128.8, 127.0, 126.43, 59.1, 51.4, 45.5, 43.3, 33.2, 23.6; MS (ES) m/z (rel intensity) 360.1 
([M+23Na]+, 100), 262.1 (9), 240.1 (15); HRMS (ES) Calcd for C17H23NO4NaS (M+
23Na) 
360.1245, found 360.1253. 
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3-[(3S)-Benzyl-1-(2-methylpropane-2-sulfonyl)-aziridin-(2S)-yl]-(E)-acrylic acid
 (112).   To a solution of 0.25 g (0.80 mmol) of 105 in 10 mL of CH2Cl2 at –78 
oC was 
added 1.2 mL (1.2 mmol) of a 1 M solution of DiBAL in hexanes.  The reaction mixture 
was stirred for 30 min, quenched with 1 mL of cold (-78 oC) MeOH, warmed to rt, treated 
with 5 mL of a 10% aqueous solution of citric acid and extracted with EtOAc (3x).  The 
combined organic layers were washed with NaHCO3, dried (MgSO4), and concentrated in 
vacuo.  The resulting aldehyde was washed with benzene, concentrated in vacuo (3x) and 
placed under high vacuum.  To a solution of 0.43 mg  (1.6 mmol) of trimethylsilyl 
diethylphosphonoacetate in Et2O at 0 
oC was added 1.0 mL (1.6 mmol) of a 1.6 M 
solution of n-BuLi in hexanes.  The ice bath was removed and the reaction mixture was 
warmed to room temperature, stirred for 1.5 h and cooled again to 0 oC.  A solution of the 
aldehyde in 1.3 mL of 1:1 mixture of THF/Et2O was added dropwise.  The resulting 
solution was stirred for 1.25 h, poured over 10 mL of 2 M aqueous NaHSO4, immediately 
extracted with EtOAc (3x), dried (Na2SO4) and concentrated in vacuo.  The residue was 
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purified by chromatography on SiO2 (30-100% EtOAc/Hexane) to yield 0.15 g (57%) of 
112 as an off-white gummy solid:  Mp 98.4-108.1 oC (CH2Cl2); [?]D25 –40 (c 0.85, 
CH2Cl2); IR (KBr) 2990, 1686, 1651, 1455, 1423, 1308, 1206, 1129, 979, 859  cm
-1; 1H 
NMR (Acetone d6) ? 7.38-7.17 (m, 5 H), 6.89 (dd, 1 H, J = 15.6, 7.2 Hz), 6.31 (dd, 1 H, J 
= 15.6, .8 Hz), 3.50 (dt, 1 H, J = 7.2, 0.8 Hz), 3.19 (dt, 1 H, J = 7.2, 6.2 Hz), 3.04 (dd, 1 
H, J = 14.8, 6.2 Hz), 2.89 (dd, 1 H, J = 14.8, 7.3 Hz), 1.40 (s, 9 H); 13C NMR (Acetone 
d6) ? 166.3, 141.0, 138.1, 129.8, 129.7, 129.3, 127.5, 59.7, 45.9, 43.9, 33.8, 24.1; MS 
(ES) m/z (rel intensity) 346.1 ([M+23Na]+, 83), 306.1 (13), 275.1 (4), 259.1 (17), 247.1 
(43), 226.1 (9), 181.1 (9), 153.0 (9); HRMS (ES) Calcd for C16H21NO4NaS (M+
23Na) 
346.1089, found 346.1083. 
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2-{3-[(3S)-Benzyl-1-(2-methylpropane-2-sulfonyl)-aziridin-(2S)-yl]-(E)-acryloyl 
amino}-3-phenyl-(S)-propionic acid methyl ester (113). A solution of 0.21 g (0.63 
mmol) of 112, 0.57 g (1.9 mmol) of DEPBT, 0.67 mL (3.8 mmol) diisopropyl 
ethylamine, and 0.41 g (1.9 mmol) L-phenylalanine methyl ester•HCl in 13 mL of DMF 
was stirred for 3 h at room temperature.  The reaction mixture was quenched with 10 mL 
of a saturated aqueous solution of NH4Cl, and extracted with Et2O (5x).  The combined 
organic layers were washed with brine, dried (MgSO4) and concentrated in vacuo.  The 
resulting residue was purified by chromatography on SiO2 (30% EtOAc/Hexane) to yield 
0.14g (45%) of 113 as an 8:1 mixture of diastereomers as a clear glass.  After purification 
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by semi-preparative reverse phase HPLC (4 mL/min, 2:1 acetonitrile/H2O) a sample of 
pure 113 was isolated:  [?]D25 3.6 (c 1.4, CHCl3); IR (KBr) 3415, 3054, 2986, 2305, 1742, 
1680, 1647, 1510, 1438, 1309, 1266, 1127 cm-1; 1H NMR (Acetone-d6) ? 7.69 (d, 1 H, J 
= 8.1 Hz), 7.38- 7.16 (m, 10 H), 6.72 (dd, 1 H, J = 15.5, 7.0 Hz), 6.51 (d, 1 H, J = 15.3 
Hz), 4.80 (ddd, 1 H, J = 8.0, 8.0, 2.8 Hz), 3.66 (s, 3 H), 3.41 (t, 1 H, J = 13.8 Hz), 3.16 
(dd, 2 H, J = 13.5, 5.9 Hz), 3.07-2.92 (m, 2 H), 2.82 (dd, 1 H, J = 14.6, 7.3 Hz), 1.49 (s, 
9 H); characteristic signals for the minor isomer: 1H NMR (Acetone-d6) ? 7.55 (d, 1 H, J 
= 7.4 Hz), 4.11 (t, 1 H, J = 5.6 Hz), 3.61 (s, 3 H); 13C NMR (Acetone-d6) ? 171.7, 163.6, 
137.4, 137.0, 135.1, 129.2, 129.1, 128.9, 128.5, 128.3, 126.6, 58.7, 53.8, 51.4, 45.0, 43.3, 
37.4, 32.8, 23.4; MS (ES) m/z (rel intensity) 507.2 ([M+23Na]+, 100), 387.2 (7); HRMS 
(ES) Calcd for C26H32N2O5NaS (M+
23Na) 507.1930, found 507.1922. 
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(2R)-Isopropyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-
(E)-enoic acid methyl ester (114b).  To a solution of 50 mg (0.56 mmol) of CuCN in 5.5 
mL of THF was added at –78 oC 0.28 mL (0.56 mmol) of a 2 M solution of i-propyl 
magnesium chloride in THF.  The resulting mixture was stirred for 10 min, warmed to 0 
oC, stirred for 15 min, and cooled to –20 oC.  A solution of 50 mg (0.14 mmol) of 108 in 
0.6 mL of THF was added. The resulting solution was stirred for 3 h, quenched with 3 
mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (10% 
EtOAc/Hexanes) to yield 30 mg (55%) of a 9:1 mixture of 114b/115b as a colorless oil.  
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After repeated chromatography on SiO2 a pure sample of 114b was isolated: [?]D25 55 (c 
0.72, CHCl3); IR (neat) 3023, 1727, 1218, 1126, 758 cm
-1; 1H NMR ? 7.37-7.18 (m, 5 H), 
5.25 (d, 1 H, J = 10.2 Hz), 4.59 (ddd, 1 H, J =  9.1, 9.1, 4.5 Hz), 3.84 (d, 1 H, J = 9.0 
Hz), 3.67  (s, 3 H), 3.11 (t, 1 H, J = 9.7 Hz), 2.85 (dd, 1 H, J = 13.7, 4.6 Hz), 2.72 (dd, 1 
H, J = 13.6, 9.22 Hz), 2.07-1.93 (m, 1 H), 1.74 (d, 3 H, J = 1.2 Hz), 1.13 (s, 9 H), 0.95 
(d, 3 H, J = 6.8 Hz), 0.93 (d, 3 H, J = 6.8 Hz); 13C NMR ? 174.04, 138.63, 137.22, 
129.58, 128.66, 126.98, 124.68, 59.79, 56.66, 51.65, 51.52, 41.74, 31.52, 23.94, 20.61, 
20.02, 19.09; MS (ES) m/z (rel intensity) 418.5 ([M+23Na]+, 100), 298.4 (12), 259.4 (16), 
199.3 (11), 143.2 (5); HRMS (ES) Calcd for C21H33NO4NaS (M+
23Na) 418.2028, found 
418.2025. 
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(2S)-Isopropyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-
(Z)-enoic acid methyl ester (115b). Isolated as the minor isomer from the reaction 
yielding 114b: [?]D25 33 (c 0.39, CHCl3); IR (neat) 3054, 2986, 1731, 1421, 1265, 1127, 
984, 896 cm-1; 1H NMR ? 7.30-7.10 (m, 4 H), 7.12 (d, 1 H, J = 7.1 Hz), 5.19 (d, 1 H, J = 
9.9 Hz), 4.25-4.08 (m, 1 H), 4.03 (d, 1 H, J = 9.4 Hz), 3.63 (s, 3 H), 2.98 (m, 3 H), 1.87 
(dq, 1 H, J = 17.1, 6.6 Hz), 1.73 (s, 3 H), 1.26 (s, 9 H), 0.81 (d, 3 H, J = 6.6 Hz), 0.64 (d, 
3 H, J = 6.7 Hz); 13C NMR ? 173.9, 136.9, 136.6, 129.6, 128.4, 126.8, 125.0, 62.5, 59.73, 
52.1, 51.4, 41.4, 31.2, 24.0, 20.6, 19.4, 13.9; MS (ES) m/z (rel intensity) 418.48 
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([M+23Na]+, 100), 299.42 (5), 298.41 (17), 259.38 (13), 199.31 (10), 143.20 (5); HRMS 
(ES) Calcd for C21H33NO4NaS (M+
23Na) 418.2028, found 418.2011. 
 
HN
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(2S)-Isobutyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-
enoic acid methyl ester (114c). To a solution of 50 mg (0.56mmol) of CuCN in 5.5 mL 
of THF was added at –78 oC 0.28 mL (0.56 mmol) of a 2 M solution of i-butyl 
magnesium chloride in THF.  The resulting mixture was stirred for 10 min, warmed to 0 
oC, stirred for 15 min, and cooled to –20 oC.  A solution of 50 mg (0.14 mmol) of 108 in 
0.6 mL of THF was added. The resulting solution was stirred for 3 h, quenched with 3 
mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (40:1 
CH2Cl2/Et2O) to yield 42 mg (73%) of a 4.9:1 mixture of 114c/115c as a white solid. 
After repeated chromatography on SiO2 a pure sample of 114c was isolated: Mp 92.5-
96.6 oC, [?]D25 53 (c 0.52, CHCl3); IR (KBr) 3318, 2953, 2867, 1722, 1437, 1304, 1125 
cm-1; 1H NMR ? 7.30-7.10 (m 5 H), 5.06 (d, 1 H, J = 9.6 Hz), 4.14 (dd, 1 H, J = 8.1, 5.8 
Hz), 3.93 (d, 1 H, J = 9.2 Hz), 3.63 (s, 3 H), 3.25 (ddd, 1 H, J = 14.9, 8.3, 6.5 Hz), 3.01 
(dd, 1 H, J = 13.5, 5.7 Hz), 2.87 (dd, 1 H, J = 13.5, 7.9 Hz), 1.74 (d, 3 H, J = 1.3 Hz), 
1.49-1.41 (m, 2 H), 1.35-1.07 (m, 1 H), 1.28 (s, 9 H), 0.81 (d, 3 H, J = 6.5 Hz),  0.75 (d, 
3 H, J = 6.4 Hz); 13C NMR ? 174.7, 137.1, 136.4, 129.82, 128.7, 127.0, 126.9, 62.9, 60.0, 
51.9, 42.9, 42.0, 41.6, 26.0, 24.4, 23.1, 22.2, 13.7; MS (ES) m/z (rel intensity) 432.3 
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([M+23Na]+, 100), 313.3 (5), 312.3 (17), 273.3 (6), 24.3 (5); HRMS (ES) Calcd for 
C22H35NO4NaS (M+
23Na) 432.2185, found 432.2187. 
 
Characteristic signals for 115c: 1H NMR ? 5.26 (d, 1 H, J = 10 Hz), 4.58 (q, 1 H, J = 8.4 
Hz), 3.62 (s, 3 H), 1.76 (d, 3 H, J = 1.2 Hz), 1.27 (s, 9 H). 
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4-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-(2S)-phenethyl-6-phenylhex-3-
(E)-enoic acid methyl ester (114d). To a solution of 50 mg (0.14 mmol) of CuCN in 5.5 
mL of THF was added at –78 oC 0.56 mL (0.56 mmol) of a 1 M solution of phenethyl 
magnesium chloride in THF.  The resulting mixture was stirred for 10 min, warmed to 0 
oC, stirred for 15 min and cooled to –20 oC.  A solution of 50 mg (0.14 mmol) of 108 in 
0.6 mL of THF was added. The resulting solution was stirred for 3 h, quenched with 4 
mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (10-30% 
EtOAc/Hexanes) to yield 39 mg (61%) of a 3:1 mixture of 114d/115d as a colorless oil. 
After repeated chromatography on SiO2 a pure sample of 114d was isolated: [?]D25 32 (c 
0.73, CHCl3); IR (neat) 3054, 2986, 1731, 1421, 1265, 1127 cm
-1; 1H NMR ? 7.32-7.02 
(m, 10 H), 5.17 (d, 1 H, J = 1.0 Hz), 4.20-4.10 (m, 1 H), 4.05 (d, 1 H, J = 9.5 Hz), 3.63 
(s, 3 H), 3.23-3.13 (m, 1 H), 2.99 (dd, 1 H, J = 13.5, 5.8 Hz), 2.89 (dd, 1 H, J = 13.6, 7.3 
Hz), 2.46-2.25 (m, 2 H), 2.04-1.88 (m, 1 H), 1.75-1.60 (m, 1 H), 1.69 (s, 3 H), 1.28 (s, 9 
H); 13C NMR ? 174.3, 141.6, 137.5, 137.0, 129.9, 128.8, 128.6, 127.2, 126.2, 126.0, 62.8, 
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601, 51.9, 44.1, 41.8, 34.1, 33.1, 24.4, 14.1; MS (ES) m/z (rel intensity) 480.6 
([M+23Na]+, 100), 360.5 (12), 338.5 (7), 321.4 (15), 290.4 (5), 289.4 (15), 261.4 (9), 
183.3 (5); HRMS (ES) Calcd for C26H35NO4NaS (M+
23Na) 480.2185, found 480.2173. 
 
Characteristic signals for 115d: 1H NMR ? 5.28 (d, 1 H, J = 11.1 Hz), 4.56 (q, 1 H, J = 
8.8 Hz), 1.79 (d, 3 H, J = 1.2 Hz). 
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2-Benzyl-4-methyl-5-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic 
acid methyl ester (114e).   A solution of 24 mg (0.56 mmol) of flame-dried LiCl in 1.0 
mL of THF was stirred for 15 min and cooled to 0 oC.  To this solution was added 0.56 
mL (0.28mmol) of a 0.5 M solution of ZnCl2 in toluene and 0.14 mL (0.28 mmol) of a 2 
M solution of BnMgCl in THF. The resulting mixture was stirred for 30 min and 25 mg 
(0.28 mmol) of CuCN was added in one portion. The resulting solution was stirred for 30 
min and added to a solution of 10 mg (0.028 mmol) of 108 in 0.40 mL of THF cooled to 
0 oC.  The reaction mixture was stirred for 7 h, warmed to room temperature overnight, 
quenched with 1 mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), 
dried (MgSO4) and concentrated in vacuo.  The residue was purified by chromatography 
on SiO2 (30% EtOAc/Hexane) to yield 10 mg (81%) of 114e as a pale yellow oil: [?]D25 
4.6 (c 0.50, CHCl3); IR (neat) 3019, 2400, 1731, 1521, 1422, 1215, 1127, 983, 769 cm
-1;  
1H NMR ? 7.31-7.14 (m, 6 H), 7.09 (t, 4 H, J = 6.5 Hz), 5.22 (d, 1 H, J = 9.7 Hz), 4.08 
(ddd, 1 H, J = 9.4, 5.6, 3.9 Hz), 3.99-3.78 (m, 1 H), 3.61 (s, 3 H), 3.52 (ddd, 1 H, J = 8.7, 
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5.9, 4.5 Hz), 2.98 (dd, 1 H, J = 13.7,  7.2 Hz), 2.86 (d, 2 H, J = 6.21 Hz), 2.63 (dd, 1 H, J 
= 13.7, 7.6 Hz), 1.61 (d, 3 H, J = 2.3 Hz), 1.22 (s, 9 H); 13C NMR ? 173.8, 138.9, 137.8, 
136.8, 130.0, 129.3, 128.7, 127.2, 126.7, 125.0, 62.4, 60.1, 52.0, 46.8, 41.9, 38.7, 24.3, 
14.3; MS (ES) m/z (rel intensity) 466.3 (M+23Na+, 100); HRMS (ES) Calcd for 
C25H33NO4NaS (M+
23Na) 466.2028, found 466.2041. 
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4-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
 methyl ester (114f).  A solution of 61 mg (1.5 mmol) of flame-dried LiCl in 11 mL of 
THF was stirred for 15 min and cooled to –78 oC.  To this solution was added 0.24 mL 
(0.73 mmol) of a 3 M solution of PhMgBr in Et2O and 66 mg (0.73 mmol) of CuCN. The 
resulting mixture was stirred for 30 min.  A solution of 90 mg (0.28 mmol) of 108 in 1 
mL of THF was added dropwise.  The reaction mixture was stirred for 3 h, quenched with 
5 mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and 
concentrated in vacuo.  The resulting residue was purified by chromatography on SiO2 
(30% EtOAc/Hexane) to yield 75 mg (82%) of 114f as a brown paste: [?]D25 0.54 (c 1.0, 
CHCl3); IR (KBr) 3301, 2951, 1738, 1434, 1299, 1126, 946 cm
-1; 1H NMR ? 7.30-7.12 
(m, 5 H), 5.42 (t, 1 H, J = 7.1 Hz), 4.25-3.95 (m, 2 H), 3.65 (s, 3 H), 3.05 (d, 2 H, J = 7.1 
Hz), 1.71 (s, 3 H), 1.24 (s, 9 H); 13C NMR ? 172.1, 138.0, 137.1, 129.9, 128.7, 127.1, 
119.3, 62.7, 60.2, 52.0, 42.0, 33.6, 24.3, 14.0; MS (ES) m/z (rel intensity) 376.16 
([M+23Na]+, 100), 257.1 (3), 256.1 (20); HRMS (ES) Calcd for C18H27NO4NaS (M+
23Na) 
376.1559, found 376.1557. 
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2-Methylpropane-2-sulfonic acid ((1S)-benzyl-5-hydroxy-(2S),4-dimethyl-pent-2-
enyl)-amide (116). A solution of 76 mg (0.90 mmol) of flame-dried LiCl in 9 mL of THF 
was stirred for 15 min, cooled to 0 oC, and treated 0.45 mL (0.90 mmol) of a 2 M solution 
of Me2Zn in toluene.  The resulting solution was stirred for 15 min, cooled to –78 
oC, and 
80 mg (0.90 mmol) of CuCN was added in one portion. The resulting solution was stirred 
for 30 min, warmed to –20 oC, and an aliquot of 3.0 mL was added to a solution of 37 mg  
(0.10 mmol) of 108 in 2 mL of THF cooled to –20 oC.  The reaction mixture was stirred 
for 2 h, quenched with 3 mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc 
(3x), dried (MgSO4) and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (30% EtOAc/Hexanes) to yield 28 mg (77%) of a 12:1 mixture 
of 114a/115a as a colorless oil. To a solution of 27 mg (0.070 mmol) of this mixture in 1 
mL of CH2Cl2 was added at 0 
oC 0.22 mL (0.22 mmol) of 1 M DiBAL in hexanes.  The 
reaction mixture was stirred for 30 min, quenched with 2 mL of a saturated aqueous 
solution of NH4Cl, extracted with CH2Cl2 (3x), dried (Na2SO4), and concentrated in 
vacuo.  The residue was purified by chromatography on Si2O (30-50% EtOAc/Hexane) to 
yield 11 mg (67%) of 116 as a white solid: Mp 128.7-131.5 oC; [?]D25 –1.0 (c 0.38, 
CHCl3); IR (KBr) 3434, 3140, 2929, 1460, 1367, 1290, 1122, 1058, 1012 cm
-1; 1H NMR 
? 7.34-7.18 (m, 5 H), 4.95 (d, 1 H, J = 9.8 Hz), 4.19-3.95 (m 2 H), 3.48 (dd, 1 H, J = 
10.7, 5.3 Hz), 3.26 (dd, 1 H, J = 10.6, 8.7 Hz), 2.89 (d, 2 H, J = 6.3 Hz), 2.72-2.52 (m, 1 
H), 1.77 (s, 3 H), 1.21 (s, 9 H), 0.82 (d, 3 H, J = 6.6 Hz); 13C NMR ? 137.1, 136.1, 131.2, 
129.4, 128.6, 127.0, 67.8, 63.8, 60.1, 53.4, 41.0, 35.3, 24.0, 16.3, 12.8; MS (EI) m/z (rel 
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intensity) 248 ([M-C7H7]
+, 22), 240 (10), 172 (26), 157 (18), 143 (13), 129 (11), 128 (86), 
120 (7), 110 (14); HRMS (EI) Calcd for C11H22NO3S (M-C7H7) 248.1320, found 
248.1312. 
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2-[(2S),4-Dimethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-
enoylamino]-3-phenylpropionic acid methyl ester (117a).  A solution of 25 mg (0.60 
mmol) of flame dried LiCl in 4 mL of THF was stirred for 15 min, cooled to 0 oC, and 
treated with 0.15 mL (0.30 mmol) of a 2 M solution of Me2Zn in toluene.  The resulting 
solution was stirred for 15 min, cooled to –78 oC, and treated with 27 mg (0.30mmol) of 
CuCN in one portion.  The resulting solution was stirred for 30 min and warmed to –20 
oC.  A solution of 50 mg (0.10mmol) of 110 in 0.30 mL of THF was added.  The reaction 
mixture was stirred for 3 h, quenched with 2 mL of a 1:1 solution of NH4Cl/NH4OH, 
extracted with EtOAc (3x), dried (MgSO4) and concentrated in vacuo.  The residue was 
purified by chromatography on SiO2 (10-50% EtOAc/Hexane) to yield 52 mg (100%) of 
a 9:1 mixture of 117a/118a as a colorless oil. After repeated chromatography on SiO2 a 
pure sample of 117a was isolated:  [?]D25 1.4 (c 0.71, CHCl3); IR (neat) 3347, 2931, 
1748, 1648, 1522, 1455, 1300, 1125, 750 cm-1; 1H NMR ? 7.48-7.04 (m 10 H), 6.67 (d, 1 
H, J = 8.2 Hz), 5.27 (d, 1 H, J = 9.4 Hz), 4.79 (dd, 1 H, J = 8.6, 5.5 Hz), 4.07 (dd, 1 H, J 
= 8.3, 6.0 Hz), 3.96 (d, 1 H, J = 8.0 Hz), 3.69 (s, 3 H), 3.18 (dd, 1 H, J = 13.9, 5.9 Hz), 
3.09-2.93 (m, 2 H), 2.84 (dd, 1 H, J = 13.5, 5.9 Hz), 2.77 (dd, 1 H, J = 13.5, 8.5 Hz), 
1.61 (d, 3 H, J = 1.2 Hz), 1.16 (s, 9 H), 1.12 (d, 3 H, J = 7.0 Hz); 13C NMR ? 173.5, 
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172.3, 138.5, 137.1, 136.9, 129.3, 129.2, 128.3, 127.6, 127.0, 126.6, 64.9, 60.4, 53.6, 
52.0, 41.0, 39.1, 37.2, 24.0, 17.1, 11.6; MS (ES) m/z (rel intensity) 537..2 
([M+23Na]+,100), 515.3 (8), 379.2 (8), 378.2 (18); HRMS (ES) Calcd for C28H38N2O5NaS 
(M+23Na) 537.2365, found 537.2378. 
 
Characteristic signals for 118a: 1H NMR ? 5.19 (d, 1 H, J = 9.2 Hz), 3.70 (s, 3 H), 1.74 
(s, 3 H), 1.15 (s, 9 H).  
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2-[(2R)-Isopropyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-
(E)-enoylamino]-3-phenyl-(S)-propionic acid methyl ester (117b).  To a solution of 36 
mg (0.40 mmol) of CuCN in 4 mL of THF cooled to –78 oC was added 0.20 mL (0.40 
mmol) of a 2 M solution of i-propyl magnesium chloride in THF.  The resulting solution 
was stirred for 10 min, warmed to 0 oC, stirred for 15 min and cooled to –20 oC.  A 
solution of 50 mg (0.10 mmol) of 110 in 0.30 mL of THF was added. The reaction 
mixture was stirred for 3 h, quenched with 2 mL of a 1:1 solution of NH4Cl/NH4OH, 
extracted with EtOAc (3x), dried (MgSO4) and concentrated in vacuo.  The residue was 
purified by chromatography on SiO2 (10-50% EtOAc/Hexane) to yield 46 mg (84%) of a 
3:1 mixture of 117b/118b as a colorless oil. After repeated chromatography on SiO2 a 
pure sample of 117b was isolated: [?]D25 4.1 (c 1.2, CHCl3); IR (neat); 1H NMR ? 7.60-
7.01 (m, 10 H), 6.49 (d, 1 H, J = 7.4 Hz), 5.33 (d, 1 H, J = 9.9 Hz), 4.82 (dd, 1 H, J = 
7.9, 6.9 Hz), 4.15-3.96 (m, 2 H), 3.68 (s, 3 H), 3.16 (dd, 1 H, J = 14.0, 5.9 Hz), 3.01 (dd, 
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1 H, J = 13.9, 8.3 Hz), 2.87-2.76 (m, 3 H), 2.28-2.18 (m, 1 H), 1.60 (s, 3 H), 1.21 (s, 9 
H), 0.72 (d, 3 H, J = 6.8 Hz), 0.68 (d, 3 H, J = 6.8 Hz); 13C NMR ? 172.6, 172.3, 139.8, 
137.0, 136.8, 129.3, 129.2, 128.7, 128.3, 127.0, 126.7, 123.7, 64.7, 60.2, 53.4, 52.0, 51.5, 
41.1, 37.5, 29.8, 24.0, 20.6, 18.0, 12.2; MS (ES) m/z (rel intensity) 565.3 ([M+23Na]+, 
100), 543.3 (8), 407.3 (8), 406.2 (20); HRMS (ES) Calcd for C30H42N2O5NaS  (M+
23Na) 
565.2736, found 565.2726. 
 
Characteristic signals for 118b: 1H NMR ? 6.55 (d, 1 H, J = 8.3 Hz), 5.28 (d, 1 H, J = 9.5 
Hz), 3.70 (s, 3 H), 1.71 (s, 3 H), 1.21 (s, 9 H), 0.50 (d, 3 H, J = 6.8 Hz). 
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2-[4-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-(2S)-phenethyl-6-phenylhex-3-
(E)-enoylamino]-3-phenyl-(S)-propionic acid methyl ester (117d).  To a solution of 36 
mg (0.40 mmol) of CuCN in 4 mL of THF cooled to –78 oC was added 0.40 mL of a 1 M 
solution of i-butyl magnesium chloride in THF.  The resulting solution was stirred for 10 
min, warmed to 0 oC, stirred for 15 min and cooled to –20 oC.  A solution of 50 mg (0.10 
mmol) of 110 in 0.30 mL of THF was added. The reaction mixture was stirred for 3 h, 
quenched with 2 mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), 
dried (MgSO4) and concentrated in vacuo.  The residue was purified by chromatography 
on SiO2 (10-50% EtOAc/Hexanes) to yield 40 mg (67%) of a 7:1 mixture of 117d/118d 
as a white foam. After repeated chromatography on SiO2 a pure sample of 117d was 
isolated: [?]D25 12 (c 0.46 CHCl3); IR (KBr) 3344, 3027, 2928, 1747, 1648, 1521, 1496, 
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1455, 1300, 1212, 1126, 1058, 942 cm-1; 1H NMR ? 7.51-7.11 (m, 13 H), 7.05 (d, 2 H), 
6.67 (d, 1 H, J = 8.0 Hz), 5.30 (d, 1 H, J = 9.7 Hz), 4.80 (dd, 1 H, J = 8.2, 6.1 Hz), 4.0-
4.05 (m, 2 H), 3.68 (s, 3 H), 3.18 (dd, 1 H, J = 13.9, 5.7 Hz), 3.00 (dd, 1 H, J =  13.9, 8.7 
Hz), 2.91 (dt, 1 H, J = 9.7, 4.1 Hz), 2.82 (d, 2 H, J = 6.3 Hz), 2.43-2.10 (m, 2 H), 1.83-
1.57 (m, 2 H), 1.55 (s, 3 H), 1.21 (s, 9 H); 13C NMR ? 172.7, 172.2, 141.6, 139.8, 137.0, 
129.2, 128.2, 127.1, 126.7, 126.4, 125.8, 64.8, 60.3, 53.5, 52.1, 44.3, 40.9, 37.3, 33.2, 
33.0, 24.0, 11.9; MS (ES) m/z (rel intensity) 627.3 ([M+23Na]+, 100), 605.3 (11), 469.3 
(9), 468.3 (13); HRMS (ES) Calcd for C35H44N2O5NaS (M+
23Na) 627.2869, found 
627.2878. 
 
Characteristic signals for 118d: 1H NMR ? 6.60 (d, 1 H, J = 7.5 Hz), 5.25 (d, 1 H, J = 
10.4 Hz), 3.69 (s, 3 H), 1.82 (d, 3 H, J = 1.2 Hz). 
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2-[(2R)-Isobutyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-
(Z)-enoylamino]-3-phenyl-(S)-propionic acid methyl ester (108c). To a solution of 36 
mg (0.40 mmol) of CuCN in 4 mL of THF was added at –78 oC 0.20 mL (0.40 mmol) of 
a 2 M solution of i-butyl magnesium chloride in THF.  The resulting solution was stirred 
for 10 min, warmed to 0 oC, stirred for 15 min and cooled to –20 oC.   A solution of 50 
mg (0.10mmol) of 110 in 0.30 mL of THF was added. The reaction mixture was stirred 
for 3 h, quenched with 2 mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc 
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(3x), dried (MgSO4) and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (10-50% EtOAc/Hexanes) to yield 40 mg (66%) of a 3:1 
mixture of 118c/117c as a colorless solid:  Mp 138.7-139.9 oC; [?]D25 –64 (c 0.85, 
CHCl3); IR (KBr) 3375, 3332, 3200, 3063, 3030, 2952, 2869, 1757, 1735, 1673, 1650, 
1559, 1527, 1496, 1455, 1364, 1297 cm-1; 1H NMR ? 7.50-7.10 (m, 10 H), 7.05 (d, 1 H, J 
= 7.8 Hz), 4.93 (d, 1 H, J = 10.6 Hz), 4.74 (dd, 1 H, J = 8.8, 5.8 Hz),  4.52 (q, 1 H, J = 
7.8 Hz), 4.21 (d, 1 H, J = 8.6 Hz), 3.66 (s, 3 H), 3.31 (ddd, 1 H, J = 14.4, 7.9, 6.5 Hz), 
3.12 (dd, 1 H, J = 13.7, 5.7 Hz), 2.93 (dd, 1 H, J = 13.7, 9.1 Hz), 2.81 (bd, 2 H, J = 7.4 
Hz), 1.82 (d, 3 H, J = 1.0 Hz), 1.75-1.65 (m, 1 H), 1.60-1.35 (m, 1 H), 1.17 (s, 9 H), 0.86 
(d, 6 H, J = 6.5 Hz), 0.75-0.58 (m, 1 H); 13C NMR ? 172.9, 172.3, 137.1, 136.8, 135.2, 
129.4, 128.8, 128.5, 128.2, 127.1, 126.5, 60.3, 56.8, 53.8, 51.8, 42.8, 40.7, 40.3, 37.8, 
25.6, 23.8, 22.4, 17.8; MS (ES) m/z (rel intensity) 579.3 ([M+23Na]+, 100); HRMS (ES) 
Calcd for C31H44N2O5NaS (M+
23Na) 579.2869, found 579.2848. 
 
Characteristic signals for 117c: 1H NMR ? 6.65 (d, 1 H, J = 8.5 Hz), 5.17 (d, 1 H, J = 9.7 
Hz), 3.68 (s, 3 H), 0.78 (d, 3 H, J = 6.6 Hz), 0.68 (d, 3 H, J = 6.5 Hz). 
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(2R)-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
methyl ester (119a).  A solution of 23 mg (0.54 mmol) of flame-dried LiCl in 3 mL of 
THF was stirred for 15 min, cooled to 0 oC, and treated with 0.14 mL (0.27 mmol) of a 2 
M solution of Me2Zn in toluene.  The resulting solution was stirred for 15 min, cooled to 
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–78 oC, and 24 mg (0.27 mmol) of CuCN was added in one portion. The resulting 
solution was stirred for 30 min and warmed to –20 oC.  A solution of 30 mg (0.090 
mmol) of 111 in 0.30 mL of THF was added.  The reaction mixture was stirred for 3 h, 
quenched with 2 mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), 
dried (MgSO4) and concentrated in vacuo.  The residue was purified by chromatography 
on SiO2 (30% EtOAc/Hexanes) to yield 31 mg (100%) of 119a as a colorless oil: [?]D25 –
21 (c 1.4, CHCl3); IR (neat) 2978, 1736, 1644, 1496, 1455, 1395, 1365, 1305, 1169, 
1127, 1049, 969, 750 cm-1; 1H NMR ? 7.35-7.10 (m, 5 H), 5.66 (ddd, 1 H, J = 15.6, 5.2, 
1.0 Hz), 5.54 (dd, 1 H, J = 15.6, 5.7 Hz), 4.26-4.17 (m, 1 H), 3.81 (d, 1 H, J = 9.7 Hz), 
3.67 (s, 3 H), 3.14 (p, 1 H, J = 7.0 Hz), 2.94 (d, 2 H, J = 6.2 Hz), 1.29 (s, 9 H), 1.23 (d, 3 
H, J = 7.1 Hz); 13C NMR ? 174.6, 136.3, 131.5, 130.4, 130.0, 128.4, 126.9, 59.9, 57.1, 
51.8, 43.3, 42.3, 24.0, 17.1; MS (ES) m/z (rel intensity) 376.0 ([M+23Na]+, 100), 362.5 
(5), 257.1 (5), 256.1 (45), 240.1 (5); HRMS (ES) Calcd for C18H27NO4NaS (M+
23Na) 
376.1559, found 376.1571. 
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(2S)-Isopropyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic 
acid methyl ester (119b). To a solution of 32 mg (0.36 mmol) of CuCN in 3 mL of THF 
was added at –78 oC 0.18 mL (0.36 mmol) of a 2 M solution of i-propyl magnesium 
chloride in THF.  The resulting solution was stirred for 10 min, warmed to 0 oC, stirred 
for 15 min and cooled to –20 oC.   A solution of 30 mg (0.090 mmol) of 111 in 0.30 mL 
of THF was added. The reaction mixture was stirred for 3 h, quenched with 2 mL of a 1:1 
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solution of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and concentrated 
in vacuo.  The residue was purified by reverse phase HPLC (50% acetonitrile/H2O, 4 
mL/min) to yield 24 mg (72%) of 119b as a colorless oil: [?]D25 -35 (c 0.56, CHCl3); IR 
(neat) 3373, 3271, 3020, 2873, 1729, 1496, 1479, 1454, 1435, 1395, 1367, 1311, 1215, 
1136, 1126, 750 cm-1; 1H NMR ? 7.40-7.00 (m, 5 H), 5.58 (dd, 1 H, J = 15.5, 8.2 Hz), 
5.50 (dd, 1 H, J = 15.4, 5.7 Hz), 4.21 (dt, 1 H, J = 11.4, 5.9 Hz), 3.78 (d, 1 H, J = 11.2 
Hz), 3.65 (s, 3 H), 2.93 (bd, 2 H, J = 6.4 Hz), 2.68 (t, 1 H, J = 8.3 Hz), 1.95 (dq, 1 H, J = 
14.2, 6.7 Hz), 1.28 (s, 9 H), 0.87 (d, 3 H, J = 6.6 Hz), 0.81 (d, 3 H, J = 6.7 Hz); 13C NMR 
? 173.9, 136.3, 133.3, 130.0, 128.6, 128.5, 126.8, 60.0, 57.4, 56.5, 43.3, 30.9, 24.0, 20.7, 
19.7; MS (ES) m/z (rel intensity) 404.1 ([M+23Na]+, 100), 285.2 (11), 284.1 (72); HRMS 
(ES) Calcd for C20H31NO4NaS (M+
23Na) 404.1872, found 404.1853. 
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(2R)-Isobutyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid 
methyl ester (119c). To a solution of 32 mg (0.36 mmol) of CuCN in 3 mL of THF was 
added at –78 oC 0.18 mL (0.36 mmol) of a 2 M solution of i-butyl magnesium chloride in 
THF.  The resulting mixture was stirred for 10 min at –78 oC, warmed to 0 oC, stirred for 
15 min and cooled to –20 oC.  A solution of 30 mg (0.090 mmol) of 111 in 0.30 mL of 
THF was added. The reaction mixture was stirred for 3 h, quenched with 2 mL of a 1:1 
solution of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and concentrated 
in vacuo.  The residue was purified by reverse phase HPLC (50% acetonitrile/H2O, 4 
mL/min) to yield 33 mg (95%) of 119c as a colorless oil:  [?]D25 –38 (c 0.26, CHCl3); IR 
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(neat) 3019, 1731, 1315, 1215, 1126 cm-1; 1H NMR ? 7.42-7.16 (m, 5 H), 5.85-5.49 (m, 2 
H), 4.29-4.17 (m, 1 H), 3.76 (d, 1 H, J = 9.9 Hz), 3.66 (s, 3 H), 3.13-3.05 (m, 1 H), 2.96 
(dd, 1 H, J = 13.7, 5.9 Hz), 2.94 (dd, 1 H, J = 13.1, 6.4 Hz), 1.60-1.54 (m, 1 H), 1.51-
1.43 (m, 1 H), 1.42-1.35 (m, 1 H), 1.30 (s, 9 H), 0.88 (d, 3 H, J = 6.6 Hz), 0.86 (d, 3 H, J 
= 6.5 Hz); 13C NMR ? 174.4, 136.2, 132.3, 130.0, 129.6, 128.4, 126.9, 60.0, 57.1, 51.7, 
46.8, 43.3, 41.2, 25.5, 24.0, 22.7, 21.9; MS (ES) m/z (rel intensity) 418.2 ([M+23Na]+, 
100), 299.2 (12), 298.2 (67); HRMS (ES) Calcd for C21H33NO4NaS (M+
23Na) 418.2028, 
found 418.2029. 
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(5S)-(2-Methylpropane-2-sulfonylamino)-(2R)-phenethyl-6-phenylhex-3-(E)-enoic 
acid methyl ester (119d). To a solution of 32 mg (0.36 mmol) of CuCN in 3 mL of THF 
was added at –78 oC 0.36 mL (0.36 mmol) of a 1 M solution of phenethyl magnesium 
chloride in Et2O.  The resulting mixture was stirred for 10 min, warmed to 0 
oC, stirred 
for 15 min and cooled to –20 oC.  A solution of 30 mg (0.090 mmol) of 111 in 0.30 mL of 
THF was added. The reaction mixture was stirred for 3 h, quenched with 2 mL of a 1:1 
solution of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and concentrated 
in vacuo.  The residue was purified by reverse phase HPLC (50% acetonitrile/H2O, 4 
mL/min) to yield 31 mg (79%) of 119d as a colorless oil:  [?]D25 –34 (c  0.27, CHCl3); IR 
(neat) 3019, 1731, 1216, 758 cm-1; 1H NMR ? 7.45-7.08 (m, 10 H), 5.60 (d of AB, 1 H, J 
= 15.5, 8.2 Hz), 5.56 (d of AB, 1 H, J = 15.4, 5.4 Hz), 4.24 (dq, 1 H, J = 5.8, 2.8 Hz), 
3.76 (d, 1 H, J = 9.9 Hz), 3.66 (s, 3 H), 3.03 (q, 1 H, J = 3.5 Hz), 2.95 (d of AB, 1 H, J = 
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6.2, 2.9 Hz), 2.93 (d of AB, 1 H, J = 6.7, 3.3 Hz), 2.65-2.47 (m, 2 H), 2.07 (ddd, 1 H, J = 
6.7, 4.7, 3.3 Hz), 1.81 (dddd, 1 H, J = 8.5, 4.6, 3.9, 3.1 Hz), 1.29 (s, 9 H); 13C NMR ? 
179.9, 141.1, 136.2, 133.0, 130.0, 129.0, 128.5, 128.4, 128.4, 126.9, 126.0, 60.0, 57.3, 
51.8, 48.0, 43.2, 33.7, 33.1, 24.0; MS (ES) m/z (rel intensity) 466.20 ([M+23Na]+, 100), 
347.19 (12), 346.18 (52); HRMS (ES) Calcd  for C25H33NO4NaS (M+
23Na) 466.2028, 
found 466.2018. 
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2-[2-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoyl 
amino]-3-phenyl-(S)-propionic acid methyl ester (120).  A solution 5.0 mg (0.12 
mmol) of flame dried LiCl in 1 mL of THF was stirred for 15 min, cooled to 0 oC, and 
treated with 0.030 mL (0.060 mmol) of a 2 M solution of Me2Zn in toluene.  The 
resulting solution was stirred for 15 min, cooled to –78 oC, and 6.0 mg (0.060 mmol) of 
CuCN was added in one portion.  The resulting solution was stirred for 30 min and 
warmed to –20 oC.  A solution of 10 mg (0.020 mmol) of 113 in 0.10 mL of THF was 
added.  The reaction mixture was stirred for 3 h, quenched with 1.0 mL of a 1:1 solution 
of NH4Cl/NH4OH, extracted with EtOAc (3x), dried (MgSO4) and concentrated in vacuo.  
The residue was purified by chromatography on SiO2 (50% EtOAc/Hexane) to yield 6.3 
mg (61%) of 120 as a colorless oil: [?]D25 0.96 (c 0.28, CHCl3); IR (neat) 3290, 2928, 
1744, 1653, 1520, 1454, 1301, 1211, 1125 cm-1; 1H NMR ? 7.37-6.83 (m, 10 H), 6.14 (d, 
1 H, J = 7.9 Hz), 5.66 (d of AB, 1 H, J = 15.7, 6.4 Hz), 5.60 (d of AB, 1 H, J = 15.3, 4.9 
Hz), 4.81 (ddd, 1 H, J = 7.3, 6.9, 6.0 Hz), 4.24-4.11 (m, 1 H), 3.75 (d, 1 H, J =  9.6 Hz), 
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3.72 (s, 3 H), 3.15 (dd, 1 H, J = 13.8, 5.9 Hz), 3.07-2.87 (m, 3 H), 2.81 (dd, 1 H, J = 
13.5, 6.8 Hz), 1.24 (s, 9 H), 1.17 (d, 3 H, J = 7.1 Hz); 13C NMR ? 173.3, 172.1, 136.5, 
136.2, 133.2, 130.8, 129.8, 129.3, 128.6, 128.4, 127.0, 126.97, 60.0, 57.7, 53.2, 52.2, 
43.7, 42.7, 37.7, 24.0, 16.9; MS (ES) m/z (rel intensity) 523.2 ([M+23Na]+, 100); HRMS 
(ES) Calcd for C27H36N2O5NaS (M+
23Na) 523.2243, found 523.2219. 
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3-[(3S)-Benzyl-(2S)-methyl-1-(2-methylpropane-2-sulfonyl)-aziridin-2-yl]-(E)-acrylic 
acid methyl ester (121). To a solution of 0.10 g (0.31 mmol) of 104 in 2 mL of CH2Cl2 
at –78 oC was added 0.62 mL (0.62 mmol) of a 1 M solution of DiBAL in hexanes.  The 
reaction mixture was stirred for 30 min, quenched with 2 mL of cold (-78 oC) MeOH, 
warmed to rt, treated with 2 mL of a saturated aqueous solution of NH4Cl, extracted with 
CH2Cl2 (3x), dried (Na2SO4), and concentrated in vacuo.  The resulting aldehyde was 
washed with benzene, concentrated in vacuo (3x) and dried under high vacuum.  To a 
solution of 0.13 g (0.62 mmol) of methyl diethylphosphonoacetate in 0.5 mL Et2O at 0 
oC 
was added 0.39 mL (0.62 mmol) of a 1.6 M solution of n-BuLi in hexanes.  The ice bath 
was removed and the reaction mixture was warmed to room temperature, stirred for 1 h 
and cooled again to 0 oC.  A solution of the aldehyde in 0.5 mL of a 1:1 solution of 
THF/Et2O was added dropwise.  The reaction mixture was stirred for 3 h, quenched with 
2 mL of a saturated aqueous solution of NH4Cl, extracted with EtOAc (3x), dried 
(Na2SO4) and concentrated in vacuo.  The residue was purified by chromatography on 
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SiO2 (20-30%EtOAc/Hexane) to yield 76 mg (69%) of 121 as a pale yellow oil: [?]D25 –
57 (c 0.61, CH2Cl2); IR (neat) 3054, 2986, 1722, 1650, 1421, 1308, 1265, 1127 cm
-1; 1H 
NMR (Acetone-d6) ? 7.43-7.17 (m, 5 H), 6.94 (d, 1 H, J = 15.5 Hz), 6.18 (d, 1 H, J = 
15.5 Hz), 3.77 (s, 3 H), 3.24 (dd, 1 H, J = 8.5, 5.0 Hz), 3.08 (dd 1 H, J = 14.8, 5.0 Hz), 
2.77 (dd, 1 H, J = 14.8, 8.5 Hz), 1.82 (s, 3 H), 1.44 (s, 9 H); 13C NMR (Acetone-d6) ? 
165.7, 145.5, 137.5, 128.9, 127.0, 124.1, 60.0, 54.3, 51.3, 51.0, 34.0, 23.6, 18.6; MS (ES) 
m/z (rel intensity) 374.4 ([M+23Na]+, 100), 254.3 (23), 232.3 (21), 200.3 (7); HRMS (ES) 
Calcd for C18H25NO4SNa (M+
23Na) 374.1402, found 374.1412. 
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(2R)-4-Dimethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic 
acid methyl ester (122a).  A solution of 18 mg (0.42 mmol) of flame dried LiCl in 3 mL 
of THF was stirred for 15 min, cooled to 0 oC, and 0.21 mL (0.42 mmol) of a 2 M 
solution of Me2Zn in toluene was added.  The resulting solution was stirred for 15 min, 
cooled to –78 oC, and 19 mg (0.21 mmol) of CuCN was added in one portion.  The 
resulting solution was stirred for 30 min and warmed to –20 oC.  A solution of 25 mg 
(0.071 mmol) of 121 in 0.30 mL of THF was added.  The reaction mixture was stirred for 
3 h, quenched with 2 mL of a 1:1 solution of NH4Cl/NH4OH, extracted with EtOAc (3x), 
dried (MgSO4) and concentrated in vacuo.  The residue was purified by chromatography 
on SiO2 (30% EtOAc/Hexanes) to yield 25 mg (97%) of 122a as a colorless oil: [?]D25 –
18 (c 1.2, CHCl3); IR (neat) 2981, 1736, 1454, 1305, 1127, 942 cm
-1; 1H NMR ? 7.37-
7.07 (m, 5 H), 5.19 (d, 1 H, J = 9.4 Hz), 4.18-4.00 (m, 2 H), 3.60 (s, 3 H), 3.32 (dq, 1 H, 
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J = 14.0, 9.2 Hz),  2.94 (dd, 1 H, J = 13.5, 5.9 Hz), 2.90 (dd, 1 H, J = 13.8, 6.7 Hz), 1.73 
(d, 3 H, J = 1.0 Hz), 1.26 (s, 9 H), 1.17 (d, 3 H, J = 6.9 Hz); 13C NMR ? 175.0, 136.6, 
135.7, 129.8, 128.5, 127.0, 126.9, 62.3, 59.9, 51.9, 41.7, 38.7, 24.1, 17.6, 13.5; MS (ES) 
m/z (rel intensity) 390.2 ([M+23Na]+, 100), 270.2 (18), 213.1 (9); HRMS (ES) Calcd for 
C19H29NO4NaS (M+
23Na) 390.1715, found 390.1708. 
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(2R)-Isobutyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-
enoic acid methyl ester (122b). To a solution of 25 mg (0.28 mmol) CuCN in 2.8 mL of 
THF was added at –78 oC 0.14 mL (0.28 mmol) of a 2 M solution of i-butyl magnesium 
chloride in THF.  The resulting solution was stirred for 10 min, warmed to 0 oC, stirred 
for 15 min and cooled to –20 oC.  A solution of 30 mg (0.072 mmol) of 121 in 0.3 mL of 
THF was added. The reaction mixture was stirred for 3 h, quenched with 2.0 mL of a 1:1 
solution of NH4Cl/NH4OH, and extracted with EtOAc (3x), dried (MgSO4) and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (10-30% 
EtOAc/Hexane) to yield 20 mg (70%) of 122b as a colorless oil: [?]D25 –28 (c 0.63, 
CHCl3); IR (neat) 3054, 2986, 1731, 1421, 1265, 1127, 983, 896 cm
-1; 1H NMR ? 7.34-
7.18 (m, 3 H), 7.17-7.11 (m, 2 H), 5.13 (d, 1 H, J = 9.7 Hz), 4.18-4.09 (m, 1 H), 4.05 (d, 
1 H, J = 9.5 Hz), 3.59 (s, 3 H), 3.31 (ddd, 1 H, J = 9.5, 7.6, 7.6 Hz)), 2.98 (dd, 1 H, J = 
13.5, 5.9 Hz), 2.91 (dd, 1 H,  J = 13.5, 6.9 Hz), 1.76 (s, 3 H), 1.60-1.49 (m, 1 H), 1.47-
1.31 (m, 2 H), 1.28 (s, 9 H), 0.89 (d, 3 H, J = 6.3 Hz), 0.86 (d, 3 H, J = 6.3 Hz); 13C 
NMR ? 174.4, 136.5, 136.1, 129.6, 128.4, 126.8, 126.1, 62.3, 59.8, 51.6, 42.6, 41.4, 25.6, 
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24.0, 22.7, 22.1, 13.6; MS (ES) m/z (rel intensity) 432.2 ([M+23Na]+, 89), 377.1 (8), 312.2 
(9), 213.2 (10); HRMS (ES) Calcd for C22H35NO4NaS (M+
23Na) 432.2185, found 
432.2160. 
 
General procedure for solid phase synthesis of compounds 132. To a 3 mL fritted 
reaction tube placed on the Mini-Bohdan reaction block loaded with 56 mg of Nova-
Biochem Fmoc Rink resin (loading: 0.62 mmol/g), was added 1 mL of a 2:8 solution of 
piperidine / DMF. The reaction block was shaken for 10 min. The solution was drained 
and the procedure was repeated.  The tube was washed with DMF (5 x 1 mL for 5 min). 
To the resin was added 1 mL of a solution of 0.072 mmol of Fmoc-amino acid, DEPBT 
(21.5 mg, 0.062 mmol), and DIPEA (12 μL, 0.062 mmol) in DMF. The reaction block 
was vigorously shaken for 3 h. The solution was drained, the resin was washed with 
DMF (5 x 1 mL for 5 minutes) and treated with 1 mL of a 2:8 solution of piperidine / 
DMF and was shook 10 min. The solution was drained and the procedure was repeated.  
The resin was washed with DMF (5 x 1 mL for 5 min), and 1.2 mL of a solution of 0.056 
mmol of aziridine 109 or 112, TFFH (18.5 mg, 0.072 mmol), and DIPEA (12 μL, 0.072 
mmol) in DMF was added. The reaction block was vigorously shaken for 3 h, and the 
solution was drained, the resin was washed with DMF (5 x 1 mL for 5 min), H2O (5 x 1 
mL for 5 min), DMF (5 x 1 mL for 5 min), MeOH (3 x 3 mL for 5 min), CH2Cl2 (3 x 3 
mL for 5 min) and dried under high vacuum for 12 h. To a solution of 17 mg (0.36 mmol) 
of LiCl in 1 mL of THF cooled to 0 oC was added R32Zn (0.20 mmol). The mixture was 
stirred for 10 min, cooled to -78 °C, treated with 18 mg (0.20 mmol) of CuCN and stirred 
for 30 min. The resulting solution was added to the resin at –20 oC.  The reaction block 
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was shaken for 3 h. The mixture was quenched with 1 mL of a 1:1 solution of NH4Cl / 
NH4OH, shaken for 30 min, and the solution was drained.  The resin was washed with a 
saturated aqueous solution of NH4Cl (5 x 1 mL for 5 min), H2O (5 x 1 mL for 5 min), 
MeOH (5 x 1 mL for 5 min), and CH2Cl2 (3 x 1 mL for 5 min) and dried under high 
vacuum for 12 h. The resulting resin was treated with 1.0 mL of a 3:7 solution of TFA / 
CH2Cl2 at room temperature, and shaken for 10 min. The reaction tube was drained and 
the solution was collected. This process was repeated and the combined CH2Cl2 layers 
were neutralized with 2 mL of a 10% aqueous solution of NH4OH, extracted with CH2Cl2 
(3x), dried (Na2SO4) and concentrated in vacuo. The residue was purified by 
chromatography on SiO2 (0-100% EtOAc/Hexane). 
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(2S),4-Dimethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic 
acid ((1S)-carbamoyl-2-phenylethyl)-amide (132a).  According to the general
 procedure, 24 mg of L-Fmoc-Phe-OH (0.062 mmol), 17 mg (0.050 mmol) of aziridine 
109 and 0.18 mL (0.36 mmol) of a 2 M solution of Me2Zn in toluene afforded 7.2 mg 
(40%) of 132a as a colorless oil:  [?]D25 –1.4 (c 0.28, CHCl3); IR (film) 3345, 3028, 2973, 
2929, 1654, 1497, 1478, 1455, 1292, 1122, 1057, 952, 752 cm-1;  1H NMR ? 7.35-7.07 
(m, 10 H), 6.72 (d, 1 H, J = 8.1 Hz), 6.32 (bs, 1 H), 5.39 (bs, 1 H), 5.23 (d, 1 H, J = 9.9 
Hz), 4.74-4.65 (m, 1 H), 4.26 (d, 1 H, J = 8.3 Hz), 4.03 (dd, 1 H, J = 8.7, 6.1 Hz), 3.26 
(dd, 1 H, J = 14.3, 5.6 Hz), 3.05-2.92 (m, 2 H), 2.87-2.72 (m, 2 H), 1.57 (d, 3 H, J = 1.1 
Hz), 1.14 (s, 9 H), 1.12 (d, 3 H, J = 7.1 Hz) ; 13C NMR ? 173.9, 138.6, 137.5, 137.0, 
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129.2, 128.7, 128.4, 128.0, 127.1, 126.6, 65.3, 60.5, 54.8, 40.5, 39.0, 38.5, 36.8, 23.9, 
16.7, 11.1; MS (ES) m/z (rel intensity) 522.3 ([M+23Na]+, 100), 483.3 (7), 375.2 (5), 
318.2 (4); HRMS (ES) Calcd for C27H37N3O4NaS (M+
23Na) 522.2402, found 522.2380. 
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(2S)-Ethyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-
enoic acid ((1S)-carbamoyl-2-phenylethyl)-amide (132b). According to the general 
procedure, 24 mg of L-Fmoc-Phe-OH (0.062 mmol), 17 mg (0.050 mmol) of aziridine 
109 and 0.36 mL (0.36 mmol) of a 1 M solution of Et2Zn in toluene afforded 5.9 mg (32 
%) of impure 132b as a colorless oil: [?]D25 –0.53 (c 0.24, CHCl3); IR (film) 3321, 3028, 
2927, 1670, 1653, 1558, 1506, 1455, 1295, 1123 cm-1; 1H NMR ? 7.34-7.16 (m, 10 H), 
6.67 (d, 1 H, J = 8.0 Hz), 6.25 (bs, 1 H), 5.33 (bs, 1 H), 5.21 (d, 1 H, J = 9.9 Hz), 4.70 
(ddd, 1 H, J = 8.4, 8.0, 5.9 Hz), 4.19 (d, 1 H, J = 8.2 Hz), 4.07 (q, 1 H, J = 7.2 Hz), 3.26 
(dd, 1 H, J = 14.4, 5.9 Hz), 2.97 (dd, 1 H, J = 14.2, 9.6 Hz), 2.82 (d, 2 H, J = 7.5 Hz), 
2.81-2.76 (m, 1 H), 1.91-1.82 (m, 2 H), 1.57 (s, 3 H), 1.18 (s, 9 H), 0.64 (t, 3 H, J = 7.4 
Hz); 13C NMR ? 173.8, 173.3, 139.6, 137.5, 135.9, 129.2, 128.7, 128.4, 127.1, 126.6, 
65.2, 60.4, 54.6, 46.3, 40.7, 36.8, 29.7, 24.5, 23.9, 11.3; MS (ES) m/z (rel intensity) 536.3 
([M+23Na]+, 100), 488.3 (20), 332.2 (12); HRMS (ES) Calcd for C28H39N 
3O4NaS (M+
23Na) 536.2559, found 536.2558. 
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(2S),4-Dimethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic 
acid ((1R)-carbamoyl-2-phenylethyl)-amide (132d).  According to the general
 procedure, 24 mg of D-Fmoc-Phe-OH (0.062 mmol), 17 mg (0.050 mmol) of aziridine 
109 and 0.18 mL (0.36 mmol) of a 2 M solution of Me2Zn in toluene afforded 6.4 mg 
(36%) of 132d as a colorless oil: [?]D25 0.59 (c 0.75, CHCl3); IR (film) 3204, 2925, 1690, 
1668, 1552, 1454, 1295, 1119 cm-1; 1H NMR ? 7.36-7.21 (m, 10 H), 6.68 (d, 1 H, J = 8.3 
Hz), 6.32 (bs, 1 H), 5.71 (bs, 1 H), 5.14 (d, 1 H, J = 8.9 Hz), 4.77 (d, 1 H, J = 8.5 Hz), 
4.72-4.63 (m, 1 H), 4.02 (q, 1 H, J = 8.1 Hz), 3.23 (dd, 1 H, J = 14.0, 5.6 Hz), 3.09 (dd, 1 
H, J = 8.8, 7.1 Hz), 2.91 (dd, 1 H, J = 14.0, 10.0 Hz), 2.83 (d, 2 H, J = 7.3 Hz), 1.66 (d, 
3 H, J = 0.9 Hz), 1.14 (s, 9 H), 0.97 (d, 3 H, J = 7.1 Hz); 13C NMR ? 174.6, 174.5, 140.3, 
137.4, 137.3, 129.2, 128.6, 128.4, 127.1, 127.0, 126.7, 67.6, 60.4, 55.2, 40.1, 39.6, 37.5, 
23.7, 17.9, 11.4; MS (ES) m/z (rel intensity) 522.2 ([M + 23Na]+, 100), 488.3 (18); HRMS 
(ES) Calcd for C27H37N3O4NaS (M+
23Na) 522.2402, found 522.2379 
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(2S)-Ethyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-
enoic acid ((1R)-carbamoyl-2-phenylethyl)-amide (132e). According to the general 
procedure, 24 mg (0.062 mmol) of D-Fmoc-Phe-OH, 17 mg (0.050 mmol) of aziridine 
109 and 0.36 mL (0.36 mmol) of a 2 M solution of Et2Zn in toluene afforded 5.3 mg 
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(29%) of 132e as a colorless oil: [?]D25 –2.6 (c 0.15, CHCl3); IR (film) 3204, 2960, 2927, 
1689, 1659, 1551, 1496, 1455, 1295, 1118 cm-1; 1H NMR ? 7.35-7.18 (m, 10 H), 6.62 (d, 
1 H, J = 8.4 Hz), 6.31 (bs, 1 H), 5.53 (bs, 1 H), 5.14 (d, 1 H,  J = 8.9 Hz), 4.67 (ddd, 1 H, 
J = 10.4, 8.4, 5.4 Hz), 4.44 (d, 1 H, J = 8.4 Hz), 4.08 (q, 1 H, J = 7.8 Hz), 3.23 (dd, 1 H, J 
= 14.2, 6.2 Hz), 2.97-2.89 (m, 2 H), 2.84 (d, 2 H, J = 7.5 Hz), 1.66 (d, 3 H, J = 1.0 Hz), 
1.19 (s, 9 H), 1.19-1.05 (m, 2 H), 0.55 (t, 3 H, J = 7.4 Hz); 13C NMR ? 174.7, 173.8, 
141.0, 137.3, 129.4, 129.2, 128.6, 128.4, 126.9, 126.6, 125.8, 65.5, 60.3, 55.2, 46.6, 40.1, 
37.3, 25.4, 23.7, 11.5, 11.0; MS (ES) m/z (rel intensity) 536.2 ([M+23Na]+, 100), 332.2 
(10); HRMS (ES) Calcd for C28H39N3O4NaS 536.2447 (M+
23Na), found 536.2465.  
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(2S),4-Dimethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic 
acid ((1S)-carbamoyl-3-methylbutyl)-amide (132g).  According to the general
 procedure, 22 mg (0.062 mmol) of L-Fmoc-Leu-OH, 17 mg (0.050 mmol) of aziridine 
109 and 0.18 mL (0.36 mmol) of a 2 M solution of Me2Zn in toluene, afforded 6.0 mg 
(36%) of 132g as a colorless oil: [?]D25 –1.1 (c 0.35, CHCl3); IR (film) 3336, 3209, 2957, 
2931, 2871, 1675, 1654, 1517, 1455, 1295, 1123 cm-1; 1H NMR ? 7.34-7.19 (m, 5 H), 
6.76 (d, 1 H, J = 8.2 Hz), 6.53 (bs, 1 H), 6.05 (bs, 1 H), 5.32 (d, 2 H, J = 8.3 Hz), 4.50-
4.40 (m, 1 H), 4.25 (d, 1 H, J = 8.4 Hz) 4.10-4.00 (m, 1 H), 3.18 (dd, 1 H, J = 13.2, 6.0 
Hz), 2.94-2.79 (m, 2 H), 1.71 (s, 3 H), 1.30-1.23 (m, 2 H), 1.12 (d, 3 H, J = 7.0 Hz), 1.10 
(s, 9 H), 0.93-0.87 (m, 6 H); 13C NMR ? 174.9, 174.2, 138.8, 137.1, 129.3, 128.7, 128.1, 
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127.2, 65.4, 60.5, 52.2, 40.6, 39.6, 39.3, 24.9, 23.9, 21.6, 17.1, 11.2; MS (ES) m/z (rel 
intensity) 488.3 ([M+23Na]+, 100), 459.3 (8), 403.3 (9), 347.2 (6), 284.2 (7); HRMS (ES) 
Calcd for C24H39N3O4NaS (M+
23Na) 488.2559, found 488.2545. 
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(2S)-Ethyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-
enoic acid ((1S)-carbamoyl-3-methylbutyl)-amide (132h). According to the general 
procedure, 22 mg (0.062 mmol) of L-Fmoc-Leu-OH, 17 mg (0.050 mmol) of aziridine 
109 and 0.36 mL (0.36 mmol) of a 1 M solution of Et2Zn in toluene afforded 6.2 mg 
(39%) of 132h as a colorless oil:  [?]D25 –1.2 (c 0.31, CHCl3); IR (film) 3326, 2958, 2930, 
2871, 1671, 1654, 1455, 1296, 1123 cm-1;  1H NMR ? 7.34-7.17 (m, 5 H), 6.66 (d, 1 H, J 
= 7.8 Hz), 6.37 (bs, 1 H), 5.37 (bs, 1 H), 5.28 (d, 1 H, J = 9.6 Hz), 4.45 (q, 1 H, J = 7.1 
Hz), 4.32 (d, 1 H, J = 8.7 Hz), 4.09 (q, 1 H, J = 6.8 Hz), 3.01 (dt, 1 H, J = 9.1, 3.8 Hz), 
2.81 (d, 2 H, J = 7.4 Hz), 2.01–1.86 (m, 1 H), 1.74 (s, 3 H), 1.52-1.34 (m, 2 H), 1.16 (s, 9 
H), 0.93 (d, 3 H, J = 5.7 Hz), 0.89 (d, 3 H, J = 5.6 Hz),  0.71 (t, 3 H, J = 7.3 Hz); 13C 
NMR ? 175.2, 173.7, 140.0, 137.0, 129.2, 128.7, 127.1, 126.6, 65.5, 60.4, 51.9, 46.3, 
40.5, 39.3, 24.8, 23.9, 22.9, 21.5, 11.4, 11.3; MS (ES) m/z (rel intensity) 502.3 
([M+23Na]+, 100), 298.2 (10); HRMS (ES) Calcd for C25H41N3O4S (M+
23Na) 502.2715, 
found 502.2727. 
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(2S),4-Dimethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic 
acid ((1R)-carbamoyl-3-methylbutyl)-amide (132j). According to the general 
procedure, 22 mg (0.062 mmol) of D-Fmoc-Leu-OH, 17 mg (0.050 mmol) of aziridine 
109 and 0.18 mL (0.36 mmol) of a 2 M solution of Me2Zn in toluene afforded 4.0 mg 
(24%) of impure 132j as a colorless oil: [?]D25 1.9 (c 0.10, CHCl3); IR (film) 3360, 3207, 
2962, 2927, 1688, 1669, 1655, 1558, 1540, 1456, 1302, 1120, 1057 cm-1; 1H NMR ? 
7.36-7.18 (m, 5 H), 6.66 (d, 1 H, J = 7.5 Hz), 6.30 (bs, 1 H), 5.42 (bs, 1 H), 5.31 (d, 1 H, 
J = 9.1 Hz), 4.48-4.39 (m, 2 H), 4.07 (q, 1 H, J = 8.8 Hz), 3.20 (dd, 1 H, J = 9.2, 7.2 Hz), 
2.90-2.77 (m, 2 H), 1.73 (d, 3 H, J = 1.1 Hz), 1.65-1.56 (m, 3 H), 1.23 (d, 3 H, J = 7.1 
Hz), 1.13 (s, 9 H), 0.93 (d, 3 H, J = 6.2 Hz), 0.89 (d, 3 H, J = 6.2 Hz); MS (ES) m/z (rel 
intensity) 488.3 ([M+23Na]+, 100); HRMS (ES) Calcd for C24H39N3O4NaS (M+
23Na) 
488.2559, found 488.2545. 
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(2S)-Ethyl-4-methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-
enoic acid ((1R)-carbamoyl-3-methylbutyl)-amide (132k). According to the general 
procedure, 22 mg (0.062 mmol) of D-Fmoc-Leu-OH, 17 mg (0.050 mmol) of aziridine 
109 and 0.36 mL (0.36 mmol) of a 1 M solution of Et2Zn in toluene afforded 5.2 mg 
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(30%) of impure 132k as a colorless oil: [?]D25 0.28 (c 0.49, MeOH); IR (film) 3357, 
3203, 2959, 2927, 2872, 1687, 1668, 1655, 1301, 1118 cm-1; 1H NMR (DMSO-d6) ? 7.63 
(d, 1 H, J = 8.2 Hz), 7.25-7.13 (m, 5 H), 6.87 (bs, 1 H), 5.12 (d, 1 H, J = 9.7 Hz), 4.17 
(dd, 1 H, J = 14.5, 8.4 Hz), 3.79 (dd, 2 H, J = 15.8, 7.6 Hz), 2.96 (dd, 1 H, J = 15.8, 6.0 
Hz), 2.73 (d, 2 H, J = 7.6 Hz), 1.64 (s, 3 H), 1.53-1.31 (m, 4 H), 1.04 (s, 9 H), 0.85-0.78 
(m, 6 H), 0.57 (t, 3 H, J = 7.3 Hz); 13C NMR (DMSO-d6) ? 174.6, 173.3, 139.1, 137.1, 
129.7, 128.4, 126.9, 126.5, 64.2, 58.5, 51.1, 47.8, 46.5, 44.7, 26.2, 25.3, 24.6, 24.1, 23.5, 
22.1, 19.2, 13.1, 11.7; MS (ES) m/z (rel intensity) 502.3 ([M+23Na]+, 100); HRMS (ES) 
Calcd for C25H41N3O4NaS (M+
23Na) 5022.2715, found 502.2701. 
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(2R)-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
 ((1S)-carbamoyl-2-phenyl-ethyl)-amide (132m). According to the general procedure,  
24 mg (0.062 mmol) of L-Fmoc-Phe-OH, 16 mg (0.050 mmol) of aziridine 112 and 0.18 
mL (0.36 mmol) of a 2 M solution of Me2Zn in toluene afforded 5.1 mg (29%) of 132m 
as a colorless oil: [?]D25 –1.9 (c 0.47, CHCl3); IR (film) 3288, 2974, 2930, 1652, 1520, 
1496, 1455, 1296, 1123 cm-1;  1H NMR ? 7.36-7.17 (m, 10 H), 6.42 (d, 1 H, J = 7.8 Hz), 
6.10 (bs, 1 H), 5.67 (d of AB, 1 H, J = 15.6, 6.5 Hz), 5.61 (d of AB, 1 H, J = 15.6, 5.3 
Hz), 5.43 (bs, 1 H), 4.64 (q, 1 H, J = 8.1 Hz), 4.25-4.03 (m, 1 H), 4.02 (bs, 1 H), 3.17 
(dd, 1 H, J = 13.9, 6.6 Hz), 3.05-2.86 (m, 3 H), 2.78 (dd, 1 H, J = 13.5, 7.3 Hz), 1.20 (s, 
9 H), 1.08 (d, 3 H, J = 7.0 Hz); 13C NMR ? 174.09, 173.32, 137.09, 136.59, 133.58, 
130.69, 129.71, 129.31, 128.67, 128.54, 127.10, 126.83, 60.16, 58.17, 54.44, 43.64, 
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42.44, 37.48, 23.96, 16.60; MS (ES) m/z (rel intensity) 508.2 ([M+23Na]+, 100), 304.2 
(12); HRMS (ES) Calcd for C26H35N3O4NaS (M+
23Na) 508.2246, found 508.2223. 
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(2R)-Ethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
((1S)-carbamoyl-2-phenylethyl)-amide (132n). According to the general procedure, 24 
mg (0.062 mmol) of L-Fmoc-Phe-OH, 16 mg of aziridine 112 (0.050 mmol) and 0.36 mL 
(0.36 mmol) of a 1 M solution of Et2Zn in toluene afforded 2.8 mg (17%) of 132n as a 
colorless oil: [?]D25 –3.5 (c 0.21, CHCl3); IR (Film) 3301, 2926, 1641, 1539, 1496, 1296, 
1123 cm-1; 1H NMR ? 7.35-7.17 (m, 10 H), 6.33 (d, 1 H, J = 7.7 Hz), 6.05 (bs, 1 H), 
5.67-5.53 (m, 2 H), 5.37 (bs, 1 H), 4.64 (q, 1 H, J = 7.9 Hz), 4.20-4.11 (m, 1 H), 3.96 (bd, 
1 H, J = 9.3 Hz), 3.16 (dd, 1 H, J = 13.9, 6.6 Hz), 3.02-2.90 (m, 2 H), 2.86-2.71 (m, 2 
H), 1.45-1.37 (m, 2 H), 1.23 (s, 9 H), 0.74 (t, 3 H, J = 7.4 Hz); 13C NMR ? 173.6, 173.4, 
137.1, 136.6, 134.7, 129.9, 129.4, 128.8, 128.5, 127.2, 127.0, 60.2, 58.2, 54.5, 51.5, 42.5, 
37.6, 24.0, 11.7; MS (ES) m/z (rel intensity) 522.2 ([M+23Na]+, 100), 318.2 (12); HRMS 
(ES) Calcd for C27H37N3O4NaS (M+
23Na) 522.2402, found 522.2393. 
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(2R)-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
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((1R)-carbamoyl-2-phenylethyl)-amide (132p). According to the general procedure, 24 
mg (0.062 mmol) of D-Fmoc-Phe-OH, 16 mg (0.050 mmol) of aziridine 112 and 0.18 
mL (0.36 mmol) of a 2 M solution of Me2Zn in toluene afforded 4.5 mg (26%) of 132p as 
a colorless oil: [?]D25 –0.21 (c 0.24, CHCl3); IR (film) 3324, 3202, 3087, 3063, 3028, 
2974, 2930, 2873, 1655, 1521, 1497, 1454, 1294, 1123, 752 cm-1; 1H NMR ? 7.33-7.17 
(m, 10 H), 6.56 (bs, 1 H), 6.33 (bs, 1 H), 5.73-5.43 (m, 2 H), 4.71 (q, 1 H, J = 7.4 Hz), 
4.48 (bs, 1 H), 4.17-4.03 (m, 1 H), 3.18 (dd, 1 H, J = 14.0, 6.2 Hz), 3.05-2.85 (m, 3 H), 
2.78 (dd, 1 H, J = 13.5, 7.8 Hz), 1.25-1.00 (m, 12 H); 13C NMR ? 174.1, 173.7, 137.0, 
136.9, 134.0, 130.3, 129.8, 129.3, 128.6, 128.5, 127.0, 126.8, 60.1, 57.9, 54.5, 43.4, 42.0, 
37.7, 23.8, 16.8; MS (ES) m/z (rel intensity) 508.3 ([M+23Na]+, 100), 469.3 (5), 361.2 (6), 
304.2 (3); HRMS (ES) Calcd for C26H35N3O4NaS (M+
23Na) 508.2246, found 508.2242. 
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(2R)-Ethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
 ((1R)-carbamoyl-2-phenylethyl)-amide (132q). According to the general procedure, 24 
mg (0.062 mmol) of D-Fmoc-Phe-OH, 16 mg (0.050 mmol) of aziridine 112 and 0.36 
mL (0.36 mmol) of a 1 M solution of Et2Zn in toluene afforded 5.4 mg (30%) of 132q as 
a colorless oil:  [?]D25 –1.1 (c 0.22, CHCl3); IR (film) 3303, 3028, 2963, 2929, 1661, 
1640, 1533, 1454, 1297, 1122 cm-1; 1H NMR ? 7.33-7.17 (m, 10 H), 6.53 (bd, 1 H, J = 
6.4 Hz), 6.29 (bs, 1 H), 5.69-5.55 (m, 3 H), 4.75 (dd, 1 H, J = 14.5, 7.9 Hz), 4.51 (bs, 1 
H), 4.15-4.05 (m, 1 H), 3.16 (dd, 1 H, J = 14.0, 6.2 Hz), 3.04-2.89 (m, 2 H), 2.79 (dd, 1 
H, J = 13.6, 7.6 Hz), 2.68–2.62 (m, 1 H), 1.89-1.69 (m, 1 H), 1.49–1.37 (m, 1 H), 1.19 (s, 
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9 H), 0.76 (t, 3 H, J = 7.3 Hz); 13C NMR ? 173.7, 148.0, 137.3, 137.0, 135.1, 130.1, 
129.6, 128.9, 128.8, 127.3, 127.2, 60.4, 58.1, 54.6, 51.6, 42.6, 38.1, 25.1, 24.2, 11.9; MS 
(ES) m/z (rel intensity) 522.2 ([M+23Na]+, 100), 483.2 (12); HRMS (ES) Calcd for 
C27H37N3O4NaS (M+
23Na) 522.2402, found 522.2414. 
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(2R)-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
((1S)-carbamoyl-3-methylbutyl)-amide (132s). According to the general procedure, 22 
mg (0.062 mmol) of L-Fmoc-Leu-OH, 16 mg (0.050 mmol) of aziridine 112 and 0.18 mL 
(0.36 mmol) of a 2 M solution of Me2Zn in toluene afforded 4.7 mg (30%) of 132g as a 
colorless oil: [?]D25 –2.7 (c  0.16, CHCl3); IR (film) 3304, 2957, 2930, 2871, 1654, 1528, 
1454, 1295, 1123, 969, 751 cm-1;  1H NMR ? 7.38-7.16 (m, 5 H), 6.38 (d, 2 H, J = 7.9 
Hz), 5.75 (d of AB, 1 H, J = 15.6, 6.6 Hz), 5.73 (d of AB, 1 H, J = 15.6, 4.7 Hz), 5.44 
(bs, 1 H), 4.48-4.35 (m, 1 H), 4.25-4.08 (m, 2 H), 3.14-3.00 (m, 1 H), 2.96 (dd, 1 H, J = 
15.2, 5.3 Hz), 2.79 (dd, 1 H, J = 13.4, 7.2 Hz), 1.70-1.55 (m, 3 H), 1.29 (d, 3 H, J = 7.1 
Hz), 1.19 (s, 9 H), 0.93 (d, 3 H, J = 5.9 Hz) 0.89 (d, 3 H, J = 5.6 Hz) 13C NMR ? 174.6, 
174.4, 136.5, 134.1, 130.5, 129.7, 128.7, 127.2, 60.2, 58.3, 51.7, 43.7, 42.3, 39.9, 24.7, 
23.9, 22.9, 21.7, 16.9; MS (ES) m/z (rel intensity) 474.3 ([M+23Na]+, 100), 435.3 (4), 
407.3 (5), 270.2 (5); HRMS (ES) Calcd for C23H37N3O4NaS (M+
23Na) 474.2402, found 
474.2393. 
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(2R)-Ethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
((1S)-carbamoyl-3-methylbutyl)-amide (132t). According to the general procedure, 22 
mg (0.062 mmol) of D-Fmoc-Leu-OH, 16 mg (0.050 mmol) of aziridine 112 and 0.36 
mL (0.36 mmol) of a 1 M solution of Et2Zn in toluene afforded 6.0 mg (36%) of 132t as a 
colorless oil: [?]D25 –2.9 (c 0.31 , CHCl3); IR (film) 3306, 2959, 2930, 2872, 1668, 1651, 
1539, 1455, 1297, 1123 cm-1;  1H NMR ? 7.34-7.16 (m, 5 H), 6.38 (bs, 1 H), 6.31 (d, 1 H, 
J = 8.0 Hz), 5.71 (d, 2 H, J = 5.2 Hz), 5.42 (bs, 1 H), 4.47-4.39 (m, 1 H), 4.17 (s, 2 H), 
3.00-2.77 (m, 3 H), 1.95-1.80 (m, 1 H), 1.62-1.48 (m, 4 H), 1.22 (s, 9 H), 0.94-0.85 (m, 9 
H); MS (ES) m/z (rel intensity) 488.3 ([M+23Na]+, 100), 368.2 (8), 284.2 (10); HRMS 
(ES) Calcd for C24H39N3O4NaS (M+
23Na) 488.2559, found 488.2554. 
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(2R)-Methyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
((1R)-carbamoyl-3-methylbutyl)-amide (132v).   According to the general procedure, 
22 mg (0.062 mmol) of D-Fmoc-Leu-OH, 16 mg (0.050 mmol) of aziridine 112 and 0.18 
mL (0.36 mmol) of a 2 M solution of Me2Zn in toluene afforded 4.7 mg (36%) of 132v as 
a colorless oil: [?]D25 0.39 (c 0.25, CHCl3); IR (film) 3304, 3206, 2957, 2931, 2871, 1651, 
1538, 1294, 1123, 753 cm-1; 1H NMR ? 7.36-7.18 (m, 5 H), 6.49 (d, 1 H, J = 8.5 Hz), 
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6.45 (bs, 1 H),  5.79-5.74 (m, 2 H), 5.49 (bs, 1 H), 4.55-4.43 (m, 2 H), 4.19-4.09 (m, 1 
H), 3.07 (qn, 1 H, J = 6.6 Hz),  2.96 (dd, 1 H, J = 13.4, 5,5 Hz), 2.80 (dd, 1 H, J = 13.5, 
8.1 Hz), 1.69-1.55 (m, 3 H), 1.28 (d, 1 H, J = 7.1 Hz), 1.16 (s, 9 H), 0.94 (d, 3 H, J = 6.0 
Hz), 0.92 (d, 3 H, J = 6.0 Hz); 13C NMR ? 174.8, 174.2, 136.8, 134.2, 130.6, 129.7, 
128.6, 127.1, 60.1, 58.1, 43.4, 41.9, 40.5, 24.9, 23.8, 23.0, 21.8, 17.0; MS (ES) m/z (rel 
intensity) 474.3 ([M+23Na]+, 100), 453.3 (10), 452.4 (55), 450.4 (10), 435.3 (45), 408.4 
(5), 407.3 (22); HRMS (ES) Calcd for C23H37N3O4NaS (M+
23Na) 474.2402, found 
474.2380. 
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(2R)-Ethyl-(5S)-(2-methylpropane-2-sulfonylamino)-6-phenylhex-3-(E)-enoic acid
 ((1R)-carbamoyl-3-methyl-butyl)-amide (132w). According to the general procedure, 
22 mg (0.062 mmol) of D-Fmoc-Leu-OH, 16 mg (0.050 mmol) of aziridine 112 and 0.36 
mL (0.36 mmol) of a 1 M solution of Et2Zn in toluene afforded 4.4 mg (26%) of 132w as 
a colorless oil: [?]D25 –1.7 (c 0.22, CHCl3); IR (film) 3220, 2959, 2929, 2872, 1651, 1552, 
1455, 1296, 1216, 1122 cm-1; 1H NMR ? 7.34-7.19 (m, 5 H), 6.47 (bs, 2 H), 5.75 (d of 
AB, 1 H J = 15.6, 4.7 Hz), 5.67 (d of AB, 1 H, J = 15.9, 7.3 Hz), 5.50 (bs, 1 H), 4.58-
4.45 (m, 2 H), 4.20-4.10 (m, 1 H), 2.97 (dd, 1 H, J = 13.5, 5.6 Hz), 2.87-2.78 (m, 2 H), 
1.97-1.82 (m, 2 H), 1.59-1.47 (m, 3 H), 1.16 (s, 9 H), 0.96-0.84 (m, 9 H); 13C NMR ? 
175.0, 173.7, 137.0, 135.0, 129.8, 129.1, 128.6, 127.0, 60.1, 58.0 51.7, 51.3, 41.9, 40.7, 
29.7, 25.1, 24.9, 23.9, 23.0, 21.8, 11.7; MS (ES) m/z (rel intensity) 488.3 ([M+23Na]+, 
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100), 284.2 (12); HRMS (ES) Calcd for C24H39N3O4NaS (M+
23Na) 488.2559, found 
488.2566. 
 
Table 13. Summary of yields and purities of (E)-alkene peptide library members 
 (Scheme 15) 
Entry Amino 
Acid 
R2 R3 Puritya Yieldb Entry Amino 
Acid 
R2 R3 Puritya Yieldb 
132a L-Phe Me Me ND 40% 132m L-Phe H Me 60% 29% 
132b L-Phe Me Et 50% 32% 132n L-Phe H Et 68% 17% 
132d D-Phe Me Me ND 36% 132p D-Phe H Me 66% 26% 
132e D-Phe Me Et 55% 29% 132q D-Phe H Et 61% 30% 
132g L-Leu Me Me ND 36% 132s L-Leu H Me 54% 30% 
132h L-Leu Me Et 37% 39% 132t L-Leu H Et 55% 36% 
132j D-Leu Me Me 47% 24% 132v D-Leu H Me 55% 36% 
132k D-Leu Me Et 55% 30% 132w D-Leu H Et 60% 26% 
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2.0  SYNTHESIS AND BIOLOGICAL EVALUATION OF THIO-HALENAQUINONE 
AND RELATED ANALOGS 
2.1 INTRODUCTION 
Halenaquinone (135) was isolated in 1983 from the Pacific sponge Xestospongia exigua.95 The 
structure of 135 was determined by NMR analysis and single crystal X-ray diffraction. The 
absolute configuration of the molecule was not assigned at the time of isolation but was later 
determined using a combination of circular dichroism calculations96,97 and total synthesis.98  
While the pentacyclic structure of halenaquinone was initially unique among known natural 
products, numerous structurally similar compounds were isolated subsequently such as 
xestoquinone (136),99 halenaquinol (137), xestoquinol (138), adociaquinone A (139), 
adociaquinone B (140) and 3-ketoadociaquinone A (141).100    Biological assays of 135 revealed 
a wide array of activities including antibiotic,95 cardiotonic,99 cytotoxic,101,102 
antifungal,102activities as well as inhibition of protein tyrosine kinase,103-105 phosphatidylinositol 
3 (PI-3) kinase,106 Cdc25B dual specificity phosphatase.107   and pfnek-1.108  Pfenk-1 may be an 
important target for the treatment of malaria. 
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Figure 19.  Structures of halenaquinone (135) and related compounds. 
2.1.1 Malaria 
Malaria accounts for more than one million deaths a year.109  The disease is prevalent in most 
tropical climates, but the majority of fatalities occur in sub-Saharan Africa (Figure 20).110  
Malaria is caused by a protozoan parasite of the genus Plasmodium, and is introducted into 
humans via several species of female anopheles mosquitoes.111 There are four Plasmodium 
species that account for almost all human infections: P. falciparum, P. vivax, P. malariae, and P. 
ovale.109  Of these species, P. falciparum accounts for over 80% of all infections.112 
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Figure 20. Areas of the world affected by malaria (from Abu-Raddad, L. J.; Patnaik, P.; 
 Kublin J. G. Science 2006, 314, 1603). 
 
2.1.1.1 The impact of malaria 
 
The exact impact malaria is difficult to quantify.113  Most deaths occur in the home and not under 
the care of medical professionals, and as a result, the only way to determine the number of deaths 
is by post-mortem questionnaires, which lack accuracy.114,115  Not all malaria infections are fatal 
but as with the death totals, the morbidity rate is difficult to measure.  Extensive work indicates 
that there are 0.5 billion clinical attacks of malaria each year.109  Malaria is also believed to be 
responsible for up to 25% of severe maternal anaemia and 10-20% of low birthweight babies in 
Africa.116,117   
 90 
Illness and death due to malaria have a severe impact on the economy.118-120  Malaria 
infection can limit school attendance, productivity at work and intellectual development.121  The 
gross natural product of countries in endemic areas has risen 2% less than in similar countries 
where malaria is not endemic.  The majority of malaria related hardships directly affect the poor 
and vulnerable.122 
2.1.1.2 The life cycle of Plasmodium 
 
 The life cycle of the malaria parasite Plasmodium relates to its spread and the course of human 
infection.123,124  The parasite is transmitted to its host in the saliva of mosquitoes as sporozoites 
(Figure 21).125  These sporozoites then localize themselves in the hepatocyctes and spread by 
asexual division (exoerythrocytic schizogony). The resulting merozoites enter the bloodstream 
and invade erythrocytes.  Within erythrocytes more asexual division occurs (erythrocytic 
schizogony) and, at this stage, the resultant daughter cells may be differentiated as either more 
merozoites or sexed cells - gametocytes.  Sexed gametocytes upon ingestion by a new mosquito 
host become activated in the midgut, leading to the formation of fertilization-competent gametes.  
After fertilization, the Plasmodium zygotes develop into new sporozoites, which, upon 
accumulation in the insect’s salivary glands, may be transmitted to a new human host 
continuning the life cycle of the parasite. 
2.1.1.3 Methods for the prevention of malaria 
 
Malaria prevention is a major area of focus for the international community.  Chemoprophylaxis, 
the treatment with drugs to prevent an infection, is used regularly by those traveling to malaria-
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endemic areas.109  This technique is not currently approved for the treatment of the native people 
due to the possibility of drug resistance and the delay of the natural immunity.126 Yet intermittent 
preventive therapy with sulfadoxine-pyrimethamine is highly effective in the prevention of 
malaria in pregnant women helping to avoid the related complications.127-129  Similar treatment 
of infants less than one year in age lowered the incidence of malaria as well.130,131  
 
 
Figure 21. Life cycle of Plasmodium (from  NIH Aminco-Bowman SPF: Special 
 Spotlights, http://history.nih.gov/exhibits/bowman/SSmalaria.htm). 
 
Control of the mosquito population and limiting their contact with humans is also a major 
area of interest for the prevention of malaria.  There is an ongoing program to develop 
genetically altered mosquitoes that are resistant to Plasmodium132  but genetic modifications that 
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are lethal to the female mosquitoes may be more promising.133  The use of insecticides, such as 
DDT, to spray the inside surfaces of homes is common.134  Insecticide-treated nets are a highly 
effective solution for the prevention of malaria.135-141  Although inexpensive,142 they are still 
outside of the means of many people at the greatest risk of malaria.143-145 
2.1.1.4 Antimalarial drugs 
 
Drugs are being developed to target the Plasmodium parasite at various stages of its life cycle in 
both human and mosquito hosts.  Drugs including chloroquine, quinine, mefloquine, 
halofantrine, pyrimethamine, sulfadoxine and artemisinin belong to a class of molecules known 
as blood schizontocides, which are used to combat the blood form of the infection and stop 
clinical symptoms (Figure 22).146  Primaquine and pyrimethamine are tissue schizontocides that 
prevent the parasite from transitioning from the liver to the erythrocytic stage.146  This method of 
treatment is difficult in practice since malaria cannot be diagnosed until the parasite enters the 
blood and symptoms are present.  Primaquine is also used to prevent the relapse of the infection 
from P. vivax and P. ovale hypnozoites that may lie dormant in the liver.146,147  Gametocytocides 
kill the sexual form of the parasite in the blood not allowing it to be transmitted to the mosquito.  
Chloroquine and quinine are effective against P. vivax and P. malariae.  Primaquine is effective 
against all species of Plasmodium in this stage.146 
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Figure 22. The structures of commonly used antimalarial drugs. 
 
The antimalaria drugs that are currently clinically used have three mechanisms of action.  Drugs 
belonging to the 4-aminoquinoline family, such as chloroquine (144), inhibit the polymerization 
of heme within the parasite, a critical detoxification mechanism during the intraerythrocytic 
stage.148 Chloroquine binds to heme and may form a toxic complex which results in cell death.  
Atemisinin and other endoperoxides generate free radicals in the presence of heme iron, which 
alkylate proteins within the parasite.149-151  Finally, the antifolates, which are broken into two 
classes. Sulfones and sulfonamides are Type-I antifolates, which inhibit dihydropteroate 
synthase.152  Pyrimethanmine and proguanil are type-II antifolates that inhibit dihydrofolate 
reductase.153  
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The development of new malaria drugs has been slow over the past 30 years. Over this 
time, only two drugs were indentified. Mefloquine is a synthetic antimalarial drug and the natural 
product artemisinin was isolated, but its medicinal properties had been known for 2000 years.146  
Drugs to treat malaria need to be inexpensive, have low toxicity and be orally available. The lack 
of new drugs combined with the increasing occurrence of drug resistance is making it difficult to 
effectively fight the spread of malaria.154-157   
 
2.1.1.5 Pfnek-1 as a therapeutic target 
 
Sequencing the genome of P. falciparum has offered an increased understanding of the organism 
and new targets for possible therapeutic intervention.158,159  One such target is Pfnek-1,123  a 
Never-In-Mitosis/Aspergillus (NIMA) related protein kinase.160  Pfnek-1 is present in both the 
asexual and gametocyte forms of the parasite and is important in the regulation of an atypical P. 
falciparum mitogen-activated protein kinase (MAPK).160,161  Pfnek-1 phosphorylates Pfmap-2, 
which is critical for exflagellation in vitro and for successful completion of the sexual cycle of 
the parasite in the mosquito.161  Working in tandem these two kinases are able to phosphorylate 
an exogenous substrate, suggesting that phosphorylation by Pfnek-1 activates Pfmap-2.123,161 
2.1.1.6 Inhibition of Pfnek-1 by xestoquinone and halenaquinone 
 
Xestoquine (136) and halenaquinone (135) have been reported to be inhibitors of Pfnek-1.108  
Xestoquinone was found to have an IC50 of 1.1 ?M while halenaquinone was less potent at 3.0 
?M.  Xestoquine was examined further due to its superior activity and greater abundance.  
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Screening against a number of P. falciparum kinases showed that xestoquinone had modest 
activity against PfPK5 and no activity toward other screened kinases (Table 14).108  Screening 
against kinases from higher eukaryotes revealed activity against Erk2.  Xestoquinone was 10-
fold less potent against Erk2 than Pfnek-1.   
Xestoquinone was also shown to possess antiplasmodial activity with an IC50 value of 3 
?M.  The selectivity index (SI), which is defined as the ratio of cyctotoxicity to antiplasmodial 
activity, for xestoquinone was found to be 7.  Treatment of mice infected with P. berghei, an 
animal malaria, with 5 mg/kg of 136 four times daily lead to a 50% survival rate after 10 days 
compared to only a 10% survival rate for untreated mice.  Also the amount of parasites in the 
blood was inhibited by 47% by xestoquinone.  Mice treated with 10 mg/kg chloroquine had a 
100% survival rate and no parasites were detected in their blood after 10 days. 
 
Table 14. Effects of xestoquinone on the activity of several protein kinases. 
Protein kinase IC50 (μM) Protein kinase IC50 (μM) 
Pfnek-1 1.1 CDk5/p25 >100 
PfPK 5 17 Erk2 11 
PfPK 7 >100 PKA >100 
PfGSK-3 160 pp60v-srcb 60 
GSK-3?/? 140 EGFR 60 
CDK1/cyclin B 60   
 
2.1.2 The total and partial syntheses of halenaquinone and xestoquinone 
Due to its structure and biological properties, halenaquinone has generated a great deal of 
interest in the synthetic community.  As a result, there are a number of total and partial syntheses 
found in the literature.  Harada and co-workers completed the first total synthesis of 
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halenaquinone in 1988 (Scheme 19).98  Their goal was not only the synthesis of the molecule, but 
also the validation of the computational methods used to assign the absolute stereochemistry.96,97  
The synthesis began with enantiopure Wieland-Miescher ketone 151, which was protected as the 
acetal followed by reduction and trapping of the resulting enolate as the TMS-enol ether.  
Treatment with MeLi, addition of formaldehyde and subsequent reduction of the ketone gave 
diol 152.  The acetal was cleaved and the resulting ketone was reduced.  Protection of the diol as 
the acetonide followed by allylic oxidation provided enone 153.  Heating this compound in 
benzene in the presence of benzocyclobutane 154 afforded the Diels-Alder adduct 155.  The 
resulting cyclohexane ring was oxidized to give the naphthalene and ?-oxidation of the ketone 
by O2 in the presence of base afforded the enol.  The acetonide was removed with aqueous acetic 
acid and the furan was formed via oxidation of the primary alcohol, cyclization and elimination 
of water.  Finally, CAN oxidation of the naphthalene gave halenaquinone (135) in 16 steps.  
Shibasaki and co-workers completed the second synthesis of 135 that employed an 
asymmetric Heck reaction to set the quaterny carbon stereocenter (Scheme 20).162,163   A five 
step sequence converted commercially available tetralone 157 to naphthol 158 in 58% overall 
yield.  Compound 158 was then mono-protected as the silyl ether and subsequent treatment with 
Tf2O gave 159.   Heck precursor 161 was synthesized via Suzuki cross couping of 159 with alkyl 
borane 160, removal of the silyl group and conversion to the triflate.  Treatment of this 
intermediate with Pd(OAc)2, (S)-BINAP and K2CO3 in THF at 60 °C affored tricycle 162 in high 
yield and 87% ee.  Deprotection of the TBDPS ether, reduction, activation of the alcohol as the 
triflate and displacement with acyl anion equvalent 163 gave 164. After protecting group 
manipulations, the acetal was subjected to benzylic oxidation with DDQ followed by O2 gave 
165.  Iodination and acetyl removal followed by palladium-catalyzed cyclization afforded 166.  
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Removal of the silyl group and CAN oxidation gave halenaquinone in 24 steps and 1.9% overall 
yield.  
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Scheme 19.  Harada's synthesis of halenaquinone. 
 
The Trauner group has completed the most recent synthesis of (-)-halenaquinone to 
date.164  Protection of known alcohol 167 followed by introduction of the aldehyde and Heck 
cyclization gave 168 (Scheme 21).  Treatment of 169 with n-BuLi and addition to aldehyde 168 
followed by deprotection, oxidation of the diol and oxidation to the quinone gave 170.  A Diels-
Alder reaction at high pressure and oxidation gave (-)-135.   
 Rodrigo and co-workers applied a different strategy to a formal synthesis of 
halenaquinone,165  employing a tandem Diels-Alder-Cope sequence to construct the tricyclic core 
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of the molecule (Scheme 22).166  Oxidation of methylguaiacol 171 with 
[bis(trifluoroacetoxy)iodo)]benzene led to the formation of an o-benzoquinone monoketal 
derivative which participated in a Diels-Alder reaction with diene 172.  Under the reaction  
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Scheme 20. Shibasaki's synthesis of halenaquinone. 
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conditions, a mixture of the Cope rearrangement product 173 and the Diels-Alder adduct 174 
were isolated.  Heating this mixture in 1,2,4 trimethylbenzene gave only 173.  The tricycle was 
then heated in the presence of naphthofuranone 175 to afford 176, which contained the entire 
carbon framework of halenaquinone.  Treatment with base facilitated aromatization to the 
naphthalene and subsequent exposure to TFA and p-chloranil oxidized the tetrahydrofuran to the 
furan.  The vinyl sulfide moiety was converted to the ketone by refluxing in AcOH with TiCl4.  
This compound intersects the Harada intermediate, which was only a single step from 135. 
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Scheme 21. Truaner's synthesis of (-)-halenaquinone. 
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Scheme 22. Rodrigo's formal total synthesis of halenaquinone. 
 
Nemoto and co-workers have published the synthesis of the tetracyclic core of 
halenaquinone.167,168  The key step in this route was an intramolecular Diels-Alder reaction 
between a furan and a benzocyclobutane which constructed the B-ring of halenaquinone 
(Scheme 23).  Conversion of the known alcohol 177 to the bromide followed by alkylation with 
178 afforded the Diels-Alder precursor.  Heating this compound at reflux in ortho-
dichlorobenzene (o-DCB) led to 180, which contained the core of halenaquinone.  Treatment 
with PhSeCl in methanol and subsequent elimination gave 181, which, upon exposure to acid, 
afforded furan 182.  This compound was not used to complete a total synthesis of halenaquinone, 
but the Sorensen group employed a similar Diels-Alder strategy in the synthesis of viridin.169 
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Scheme 23. Nemoto's approach to the tricycle core of halenaquinone. 
 
The Keay laboratory realized a synthesis of xestoquinone (136) that featured a palladium-
catalyzed polyene cyclization to set the quaternary carbon center and construct the A,B-rings of 
the tricyclic core (Scheme 24).170,171  The required naphthalene 184 was synthesized in three 
steps from known 183.172  Furan 185 was selectively metalated with n-BuLi and the resulting 
anion was quenched with B(O-iPr)3 and then subjected to Suzuki cross-coupling with 2-
bromopropene.  Oxidation of the primary alcohol followed by Wittig olefination afforded diene 
186. Deprotonation with n-BuLi and addition to 184 gave ketone 187.  Removal of the silyl 
protecting groups and installation of the aryl triflate gave Heck precursor 188.  Treatment with 
Pd2(dba)3 and S-BINAP afforded the cyclized product in high yield and 68% ee.  Hydrogenation 
with Pd/C and CAN oxidation afforded (+)-xestoquinone.     
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Scheme 24. Keay's synthesis of (+)-xestoquinone. 
2.1.3 Replacement of the furan in furanosteroids with thiophene 
The key structural feature of 135, wortmannin (190) and viridin (191) is the strained tricyclic 
furanodecaline core (Figure 23).  The naphtha[1,8-bc]furan subunit is flanked by electron-
withdrawing carbonyl groups that increase the electrophilicity of the unsubstituted ?-carbon of 
the furan, which, in combination with the strained nature of the tricycle, further enhances furan 
reactivity.  This moiety is responsible for the irreversible conjugation of wortmannin to PI-3 
kinase,173 and this reactivity could also account for the low kinase subtype selectivity, in vivo 
toxicity and poor bioavailability of wortmannin.174   In the case of wortmannin, the strain of this 
ring system is approximately 12.1 kcal mol-1, based on a comparison of the relative differences 
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in the energy of hydrogenation of 192 and 194 (Figure 24).175  Similar calculations performed on 
the core of 135 indicate that replacement of the furan with a thiophene decreases the relative 
energy of hydrogenation of tricycle 196 vs 198 by 2.6 kcal mol-1.176  This is mainly due to a 
decrease in the angle strain of the fused ring systems.  Isoelectronic replacement of the furan 
with a thiophene should therefore significantly decrease the electrophilic, alkylating properties of 
the heterocycle and increase the biological target selectivity.  The replacemnt of a furan moiety 
in natural products, such as salvinorin A177 and cyclazosin,178 with other heterocycles has not 
improved their biological activity relative to the target to interest.  To investigate our hypothesis 
and to gain access to natural product analogs with an improved kinase selectivity profile, we 
embarked on the preparation of a thiophene analog of halenaquinone. 
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Figure 23. Structures of wortmannin (190) and viridin (191). 
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Figure 24. Approximate reaction ethalpies for partial hydrogenations determined at the 
 B3LYP/6-31G* level in Spartan 04.175 
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Figure 25.  Selected bond angles of furanodecaline (196) and thiophenodecaline (198), 
 and approximate reaction enthalpies for hydrogenations determined at the B3LYP/6-
 31G* level in Spartan 04.176 
2.2 SYNTHESIS OF THIO-HALENAQUINONE 
2.2.1 Retrosynthetic analysis of thio-halenaquinone 
The retrosynthetic analysis of thio-halenaquinone (200) is shown in Figure 26.  We envisioned 
installing the A-ring via a ring closing metathesis of 201.  The key intermediate tetracycle 202 
would arise from a Heck cyclization to install the quaternary center.  Sequential metalations of 
the commercially available 3,4-dibromothiophene 206 were envisioned to lead to trisubstituted 
thiophene 205. Recently, heterocycle metalations have been used with considerable success for 
the preparation of polyfunctionalized heteroaromatic systems.179 
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Figure 26. Retrosynthetic analysis of thio-halenaquinone (200). 
2.2.2 Synthesis of a trisubstituted thiophene fragment 
To begin our synthetic efforts towards thio-halenaquinone, treatment of 3,4-dibromothiophene 
with n-BuLi and quenching with acetaldehyde gave alcohol 207 in quantative yield (Scheme 25). 
PCC oxidation and Wittig olefination of the methyl ketone180 afforded the trisubstituted olefin 
208 in 89% yield as a 2:1 mixture of alkene isomers, which were carried on without separation. 
The thiophene ring was further modified by a bromine-lithium exchange reaction followed by 
quenching with DMF and subsequent sodium borohydride reduction of the intermediate 
aldehyde to give 65% of alcohol 209. The remaing ring substituent was installed by an alkoxide-
directed metalation181 at the 5-position of the thiophene, followed by trapping with TMSCl. The 
resulting bis-TMS protected compound was treated with citric acid to yield the primary alcohol 
210. Protection of the hydroxyl group with the more robust TBS-ether proceeded in excellent 
yield to afford the trisubstituted thiophene 205. 
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S
Br Br  n-BuLi, Et2O, -78 °C,
 then acetaldehyde
           quant.
S
Br 1. PCC, DCM, 84%
2. n-BuLi, EtPPh3Br,
    THF, 0 °C to rt, 89%
1. n-BuLi, Et2O, -78 °C
   then DMF
2. NaBH4, EtOH
     65% (2 steps)
S
Br
S
HO
TMS
1. n-BuLi, Et2O, -78 °C
   then TMSCl/Et3N (1:1)
2. 5% citric acid, MeOH
      
        76 % (2 steps)
TBSCl, imid, DMF
     
           90% S
TBSO
TMS
S
HO
2 : 1
HO
209
206 207 208
210
205  
Scheme 25. Synthesis of trisubstituted thiophene 205. 
 
Although the synthesis of 205 was high yielding, it was lengthy, consisting of 8 steps, 
and in an attempt to shorten this sequence a Suzuki reaction was employed for the installation of 
the as a single isomer (Scheme 26).  Treatment of 206 with n-BuLi and quenching with DMF 
followed by reduction of the aldehyde with sodium borohydride gave alcohol 211 in 70%.  After 
significant optimization (Table 15), exposure of 211 to 10 mol% Pd(PPh3)4, 5 equiv of boronic 
acid 212182 and KOAc yielded thiophene 213 as a single olefin isomer in 53% yield.   The 
primary alcohol was protected as the silyl ether and treatment with n-BuLi and HMPA facilitated 
silyl migration from the oxygen to the carbon of the thiophene to give 214.170  Protection of the 
resulting alcohol as the TBS-ether afforded 215.  This route proved to be shorter than the 
previous synthesis, but it was also less efficient.  The yield of the TBS-protections could have 
been further optimized, but the Suzuki reaction and the conversion from 213 to 214 were not 
amenable to scale up. 
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S
Br Br
1. n-BuLi, Et2O, -78 °C
   then DMF
2. NaBH4, EtOH
     70% (2 steps)
S
HO
211
Br
Pd(Ph3P)4 (10 mol%)
212 (5 equiv)
KOAc (5 equiv)
xylene, reflux
         53%
S
HO
+
B(OH)2
206
213
1. TBSCl, imid, DMF; 60%
2. n-BuLi, HMPA, 
    THF, -78 °C; 66% S
HO
TBS
TBSCl, imid, DMF
     
           65% S
TBSO
TBS
214 215
212
 
Scheme 26.  Synthesis of trisubstituted thiophene 215. 
 
Table 15.  Optimization of Suzuki coupling to give 213. 
S
HO
213
S
HO
211
Br
+
B(OH)2
212
Pd(PPh3)4 (5 mol%)
base, solvent
overnight  
Entry Base (equiv) 212 (equiv) Solvent Temp (°C) Result 
1 K2CO3 (2) 2 xylenes 130 trace of 213 
2 NaOAc (2) 2 xylenes 130 trace of 213 
3 TlOEt (2) 2 xylenes 130 39% 
4 TlOEt (2) 2 THF rt Recovered SM 
5 TlOEt (2) 2 3:1 THF/H2O rt Recovered SM 
6 NaOAc (2) 5 xylenes 130 trace of 213 
7 LiOAc (2) 2 xylenes 130 trace of 213 
8 KOAc (2) 2 xylenes 130 31% 
9 AgOAc (2) 2 xylenes 130 dec. 
10 NaOEt (2) 2 xylenes 130 trace of 213 
11 NaOAc (2) 2 DMF 130 trace of 213 
12 TlOEt (2) 2 THF 65 trace of 213 
13 TlOEt (2) 2 DMF 130 Recovered SM 
14 KOAc (5) 5 xylenes 130 53% 
15 KOAc (2) 2 DMF 130 dec. 
16 KOAc (2) 2 DME 85 dec. 
17 TlOEt (2) 2 DME 85 trace of 213 
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2.2.3 First generation approach for the synthesis of the Heck cyclization precursor 
Based on work by Keay (Scheme 24), the simplest method for the generation of 203 would be 
via the addition of metalated 205 to the known acid chloride 204.171  However, treatment of 205 
with n-BuLi followed by addition of 204 did not lead to the desired product but only recovery of 
the thiophene.  Variation of the order of addition did not improve the results. Compound 205 was 
treated with n-BuLi and quenched with D2O.  Dueterium had been incorporated at C(5) as 
determined by 1H NMR which confirmed that the anion had been generated.  The lack of 
reactivity of lithitated 205 with the acid chloride could be due to the steric bulk of the 
trisubstituted olefin at the 4-position.    
 
S
TBSO
TMS
OMe
OMe
O
Cl
Br
+
n-BuLi, THF
MeO
OMe
O
Br
S
TMSTBSO205
204
203
C(5)
 
Scheme 27.  Attempted addition of 205 to acid chloride 204. 
2.2.4 Diels-Alder approach to the Heck precursor 
Due to the steric hindrance near C(5), it was clear that large electrophiles could not be used to 
install the naphthalene unit of 203.  Instead, the naphthalene moiety could be constructed via a 
Diels-Alder reaction similar to the method used to synthesize 183.172  Metalation at C(5) and 
introduction of the aldehyde (n-BuLi, then DMF) was followed by addition of ethynyl Grignard 
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reagent to give the desired thiophene 216 in 85% yield from 205 (Scheme 28). Oxidation of 
thiophene 216 with manganese dioxide and bromination of the alkynyl ketone with NBS in the 
presence of catalytic silver nitrate183 provided the Diels-Alder precursor 217. Microwave 
irradition in ortho-dichlorobenzene (o-DCB) was used to mediate the cycloaddition of 217 and 
benzocyclobutane 218,172,184,185 and 4 Å molecular sieves and K2CO3 quenched methanol and 
hydrobromic acid formed during the process. After removal of solvent and other volatiles by 
distillation, microwave irradiation of a solution of crude 203 in NMP in the presence of 20 mol% 
Pd(Ph3P)4 and 20 equiv Et3N for 5 min at 210 °C gave the desired tetracyclic product 8 in 10% 
overall yield from 216.  Attempts were made to improve the Heck cyclization by changing the 
Pd source, solvent, temperature and time; however, the yield was never increased beyond 53%  
(Table 16). The intermediates in this sequence were not stable to any chromatographic conditions 
and could not be isolated as pure compounds.  Under conventional heating in NMP at reflux, a 
36 h reaction time was necessary for the Heck reaction to reach completion.    
 
1. MnO2, DCM
2. NBS, cat. AgNO3,
    acetone
S
TMS
TBSO
OMe
MeO
OMe
O
Br
4 Å MS (200 wt%),
K2CO3, o-DCB, 
?wave, 220 °C
Pd(Ph3P)4 (20 mol%)
Et3N (20 equiv), NMP,
?wave, 5 min, 210 °C
     10% (4 steps)
MeO
OMe
O
Br
S
TMSTBSO S
MeO
OMe
OTBSO
TMS
1.  n-BuLi, Et2O, 0 °C
     then DMF
2. Ethynyl MgBr,
    THF, 0 °C
    85% (2 steps)
S
TBSO
TMS
OH
205
216
217
202
203
218
 
Scheme 28. Diels-Alder-Heck cyclization sequence to give tetracycle 202. 
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2.2.5 Completion of the synthesis of thio-halenaquinone 
After the successful realization of the sequential Diels-Alder – Heck cyclization strategy for the 
formation of B, C, and E rings of thio-halenaquinone, formation of ring A by ring closing 
metathesis required installing at least an additional two-carbon chain onto intermediate 202. 
However, we found that the sequence provided a higher yield of cyclohexene if an allyl group 
was added instead of the terminal vinyl function. Removal of the silyl-protecting group in 202 
with TBAF and oxidation of the primary alcohol gave 219 (Scheme 29). This aldehyde was  
 
Table 16. Optimization of the Heck cyclization. 
Pd source (20 mol%)
Et3N (20 equiv.)
solvent, ?wave
MeO
OMe
O
Br
S
TMSTBSO
S
MeO
OMe
OTBSO
TMS
202
203  
Entry Pd Complex Ligand Solvent Temp (°C) Time (min) Yield 
1 Pd(PPh3) - NMP 220 30 39% 
2 Pd(PPh3) - NMP 220 15 48% 
3 Pd(PPh3) - NMP 220 10 43% 
4 Pd(PPh3) - o-DCB 220 15 33% 
5 Pd(PPh3) - toluene 170 30 33% conversion of 203 
6 Pd(PPh3) - DMF 220 15 48% 
7 Pd(PPh3) - DMSO 220 15 trace 
8 Pd(PPh3) - NMP 220 5 53% 
9 Pd(PPh3) - NMP 220 1 53% 
10 Pd2(dba)3•CHCl3 - NMP 220 5 10% conversion of 203 
11 Pd2(dba)3•CHCl3 (furyl)3P NMP 220 5 dec. 
12 Pd2(dba)3•CHCl3 
tBu3P NMP 220 5 45% 
13 Pd(PtBu3)2 - NMP 220 5 16% 
14 Pd2(dba)3•CHCl3 DPPE NMP 220 5 55% conversion of 203 
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treated with a variety of vinyl organometallics, but difficult to separate product mixtures were 
obtained in all cases and the desired allylic alcohol could not be isolated in satisfactory yield. 
Fortunately, treatment with tributylallylstannane in the presence of BF3•OEt2
186-188 gave the 
homoallylic alcohol in 95% yield and a 6:1 diastereoselectivity. The major isomer was not 
assigned, and the mixture of stereoisomers was carried on without separation.  Oxidation of the 
alcohol with Dess-Martin reagent followed by treatment with DBU gave enone 221.  Exposure 
of 221 to a variety of metathesis catalysts189-192 afforded poor mass recovery of the starting 
material and none of the desired product.  As an alternative, the terminal alkene moiety of 220 
was readily isomerized in the presence of a Ru-hydride catalyst193-196 to give the allylic alcohol.  
Ring closing metathesis with ruthenium catalyst 223197,198 afforded cyclohexenol 224 in 56% 
yield.199,200 The ring closing metathesis was run at a concentration of 0.006 M to prevent 
dimerization. Oxidation with Dess-Martin periodane and treatment of the enone with Stryker’s 
reagent201 afforded the conjugate reduction product. Finally, oxidation of the dimethoxyarene 
moiety with CAN afforded thio-halenaquinone 200. 
In summary, we completed a synthesis of (+/-)-thio-halenaquinone in 22 steps and 0.3% 
overall yield from 3,4-dibromothiophene.  Key transformations of this sequence included 
multiple selective metalations of thiophene hetrocycles to install four different substituents, the 
Diels-Alder reaction of the highly functionalized alkynyl ketone 217 with benzocyclobutane 218 
followed by a Heck cyclization to form the fused B,C,D,E-ring system, and an alkene 
isomerization - ring closing metathesis reaction to annulate the remaining cyclohexanone. 
Biological evaluation of 200 along with synthetic intermediates was conducted to determine the 
Pfnek-1 inhibition profile of these sulfur-containing natural products analogs.  Compound 200 
was found to be an inhibitor of Pfnek-1 with an IC90 value of 2.8-3.9 ?M. 
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1. TBAF, THF, 0 °C
2. MnO2, DCM
     80% (2 steps)
Allyltributyltin, 
BF3•OEt2, DCM
-78 °C; 95%
1. (CO)RuHCl(Ph3P)3 (10 mol%)
     benzene, reflux
2.
1. Dess-Martin, DCM; 87%
2. Stryker's Reagent, 
    toluene, ?wave, 
    140 °C; 53%
3. CAN, 2:1 MeCN:H2O; 
    66%
S
MeO
OMe
OO
S
MeO
OMe
OHO
6 : 1
Ru
Cl
Cl
NMesMesN
O
223 (20 mol%)
DCM, reflux, 
56% (2 steps)
S
MeO
OMe
OHO
202
219 220
1. Dess-Martin, DCM; 68%
2. DBU, DCM; quant.
S
MeO
OMe
OO
221
i) Grubbs I
ii) Grubbs II
iii) 223
iv) Grela Grubbs S
MeO
OMe
OO
222
220
224
200
 
Scheme 29. Alkene isomerization - RCM reaction and completion of the synthesis of 
 thio-halenaquinone. 
 
2.3 THE ANTIMALARIAL PROPERTIES OF THIO-HALENAQUINONE AND 
RELATED ANALOGS. 
While the synthesis of 200 was gratifying, our biological proposal had not yet been tested.  To 
probe our initial hypothesis, the target compound and several synthetic intermediates were 
screened for their activity against Pfnek-1 by the Dow laboratory at the Walter Reed Army 
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Institute of Research (WRAIR) (Table 17).202-205 Compounds 200 and 222 showed the best 
activity in this assay with IC90 values of 2.8-3.9 and 4.6-6.7 ?M, respectively. Compound 225, 
which lacks the enone moiety, was inactive, which suggests it is more important for Pfnek-1 
inhibition than the quinone.  These initial tests provided preliminary structure activity 
relationship data that guided the development of future analogs. 
 
 Table 17.  IC90 values for 200 and other analogs. 
S
MeO
OMe
OO
S
MeO
OMe
OHO
S
MeO
OMe
OO
S
O
O
OO
224222 225 200  
Compound IC90 (μM) 
222 2.8-3.9 
224 >2500 
225 >2500 
200 4.6-6.7 
 
S
OO
O
O
thio-halenaquinone (200)
enone more active than 
the saturated compound
alcohol inactive
quinone more active
than dimethoxyl arene
 
 Figure 27. Summary of SAR studies. 
 114 
2.4 SYNTHESIS OF THIO-HALENAQUINONE ANALOGS 
2.4.1 Analog selection 
Based on the biological results summarized in Table 17, it was decided that new analogs for 
improved biological activity should be prepared by a synthetic sequence.  The targets, 226-228, 
are closely related to viridin (191) and no longer contain the quinone found in 200 since it was 
shown to not be necessary for Pfnek-1 inhibition (Figure 28).  The first analog to be synthesized 
was 227, due to the presence of the acetophenone function, which is similar to the carbonyl 
group found on the D-ring of viridin, wortmannin and thio-halenaquinone.  Furthermore, the 
methods developed for the synthesis of 200 should be readily transferred to this target. 
 
O
OO
S
226
O
OO
S
227
OO
S
228  
Figure 28.  Three new analogs of thio-halenaquinone. 
2.4.2 Retrosynthetic analysis of analog 227 
A retrosynthetic analysis of 227 is shown in Figure 29.  We envisioned the installation of the A-
ring from an alkene isomerization followed by the ring closing metathesis of 229.  The key 
tricyclic intermediate 230 would arise from a Heck cyclization to install the quaternary center.  
 115 
Addition of 231 to aldehyde 232 would afford the cyclization precursor.   The functionalized 
aromatic ring could be easily derived from 4-hydroxyacetophenone. 
 
227
O
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O
OHO
S
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S
TBSO
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S
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S
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Figure 29. Retrosynthetic analysis of analog 227. 
2.4.3 The attempted synthesis of analog 227 
Treatment of 4-hydroxyacetophenone with sodium hydride, quenching with MOMCl and 
subsequent reduction with sodium borohydride gave alcohol 234 in 55% yield (Scheme 30).  
Protection of the benzylic alcohol as the TBS-ether gave 231.  Metalation of 205 at C(5) and 
introduction of the aldehyde was followed by addition of lithiated 231 and oxidation of the 
resulting alcohol afforded 235.  Removal of the MOM-ether with MgBr2 afforded the free phenol 
236.  Introduction of the triflate followed by Heck cyclization did not afford the desired tricycle 
in high yield (Table 18).  The cyclization only yielded trace amounts of product and significant 
amounts of reduced starting material.  Even after significant optimization varying the palladium 
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source, ligands, base and solvent, the efficiency of this reaction could not be improved.    Due to 
the poor yield of the Heck cyclization, the synthesis of this analog was abandoned. 
 
OH
O
1. NaH, DMF then
    MOMCl
2. NaBH4, EtOH
     55% (2 steps)
OMOM
HO
233 234
TBSCl, imid. DMF
             86%
OMOM
TBSO
205
1. n-BuLi, Et2O, 0 °C
    then DMF
2. 231, s-BuLi, Et2O, 0 °C; 
    77% (2 steps)
3. Dess-Martin, DCM; 86% S
TBSO
TMS
O OMOM
OTBS
MgBr2, Et2O
       95%
S
TBSO
TMS
O OH
OTBS
1. Tf2NPh, NaH, 99%
2. 20 mol% Pd source, 
    base, solvent, ?wave
STBSO
O
TBSO
235
236 230
231
 
Scheme 30. Synthesis of 215 and failed route to analog 206. 
2.4.4 Retrosynthetic analysis of analog 228 
After abandoning the synthesis of 227, we turned our focus toward constructing 228.  This 
compound contains the same core as 200 and 227 but lacks the ketone function, which should 
simplify the synthesis while maintaining biological activity.  The retrosynthetic analysis of 227 is 
shown in Figure 30.  As before, we envisioned the construction of the A-ring though an alkene 
isomerization and ring closing metathesis of 237.  The quaternary center could be installed by a 
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Heck cyclization of 239.  Selective metalation of thiophene 241206 and addition to 240 would 
afford the cyclization precursor. The previous synthesis of the thiophene fragment required eight  
 
Table 18. Conditions for the Heck cyclization to form 230. 
 Entry Pd Complex Ligand Base 
(equiv) 
Solvent Temp 
(°C) 
Time 
(min) 
Yield of 230/ 
Result 
1 Pd(PPh3) - Et3N (20) NMP 220 5 trace of 230 
2 Pd(PPh3) - Et3N (20) THF 120 10 trace of 230 
3 Pd(PPh3) - Et3N (20) NMP 200 5 trace of 230 
4 Pd(PPh3) - Et3N (20) toluene 170 5 trace of 230 
5 Pd(OAc)2 dppb K2CO3 (3) toluene 170 5 trace of 230 
6 Pd(OAc)2 dppb K2CO3 (3) toluene 170 30 trace of 230 
7 Pd(OAc)2 dppp K2CO3 (3) toluene 150 5 trace of 230 
8 Pd(OAc)2 dppp K2CO3 (3) toluene 170 30 trace of 230 
9 Pd(OAc)2 BINAP K2CO3 (3) toluene 170 5 trace of 230 
10 Pd(OAc)2 BINAP K2CO3 (3) THF 120 30 17% 
11 Pd(OAc)2 dppp K2CO3 (3) THF 120 30 - 
12 Pd(OAc)2 dppb K2CO3 (3) THF 120 30 - 
13a Pd(OAc)2 BINAP K2CO3 (3) THF 120 30 - 
14 Pd(OAc)2 dppf K2CO3 (3) THF 120 30 - 
15 Pd2•dba3 BINAP K2CO3 (3) THF 120 30 trace of 230 
16 Pd(PtBu3)2 BINAP K2CO3 (3) THF 120 30 trace of 230 
17 Pd(OAc)2 BINAP K2CO3 (3) NMP 120 30 trace of 230 
18 Pd(OAc)2 BINAP K2CO3 (3) DMA 120 30 34%
 
19 Pd(OAc)2 BINAP K2CO3 (3) DMSO 120 30 trace of 230 
20 Pd(OAc)2 BINAP K2CO3 (3) DMA 120 10 low conversion 
21 Pd(OAc)2 BINAP K2CO3 (3) DMA 160 2 25%
 
22 Pd(OAc)2 BINAP K2CO3 (3) DMA 120 15 low conversion 
23 Pd(OAc)2 BINAP K2CO3 (3) DMA 160 1 28% 
 
24 Pd(OAc)2 BINAP K2CO3 (3) DMA 140 2 low conversion 
25 Pd(OAc)2 BINAP K2CO3 (3) DMA 150 2 low conversion 
26 Pd(OAc)2 BINAP K2CO3 (3) DMA 155 1 Mixture 
27 Pd(OAc)2 BINAP Cs2CO3 (3) DMA 160 1 28%
 
28 Pd(OAc)2 BINAP Li2CO3 (3) DMA 160 1 low conversion 
29 PdCl2 BINAP K2CO3 (3) DMA 160 1 Starting Material 
30 PdI2 BINAP K2CO3 (3) DMA 160 1 trace of 230 
31 Pd(OAc)2 (furyl)3P K2CO3 (3) DMA 160 1 - 
32b Pd(OAc)2 BINAP K2CO3 (3) DMA 95 120 trace of 230 
33b Pd(OAc)2 BINAP K2CO3 (3) DMA 95 240 trace of 230 
34b Pd(PPh3)4 - K2CO3 (3) DMA 95 240 trace of 230 
a2 eq KBr added  bconventional heating 
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steps and multiple protecting groups; in this new route the functionalized thiophene intermediate 
is synthesized in only three steps from 206. 
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S
228
OHO
S
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S
TrO
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S
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S
Br
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+
TrO
239
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S
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Figure 30. Retrosynthetic analysis of analog 228. 
2.4.5 Synthesis of analog 228 
Aldehyde 240 was synthesized by bromine-lithium exchange of known 242207 and quenching 
with DMF (Scheme 31). Protection of alcohol 211 with TrCl afforded 241 in 92%. Selective 
metalation the 5-position with LDA followed by addition to 240 and oxidation with manganese 
dioxide gave 239 in excellent yield.  Microwave irradiation of a solution of 239 in NMP in the 
presence of 20 mol % Pd(PPh3)4 and 20 equiv Et3N for 5 min at 220 °C afforded the desired 
tricylic product in 60% yield.  Removal of the trityl group in 238 with concentrated HCl and 
oxidation of the primary alcohol yielded aldehyde 243.  Treatment with tributylallylstannane in 
the presence of BF3•OEt2
186-188 gave homoallylic alcohol 237 in 95% yield in a 6:1 
diastereoselectivity.  The terminal alkene moiety was isomerized in the presence of a Ru-H 
catalyst193-196 to give the allylic alcohol.  Ring closing metathesis with ruthenium catalyst 
223
197,198 afforded cyclohexenol 244 in a disappointing 39% yield, and oxidation to the ketone 
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with Dess-Martin periodinane gave 228 in 70% yield.  This synthesis was completed in 12 steps 
and 6.8% overall yield from 3,4-dibromothiophene.  
 
S
BrHO
211
TrCl, AgNO3, DMF
          92% S
BrTrO
Br
n-BuLi, Et2O, -78 °C
then DMF
              87%
O
242 240
1. LDA, THF, 0 °C
    then 240; 89%
2. MnO2, DCM; 94%
S
TrO Br
O
241
239
STrO
Pd(Ph3P)4 (20 mol%)
Et3N (20 equiv), NMP,
?wave, 5 min, 220 °C
               60%
238
1. conc. HCl, THF
2. MnO2, DCM
    81% (2 steps)
SO
O
Allyltributyltin, 
BF3•OEt2, DCM
-78 °C; 95%
S
OHO
6 : 1
243 237
1. (CO)RuHCl(Ph3P)3 (10 mol%)
     benzene, reflux
2. 223, DCM, reflux
              39% (2 steps)
S
OHO
Dess-Martin, DCM
           70%
228
244  
Scheme 31. Synthesis of analog 228. 
 
It is interesting to note that treatment of 228 with 10 equiv of diallylamine or thiophenol 
in DCM for 24 h, does not lead to nucleophilic addition to the thiophene.  Even heating the 
reaction to reflux for 2 h does not give the thiophene addition product by NMR. This is in stark 
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contrast to wortmannin which readily undergoes addition of these nucleophiles in less than 1 h at 
0 °C to room temperature.174  This results helps to verify our hypothesis that replacement of the 
furan with a thiophene would reduce the electrophility of this core. 
 
 
Figure 31.  X-ray crystal structure of 228. 
 
2.4.6 Rationale for the allylation selectivity 
The allylation of compounds 220 and 243 with allyltributyltin proceeded with a 
diastereoselectivity of 6:1, which indicated that the remote quaternary carbon center influenced 
the approach of the allyl metal reagent.  Transition states 245 and 247 show the antiperiplanar 
orientation of the allylstannane, both should be disfavored due to strong steric interactions 
between the tin and the quaternary carbon center (Figure 32).  These interactions can be avoided 
if the reaction takes place via the synclinal transition state, 249 and 250. Approach of the allyl 
metal syn to the vinyl moiety would give the observed major product, transition state 250.  
Rotation of the aldehyde about the single bond and placing oxygen toward the quaternary center 
is illustrated in models 251-254. In these transition states, there is no clear bias for attack of the 
aldehyde, which should lead to low selectivity.  These transition states may also be disfavored 
due to steric interactions between the carbon center and the solvated lewis acid.  Due to the high 
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observed selectivity and a minimization of steric interactions, the reaction seems to proceed 
through transition state 250.  
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Figure 32. Possible transition states for the allylation of 222. 
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2.4.7 Pfnek-1 inhibtion properties of thio-halenaquinone analog 228 and related 
compounds 
Compound 228 and the related compounds 237 and 243 generated during the synthesis were 
tested for their inhibition of Pfnek-1 by the Dow laboratory at WRAIR (Table 19).202-205  
Compound 228 had an IC90 of 3.0-5.3 ?M which is similar to that of thio-halenaquinone.  This 
supports our hypothesis that the quinone or dimethoxy arene are not needed for biological 
activity.  The two other compounds screened, 237 and 243, showed lower activity, which was 
expected since they do not contain the cyclohexenone moiety.  Furthermore, 228 showed an 
selectivity index of 5.1, which is similar to that of 7 by xestoquinone (136). Though compound 
237 had good activity, it was not taken forward since no other compound without the final 
cyclohexanone moiety was active and the data may have been an artifact of the assay.  Based on 
this data, 228 was selected to move into animal testing and 200 mg of the compound was 
required. 
 
Table 19. Pfenk-1 inhibition by 228 and related compounds. 
SO
O
S
OHO
243 237
O
228
O
S
 
Compound IC90 (μM) Seletivity Index 
243 >5200 - 
237 8.4-14.5 >10 
228 3.0-5.3 5.1 
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S
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alcohol homoallylic
alcohol is more active
than the aldehyde
removal of the
dimethoxy hydroquinone
does not decrease activity
MeO
OMe
222  
Figure 33. Summary of SAR studies. 
2.5 SECOND-GENERATION APPROACH AND SCALE-UP OF ANALOG 228 
The isomerization and ring closing metathesis sequence in the synthesis of 228 was very low 
yielding.  Careful monitoring of the isomerization reaction by NMR showed the generation of a 
major unidentified side product.  Varying the reaction temperature, time, and catalyst batch did 
not eliminate this side product.  As in the synthesis of 200, addition of vinyl metal reagents led to 
product mixtures that were difficult to separate and the desired allylic alcohol could not be 
isolated in satisfactory yield.  A new route was required to allow for the rapid access to the 
quantity of material needed for animal testing. 
2.5.1 Second-generation retrosynthetic analysis of analog 228 
The retrosynthetic analysis of analog 228 is shown in Figure 34.  The A-ring could be introduced 
by ring closing metathesis of 255.  The key tricylic intermediate 256 will be derived from a Heck 
cyclization.  The precursor for this cyclization could be arrived at by selective metalation of 258 
and addition to 240.  Thiophene 258, which already contains the olefin required for the ring 
closing metathesis, could be synthesized from 206. 
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Figure 34. Second-generation retrosynthesis of analog 228. 
2.5.2 Attempted second-generation synthesis of analog 228 
Treatment of 206 with n-BuLi and quenching with acrolein afforded alcohol 259 in 60% yield.  
Protection of the hydroxyl group with TrCl gave 258 in 53% yield (Scheme 32).208  Selective 
metalation at the 5-position with LDA and HMPA, and addition to 240 followed by manganese 
dioxide oxidation gave ketone 257.  Subjecting 257 to the previously developed Heck cyclization 
conditions afforded tricycle 256 in 38% yield.  Surprisingly, there was only a single diastereomer 
isolated from the reaction and the relative configuration was determined by X-ray 
crystallography (Figure 35).  Treatment of 256 with Brønsted or Lewis acids did not afford the 
desired deprotected product.  The material isolated from the reaction of 256 with Brønsted acid 
resulted from the generation of a cation at the benzylic position of the thiophene.  Lewis acids 
only resulted in recovered starting material from the reaction mixtures.  To circumvent this 
problem,  we attempted the ring closing metathesis with the protecting group in place; however, 
only starting material was recovered. 
 125 
 
S
Br Br  n-BuLi, Et2O, -78 °C
 then acrolein
              60% S
BrHO
206 259
TrCl, AgNO3, DMF
          53% S
BrTrO
1. LDA, HMPA,
    THF, 0 °C
    then 240; 70%
2. MnO2, DCM; 90%
S
TrO Br
O
258
257
Pd(Ph3P)4 (20 mol%)
Et3N (20 equiv), NMP,
?wave, 5 min, 220 °C
               38%
256
Brønsted or Lewis Acid
SHO
O
H
STrO
O
H
255  
Scheme 32.  Attempted second-generation synthesis of analog 228. 
 
 
Figure 35. X-ray crystal structure of 256. 
2.5.3 Second-generation synthesis of analog 228 with TIPS-protected alcohol 
Because the trityl group of 256 could not be removed, a TIPS-ether, which is similarly large and 
would shield the 2-position from deprotonation yet could be removed with TBAF or another 
basic fluoride source, was employed instead.  Protection of 259 as the TIPS-ether succeeded in 
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88% yield (Scheme 33).  Selective metalation and addition to 240 followed by oxidation with 
manganese dioxide gave ketone 261.  Microwave irradiation of a solution of 261 in NMP in the 
presence of 20 mol % of Pd(Ph3P)4 and 20 equiv of Et3N gave a tricycle in 20-55% yield as a 2:1 
mixture of diastereomers.  The yield was greatly impacted by the E/Z ratio of the olefin in 261.  
After multiple purifications, a sample of the pure major isomer of 261, the (Z)-alkene, was 
isolated and subjected to the cyclization conditions; however, surprisingly no product was 
observed.   
 
1. LDA, HMPA, 
   THF, 0 °C then 
   240; 53%
2. MnO2, DCM; 86%
S
BrTIPSO
260
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O
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Scheme 33. Progress toward 228: Heck cyclization with a mixture of olefin isomers. 
 
Since the major olefin isomer did not undergo cyclization, 261 could no longer be 
prepared as a mixture.  Suzuki cross-coupling of commercially available 263 with (E)-2-
bromobutene gave alcohol 264 in 84% yield (Scheme 34).  Oxidation with PCC yielded the 
aldehyde as a single (E)-olefin isomer.  Addition of 260 to the aldehyde and oxidation gave the 
cyclization precursor.  Exposure of 266 to the Heck conditions gave the tricyle in 83% yield as a 
2:1 mixture of diastereomers at the newly formed quaternary carbon center.  Removal of the 
silyl-protecting group in 262 with TBAF proceeded in 87% yield.  Ring closing metathesis with 
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223 afforded cyclohexenol 267 in a 3:1 ratio of diastereomers and 63% combined yield.  The 
relative stereochemistry of the major isomer was determined by X-ray crystallography (Figure 
36) after derivativization (Scheme 35).  Oxidation with Dess-Martin periodinane gave enone 228 
in 70% yield.  This route was used to produce 200 mg of this analog for biological testing in 8 
linear steps and 8.3% yield from 3,4-dibromothiophene. 
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Scheme 34. Heck cyclization with a single olefin isomer and completion of the synthesis 
 of  228. 
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Scheme 35.  Convertion of the major isomer of 255 to 268. 
 
Figure 36. X-ray crystal structure of 268. 
2.5.4 Rationale for the Heck selectivity 
The Heck cyclization to form compounds 256 and 262 was interesting due to the fact that only 
one olefin isomer was reactive and that the reaction was diastereoselective, which can be 
rationalized by a conformation of the secondary alcohol that minimizes A1,3 strain and 
comparing the four possible transition states (Figure 37).  In transition state models 269 and 271, 
the olefin coordinates palladium from the same face of the thiophene as the protected alcohol. 
This approach is disfavored due to strong steric interactions with the large protecting groups 
(trityl and TIPS) on the alcohol. These problematic interactions are avoid by coordination from 
the opposite face of the thiophene ring is shown in 273 and 274.  Although transition state 273 
minimizes the interaction of the olefin and the protected alcohol, the methyl groups on the olefin 
are placed directly under the thiophene ring, which would be disfavored due to steric 
considerations.  In model 274, the olefin is coordinated opposite to the large protecting group 
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and the olefinic methyl groups are orientated away from the thiophene resulting in the least 
sterically-encumbered transition state model and leading to the major observed diastereomer. 
When the alcohol is protected as the TIPS-ether, the olefin is able to coordinate palladium from 
the same face as the alcohol as shown in 271, giving rise to the minor isomer, 272.  The Z-olefin 
may not be reactive since there is no way in which it can coordinate to palladium that eliminates 
the steric interactions between the substitutent at the 4-position of the thiophene and both methyl 
groups of the olefin as seen in structures 275 and 276.   
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Figure 37. Possible transition states for the Heck cyclization. 
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2.6 SECOND GENERATION APPROACH TO THIO-HALENAQUINONE 
After completing the scale-up of 228, we decided to revisit the synthesis of thio-halenaquinone 
and apply what we had learned by synthesizing this analog on scale to improve the route.  We 
proposed a formal total synthesis of thio-halenaquinone via the synthesis of 200 from key 
intermediate cyclohexenol 224.  The retrosynthesis is identical to that shown in Figure 27, 
however thiophene 260 replaced 258 and a functionalized naphthalene replaced 240.  The 
second-generation approach began with the reduction of known naphthalene 163171,172 with 
DiBAL to afford the alcohol (Scheme 36).  Suzuki cross-coupling with boronic acid 212 
proceeded in 73% yield.  Unfortunately, the subsequent oxidation to aldehyde 280 proceeded in 
low yield.  Switching the order of the oxidation and coupling steps could avoid this low yielding 
step and oxidation of 277 with Dess-Martin periodane proceded in excellent yield.  Finally, 
installation of the trisubstituted olefin via a Suzuki reaction gave the desired naphthalene 280 in 
67% as a single olefin isomer.   
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Scheme 36.  Synthesis of aldehyde 280. 
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With the aldehyde in hand, the synthesis of 224 started by treatment of 260 with LDA 
and HMPA and addition to 280 followed by oxidation to give ketone 281 under unoptimized 
conditions (Scheme 37). Gratifyingly, the Heck cyclization and removal of the silyl ether gave 
the desired tetracycle in 60% yield over 2 steps as a 2:1 mixture of diastereomers at the newly 
formed quaternary carbon center. Ring closing metathesis with 223197,198 afforded cyclohexenol 
224 in a 3:1 ratio of diastereomers in 87% combined yield.  The coupling constants of the vinyl 
protons for the major diastereomer match those of the major isomer of 267 exactly, allowing for 
the relative stereochemistry to be assigned as shown.  The route to this intermediate is nine steps 
shorter than the previous synthesis, reducing the total synthesis from 22 to 13 steps and 
eliminating the low yielding Heck-Diels-Alder sequence.  The overall yield of this new sequence 
could be further improved by optimizing the aldehyde addition and oxidation steps. 
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Scheme 37.  Second generation synthesis of cyclohexenol 224. 
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2.7 CONCLUSION 
We were able to realize the synthesis of thio-halenaquinone and several analogs and evaluate 
their Pfnek-1 inhibitor profiles.  The synthesis of 200 was completed in 13 steps and 0.6% 
overall yield from 3,4-dibromothiophene. Key transformations of this sequence included 
multiple selective metalations of thiophene hetrocycles to install four different substituents, the 
Diels-Alder reaction of the highly functionalized alkynyl ketone 217 with benzocyclobutane 218 
followed by a Heck cyclization to form the tetracyclic B,C,D,E-ring system, and an alkene 
isomerization - ring closing metathesis reaction to annulate the remaining cyclohexanone.  This 
compound was found to have an IC90 of ~5 ?M while compound 222 had a ~3 ?M IC90 against 
Pfnek-1.  Based on this data, we embarked on the synthesis of 228, a simplified analog.  We 
completed the initial synthesis in 12 linear steps from 3,4-dibromothiophene in 6.8% yield.  The 
key steps in this sequence were a directed metalation of a functionalized thiophene and 
subsequent aldehyde addition, Heck cyclization to form the tricylic core and an alkene 
isomerization – ring closing metathesis reaction to construct the final cyclohexenone.  This 
compound was found to possess an IC90 of ~4 ?M and was selected to move into animal studies.  
A new, more scalable route was developed which allowed access to 200 mg of material in 8 
linear steps and 8.3% overall yield from 3,4-dibromothiophene.  The biological evaluation of this 
compound at the WRAIR is still ongoing.  
 133 
2.8 EXPERIMENTAL SECTION 
General:  All moisture-sensitive reactions were performed under an atmosphere of N2.  
Glassware was flame dried prior to use.  THF and Et2O were dried by distillation over 
Na/benzophenone.   CH2Cl2 was dried by distillation over NaH.  Unless otherwise stated, 
solvents and reagents were used as received.  Analytical thin layer chromatography was 
performed on pre-coated SiO2 60 F-254 plates (particle size 0.040-0.055 mm, 230-400 mesh) 
and visualization was accomplished with a 254 or 210 nm UV light or by staining with an 
anisaldehyde solution (7.5mL of p-anisaldehyde, 25 mL of concentrated H2SO4 and 7.5 mL of 
glacial acetic acid in 675 mL of 95% ethanol) or KMnO4 solution (1.5 g of KMnO4, 10 g of 
potassium carbonate and 2.5 mL of 5% aqueous NaOH in 150 mL of H2O).  Flash 
chromatography on SiO2 was used to separate and purify the crude reaction mixtures.  NMR 
spectra were recorded at 300 MHz/75 MHz (1H NMR/13C NMR) at 21 oC in CDCl3 unless 
otherwise noted.  Chemical shifts (?) are reported as follows: chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, dd=doublet of doublet, ddd= doublet of doublet of 
doublet, dt=doublet of triplet, dq=doublet of quartet, qq=quartet of quartet, m=multiplet, 
b=broad, a=apparent). Microwave reactions were conducted using the Biotage Initiator 
microwave system (absorption level set to “very high”). Infrared spectra were measured on a 
Nicolet AVATAR 360 FTIR E.S.P. spectrometer. Mass spectra were obtained on a double 
focusing instrument. Optical rotations were measured on a Perkin-Elmer 241 polarimeter at 25 
oC.  
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1-(3-Bromo-4-thienyl)-ethanol (207).  To a solution of 9.9 g (41 mmol) of 206 in 50 mL of 
Et2O at  –78 °C was added 20 mL (42 mmol) of a 2.1 M solution of n-BuLi in hexanes. The 
resulting mixture was stirred for 15 min, then 20 mL (360 mmol) of acetaldehyde was added.  
The solution was stirred for 15 min, warmed to rt, and treated with a saturated aqueous solution 
of NH4Cl. The layers were separated, and the aqueous layer was extracted with Et2O (3x). The 
combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated in 
vacuo.  Purification by Kugelrohr distillation at 75 °C and 0.5 Torr provided 8.4 g (quant.) of 
207 as a clear, colorless oil: IR (film) 3351, 3109, 2974, 2927, 1521, 1369 cm-1; 1H NMR ? 7.30 
(dd, 1 H, J = 3.3, 0.6 Hz), 7.28 (d, 1 H, J = 3.6 Hz), 4.99 (q, 1 H, J = 6.3 Hz), 1.97 (bs, 1 H), 1.55 
(d, 3 H, J = 6.3 Hz); 13C NMR ? 144.9, 123.4, 121.1, 109.6, 65.7, 23.3; MS (EI) m/z (rel 
intensity) 208 (35), 206 (M+, 35), 193 (75), 191 (80), 165 (17), 163 (20), 83 (100); HRMS (EI) 
Calcd for C6H7OSBr 205.9400, found 205.9403. 
 
S
Br
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1-(3-Bromo-4-thienyl)ethanone.
180 To a suspension of 22 g of celite and 17 g (79 mmol) of 
PCC in 100 mL of DCM in a 3-neck flask equipped with a mechanical stirrer was added 11 g (53 
mmol) of 207 in 30 mL of DCM.  The suspension was stirred for 2.5 h, filtered through a plug of 
SiO2, which was washed repeatedly with DCM, and the combined filtrates were concentrated in 
vacuo.  Purification by Kugelrohr distillation at 80 °C and 0.5 Torr provided 9.2 g (84%) of 1-(3-
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bromo-4-thienyl)-ethanone as a clear oil: IR (film) 3104, 1684, 1488, 1416, 1370, 1227 cm-1; 1H 
NMR ? 8.03 (d, 1 H, J = 3.6 Hz), 7.33 (d, 1 H, J = 3.3 Hz), 2.61 (s, 3 H); 13C NMR ? 191.4, 
138.7, 133.8, 125.5, 109.4, 28.8; MS (EI) m/z (rel intensity) 206 (30), 204 (M+, 30), 191 (100), 
189 (95), 161 (10), 163 (10), 81 (50); HRMS (EI) Calcd for C6H5OSBr 203.9244, found 
203.9245. 
 
S
Br
 
3-Bromo-4-(but-2-en-2-yl)thiophene (208).  To a suspension of 22 g (59 mmol) of 
(ethyl)triphenylphosphonium bromide in 100 mL of THF at 0 °C  was added 25 mL (52 mmol) 
of a 2.1 M solution of n-BuLi in hexanes.  The resulting solution was stirred for 1 h, then 9.2 g 
(45 mmol) of 1-(3-bromo-4-thienyl)-ethanone in 40 mL of THF was added via syringe. The 
solution was stirred overnight, filtered through a plug of SiO2, and concentrated.  After addition 
of SiO2 and hexanes, the suspension was filtered through a plug of SiO2, which was rinsed with 
hexanes.  The combined filtrates were concentrated in vacuo to yield 8.7 g (89%) of 208 as a 
colorless, oily 2:1 mixture of alkene isomers: IR (film) 3109, 2967, 2913, 2854 cm-1; major 
isomer 1H NMR ? 7.28 (d, 1 H, J = 3.3 Hz), 6.98 (d, 1 H, J = 3.3 Hz), 5.69 (q, 1 H, J = 5.7 Hz), 
1.97 (bs, 3 H), 1.48 (add, 3 H, J = 6.6, 1.2 Hz); 13C NMR ? 142.1, 131.0, 125.2, 122.9, 121.8, 
111.5, 24.7, 14.9; characteristic signals for minor isomer 1H NMR ? 7.22 (d, 1 H, J = 3.6 Hz), 
7.01 (d, 1 H, J = 3.3 Hz), 1.78 (d, 3 H, J = 6.9 Hz); 13C NMR ? 145.4, 130.5, 125.8, 125.2, 
123.2, 121.3, 110.8, 16.8, 13.8; MS (EI) m/z (rel intensity) 218 (55), 216 (M+, 55), 191 (55), 189 
(45), 122 (100); HRMS (EI) Calcd for C8H9SBr 215.9608, found 215.9609. 
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(4-(But-2-en-2-yl)thiophen-3-yl)methanol  (209).  To a solution of 7.6 g (35 mmol) of 208 in 
180 mL of Et2O at -78 °C was added 25 mL (41 mmol) of a 1.6 M solution of n-BuLi in hexanes. 
The reaction mixture was stirred for 30 min, then 27 g (370 mmol) of DMF was added and the 
resulting solution was removed from the dry ice bath and allowed to warm to room temperature 
for 45 min.  At this time, a saturated aqueous solution of NH4Cl was added, then the mixture was 
diluted with brine and the layers were separated.  The aqueous layer was extracted with Et2O 
(3x), and the combined organic layers were washed with brine (2x), dried (MgSO4), filtered and 
concentrated in vacuo.  To a solution of 1.3 g (35 mmol) of NaBH4 in 40 mL of EtOH was added 
a solution of the aldehyde in 60 mL of EtOH. The reaction mixture was stirred for 2 h, quenched 
by slow addition of conc. HCl, diluted with H2O and extracted with DCM (3x).  The combined 
organic layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo.  The 
residue was purified by chromatography on SiO2 (5?10% EtOAc/hexanes) to yield 3.8 g (65%) 
of 208 as a colorless, oily 1.5:1 mixture of alkene isomers: IR (film) 3324, 2914, 2857, 1441, 
1374 cm-1; 1H NMR ? 7.29 (d, 1 H, J = 3.3 Hz), 6.96 (d, 1 H, J = 3.3 Hz), 5.69-5.58 (m, 1 H), 
4.56 (s, 2 H), 1.98-1.96 (m, 3 H), 1.64 (s, 1 H), 1.46 (dq, 3 H, J = 6.6, 1.5 Hz); characteristic 
signals for minor isomer: 1H NMR ? 7.25 (d, 1 H, J = 3.3 Hz), 7.03 (d, 1 H, J = 3.0 Hz), 4.66 (s, 
2 H), 1.77 (add, 3 H, J = 6.9, 0.9 Hz); 13C NMR ? 144.7, 141.0, 140.5, 140.1, 131.8, 131.0, 
123.9, 123.8, 122.9, 122.3, 121.9, 121.4, 59.9, 59.6, 25.4, 17.2, 14.7, 13.8; MS (EI) m/z (rel 
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intensity) 168 (M+, 30), 150 (35), 139 (42), 135 (100); HRMS (EI) Calcd for C9H12OS 168.0608, 
found 168.0604. 
S
HO
TMS  
(4-(But-2-en-2-yl)-2-(trimethylsilyl)thiophen-3-yl)methanol (210).  To a solution of 3.8 g (22 
mmol) of 209 in 20 mL of THF at 0 °C was added 31 mL (50 mmol) of a 1.6 M solution of n-
BuLi in hexanes.  The reaction mixture was allowed to stir for 15 min, then 15 mL of a 1:1 
solution of TMSCl/Et3N was added. The resulting mixture was stirred for 15 min, removed from 
the ice bath and allowed to warm to room temperature for 1 h. At this time, a saturated aqueous 
solution of NH4Cl was added, and the mixture was extracted with DCM (3x). The combined 
organic layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo.  To a 
solution of the resulting residue in 15 mL of MeOH was added 2.5 mL of a 5% aqueous solution 
of citric acid. The reaction mixture was stirred for 30 min, diluted with H2O, and extracted with 
DCM (3x).  The combined organic layers were washed with saturated aqueous NaHCO3, dried 
(MgSO4), filtered and concentrated in vacuo.  The residue was purified by chromatography on 
SiO2 (5% EtOAc/hexanes) to yield 4.1 g (76%) of 210 as a colorless, oily 1.4:1 mixture of alkene 
isomers: IR (film) 3321, 2955, 1249 cm-1; 1H NMR (acetone-d6) ? 7.23 (s, 1 H), 5.64-5.56 (m, 1 
H), 4.53 (d, 2 H, J = 5.1 Hz), 3.8 (app q, 1 H, J = 4.5 Hz), 1.97-1.93 (m, 3 H), 1.38 (dq, 3 H, J = 
6.6 Hz, 1.5 Hz), 0.37 (bs, 9 H); characteristic signals for minor isomer: 1H NMR (acetone-d6) ? 
7.30 (s, 1 H), 4.60 (s, 2 H), 1.74 (app dd, 3 H, J = 6.9, 0.9 Hz); 13C NMR (acetone-d6) ? 149.6, 
148.4, 147.9, 145.4, 138.2, 137.7, 133.8, 132.6, 126.6, 126.5, 124.4, 123.9, 59.1, 26.4, 18.2, 15.2, 
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14.2, 0.88; MS (EI) m/z (rel intensity) 240 (M+, 60), 225 (100), 207 (50); HRMS (EI) Calcd for 
C12H20OSiS 240.1004, found 240.0996. 
S
TBSO
TMS  
((4-(But-2-en-2-yl)-2-(trimethylsilyl)thiophen-3-yl)methoxy)(tert-butyl)dimethylsilane (205).  
To a solution of 6.9 g (29 mmol) of 210 in 300 mL of DMF at 0 °C was added 6.6 g (44 mmol) 
of TBSCl followed by 5.3 g (78 mmol) of imidazole.  The reaction mixture was allowed to stir at 
room temperature overnight and diluted with Et2O. After addition of brine, the layers were 
separated and the aqueous layer was extracted with Et2O (3x). The combined organic layers were 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by chromatography on SiO2 (0?2% EtOAc/hexanes) to yield 9.1 g (90%) of 205 as a colorless, 
oily 2:1 mixture of alkene isomers: IR (film) 2956, 1471, 1373, 1361, 1251, 1174, 1069 cm-1; 1H 
NMR ? 7.10 (s, 1 H), 5.62-5.52 (m, 1 H), 4.51 (s, 2 H), 1.97-1.94 (m, 3 H), 1.40 (dq, 3 H, J = 
6.6, 1.5 Hz), 0.91 (bs, 9 H), 0.37 (bs, 9 H), 0.09 (s, 6 H); characteristic signals for minor isomer: 
1H NMR ? 7.17 (s, 1 H), 4.59 (s, 2 H), 1.75 (dq, 3 H, J = 6.9, 0.9 Hz), 0.10 (s, 6 H); 13C NMR ? 
149.4, 146.1, 145.7, 145.2, 138.4, 137.9, 133.1, 131.8, 125.8, 125.7, 123.9, 123.1, 59.0, 58.8, 
26.2, 26.1, 26.0, 18.5, 18.3, 18.2, 15.0, 13.9, 0.5, -5.3, -5.4; MS (EI) m/z (rel intensity) 354 (M+, 
70), 339 (40), 297 (25), 209 (25), 72 (100); HRMS (EI) Calcd for C18H34OSi2S 354.1864, found 
354.1868. 
 
S
HO Br
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(4-Bromothiophen-3-yl)methanol (211). To a solution of 5.0 g (21 mmol) of 206 in 28 mL of 
Et2O at -78 °C was added 15 mL (21 mmol) of a 1.6 M solution of n-BuLi in hexanes. The 
reaction mixture was stirred for 20 min, then 10 g (11 mmol) of DMF was added and the 
resulting solution was stirred for 1 h.  At this time, a saturated aqueous solution of NH4Cl was 
added and the solution was warmed to room temperature, then the mixture was diluted with brine 
and the layers were separated.  The aqueous layer was extracted with Et2O (3x), and the 
combined organic layers were washed with brine (2x), dried (MgSO4), filtered and concentrated 
in vacuo.  To a solution of 0.92 g (25 mmol) of NaBH4 in 23 mL of EtOH was added a solution 
of the aldehyde in 37 mL of EtOH. The reaction mixture was stirred for 1 h, quenched by slow 
addition of a saturated aqueous solution of NH4Cl, diluted with 10% aqueous HCl and extracted 
with DCM (3x).  The combined organic layers were washed with saturated aqueous NaHCO3, 
brine, dried (MgSO4), filtered and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (10% EtOAc/hexanes) to yield 2.8 g (70%) of 206 as a colorless oil: IR 
(film) 3392, 3107, 2927, 1318, 1052 cm-1; 1H NMR ? 7.31 (d, 1 H, J = 3.6 Hz), 7.29 (d, 1 H, J = 
3.6 Hz), 4.67 (d, 2 H, J = 5.7 Hz), 1.86 (t, 1 H, J = 5.7 Hz); 13C NMR ? 140.2, 123.7, 123.3, 
110.2, 60.1; MS (EI) m/z (rel intensity) 194 (90), 193 (20), 192 (90), 191 (M+, 20), 177 (35), 175 
(35), 165 (35), 163 (35), 161 (30), 159 (30), 113 (45); HRMS (EI) Calcd for C5H5OSBr 
191.9244, found 191.9239. 
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(E)-(4-(But-2-en-2-yl)thiophen-3-yl)methanol (213).  To a solution of 1.0 g (5.2 mmol) of 211 
in 20 mL of xylenes was added 0.60 g (0.52 mmol) of Pd(PPh3)4, 2.6 g (26 mmol) of 192,
182 and 
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2.6 g (26 mmol) of KOAc.  The reaction mixture was heated at reflux overnight, cooled, diluted 
with H2O, and filtered through celite.  The aqueous layer was extracted with DCM (3x) and the 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue 
was purified by chromatography on SiO2 (5% EtOAc/hexanes) to yield 0.45 g (53%) of 213 as a 
colorless oil: IR (film) 3332, 3100, 2917, 1380 cm-1; 1H NMR ? 7.25 (dt, 1 H, J = 3.3, 0.7 Hz), 
7.03 (d, 1 H, J = 3.3 Hz), 5.62 (qq, 1 H, J = 6.8, 1.4 Hz), 4.66 (d, 2 H, J = 4.8 Hz), 1.97 (m, 3 H), 
1.78 (dq, 3 H, J = 6.8, 0.9 Hz); 13C NMR ? 144.5, 139.9, 130.9, 123.7, 122.7, 121.2, 59.6, 17.0, 
13.7; MS (EI) m/z (rel intensity) 168 (M+, 55), 149 (40), 139 (45), 135 (100); HRMS (EI) Calcd 
for C9H12OS 168.0608, found 168.0615. 
 
 
S
OH
TBS  
(E)-(4-(But-2-en-2-yl)-2-(tert-butyldimethylsilyl)thiophen-3-yl)methanol (214). To a solution 
of 0.17 g (1.0 mmol) of 213 in 10 mL of DMF at 0 °C was added 0.23 g (1.5 mmol) of TBSCl 
followed by 0.18 g (2.8 mmol) of imidazole.  The reaction mixture was allowed to stir overnight 
at room temperature, quenched with brine, and extracted with Et2O (3x).  The combined organic 
extracts were washed with brine (2x), dried (MgSO4), filtered and concentrated in vacuo.  The 
residue was purified by chromatography on SiO2 (1% Et2O/hexanes) to yield 0.16 g (60%) of the 
silyl ether as a colorless oil: IR (film) 2954, 2928, 2856, 1471, 1253 cm-1; 1H NMR ? 7.21 (dt, 1 
H, J = 3.6, 1.2 Hz), 6.99 (d, 1 H, J = 3.3 Hz), 5.54 (qq, 1 H, J = 6.6, 1.5 Hz), 4.65 (d, 2 H, J = 0.9 
Hz), 1.95-1.93 (m, 3 H), 1.75 (dq, 3 H, J = 6.6, 0.9 Hz), 0.94 (s, 9 H), 0.10 (s, 6 H); 13C NMR ? 
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144.6, 140.5, 131.3, 123.7, 122.2, 121.2, 60.9, 25.9, 18.3, 17.2, 13.9, -5.3.  To a solution of 46 
mg (0.17 mmol) of the silyl ether and 33 mg (0.18 mmol) of HMPA in 1.0 mL of THF at -78 °C 
was added 0.11 mL (0.18 mmol) of a 1.6 M solution of n-BuLi in hexanes.  The resulting 
solution was stirred for 2 h, quenched with a saturated aqueous solution of NH4Cl and diluted 
with H2O.  The mixture was extracted with DCM (3x) and the combined organic layers were 
dried (MgSO4), filtered and concentrated in vacuo.  The residue was purified by chromatography 
on SiO2 (5% EtOAc/hexanes) to yield 30 mg (66%) of 214 as a colorless oil: IR (film) 3299, 
2953, 2928, 2856, 1470, 1443, 1252 cm-1; 1H NMR ? 7.25 (s, 1 H), 5.68 (qq, 1 H, J = 6.6, 1.2 
Hz), 4.63 (d, 2 H, J = 5.3 Hz), 2.01 (m, 3 H), 1.78 (dq, 3 H, J = 6.8, 1.1 Hz), 1.58 (t, 1 H, J = 5.5 
Hz), 0.94 (s, 9 H), 0.40 (s, 6 H); 13C NMR ? 148.4, 146.4, 135.9, 132.0, 127.2, 124.4, 59.3, 26.6, 
17.9, 17.4, 14.0, -3.7; MS (EI) m/z (rel intensity) 282 (M+, 10), 267 (15), 253 (85), 225 (100), 
207 (90), 75 (60); HRMS (EI) Calcd for C15H26OSiS 282.1473, found 282.1478. 
 
S
OTBS
TBS  
(E)-((4-(But-2-en-2-yl)-2-(tert-butyldimethylsilyl)thiophen-3-yl)methoxy)(tert-
butyl)dimethylsilane (215). To a solution of 30 mg (0.11 mmol) of 214 in 1.0 mL of DMF at 0 
°C was added 25 mg (0.17 mmol) of TBSCl followed by 20 mg (0.30 mmol) of imidazole.  The 
reaction mixture was allowed to stir at room temperature overnight, quenched with brine, and 
extracted with Et2O (3x).  The combined organic extracts were washed with brine (2x), dried 
(MgSO4), filtered and concentrated in vacuo.  The residue was purified by chromatography on 
SiO2 (1% Et2O/hexanes) to yield 29 mg (65%) of 214 as a colorless oil: IR (film) 2928, 2883, 
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2856, 1471, 1252 cm-1; 1H NMR ? 7.20 (s, 1 H), 5.55 (qq, 1 H, J = 6.6, 1.2 Hz), 4.57 (s, 2 H), 
1.96 (s, 3 H), 1.75 (dd, 3 H, J = 6.9, 0.6 Hz), 0.94 (s, 9 H), 0.91 (s, 9 H), 0.38 (s, 6 H), 0.10 (s, 6 
H); 13C NMR ? 149.4, 146.2, 135.4, 132.1, 126.4, 123.4, 58.9, 26.8, 25.9, 18.3, 18.2, 17.4, 13.8, 
-3.6, -5.4; MS (EI) m/z (rel intensity) 396 (M+, 5), 381 (20), 339 (80), 147 (100), 73 (95), 57 
(70); HRMS (EI) Calcd for C21H40OSi2S 396.2338, found 396.2319. 
 
 
 
S
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1-(3-(But-2-en-2-yl)-4-((tert-butyldimethylsilyloxy)methyl)-5-(trimethylsilyl)thiophen-2-
yl)prop-2-yn-1-ol (216).  To a solution of 5.0 g (14 mmol) of 205 in 70 mL of THF at 0 °C was 
added 13 mL (21 mmol) of a 1.6 M solution of n-BuLi in hexanes.  The reaction mixture was 
stirred for 15 min, then 21 g (280 mmol) of DMF was added and the solution was stirred for 45 
min. At this time, a saturated aqueous solution of NH4Cl was added. The solution was diluted 
with brine and extracted 3x with Et2O.  The combined organic layers were washed with brine 
(3x), dried (MgSO4), filtered and concentrated in vacuo.  To a solution of the resulting aldehyde 
in 75 mL of THF at 0 °C was added 56 mL (28 mmol) of a 0.5 M solution of ethynyl magnesium 
bromide in THF.  The reaction mixture was allowed to stir for 30 min and was then quenched 
with a saturated aqueous solution of NH4Cl.  The solution was diluted with H2O, extracted with 
Et2O (3x), and the combined organic layers were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by chromatography on SiO2 (5% 
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EtOAc/hexanes) to yield 4.9 g (85%) of 216 as a yellow, oily 2.9:1 mixture of alkene isomers: IR 
(film) 3312, 2956, 2929, 2857, 1251cm-1; 1H NMR (acetone-d6) ? 5.73-5.69 (m, 1 H), 5.48 (ddd, 
1 H, J = 5.1, 4.4, 2.3 Hz), 5.02 (dd, 1 H, J = 11.4, 5.5 Hz), 4.50-4.49 (m, 2 H), 3.02 (dd, 1 H, J = 
5.6, 2.3 Hz), 1.96-1.93 (m, 3 H), 1.39-1.33 (m, 3 H), 0.91 (s, 9 H), 0.37 (s, 9 H), 0.12 (s, 6 H); 
characteristic signals for minor isomer: 1H NMR (acetone-d6) ? 5.56 (dd, 1 H, J = 7.9, 5.6 Hz), 
5.42-5.34 (m, 1 H), 5.10 (d, 1 H, J = 5.2 Hz), 4.53 (s, 2 H), 1.90-1.89 (m, 3 H), 1.76 (dq, 3 H, J = 
6.7, 1.1 Hz), 0.90 (s, 9 H), 0.35 (s, 9 H), 0.11 (s, 6 H); 13C NMR (acetone-d6) ? 147.0, 146.9, 
146.6, 146.5, 145.1, 144.8, 144.6, 143.1, 142.4, 137.7, 137.4, 137.0, 132.9, 132.8, 132.0, 126.3, 
125.4, 125.2, 85.5, 85.4, 74.4, 74.3, 74.2, 59.8, 59.7, 58.9, 58.8, 58.6, 26.4, 26.3, 25.7, 25.5, 18.9, 
18.8, 18.6, 15.2, 13.9, 0.7, -5.2, -5.3; MS (EI) m/z (rel intensity) 393 ([M-C2H]
+, 25), 380 (65), 
351 (30), 333 (50), 276 (35), 261 (80), 73 (100); HRMS (EI) Calcd for C21H36O2Si2S 408.1974, 
found 408.1979. 
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3-((tert-Butyldimethylsilyloxy)methyl)-4-methyl-2-(trimethylsilyl)-4-vinylanthra[2,3-
b]thiophen-11(4H)-one (202).   To a solution of 2.3 g (5.5 mmol) of 216 in 120 mL of DCM 
was added 24 g (280 mmol) of MnO2.  After 1 h, the reaction mixture was filtered through celite 
and concentrated in vacuo to give the ketone as a 2.7:1 white, solid mixture of olefin isomers: 
Mp 114.9-119.8 °C; IR (KBr) 3259, 2951, 2928, 2856, 2093, 1632 cm-1; 1H NMR (acetone-d6) ? 
5.65 (qq, 1 H, J = 8.3, 1.5 Hz), 4.55 (s, 2 H), 4.20 (s, 1 H), 1.99 (dq, 3 H, J = 1.5, 1.5 Hz), 1.31 
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(dq, 3 H, J = 6.7, 1.5 Hz), 0.91 (s, 9 H), 0.43 (s, 9 H), 0.12 (s, 6 H); characteristic signals for 
minor isomer: 1H NMR (acetone-d6) ? 5.38 (qq, 1 H, J = 6.7, 1.5 Hz), 4.24 (s, 1 H), 1.93 (dq, 3 
H, J = 1.2, 1.2 Hz), 1.76 (dq, 3 H, J = 6.8, 1.1 Hz), 0.90 (s, 9 H), 0.40 (s, 9 H), 0.09 (s, 6 H); 13C 
NMR (acetone-d6) ? 168.9, 168.6, 155.0, 151.4, 150.6, 150.1, 149.4, 149.0, 142.4, 141.6, 132.7, 
131.9, 126.3, 124.9, 82.1, 81.7, 81.5, 81.4, 59.3, 59.2, 26.4, 26.3, 25.0, 18.9, 18.8, 18.3, 15.1, 
14.0, 0.3, -5.3; MS (EI) m/z (rel intensity) 406 (M+, 25), 391 (35), 349 (30), 274 (30), 147 (40), 
73 (100).  To a solution of this ketone in 25 mL of acetone was added a catalytic amount of 
AgNO3 followed by 1.1 g (6.2 mmol) of N-bromosuccinimide.  The reaction mixture was stirred 
for 10 min, quenched with H2O, and filtered through a pad of celite, which was washed with 
hexanes.  The layers were separated and the aqueous layer was extracted with hexanes (3x). The 
combined organic layers were washed with 10% aqueous HCl, dried (MgSO4), filtered and 
concentrated in vacuo.  The residue was dissolved in 10 mL of o-DCB and divided evenly 
between 2 microwave reaction vessels loaded with 490 mg (2.5 mmol) of 218, 1.05 g of 
powdered 4 Å molecular sieves and 650 mg (5.0 mmol) of K2CO3.  The reaction mixtures were 
heated at 210 ºC for 5 min under microwave irradiation, diluted with hexanes, filtered through a 
plug of celite and concentrated in vacuo.  The solvent and other volatiles were removed via 
Kugelrohr distillation at 120 ºC and 0.5 Torr.  The residue was dissolved in 25 mL of NMP and 
divided evenly among 5 microwave reaction vessels containing 250 mg of Pd(Ph3P)4 and 1.7 mL 
of Et3N.  The solutions were heated at 220 °C for 5 min under microwave irradiation, and filtered 
through a pad of celite, which was washed with DCM, and then concentrated in vacuo.  The 
solvent and other volatiles were removed via Kugelrohr distillation at 120 ºC under high vacuum. 
The residue was purified by chromatography on SiO2 (10% EtOAc/hexanes) followed by 
crystallization from Et2O to yield 310 mg (10%) of 202 as a yellow solid: Mp 200.7-203.4 °C; IR 
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(film) 2954, 2856, 1654, 1625, 1585, 1463, 1343, 1298, 1264 cm-1; 1H NMR (acetone-d6) ? 9.13 
(s, 1 H), 8.42, (s, 1 H), 6.96 (d, 1 H, J = 8.4 Hz), 6.87 (d, 1 H, J = 8.4 Hz), 6.18 (dd, 1 H, J = 
17.4, 10.4 Hz), 5.61 (dd, 1 H, J = 17.4, 0.7 Hz), 5.46 (dd, 1 H, J = 10.4, 0.7 Hz), 5.08 (d, 1 H, J = 
11.7 Hz), 4.79 (d, 1 H, J = 11.7 Hz), 4.02 (s, 3 H), 3.98 (s, 3 H), 1.95 (s, 3 H), 0.94 (s, 9 H), 0.46 
(s, 9 H), 0.27 (s, 3 H), 0.24 (s, 3 H); 13C NMR (CD2Cl2) ? 178.6, 154.0, 152.1, 150.9, 149.2, 
148.0, 145.6, 143.3, 140.9, 128.8, 127.9, 122.5, 122.4, 114.5, 106.1, 103.7, 59.1, 56.0, 46.7, 29.1, 
26.2, 18.4, 0.56, -4.8, -4.9; MS (EI) m/z (rel intensity) 566 (M+, 100), 509 (90), 494 (35), 405 
(25), 147 (45), 73 (677); HRMS (EI) Calcd for C31H42O4Si2S 566.2308, found 566.2326. 
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4-Methyl-11-oxo-4-vinyl-4,11-dihydroanthra[2,3-b]thiophene-3-carbaldehyde (219). To a 
solution of 310 mg (0.55 mmol) of 202 in 4.0 mL of THF at 0 oC was added 1.7 mL (1.7 mmol) 
of a 1 M solution of TBAF in THF.  After 5 min, the reaction mixture was quenched with H2O 
and the layers were separated.  The aqueous layer was extracted with EtOAc (3x) and the 
combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated in 
vacuo.  The resulting material was dissolved in 28 mL of DCM and 2.9 g (33 mmol) of MnO2 
was added.  The mixture was stirred for 1 h, then filtered through a plug of celite and the filtrate 
was concentrated in vacuo. The residue was purified by chromatography on SiO2 (0?15% 
EtOAc/hexanes) to yield 166 mg (80%) of 219 as a orange yellow solid: Mp 199.3-202.8 oC; IR 
(film) 2936, 2359, 2341, 1653, 1625, 1592 cm-1; 1H NMR ? 10.29 (s, 1 H), 9.27 (s, 1 H), 8.60 (s, 
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1 H), 8.36 (s, 1 H), 6.83 (d, 1 H, J = 8.3 Hz), 6.72 (d, 1 H, J = 8.3 Hz), 6.35 (dd, 1 H, J = 17.3, 
10.4 Hz), 5.49 (d, 1 H, J = 17.3 Hz), 5.43 (d, 1 H, J = 10.4 Hz), 4.01 (s, 3 H), 3.99 (s, 3 H), 2.02 
(s, 3 H); 13C NMR ? 185.3, 178.7, 152.5, 150.7, 148.8, 144.3, 143.1, 140.8, 139.1, 128.6, 126.9, 
125.0, 123.2, 122.3, 115.2, 106.3, 103.6, 55.8, 46.1, 30.5 ; MS (EI) m/z (rel intensity) 378 (M+, 
100), 363 (75), 194 (20); HRMS (EI) Calcd for C22H18O4S 378.0892, found 378.0924. 
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3-(1-Hydroxybut-3-enyl)-6,9-dimethoxy-4-methyl-4-vinylanthra[2,3-b]thiophen-11(4H)-one 
(220). To a solution of 170 mg (0.45 mmol) of 219 and 210 mg (0.63 mmol) of 
allyltributylstanne in DCM at -78 °C was added 47 μL (0.36 mmol) of BF•OEt2.  The resulting 
solution was stirred for 1.5 h, quenched with sat. aq. NaHCO3 and warmed to room temperature.  
The aqueous layer was extracted with DCM (3x), dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (10% Et2O/ DCM) to yield 180 mg 
(95%) of 220 as a 6:1 yellow, solid mixture of diastereomers: Mp 184.3-193.1 °C; IR (film) 
3435, 2936, 1650, 1622, 1464, 1265 cm-1; 1H NMR ? 9.25 (s, 1 H), 8.30 (s, 1 H), 7.89 (s, 1 H), 
6.79 (d, 1 H, J = 8.4 Hz), 6.69 (d, 1 H, J = 8.4 Hz), 6.11 (dd, 1 H, J = 17.4, 10.5 Hz), 5.95-5.80 
(m, 1 H), 5.64 (d, 1 H, J = 17.4 Hz), 5.48 (d, 1 H, J = 10.8 Hz), 5.26-5.16 (m, 3 H), 3.99 (s, 3 H), 
3.98 (s, 3 H), 2.67-2.57 (m, 2 H), 2.52-2.40 (m, 1 H), 1.92 (s, 3 H); characteristic signals for 
minor isomer: 1H NMR 7.91 (s, 1 H), 6.25 (dd, 1 H, J = 17.4, 10.5 Hz), 1.85 (s, 3 H); 13C NMR ? 
178.8, 150.7, 150.5, 148.7, 145.9, 144.5, 142.9, 137.7, 134.5, 132.6, 128.4, 127.4, 124.9, 122.9, 
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121.9, 118.8, 114.3, 105.8, 103.3, 66.7, 55.7, 46.2, 43.6, 28.8; MS (EI) m/z (rel intensity) 420 
(M+, 100), 339 (25), 147 (35), HRMS (EI) Calcd for C25H24O4S 420.1395, found 420.1386. 
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(E)-3-But-2-enoyl-6,9-dimethoxy-4-methyl-4-vinylanthra[2,3-b]thiophen-11(4H)-one (221). 
To a solution of 30 mg (0.071 mmol) of 220 in 1.0 mL of DCM was added 36 mg (0.089 mmol) 
of Dess-Martin periodinane at room temperature.  The reaction mixture was stirred for 2.5 h at 
which time an additional 10 mg (0.024 mmol) of Dess-Martin periodinane was added and 
stirring was continued for 30 min. The mixture was then quenched with a 1:1 solution of 
saturated aqueous NaHCO3/Na2S2O3. The aqueous layer was extracted with DCM (3x), and the 
combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (10% EtOAc/Hex) to yield 22 mg 
(74%) of the ketone as a yellow orange foam: IR (film) 3081, 2936, 2834, 1693, 1654, 1625 cm-
1; 1H NMR ? 9.23 (s, 1 H), 8.31 (s, 1 H), 8.23 (s, 1 H), 6.79 (d, 1 H, J = 8.1 Hz), 6.69 (d, 1 H, J = 
8.1 Hz), 6.31 (dd, 1 H, J = 17.4, 10.5), 6.02 (dddd, 1 H, J = 17.1, 10.2, 6.6 Hz), 5.31-5.18 (m, 3 
H), 5.10 (d, 1 H, J = 17.4 Hz), 4.00 (s, 3 H), 3.98 (s, 3 H), 3.70 (dd, 1 H, J = 17.1, 6.9 Hz), 3.60 
(dd, 1 H, J = 17.1, 6.6 Hz), 2.02 (s, 3 H); 13C NMR ? 195.0, 179.1, 153.2, 150.7, 148.9, 146.6, 
142.3, 142.2, 138.9, 138.8, 130.5, 128.7, 126.9, 124.8, 122.8, 122.4, 119.2, 115.5, 106.0, 103.2, 
55.7, 47.7, 46.7, 30.0.  To a solution of 22 mg (0.053 mmol) of the ketone in 1.0 mL of DCM 
was added 0.25 mL (0.025 mmol) of a 0.1 M solution of DBU in DCM.  The reaction mixture 
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was stirred overnight then quenched with a saturated aqueous solution of CuSO4.  The aqueous 
layer was extracted with DCM (3x), the combined organic layers were washed with brine, dried 
(MgSO4), filtered and in vacuo. The residue was purified by chromatography on SiO2 (10% 
EtOAc/Hex) to yield 22 mg (quant.) of 221 as a yellow orange foam: IR (film) 3084, 2936, 2834, 
1652, 1624 cm-1; 1H NMR ? 9.24 (s, 1 H), 8.28 (s, 1 H), 7.89 (s, 1 H), 6.84-6.71 (m, 2 H), 6.68 
(d, 1 H, J = 8.4 Hz), 6.49 (dq, 1 H, J = 13.8, 1.8 Hz), 6.10 (dd, 1 H, J = 17.1, 10.2 Hz), 5.28 (d, 1 
H, J = 10.5 Hz), 5.26 (d, 1 H, J = 17.4 Hz), 3.99 (s, 3 H), 3.96 (s, 3 H), 2.00 (s, 3 H), 1.97 (dd, 3 
H, J = 6.9, 1.5 Hz); 13C NMR ? 190.5, 179.0, 153.2, 150.7, 148.8, 147.0, 145.9, 142.1, 141.3, 
138.7, 136.8, 133.2, 128.6, 127.3, 124.8, 122.9, 122.1, 115.9, 105.9, 103.3, 55.7, 46.7, 30.3, 
18.5; MS (EI) m/z (rel intensity) 418 (M+, 100), 403 (30), 373 (15); HRMS (EI) Calcd for 
C25H22O4S 418.1238, found 418.1244. 
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3-Hydroxy-8,11-dimethoxy-12b-methyl-3H-tetrapheno[5,4-bc]thiophen-6(12bH)-one (224).  
To a solution of 60 mg (0.14 mmol) of 220 in 6.0 mL of degassed benzene was added 14 mg 
(0.014 mmol) of (CO)RuHCl(Ph3P)3. The reaction vessel was sealed, lowered into a preheated 
80 °C bath, stirred for 30 min, cooled, filtered through florisil and concentrated in vacuo.  To a 
solution of the resulting residue in 24 mL of degassed DCM was added 17 mg (0.028 mmol) of 
catalyst 223, and the mixture was heated at reflux.  After 2 h, an additional 8.5 mg (0.014 mmol) 
of 223 was added and the mixture was heated overnight, cooled, filtered through florisil and 
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concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0?50% 
EtOAc/hexanes) to yield 29 mg (56%) of 224 as a 8:1 ratio of a red-orange, solid mixture of 
diastereomers: Mp 198.9-200.1 °C; IR (film) 3583, 3396, 2923, 1651, 1622, 1464, 1436, 1344 
cm-1; 1H NMR (DMSO-d6) ? 9.02 (s, 1 H), 8.54 (s, 1 H), 8.07 (d, 1 H, J = 1.2 Hz), 7.57 (d, 1 H, J 
= 8.7 Hz), 6.94 (d, 1 H, J = 8.4 Hz), 6.82 (dd, 1 H, J = 9.9, 2.7 Hz), 6.16 (dd, 1 H, J = 9.9, 1.5 
Hz), 5.99 (d, 1 H, J = 7.2 Hz), 5.37-5.28 (m, 1 H), 3.99 (s, 6 H), 1.45 (s, 3 H); characteristic 
signals of minor isomer: 1H NMR (DMSO-d6) ? 9.00 (s, 1 H), 7.97 (s, 1 H), 6.35 (d, 1 H, J = 
13.5 Hz), 5.85 (d, 1 H, J = 4.8 Hz), 5.74-5.65 (m, 1 H),  3.33 (s, 6 H), 1.80 (s, 1 H); 13C NMR 
(DMSO-d6) ? 177.5, 153.8, 149.7, 148.2, 143.8, 143.1, 134.3, 130.6, 130.5, 129.0, 127.0, 124.8, 
123.7, 122.6, 118.2, 107.2, 104.5, 63.5, 55.8, 37.8, 30.4; MS (EI) m/z (rel intensity) 378 (M+, 
25), 363 (35), 347 (35), 33 (25), 317 (20), 149 (100), 121 (35), 97 (55), 87 (90), 85 (95); HRMS 
(EI) Calcd for C22H18O4S 378.0925, found 378.9261. 
 
S
MeO
OMe
OO
 
8,11-Dimethoxy-12b-methyl-3H-tetrapheno[5,4-bc]thiophene-3,6(12bH)-dione (222).  To a 
solution of 23 mg (0.06 mmol) of 224 in 3.0 mL of DCM was added 31 mg (0.07 mmol) of 
Dess-Martin periodinane at room temperature.  The reaction mixture was stirred for 30 min, and 
quenched with a 1:1 solution of saturated aqueous NaHCO3/Na2S2O3. The aqueous layer was 
extracted with DCM (3x), and the combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo. The residue was purified by chromatography on SiO2 (10% Et2O/DCM) 
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to yield 20 mg (87%) of 222 as a yellow glass: IR (film) 2932, 1654, 1624 cm-1; 1H NMR ? 9.27 
(s, 1 H), 8.53 (s, 1 H), 8.50 (s, 1 H), 8.05 (d, 1 H, J = 10.2 Hz), 6.87 (d, 1 H, J = 8.4 Hz), 6.75 (d, 
1 H, J = 8.4 Hz), 6.51 (d, 1 H, J = 10.2), 4.01 (s, 3 H), 3.99 (s, 3 H), 1.69 (s, 3 H); 13C NMR ? 
180.3, 177.8, 157.7, 150.8, 149.7, 148.6, 139.8, 137.5, 135.4, 129.6, 129.3, 127.4, 125.3, 124.7, 
116.9, 106.8, 104.0, 55.7, 43.3, 42.8; MS (EI) m/z (rel intensity) 376 (M+, 50), 361 (100), 331 
(25), 303 (20), 84 (30); HRMS (EI) Calcd for C22H16O4S 376.0769, found 376.0760. 
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8,11-Dimethoxy-12b-methyl-1H-tetrapheno[5,4-bc]thiophene-3,6(2H,12bH)-dione (225).  To 
a solution of 15 mg (0.039 mmol) of 222 in 1.2 mL of toluene in a microwave reaction vessel 
was added 150 mg (0.040 mmol) of Stryker’s reagent.  The vessel was sealed and the reaction 
mixture was heated at 150 °C for 30 min under microwave irradiation.  The mixture was diluted 
with EtOAc and washed with a solution of saturated aqueous NH4Cl (2x), then NaHCO3 (2x) and 
brine (2x).  The organic layer was dried (MgSO4), filtered and concentrated in vacuo.  The 
residue was purified by chromatography on SiO2 (0?30% EtOAc/hexanes) to yield 8.0 mg 
(53%) of 225 as a yellow glass: IR (film) 3088, 2932, 1686, 1656, 1624 cm-1; 1H NMR ? 9.26 (s, 
1 H), 8.50 (s, 1 H), 8.36 (s, 1 H), 6.84 (d, 1 H, J = 8.4 Hz), 6.73 (d, 1 H, J = 8.4 Hz), 4.00 (s, 2 
H), 3.99 (s, 3 H), 3.15-2.85 (m, 3 H), 2.47-2.34 (m, 1 H), 1.68 (s, 3 H); 13C NMR ? 192.1, 178.4, 
158.6, 150.8, 148.7, 144.8, 138.7, 136.1, 135.4, 129.2, 127.9, 124.8, 124.3, 117.9, 106.4, 103.6, 
55.7, 38.9, 35.9, 44.4, 33.3; MS (EI) m/z (rel intensity) 347 ([M-CH3O]
+, 30), 277 (20), 192 
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(100), 164 (50), 136 (100), 122 (85), 120 (55), 91 (73); HRMS (EI) Calcd for C22H18O4S 
378.0925, found 378.0930. 
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thio-Halenaquenone (200).  To a solution of 5.0 mg (0.013 mmol) of 225 in 0.50 mL of 
acetonitrile and 0.25 mL of DCM was added 22 mg (0.039 mmol) of CAN in 0.25 mL of H2O.  
The reaction mixture was stirred for 5 min, diluted with H2O, and extracted with DCM (3x). The 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue 
was purified by chromatography on C18 silica (0?100% MeOH/H2O) to yield 3.0 mg (66%) of 
200 as a white film: IR (film) 2923, 2853, 1657 cm-1; 1H NMR (DMSO-d6) ? 8.95 (s, 1 H), 8.71 
(s, 1 H), 8.38 (s, 1 H), 7.20 (s, 2 H), 3.20-2.96 (m, 2 H), 2.75 (dd, 1 H, J = 18.6, 4.5 Hz), 2.27 
(dt, 1 H, J = 12.9, 4.8 Hz), 1.62 (s, 3 H); 13C NMR (DMSO-d6) ? 191.3, 184.2, 183.8, 176.1, 
159.5, 154.8, 141.4, 139.2, 136.0, 134.7, 134.0, 130.3, 124.7, 123.5, 35.4, 31.7, 31.5; MS (EI) 
m/z (rel intensity) 348 (M+, 45), 239 (65), 78 (75), 63 (100); HRMS (EI) Calcd for C20H12O4S 
348.0456, found 348.0448. 
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1-(4-(Methoxymethoxy)phenyl)ethanol (234).  To a solution of 3.0 g (22 mmol) of 4-
hydroxyacetophenone in 220 mL of DMF at 0 °C was added 0.56 g (23 mmol) of 60 % NaH in 
mineral oil.  The reaction mixture was warmed to room temperature, stirred for 30 min, cooled to 
0 °C, and treated with 1.8 g (23.2 mmol) of MOMCl.  The solution was warmed to room 
temperature, stirred for 1.5 h, diluted with brine, and extracted with Et2O (3x).  The combined 
organic layers were washed with brine (3x), dried (MgSO4), filtered and concentrated in vacuo.  
To a solution of 0.82 g (22 mmol) of NaBH4 in 25 mL EtOH was added a solution of the ketone 
in 35 mL of EtOH.  The reaction mixture was allowed to stir for 2 h and quenched with a 
saturated aqueous solution of NH4Cl, extracted with DCM (3x), dried (MgSO4), filtered and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (20% 
EtOAc/hexanes) to yield 2.2 g (55%) of 234 as a colorless oil: IR (film) 3402, 2970, 2826, 1610, 
1586 cm-1; 1H NMR ? 7.32-7.28 (m, 2 H), 7.05-7.00 (m, 2 H), 5.18 (s, 2 H), 4.86 (q, 1 H, J = 6.0 
Hz), 3.48 (s, 3 H), 1.80 (bs, 1 H), 1.48 (d, 3 H, J = 6.6 Hz); 13C NMR ? 156.0, 139.3, 126.3, 
115.8, 94.0, 69.2, 55.5, 24.8; MS (EI) m/z (rel intensity) 182 (M+, 55), 167 (50), 137 (60), 120 
(100), 91 (35), 77 (55); HRMS (EI) Calcd for C10H14O3 182.0942, found 182.0945. 
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tert-Butyl(1-(4-(methoxymethoxy)phenyl)ethoxy)dimethylsilane (231). To a solution of 1.85 
g (10.2 mmol) of 234 in 100 mL of DMF at 0 °C was added 2.37 g (15.8 mmol) of TBSCl 
followed by 1.91 g (28.1 mmol) of imidazole.  The reaction mixture was allowed to stir at room 
temperature overnight, quenched with brine and extracted with Et2O (3x).  The combined 
organic layers were washed with brine (2x), dried (MgSO4), filtered and concentrated in vacuo.  
The residue was purified by chromatography on SiO2 (1% Et2O/hexanes) to yield 2.59 g (86%) 
of 231 as a colorless oil: IR (film) 2955, 2894, 2856, 1510 cm-1; 1H NMR ? 7.27-7.23 (m, 2 H), 
7.02-6.96 (m, 2 H), 5.18 (s, 2 H), 4.80 (q, 1 H, J = 6.3 Hz), 3.49 (s, 3 H), 1.39 (d, 3 H, J = 6.3 
Hz), 0.91 (s, 9 H), 0.05 (s, 3 H), -0.02 (s, 3 H); 13C NMR ? 156.1, 140.2, 126.1, 115.7, 94.3, 
70.3, 55.6, 27.2, 25.8, 18.1, -4.8, -4.9; MS (EI) m/z (rel intensity) 296 (M+, 4), 239 (40), 209 
(50), 165 (100), 133 (25), 75 (40); HRMS (EI) Calcd for C16H28O3Si 296.1807, found 296.1817. 
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(3-(But-2-en-2-yl)-4-((tert-butyldimethylsilyloxy)methyl)-5-(trimethylsilyl)thiophen-2-yl)(5-
(1-(tert-butyldimethylsilyloxy)ethyl)-2-(methoxymethoxy)phenyl)methanone (235).  To a 
solution of 1.0 g (2.8 mmol) of 205 in 15 mL of THF at 0 °C was added 2.6 mL (4.3 mmol) of a 
1.6 M solution of n-BuLi in hexanes.  The reaction mixture was stirred for 15 min, then 4.0 g (56 
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mmol) of DMF was added and the solution was stirred for 15 min. At this time, a saturated 
aqueous solution of NH4Cl was added. The solution was diluted with H2O and extracted with 
Et2O (3x).  The combined organic layers were washed with brine (3x), dried (MgSO4), filtered 
and concentrated in vacuo.  To a solution of 1.2 g (4.2 mmol) of 231 in 35 mL Et2O at 0 °C was 
added 3.6 mL (5.0 mmol) of a 1.4 M solution of s-BuLi in cyclohexane.  The reaction mixture 
was stirred for 30 min then a solution of the resulting aldehyde in 10 mL of Et2O was added.  
The reaction mixture was allowed to stir for 15 min and was then quenched with a saturated 
aqueous solution of NH4Cl, and extracted with Et2O (3x).  The combined organic extracts were 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo.   The residue was purified 
by chromatography on SiO2 (5% EtOAc/hexanes) to yield 1.5 g (77%) of the alcohol as a 
colorless oil.  To a solution of 0.50 g (0.74 mmol) of the alcohol in 40 mL of DCM was added 
0.38 g (0.89 mmol) of Dess-Martin periodinane at room temperature.  The reaction mixture was 
stirred for 2 h at which time an additional 0.20 g (0.44 mmol) of DMP was added. Stirring was 
continued for 30 min, and the solution was quenched with a 1:1 solution of saturated aqueous 
NaHCO3/Na2S2O3. The aqueous layer was extracted with DCM (3x), and the combined organic 
layers were dried (Na2SO4), filtered and concentrated in vacuo.  The residue was purified by 
chromatography on Si2O (5% EtOAc/hexanes) to yield 0.43 g (86%) of 235 as a colorless, oily 
2.4:1 mixture of alkene isomers: IR (film) 2954, 2856, 1654, 1607 cm-1; 1H NMR ? 7.40-7.32 
(m, 2 H), 7.09 (d, 1 H, J = 8.7 Hz), 5.57-5.46 (m, 1 H), 5.11-5.06 (m, 2 H), 4.88-4.81 (m, 1 H), 
4.47 (s, 2 H), 3.37 (d, 3 H, J = 3.3 Hz), 1.91 (d, 3 H, J = 6 Hz), 1.41-1.33 (m, 6 H), 0.89 (s, 18 
H), 0.36 (s, 9 H), 0.10 (s, 6 H), 0.06 (s, 3 H), -0.02 (s, 3 H); characteristic signals for minor 
isomer: 1H NMR ? 7.20 (d, 1 H, J = 2.1 Hz), 7.07 (d, 1 H, J = 8.4 Hz), 5.33-5.28 (m, 1 H), 4.49 
(s, 2 H), 3.39 (s, 3 H), 1.51 (d, 3 H, J = 6.6 Hz); 13C NMR ? 188.7, 187.9, 153.2, 153.1, 152.9, 
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149.3, 149.2, 147.4, 147.1, 146.7, 146.7, 142.5, 141.8, 141.7, 139.51, 139.48, 139.4, 132.6, 
131.3, 131.2, 131.1, 131.0, 128.0, 127.9, 127.7, 125.4, 125.37, 125.32, 123.05, 122.99, 114.8, 
114.7, 114.6, 94.8, 94.7, 70.04, 69.97, 58.6, 56.0, 27.0, 25.9, 25.8, 25.7, 24.5, 24.4, 18.3, 18.2, 
18.1, 18.0, 14.9, 13.6, 0.1, -4.8, -5.0, -5.6; MS (EI) m/z (rel intensity) 676 (M+, 10), 661 (35), 147 
(55), 73 (100); HRMS (EI) Calcd for C35H60O5Si3S 676.3469, found 676.3470.  
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(3-(But-2-en-2-yl)-4-((tert-butyldimethylsilyloxy)methyl)-5-(trimethylsilyl)thiophen-2-yl)(5-
(1-(tert-butyldimethylsilyloxy)ethyl)-2-hydroxyphenyl)methanone (236).  To a solution of 69 
mg (0.10 mmol) of 235 in 3.0 mL Et2O at 0 °C was added 40 mg (0.15 mmol) of MgBr2•OEt2.  
The reaction mixture was warmed to room temperature, stirred for 2 h, quenched with a saturated 
aqueous solution of NaHCO3, and extracted with Et2O (3x).  The combined organic layers were 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by chromatography on SiO2 (5% EtOAc/hexanes) to yield 61 mg (95%) of 236 as a colorless, 
oily 2.8:1 mixture of alkene isomers: IR (film) 2955, 2928, 2856 cm-1; 1H NMR ? 11.67 (s, 1 H), 
7.80 (dd, 1 H, J = 13.5, 1.8 Hz), 7.48-7.43 (m, 1 H), 6.98 (d, 1 H, J = 8.7 Hz), 5.66-5.55 (m, 1 
H), 4.81 (q, 1 H, J = 6.3 Hz), 4.54 (s, 2 H), 1.99 (bd, 3 H, J = 15.9 Hz), 1.43-1.35 (m, 6 H), 0.92 
(s, 9 H), 0.85 (s, 9 H), 0.41 (s, 9 H), 0.12 (s, 9 H), 0.05 (s, 3 H); characteristic signals of minor 
isomer: 1H NMR ? 11.70 (s, 1 H), 7.68 (d, 1 H, J = 2.1 Hz), 6.97 (d, 1 H, J = 8.4 Hz), 5.48-5.41 
(m, 1 H), 4.59 (s, 2 H), 1.62 (d, 3 H, J = 6.6 Hz), -0.03 (s, 3 H), -0.06 (s, 3 H); 13C NMR ? 195.0, 
194.1, 193.9, 161.5, 161.4, 161.2, 151.9, 148.8, 148.7, 146.9, 148.7, 144.5, 144.2, 143.6, 138.2, 
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137.74, 137.7, 137.0, 136.9, 136.9, 133.2, 133.1, 132.2, 132.1, 131.1, 129.5, 129.3, 129.2, 126.2, 
124.3, 124.2, 120.3, 120.2, 120.1, 117.7, 117.6, 117.6, 69.8, 69.7, 58.7, 26.9, 26.8, 26.0, 25.9, 
25.8, 25.7, 25.4, 25.2, 18.4, 18.3, 18.3, 18.2, 18.1, 18.0, 15.2, 15.0, 13.8, 0.3, -4.8, -4.9, -5.4, -
.5.5; MS (EI) m/z (rel intensity) 632 (M+, 40), 617 (65), 575 (15), 485 (10), 443 (15), 351 (40), 
279 (15), 219 (15), 147 (100), 84 (90), 73 (100); HRMS (EI) Calcd for C33H56O4Si3S 632.3207, 
found 632.3199.  
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7-(1-(tert-Butyldimethylsilyloxy)ethyl)-3-((tert-butyldimethylsilyloxy)methyl)-4-methyl-4-
vinylnaphtho[2,3-b]thiophen-9(4H)-one (230).  To a solution of 0.02 g (0.34 mmol) of 236 in 2 
mL of THF was added 15 mg (0.63 mmol) of NaH.  The reaction mixture was cooled to 0 °C, 
treated with 0.45 g (1.26 mmol) of PhN(Tf)2, warmed to room temperature, stirred overnight, 
quenched with H2O and extracted with DCM (3x).  The combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo.  The residue was purified by chromatography on 
SiO2 (2% EtOAc/hexanes) to yield 237 mg (99%) of the triflate as a yellow oil.  To a solution of 
3.0 mg (0.013 mmol) of Pd(OAc)2 in 0.50 mL of degassed DMA in a conical microwave 
reaction vessel was added 16 mg (0.026 mmol) of racemic BINAP.  The resulting solution stirred 
for 15 min, then 28 mg (0.20 mmol) of K2CO3 and a solution of 50 mg (0.065 nmol) of the 
triflate in 0.30 mL of degassed DMA were added.  The solution was heated at 120 °C for 30 min 
under microwave irradiation, diluted with hexanes, filtered through a plug of celite, and the 
filtrate was concentrated in vacuo.  The residue was purified by chromatography on SiO2 (2% 
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Et2O/hexanes) to give 12 mg (34%) of 230 as a colorless oil: IR (film) 2924, 2853, 1651 cm
-1; 1H 
NMR ? 8.21 (s, 1 H), 7.78 (s, 1 H), 7.65 (d, 1 H, J = 8.4 Hz), 7.46 (d, 1 H, J = 8.7 Hz), 5.89 (dd, 
1 H, J = 17.4, 11.2 Hz), 5.49 (d, 1 H, J = 17.4 Hz), 5.42 (d, 1 H, J = 10.5 Hz), 4.98 (q, 1 H, J = 
6.0 Hz), 4.89 (d, 1 H, J = 14.1 Hz), 4.75 (d, 1 H, J = 13.5 Hz), 1.71 (s, 3 H), 1.45 (dd, 3 H, J = 
8.1, 1.8 Hz), 0.96 (s, 9 H), 0.92 (s, 9 H), 0.13 (s, 3 H), 0.11 (s, 3 H), 0.07 (s, 3 H), -0.01 (s, 3 H); 
13C NMR ? 178.9, 150.1, 147.23, 147.19, 146.02, 146.00, 142.8, 141.0, 137.7, 131.1, 129.9, 
129.8, 129.59, 129.56, 128.3, 123.18, 123.16, 114.55, 114.54, 70.20, 70.18, 60.7, 45.73, 45.72, 
27.04, 27.01, 26.2, 25.9, 25.8, 18.4, 18.2, -4.79, -4.82, -5.3, -5.4; MS (ES) m/z (rel intensity) 565 
([M+23Na]+, 60), 413 (100); HRMS (ES) Calcd for C30H46O3NaSi2S 565.2604, found 565.2570. 
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2-(But-2-en-2-yl)benzaldehyde (240). To a solution of 3.0 g (14 mmol) of 1-bromo-2-(but-2-
en-2-yl)benzene (242)207 in 90 mL of Et2O at 0 °C was added 14 mL (20 mmol) of a 1.4 M 
solution of s-BuLi in cyclohexane.  The reaction mixture was stirred for 10 min, treated with 10 
g (140 mmol) of DMF, allowed to stir at room temperature for 30 min, diluted with brine, and 
extracted with Et2O (3x).  The combined organic layers were washed with brine (3x), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was purified by chromatography on 
SiO2 (0?5% EtOAc/hexanes) to yield 2.0 g (87%) of 240 as a pale yellow, oily 2.9:1 mixture of 
alkene isomers: IR (film) 3027, 2975, 2913, 2835, 1693, 1596 cm-1; 1H NMR ? 10.09 (s, 1 H), 
7.95 (dd, 1 H, J = 7.8, 0.6 Hz), 7.59 (dt, 1 H, J = 7.5, 1.5 Hz), 7.42-7.33 (m, 1 H), 7.20 (d, 1 H, J 
= 7.5 Hz), 5.78 (qq, 1 H, J = 6.9, 1.5 Hz), 2.08-2.06 (m, 3 H), 1.39 (dq, 3 H, J = 6.6, 1.5 Hz); 
characteristic signals for minor isomer: 1H NMR ? 10.11 (s, 1 H), 7.90 (dd, 1 H, J = 6.9, 0.9 Hz), 
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7.53 (dt, 1 H, J = 7.5, 1.5 Hz), 7.38-7.35 (m, 1 H), 7.33-7.29 (m, 1 H), 5.42 (qq, 1 H, J = 6.6, 1.2 
Hz), 1.85 (dq, 3 H, J = 6.6, 0.9 Hz); 13C NMR ? 191.5, 149.1, 145.8, 133.6, 133.3, 133.0, 132.8, 
132.54, 132.5, 128.9, 128.3, 127.1, 126.7, 126.6, 126.3, 124.4, 26.1, 17.9, 14.22, 13.7; MS (EI) 
m/z (rel intensity) 160 (M+, 30), 145 (100), 131 (50), 117 (60), 115 (75), 103 (30), 91 (60), 76 
(50), 61 (25); HRMS (EI) Calcd for C11H12O 160.0888, found 160.0883. 
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3-Bromo-4-(trityloxymethyl)thiophene (241).   To a solution of 1.9 g (9.8 mmol) of 211 in 30 
mL of DMF was added 3.2 g (12 mmol) of trityl chloride, 2.0 g (12 mmol) of AgNO3, and 2.8 g 
(22 mmol) of Et3N.  The reaction mixture was stirred overnight, then diluted with Et2O and 
filtered through celite.  The filtrate was diluted with brine, and extracted with Et2O (3x).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (0?10% EtOAc/hexanes), then 
crystallized from Et2O to yield 3.9 g (92%) of 241 as a white solid: Mp 123.3-126.2 °C, IR (film) 
3108, 3085, 3058, 3030, 1490, 1447 cm-1; 1H NMR ? 7.60-7.49 (m, 7 H), 7.41-7.26 (m, 10 H), 
4.16 (d, 2 H, J = 0.6 Hz); 13C NMR ? 143.8, 138.6, 128.6, 127.9, 127.1, 123.0, 122.4, 109.9, 
87.2, 62.1. 
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(3-Bromo-4-(trityloxymethyl)thiophen-2-yl)(2-(but-2-en-2-yl)phenyl)methanone (239).  To a 
solution of 1.9 g (19 mmol) of diisopropylamine in 65 mL of THF at 0 °C was added 12 mL (19 
mmol) of a 1.6 M solution of n-BuLi.  The resulting pale yellow solution was stirred for 30 min 
then a solution of 4.1 g (9.3 mmol) of 241 in 25 mL of THF was added.  The resulting red 
solution was stirred for 1 h, treated with 1.8 g (11 mmol) of 240 stirred for 1 h and quenched 
with a saturated aqueous solution of NH4Cl.  The solution was extracted with Et2O (3x), and the 
combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (0?15% EtOAc/hexanes) to yield 
5.0 g (89%) of the alcohol as a pale yellow oil.  To a solution of 5.0 (8.4 mmol) of the resulting 
alcohol in 240 mL of DCM was added 41 g (461 mmol) of MnO2.  The solution was stirred 
overnight, filtered through celite and concentrated in vacuo. The residue was purified by 
chromatography on SiO2 (0?10% EtOAc/hexanes) to yield 4.7 g (94%) of 239 as a pale yellow, 
oily 3.2:1 mixture of alkene isomers: IR (film) 3058, 1646, 1446 cm-1; 1H NMR ? 7.73 (s, 1 H), 
7.51-7.47 (m, 7 H), 7.36-7.27 (m, 12 H), 5.47 (q, 1 H, J = 6.6 Hz), 4.17 (s, 2 H), 1.92 (s, 3 H), 
1.40 (dq, 3 H, J = 5.7, 1.2 Hz); characteristic signals for minor isomer: 1H NMR ? 7.67 (s, 1 H), 
4.15 (s, 2 H), 1.87 (s, 3 H), 1.58 (d, 3 H, J = 6.9 Hz); 13C NMR ? 190.2, 188.9, 144.5, 143.6, 
141.2, 141.1, 140.9, 138.7, 138.5, 138.3, 137.7, 135.3, 134.7, 130.7, 130.4, 129.2, 128.4, 128.3, 
128.2, 127.8, 127.44, 127.4, 127.0, 126.1, 123.6, 114.6, 114.2, 87.2, 62.1, 25.6, 17.2, 15.1, 
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14.21; MS (ES) m/z (rel intensity) 617.2 ([M+23Na]+, 95), 615.2 (90), 595.2 (100), 593.2 
([M+H]+, 90); HRMS (ES) Calcd for C35H30O2SBr 593.1150, found 593.1158.  
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4-Methyl-3-(trityloxymethyl)-4-vinylnaphtho[2,3-b]thiophen-9(4H)-one (238).  A solution of 
1.6 g (2.7 mmol) of 239 in 18 mL of NMP was divided evenly among 5 microwave reaction 
vessels containing 0.12 g (0.11 mmol) Pd(Ph3P)4 and 1.1 g (11 mmol) of Et3N. The solutions 
were heated at 220 °C for 5 min under microwave irradiation and filtered through a pad of celite, 
which was washed with DCM.  The combined filtrates were diluted with brine and extracted 
with Et2O (3x) the combined organic layers were dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (5% EtOAc/hexanes) to yield 0.84 
g (60%) of 238 as a white foam: IR (film) 3059, 3030, 2247, 1649, 1598, 1490 cm-1; 1H NMR ? 
8.32 (dd, 1 H, J = 6.6, 1.2 Hz), 8.10 (bs, 1 H), 7.59-7.50 (m, 7 H), 7.45-7.19 (m, 11 H), 5.61 (dd, 
1 H, J = 17.4, 10.5 Hz), 5.03 (d, 1 H, J = 17.4 Hz), 4.99 (d, 1 H, J = 10.5 Hz), 4.29 (dd, 1 H, J = 
12.6, 0.9 Hz), 4.17 (dd, 1 H, J = 12.6, 0.6 Hz), 1.49 (s, 3 H); 13C NMR ? 178.6, 150.6, 148.7, 
143.7, 140.1, 140.0, 137.1, 132.7, 131.7, 129.8, 128.5, 128.2, 127.9, 127.1, 126.9, 126.6, 114.6, 
87.3, 61.5, 45.7, 26.0; MS (ES) m/z (rel intensity) 513 ([M+H]+, 50), 443 (100), 365 (10), 362 
(10), 243 (15), 165 (40); HRMS (ES) Calcd for C35H29O2S 513.1888, found 513.1861. 
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4-Methyl-9-oxo-4-vinyl-4,9-dihydronaphtho[2,3-b]thiophene-3-carbaldehyde (243).  To a 
solution of 0.78 g (1.5 mmol) of 238 in 14 mL of THF was added 4.7 mL (56 mmol) of conc. 
HCl.  The reaction mixture was stirred for 1 h, then quenched with a saturated aqueous solution 
of NaHCO3, and extracted with DCM (3x).  The combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo.  To a solution of the resulting alcohol in 33 mL of DCM was 
added 3.8 g (44 mmol) of MnO2. After 45 min, the mixture was filtered through celite and 
concentrated in vacuo. The residue was purified by chromatography on SiO2 (0?20% 
EtOAc/hexanes) to yield 0.33 g (81%) of 243 as a white solid: Mp 112.9-115.0 °C; IR (film) 
1683, 1651, 1519 cm-1; 1H NMR ? 10.23 (s, 1 H), 8.56 (s, 1 H), 8.34 (dd, 1 H, J = 8.1, 1.2 Hz), 
7.66 (dt, 1 H, J = 8.1, 1.2 Hz), 7.57 (d, 1 H, J = 7.8 Hz), 7.50 (dt, 1 H, J = 8.1, 1.2 Hz), 6.23 (dd, 
1 H, J = 17.4, 10.5 Hz), 5.42 (d, 1 H, J = 17.4 Hz), 5.38 (d, 1 H, J = 10.5 Hz), 1.93 (s, 3 H); 13C 
NMR ? 184.6, 178.1, 152.0, 148.8, 143.5, 141.7, 140.5, 138.2, 133.2, 129.1, 128.5, 127.1, 126.4, 
115.3, 45.7, 28.7; MS (EI) m/z (rel intensity) 268 (M+, 40), 253 (90), 225 (25), 80 (50), 68 (100); 
HRMS (EI) Calcd for C16H12O2S 268.0558, found 268.0568. 
 
S
O
HO
 
3-(1-Hydroxybut-3-enyl)-4-methyl-4-vinylnaphtho[2,3-b]thiophen-9(4H)-one (237).  To a 
solution of 0.16 g (0.58 mmol) of 243 and 270 mg (0.82 mmol) of allyltributylstanne in 9 mL  of 
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DCM at -78 °C was added 0.15 mL (1.2 mmol) of BF3•OEt2. The resulting solution was stirred 
for 30 min, quenched with a saturated aqueous solution of NaHCO3 and warmed to room 
temperature.  The aqueous layer was extracted with DCM (3x), and the combined organic layers 
were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by chromatography on SiO2 (0?20% EtOAc/hexanes) to yield 0.18 g (95%) of 237 as a 
10:1 white, pasty mixture of diastereomers: IR (film) 3443, 3078, 2978, 2938, 1642, 1598, 1525, 
1453 cm-1; 1H NMR ? 8.31 (dd, 1 H, J = 7.8, 1.2 Hz), 7.63 (s, 1 H), 7.59 (dd, 1 H, J = 6.9, 1.2 
Hz), 7.51 (d, 1 H, J = 7.2 Hz), 7.44 (dt, 1 H, J = 8.1, 1.2 HZ), 5.97 (dd, 1 H, J = 17.4, 10.5 Hz), 
5.92-5.71 (m, 1 H), 5.56 (d, 1 H, J = 17.4 Hz), 5.44 (d, 1 H, J = 10.5 Hz), 5.24-5.14 (m, 3 H), 
2.63-2.54 (m, 1 H), 2.51-2.39 (m, 1 H), 2.14-2.10 (m, 1 H), 1.83 (s, 3 H); characteristic signals 
for minor isomer: 1H NMR ? 7.64 (s, 1 H), 6.10 (dd, 1 H, J = 17.4, 10.5), 1.76 (s, 3 H); 13C NMR 
? 178.6, 150.6, 150.4, 148.9, 146.1, 141.8, 141.6, 136.6, 134.4, 134.3, 132.8, 132.5, 129.4, 128.3, 
126.9, 126.3, 118.0, 114.8, 114.7, 66.5, 66.3, 45.9, 45.7, 43.3, 43.0, 27.9, 27.2; MS (ES) m/z (rel 
intensity) 311 ([M+H]+, 25), 255 (20), 237 (15); HRMS (ES) Calcd for C19H19O2S 311.1106, 
found 311.1104.  
 
O
S
O
 
10b-Methyl-3H-phenanthro[10,1-bc]thiophene-3,6(10bH)-dione (228).  To a solution of 0.17 
g (0.53 mmol) of 237 in 21 mL of benzene was added 51 mg (0.053 mmol) of 
(CO)RuHCl(Ph3P)3. The reaction vessel was sealed, lowered into a preheated 80 °C bath, stirred 
for 30 min, cooled, filtered through florisil and concentrated in vacuo.  To a solution of the 
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resulting residue in 90 mL of DCM was added 66 mg (0.11 mmol) of 223, and the mixture was 
heated at reflux for 4 h.  The solution was cooled, filtered through florisil, which was washed 
with EtOAc, and concentrated in vacuo.  The residue was purified by chromatography on Si2O 
(0?50% EtOAc/hexanes) to yield 55 mg (39%) of the cyclohexenol.  To a solution of 55 mg 
(0.21 mmol) of the cyclohexenol in 10 mL of DCM was added 0.11 g (0.25 mmol) of Dess-
Martin periodinane at room temperature. The reaction mixture was stirred for 30 min, and 
quenched with a 1:1 solution of saturated aqueous NaHCO3/Na2S2O3. The aqueous layer was 
extracted with DCM (3x), and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. The residue was purified by chromatography on SiO2 (10% 
EtOAc/hexanes) to yield 39 mg (70%) of 228 as a white solid: Mp (dec) 145.1 °C, IR (film) 
2926, 2854, 1658, 1265, 1198 cm-1; 1H NMR ? 8.52 (s, 1 H), 8.36 (d, 1 H, J = 7.8 Hz), 7.82 (d, 1 
H, J = 9.9 Hz), 7.77 (d, 1 H, J = 7.8 Hz), 7.67 (t, 1 H, J = 7.5 Hz), 7.51 (t, 1 H, J = 7.5 Hz), 6.46 
(d, 1 H, J = 10.2 Hz), 1.68 (s, 3 H); 13C NMR ? 180.1, 177.5, 157.8, 149.0, 144.8, 137.7, 135.5, 
135.0, 133.1, 132.2, 129.8, 128.8, 127.7, 123.7, 43.2, 42.9; MS (EI) m/z (rel intensity) 266 (M+, 
35), 251 (100), 223 (30), 195 (15), 151 (10), 61 (15); HRMS (EI) Calcd for C16H10O2S 266.0401, 
found 266.0398. 
 
S
BrHO
 
1-(4-Bromothiophen-3-yl)prop-2-en-1-ol (259).  To a solution of 1.0 g (4.1 mmol) of 206 in 
5.0 mL of Et2O at -78 °C was added 2.6 mL (4.1 mmol) of a 1.6 M solution of n-BuLi in 
hexanes.  The reaction mixture was stirred for 20 min and then 0.37 g (6.2 mmol) of acrolein was 
added.  The solution was stirred for 1 h, diluted with H2O and warmed to room temperature.  The 
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layers were separated, and the aqueous layer was extracted with Et2O (3 x).  The combined 
organic layers were washed with brine (3x), dried (MgSO4), filtered and concentrated in vacuo. 
The residue was purified by chromatography on SiO2 (10% EtOAc/hexanes) to yield 0.54 g 
(60%) of 259 as a pale yellow oil: IR (film) 3356, 3108 cm-1; 1H NMR ? 7.31 (s, 2 H), 6.09 (ddd, 
I H, J = 17.1, 10.5, 5.7 Hz), 5.43 (dt, 1 H, J = 17.1, 1.2 Hz), 5.33 (bd, 1 H, J = 5.7 Hz), 5.28 (dt, 
1 H, J = 10.5, 1.2 Hz), 2.11 (bs, 1 H); 13C NMR ? 141.8, 138.0, 123.9, 123.0, 116.0, 110.3, 70.3; 
MS (EI) m/z (rel intensity) 217 (M+, 10), 204 (50), 203 (85), 202 (45), 201 (80), 191 (65), 189 
(60), 177 (25), 175 (25), 122 (100), 84 (50); HRMS (EI) Calcd for C7H7OSBr 217.9400, found 
217.9407. 
 
S
BrO
 
3-Bromo-4-(1-(trityloxy)allyl)thiophene (258).   To a solution of 2.4 g (11 mmol) of 259 in 8 
mL pyridine was added 3.7 g (13 mmol) of trityl chloride.  The reaction mixture was heated at 75 
°C overnight, cooled, diluted with H2O, and extracted with Et2O (3x).  The combined organic 
layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue 
was purified by chromatography on SiO2 (5% EtOAc/hexanes) to yield 2.7 g (53%) of 258 as a 
white solid: Mp 108.8-112.4 °C; IR (film) 3085, 3058, 3030, 1490, 1447 cm-1; 1H NMR ? 7.51-
7.45 (m, 6 H), 7.30-7.14 (m, 9 H), 7.05 (d, 1 H, J = 3.3 Hz), 6.94 (d, 1 H, J = 3.6 Hz), 5.85 (ddd, 
1 H, J = 17.1, 10.5, 3.6 Hz), 5.15 (s, 1 H), 5.11 (d, 1 H, J = 9.3 Hz), 4.99 (d, 1 H, J = 10.5 Hz); 
13C NMR ? 144.3, 141.7, 138.1, 128.8, 128.6, 127.6, 122.7, 122.1, 114.4, 109.2, 88.3, 73.3; MS 
(EI) m/z (rel intensity) 460 (M+, 10), 406 (30), 404 (30), 385 (20), 383 (20), 259 (35), 244 (85), 
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243 (100), 241 (50), 239 (45), 228 (40), 215 (35), 165 (95), 122 (90), 77 (90); HRMS (EI) Calcd 
for C26H21OSBr 460.0496, found 460.0501. 
 
O
S
O
Br
 
(3-Bromo-4-(1-(trityloxy)allyl)thiophen-2-yl)(2-(but-2-en-2-yl)phenyl)methanone (257).  To 
a solution of 0.11 g (1.1 mmol) of diisopropylamine and 0.20 g (1.1 mmol) of HMPA in 6.0 mL 
of THF at 0 °C was added 0.67 mL (1.1 mmol) of a 1.6 M solution of n-BuLi in hexanes. The 
resulting pale yellow solution was stirred for 30 min and then a solution of 0.25 g (0.54 mmol) of 
258 in 1.0 mL of THF was added. The resulting red solution was stirred for 1 h, treated with 0.10 
g (0.65 mmol) of 240, stirred for 2 h and quenched with a saturated aqueous solution of NH4Cl.  
The solution was extracted with Et2O (3x), and the combined organic layers were washed with 
brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by 
chromatography on SiO2 (0?5% EtOAc/hexanes) to yield 0.10 g (70%) of the alcohol as a 
yellow oil. To a solution of the alcohol in 15 mL of DCM was added 2.5 g (28 mmol) of MnO2.  
The mixture was stirred overnight, filtered through celite and concentrated in vacuo.  The residue 
was purified by chromatography on SiO2 (10% EtOAc/hexanes) to yield 0.21 g (90%) of 257 as 
a yellow, oily 3:1 mixture of alkene isomers: IR (film) 3086, 3059, 3024, 2977, 2913, 1643, 
1595, 1490, 1446, 1404 cm-1; 1H NMR ? 7.55-7.50 (m, 7 H), 7.47 (dd, 1 H, J = 7.2, 1.5 Hz), 7.39 
(d, 1 H, J = 6.6 Hz), 7.34 (d, 1 H, J = 7.5 Hz), 7.31-7.17 (m, 10 H), 5.95 (ddd, 1 H, J = 17.1, 
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10.2, 6.0 Hz), 5.51 (qq, 1 H, J = 6.6, 1.2 Hz), 5.28 (d, 1 H, J = 17.1 Hz), 5.24 (d, 1 H, J = 6.0 
Hz), 5.14 (d, 1 H, J = 13.5 Hz), 1.95 (d, 3 H, J = 0.9 Hz), 1.43 (dd, 3 H, J = 6.6, 1.2 Hz); 
characteristic signals of minor isomer: 1H NMR ? 1.88 (s, 3 H), 1.63 (d, 3 H, J = 6.9 Hz); 13C 
NMR ? 190.0, 188.5, 144.6, 144.4, 144.0, 141.5, 138.3, 137.4, 136.5, 135.5, 134.9, 130.7, 130.4, 
129.5, 128.9, 128.8, 128.7, 128.4, 128.2, 128.1, 127.7, 126.9, 126.1, 126.0, 123.2, 115.0, 114.2, 
113.8, 88.4, 73.03, 72.97, 34.6, 34.5, 31.5, 25.8, 25.2, 22.6, 20.7, 17.4, 15.1, 14.3, 14.1; MS (ES) 
m/z (rel intensity)  641 ([M+23Na]+, 25), 621 (80), 619 (75), 243 (75), 165 (100); HRMS (ES) 
Calcd for C37H31O2NaSBr 641.1126, found 641.1144. 
 
S
O
O
H
 
4-Methyl-3-(1-(trityloxy)allyl)-4-vinylnaphtho[2,3-b]thiophen-9(4H)-one (256). To a solution 
of 0.72 g (1.2 mmol) of 257 in 10 mL of NMP divided evenly among 2 microwave reaction 
vessels was added 0.12 g of Pd(Ph3P)4 and 1.7 mL of Et3N.  The solutions were heated at 220 °C 
for 5 min under microwave irradiation, and filtered through a plug of celite, which was washed 
with Et2O.  The filtrate was washed with brine (2x), and the organic layer was dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by chromatography on SiO2 (5% 
EtOAc/hexanes) to yield 0.24 g (38%) of 256 as a white foam: IR (film) 3059, 3029, 1648 cm-1; 
1H NMR ? 8.32 (d, 1 H, J = 6.9 Hz), 8.19 (s, 1 H), 7.56-7.22 (m, 18 H), 5.68 (dd, 1 H, J = 17.4, 
10.2 Hz), 5.41-5.17 (m, 4 H), 4.70 (d, 1 H, J = 10.5 Hz), 4.64 (d, 1 H, J = 17.1 Hz), 1.16 (s, 3 H); 
13C NMR ? 178.7, 149.6, 148.6, 144.7, 144.5, 142.0, 139.7, 133.6, 132.7, 130.0, 129.1, 128.1, 
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127.7, 127.2, 127.0, 126.6, 144.9, 114.4, 88.4, 70.7, 46.0, 27.4; MS (ES) m/z (rel intensity) 539 
([M+H]+, 100), 527 (20), 443 (20), 365 (20), 243 (10), 165 (25); HRMS (ES) Calcd for 
C37H31O2S 539.2045, found 539.2026.   
 
S
BrO
Si
 
(1-(4-Bromothiophen-3-yl)allyloxy)triisopropylsilane (260).  To a solution of 2.0 (9.3 mmol) 
of 259 in 35 mL of DCM was added 2.0 g (19 mmol) of 2,6-lutidine followed by 4.4 g (14 
mmol) of triisopropylsilyl trifluoromethanesulfonate.  The reaction mixture was stirred 
overnight, quenched with a saturated aqueous solution of NH4Cl, diluted with H2O, and extracted 
with EtOAc (3x).  The combined organic layers were dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (0?1% EtOAc/hexanes) to yield 
3.1 g (88%) of 260 as pale yellow oil: IR (film) 2943, 2866, 1463, 1384 cm-1; 1H NMR ? 7.34 (d, 
1 H, J = 3.3 Hz), 7.23 (d, 1 H, J = 3.3 Hz), 5.92 (ddd, 1 H, J = 17.1, 10.2, 5.7 Hz), 5.37 (d, 1 H, J 
= 7.5 Hz), 5.33 (d, 1 H, J = 17.1 Hz), 5.08 (d, 1 H, J = 10.2 Hz), 1.15-1.01 (m, 21 H); 13C NMR 
? 143.6, 139.8, 123.0, 122.2, 113.8, 109.2, 72.0, 18.0, 17.9, 12.2; MS (EI) m/z (rel intensity) 335 
(5), 334 (20), 333 (85), 331 ([M-C3H7]
+, 85), 203 (20), 201 (20), 122 (100), 121 (20); HRMS 
(EI) Calcd for C13H20OSiSBr 331.0187, found 331.0186. 
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(3-Bromo-4-(1-(triisopropylsilyloxy)allyl)thiophen-2-yl)(2-(but-2-en-2-yl)phenyl)methanone 
(261).  To a solution of 81 mg (0.80 mmol) of diisopropylamine and 0.14 g (0.80 mmol) of 
HMPA in 3.0 mL THF at 0 °C was added 0.50 mL (0.80 mmol) of a 1.6 M solution n-BuLi in 
hexanes. The resulting pale yellow solution was stirred for 30 min then a solution of 0.10 g (0.27 
mmol) of 260 in 0.50 mL of THF was added. The resulting red solution was stirred for 1 h., 
treated with 0.51 mg (0.31 mmol) of 240, stirred for 2 h, and quenched with a saturated aqueous 
solution of NH4Cl.  The solution was extracted with Et2O (3x), and the combined organic layers 
were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by chromatography on SiO2 (0?5% EtOAc/hexanes) to yield 76 mg (53%) of the 
alcohol as a yellow oil. To a solution of the alcohol in 18 mL of DCM was added 2.2 g (98 
mmol) of MnO2. The mixture was stirred overnight, filtered through celite and concentrated in 
vacuo.  The residue was purified by chromatography on SiO2 (10% EtOAc/hexanes) to yield 
0.15 g (86%) of 261 as a yellow, oily 3:1 mixture of alkene isomers: IR (film) 2942, 2891, 2866, 
1648 cm-1; 1H NMR ? 7.62 (s, 1 H), 7.49 (d, 2 H, J = 7.2 Hz), 7.35 (t, 1 H, J = 6.6 Hz), 7.20 (d, 1 
H, J = 7.2 Hz), 5.89 (ddd, 1 H, J = 13.5, 10.2, 5.4), 5.46-5.28 (m, 3 H), 5.10 (d, 1 H, J = 10.2 
Hz), 1.89 (s, 3 H), 1.38 (d, 3 H, J = 6.6 Hz), 1.16-1.00 (m, 21 H); characteristic signals for minor 
isomer: 1H NMR ? 7.56 (s, 1 H), 7.45 (d, 2 H, J = 7.5 Hz), 1.84 (s, 3 H), 1.54 (d, 3 H, J = 6.6 
Hz); 13C NMR ? 190.6, 189.4, 146.3, 146.2, 144.5, 141.2, 139.0, 138.9, 137.9, 135.3, 134.6, 
130.7, 130.5, 129.2, 128.3, 128.2, 127.9, 127.8, 127.6, 127.1, 126.3, 123.9, 114.2, 114.1, 113.7, 
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113.2, 71.6, 71.5, 25.5, 17.9, 17.8, 17.0, 15.1, 14.2, 12.0; MS (ES) m/z (rel intensity) 
533([M+H]+, 100), 527 (40), 443 (20), 365 (40), 362 (10); HRMS (ES) Calcd for C27H38SiSBr 
533.1545, found 533.1553.  
 
S
TIPSO
O
H
 
4-methyl-3-(1-(triisopropylsilyloxy)allyl)-4-vinylnaphtho[2,3-b]thiophen-9(4H)-one (262). 
 A solution of 0.63 g (1.2 mmol) of 261 in 12 mL of NMP was divided evenly among 3 
microwave reaction vessels containing 84 mg of Pd(Ph3P)4 and 1.2 mL of Et3N.  The solutions 
were heated at 220 °C for 5 min under microwave irradiation, and filtered through a plug of 
celite, which was washed with Et2O.  The filtrate was washed with brine (2x), and the organic 
layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by 
chromatography on SiO2 (0?2% EtOAc/hexanes) to yield 0.70 g (55%) of 262 as a yellow, oily 
2.2:1 mixture of diastereomers: IR (film) 2942, 2865, 1652, 1455 cm-1; 1H NMR ? 8.32 (d, 1 H, 
J = 7.5 Hz), 7.88 (s, 1 H), 7.58 (d, 1 H, J = 6.9 Hz), 7.50 (d, 1 H, J = 6.9 Hz), 7.44 (t, 1 H, J = 7.2 
Hz), 6.10-5.88 (m, 3 H), 5.70 (d, 1 H, J = 4.5 Hz), 5.62 (d, 1 H, J = 17.4 Hz), 5.47 (d, 1 H, J = 
10.5 Hz), 5.20 (d, 1 H, J = 18.3 Hz), 5.04 (d, 1 H, J = 10.5 Hz), 1.77 (s, 3 H), 1.17-0.95 (m, 21 
H); characteristic signals for minor isomer: 1H NMR ? 7.96 (s, 1 H), 5.78 (d, 1 H, J = 6.0 Hz), 
5.65 (d, 1 H, J = 17.4 Hz), 5.12 (d, 1 H, J = 5.1 Hz); 13C NMR ? 178.7, 178.6, 149.4, 148.6, 
148.5, 146.6, 146.5, 142.7, 141.7, 141.3, 141.2, 137.1, 136.9, 133.4, 133.3, 132.8, 130.1, 130.0, 
128.4, 128.2, 127.1, 126.7, 126.6, 115.3, 115.1, 114.7, 113.5, 69.4, 46.2, 46.1, 27.9, 27.6, 18.0, 
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17.9, 12.5, 12.3; MS (ES) m/z (rel intensity) 453 (M+, 100), 365 (20); HRMS (ES) Calcd for 
C27H37O2SSi 453.2284, found 453.2260.  
 
OH
 
(E)-(2-(But-2-en-2-yl)phenyl)methanol (264). To a solution of 0.10 g (0.66 mmol) of 2-
(hydroxymethyl)phenylboronic acid (263) in 5.0 mL of THF and 1.0 mL of 3 M NaOH was 
added 0.10 g (0.73 mmol) of (E)-2-bromobutene and 76 mg (0.07 mmol) of Pd(Ph3P)4. The 
reaction was heated at reflux for 2 h, cooled, diluted with H2O, and extracted with Et2O (3x).  
The combined organic layers were washed with brine, dried (MgSO4) filtered and concentrated 
in vacuo. The residue was purified by chromatography on SiO2 (10% EtOAc/hexanes) to yield 
90 mg (84%) of 264 as a colorless oil: IR (film) 3331, 3020, 2917, 1483, 1444 cm-1; 1H NMR ? 
7.47-7.41 (m, 1 H), 7.31-7.22 (m, 2 H), 7.15-7.10 (m, 1 H), 5.42 (qq, 1 H, J = 6.9, 1.5 Hz), 4.67 
(s, 2 H), 2.18 (s, 1 H), 1.96 (q, 3 H, J = 0.9 Hz), 1.78 (dq, 3 H, J = 6.6, 1.2 Hz); 13C NMR ? 
144.4, 137.5, 135.4, 128.1, 127.4, 126.9, 126.5, 123.9, 62.3, 18.0, 13.6; MS (EI) m/z (rel 
intensity) 162 (M+, 65), 117 (40), 115 (100), 105 (65), 91 (95); HRMS (EI) Calcd for C11H14O 
162.1044, found 162.1055. 
 
O
 
(E)-2-(But-2-en-2-yl)benzaldehyde (265). To a suspension of 0.97 g (4.5 mmol) of PCC and 
1.2 g of celite in 20 mL of DCM was added a solution of 0.490 g (3.0) mmol of 264 in 10 mL of 
DCM. The resulting mixture was stirred for 30 min, filtered through a plug of SiO2, which was 
 171 
washed with DCM, and the filtrate was concentrated in vacuo. The residue was purified by 
chromatography on SiO2 (5% EtOAc/hexanes) to yield 90 mg (99%) of 265 as a colorless oil: IR 
(film) 3061, 3020, 2982, 2917, 2856, 2744, 1691, 1650, 1596 cm-1; 1H NMR ? 10.12 (s, 1 H), 
7.90 (d, 1 H, J = 7.8 Hz), 7.53 (dt, 1 H, J = 7.2, 0.9 Hz), 7.37 (d, 1 H, J = 7.5 Hz), 7.32 (d, 1 H, J 
= 8.1 Hz), 5.43 (q, 1 H, J = 6.9 Hz), 2.08 (s, 3 H), 1.85 (d, 3 H, J = 6.9 Hz); 13C NMR ? 191.3, 
148.9, 133.2, 132.6, 132.4, 128.2, 128.1, 127.0, 126.2, 17.8, 13.6; MS (EI) m/z (rel intensity) 160 
(M+, 20), 159 (10), 146 (20), 145 (100), 131 (25), 117 (50), 115 (60), 103 (20), 91 (40); HRMS 
(EI) Calcd for C11H12O 160.0888, found 160.0887. 
 
S
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(E)-(3-Bromo-4-(1-(triisopropylsilyloxy)allyl)thiophen-2-yl)(2-(but-2-en-2-
yl)phenyl)methanone (266). To a solution of 0.49 g (4.8 mmol) of diisopropylamine and 0.87 g 
(4.8 mmol) of HMPA in 25 mL of THF at 0 °C was added 3.0 mL (4.8 mmol) of a 1.6 M 
solution n-BuLi in hexanes. The resulting pale yellow solution was stirred for 30 min then a 
solution of 0.9 g (2.4 mmol) of 260 in 4.0 mL of THF was added. The resulting red solution was 
stirred for 1 h, treated with 0.46 g (2.9 mmol) of the 265 stirred for 2 h, and quenched with a 
saturated aqueous solution of NH4Cl. The solution was extracted with Et2O (3x), and the 
combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (5% EtOAc/hexanes) to yield 0.70 
g (55%) of the alcohol as a yellow oil.  To a solution of the alcohol in 80 mL of DCM was added 
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8.7 g (98 mmol) of MnO2.  The mixture was stirred overnight, filtered through celite and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (10% 
EtOAc/hexanes) to yield 0.63 g (90%) of 266 as a yellow oil: IR (film) 2942, 2891, 2865, 1646 
cm-1; 1H NMR ? 7.57 (s, 1 H), 7.45 (d, 2 H, J = 7.5 Hz), 7.34 (dd, 1 H, J = 8.1, 1.8 Hz), 7.30 (d, 
1 H, J = 7.2 Hz), 5.88 (ddd, 1 H, J = 17.1, 10.2, 5.7 Hz), 5.44 (qq, 1 H, J = 6.9, 1.5 Hz), 5.39 (d, 
1 H, J = 5.7 Hz), 5.31 (d, 1 H, J = 17.1 Hz), 5.09 (d, 1 H, J = 10.2 Hz), 1.84 (s, 3 H), 1.55 (dd, 3 
H, J = 6.9, 0.9 Hz), 1.16-1.08 (m, 3 H), 1.04 (d, 9 H, J = 7.2 Hz), 1.02 (d, 9 H, J = 6.9 Hz); 13C 
NMR ? 190.5, 146.1, 144.5, 138.9, 138.7, 138.6, 134.6, 130.4, 128.2, 127.9, 127.6, 127.0, 126.3, 
114.0, 113.1, 71.6, 17.82, 17.80, 17.0, 14.2, 12.0; MS (ES) m/z (rel intensity) 535 (100), 533 
([M+H]+, 100); HRMS (ES) Calcd for C27H38O2SiSBr 533.1545, found 533.1552. 
 
S
HO
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3-(1-Hydroxyallyl)-4-methyl-4-vinylnaphtho[2,3-b]thiophen-9(4H)-one (255).  To a solution 
of 0.16 g (0.35 mmol) of 262 in 3.0 mL of THF at 0 °C was added 0.71 mL (0.71 mmol) of a 1 
M solution of TBAF in THF.  After 15 min, the reaction mixture was quenched with a saturated 
aqueous solution of NH4Cl, diluted with H2O, and extracted with Et2O (3x).  The combined 
organic layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by chromatography on SiO2 (25% EtOAc/hexanes) to yield 91 mg (87%) of 
255 as an off-white, sticky foam 2.2:1 mixture of diastereomers: IR (film) 3424, 1640, 1597 cm-
1; 1H NMR ? 8.33 (d, 1 H, J = 7.5 Hz), 7.79 (s, 1 H), 7.61 (d, 1 H, J = 7.5 Hz), 7.55 (d, 1 H, J = 
6.9 Hz), 7.45 (dd, 1 H, J = 7.8, 6.9 Hz), 6.20-6.08 (m, 1 H), 6.01 (dd, 1 H, J = 17.4, 10.5 Hz), 
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5.72 (s, 1 H), 5.61-5.50 (m, 2 H), 5.46-5.37 (m, 2 H), 5.27 (d, 1 H, J = 10.5 Hz), 1.92 (s, 3 H); 
characteristic signals of minor isomer: 1H NMR ? 7.85 (s, 1 H), 1.76 (s, 3 H); 13C NMR ? 178.7, 
178.6, 151.1, 150.6, 149.2, 148.8, 144.7, 144.4, 141.8, 139.4, 137.2, 137.0, 134.2, 133.0, 129.5, 
129.4, 128.3, 127.0, 126.9, 126.5, 115.7, 115.1, 115.0, 114.3, 67.6, 67.4, 46.0, 45.8, 27.9, 27.6; 
MS (EI) m/z (rel intensity) 296 (M+, 25), 281 (35), 267 (40), 253 (30), 237 (35), 94 (100), 83 
(45); HRMS (EI) Calcd for C18H16O2S 296.0871, found 296.0871.  
 
S
HO O
H
 
3-Hydroxy-10b-methyl-3H-phenanthro[10,1-bc]thiophen-6(10bH)-one (267).  To a solution 
of 106 mg (0.36 mmol) of 255 in 50 mL of DCM was added 45 mg (0.07 mmol) of 223.  The  
reaction mixture was heated at reflux for 3 h, cooled, filtered through florisil and concentrated in 
vacuo. The residue was purified by chromatography on SiO2 (0?30% EtOAc/hexanes) to yield 
46 mg (48%) of 267 as the major and less polar diastereomer as a white foam and 14 mg (15%) 
of a minor and more polar diastereomer: Characteristic signals for major diastereomer: IR (film) 
3404, 1644, 1565, 1451, 1416 cm-1; 1H NMR ? 8.35 (d, 1 H, J = 8.1 Hz), 7.82 (s, 1 H), 7.76 (d, 1 
H, J = 6.8 Hz), 7.66 (dt, 1 H, J = 7.5, 1.2 Hz), 7.49 (t, 1 H, J = 7.2 Hz), 6.75 (dd, 1 H, J = 9.9, 2.7 
Hz), 6.19 (dd, 1 H, J = 10.2, 1.8 Hz), 5.35 (s, 1 H), 2.15 (bs, 1 H), 1.47 (s, 3 H); 13C NMR ? 
178.7, 153.4, 147.6, 142.0, 132.92, 132.89, 132.6, 132.0, 131.7, 129.7, 128.0, 127.1, 125.0, 65.1, 
41.3, 37.5; MS (EI) m/z (rel intensity) 268 (M+, 10), 266 (30), 253 (85), 251 (100), 223 (30), 195 
(20); HRMS (EI) Calcd for C16H12O2S 268.0558, found 268.0556. 
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Characteristic signals for minor diastereomer: IR (film) 3401, 1645, 1596, 1452, 1328 cm-1; 1H 
NMR ? 8.35 (dd, 1 H, J = 6.6, 1.5 Hz), 7.81 (s, 1 H), 7.76 (d, 1 H, J = 7.8 Hz), 7.64 (ddd, 1 H, 
7.8, 7.5, 1.5 Hz), 7.47 (ddd, 1 H, J = 7.8, 7.2, 1.2 Hz), 6.99 (d, 1 H, J = 9.9 Hz), 6.30 (dd, 1 H, J 
= 9.6, 5.1 Hz), 5.32 (d, 1 H, J = 5.4 Hz), 1.72 (s, 3 H); 13C NMR ? 178.2, 156.9, 147.7, 138.6, 
136.7, 133.3, 132.8, 132.7, 132.1, 128.4, 128.1, 127.0, 124.3, 62.1, 41.9, 41.8; MS (EI) m/z (rel 
intensity) 268 (M+, 10), 254 (50), 253 (100); HRMS (EI) Calcd for C16H12O2S 268.0558, found 
268.0541. 
 
S
O O
O
O2N
H
 
10b-Methyl-6-oxo-6,10b-dihydro-3H-phenanthro[10,1-bc]thiophen-3-yl 4-nitrobenzoate
 (268). To a solution of 35 mg (0.13 mmol) of 267 in 2.0 mL of DCM was added 5.0 mg (0.039 
mmol) of DMAP, 40 mg (0.39 mmol) of Et3N and 50 mg (0.26 mmol) of 4-nitrobenzoyl 
chloride. The reaction mixture was stirred overnight, quenched with H2O and extracted with 
DCM (3x).  The combined organic layers were washed with a saturated aqueous solution of 
NH4Cl, H2O and brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by chromatography on SiO2 (0?15% EtOAc/hexanes) to yield 37 mg (68%) of 268 as a 
white foam: IR (film) 3108, 2969, 2921, 1725, 1650, 1598, 1527, 1453 cm-1; 1H NMR ? 8.37 
(dd, 1 H, J = 7.8, 0.6 Hz), 8.31 (s, 4 H), 7.78 (d, 1 H, J = 7.8 Hz), 7.70-7.65 (m, 2 H), 7.50 (t, 1 
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H, J = 7.5 Hz), 6.94 (dd, 1 H, J = 9.9, 2.4 Hz), 6.73 (s, 1 H), 6.20 (dd, 1 H, J = 10.2, 1.8 Hz), 
1.56 (s, 3 H); 13C NMR ? 178.2, 164.4, 152.9, 150.9, 146.9, 136.1, 134.8, 134.1, 133.4, 133.0, 
131.8, 131.0, 129.7, 128.2, 127.31, 127.29, 124.7, 123.7, 67.8, 41.3, 38.5; MS (EI) m/z (rel 
intensity) 417 (M+, 65), 368 (10), 83 (50), 69 (85), 57 (100); HRMS (EI) Calcd for C23H15NO5S 
417.0670, found 417.0668. 
 
OMe
OMe
OH
Br
 
(3-Bromo-5,8-dimethoxynaphthalen-2-yl)methanol (277). To a solution of 145 mg (0.42 
mmol) of 183171,172 in 4.0 mL of DCM at -78 °C was added 0.94 mL (0.94 mmol) of DiBAL.  
The resulting solution was stirred for 15 min, quenched with a saturated aqueous solution of 
NH4Cl and warmed to room temperature.  The solution was then diluted with H2O and the 
aqueous layer was extracted with DCM (3x).  The combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by chromatography on SiO2 
(0?25% EtOAc/hexanes) to yield 91 mg (72%) of 277 as a white solid: Mp 139.9-140.3 °C; IR 
(film) 3583, 3333, 2925 cm-1; 1H NMR ? 8.42 (s, 1 H), 8.27 (s, 1 H), 6.75 (s, 2 H), 4.90 (s, 2 H), 
3.96 (s, 6 H), 2.10 (t, 1 H, J = 6.3 Hz); 13C NMR ? 149.4, 148.4, 136.8, 126.7, 125.8, 125.2, 
122.0, 120.8, 104.3, 103.9, 65.5, 55.71, 55.67; MS (EI) m/z (rel intensity) 296 (M+, 50), 283 (40), 
281 (40), 111 (35), 109 (25); HRMS (EI) Calcd for C13H13O3Br 296.0048, found 296.0045.  
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(E)-(3-(But-2-en-2-yl)-5,8-dimethoxynaphthalen-2-yl)methanol (278). To a solution of 90 mg 
(0.30 mmol) of 277 in 3.0 mL of 5:1 THF/ 3 M NaOH was added 45 mg (0.45 mmol) 212182 and 
32 mg (0.030 mmol) of Pd(PPh3)4. The resulting solution was heated at reflux for 1 h, cooled, 
diluted with H2O and extracted with Et2O (3x).  The combined organic layers were washed with 
brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by 
chromatography on SiO2 (0?25% EtOAc/hexanes) to yield 60 mg (73%) of 278 as a yellow oil: 
IR (film) 3384, 2936, 2833, 1598, 1461, 1434 cm-1; 1H NMR ? 8.26 (s, 1 H), 7.93 (s, 1 H), 6.68 
(s, 2 H), 5.53 (qq, 1 H, J = 6.6, 1.2 Hz), 4.82 (d, 2 H, J = 5.7 Hz), 3.96 (s, 6 H, 2.03 (s, 3 H), 1.95 
(t, 1 H, J = 6.0 Hz), 1.81 (d, 3 H, J = 6.6 Hz); 13C NMR ? 149.4, 149.2, 142.9, 136.5, 136.1, 
125.5, 125.1, 124.5, 121.1, 120.5, 103.2, 102.9, 63.7, 55.59, 55.55, 18.3, 13.9; MS (EI) m/z (rel 
intensity) 272 (M+, 100), 257 (100), 213 (45), 115 (50); HRMS (ES) Calcd for C17H20O3Na 
295.1310, found 295.1314. 
 
OMe
OMe
O
Br
 
3-Bromo-5,8-dimethoxy-2-naphthaldehyde (279). To a solution of 50 mg (0.17 mmol) of 277 
in 2.0 mL of DCM was added 86 mg (0.2 mmol) of Dess-Martin periodinane at room 
temperature.  The reaction mixture was stirred for 30 min, and quenched with a 1:1 solution of 
saturated aqueous NaHCO3/Na2S2O3. The aqueous layer was extracted with DCM (3x), and the 
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combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue 
was purified by chromatography on SiO2 (10% EtOAc/hexanes) to yield 48 mg (97%) of 279 as 
a yellow solid: Mp 164.0-166.2 °C; IR (film) 2962, 2836, 1739, 1688, 1620, 1574, 1461, 1430 
cm-1; 1H NMR ? 10.62 (s, 1 H), 8.69 (s, 1 H), 8.36 (s, 1 H), 6.78 (d, 1 H, J = 8.4 Hz), 6.69 (d, 1 
H, J = 8.4 Hz), 3.93 (s, 6 H); 13C NMR ? 191.9, 150.6, 147.9, 129.9, 129.3, 126.9, 126.5, 124.4, 
120.9, 107.6, 104.3, 55.7, 55.6; MS (EI) m/z (rel intensity) 294 ([M]+, 80), 281 (100), 279 (100). 
 
OMe
OMe
O
 
(E)-3-(but-2-en-2-yl)-5,8-dimethoxy-2-naphthaldehyde (280). To a solution of 52 mg (0.17 
mmol) of 279 in 1.3 mL of 5:1 THF/ 3 M NaOH was added 26 mg (0.26 mmol) of 212182 and 19 
mg  (0.018 mmol) Pd(PPh3)4. The resulting solution was heated at reflux for 1 h, cooled, diluted 
with H2O and extracted with Et2O (3x).  The combined organic layers were washed with brine, 
dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by chromatography 
on SiO2 (0?25% EtOAc/hexanes) to yield 32 mg (67%) of 280 as a yellow oil: IR (film) 2936, 
2835, 1688, 1637, 1625, 1462, 1433 cm-1; 1H NMR ? 10.24 (s, 1 H), 8.79 (s, 1 H), 8.05 (s, 1 H), 
6.80 (d, 1 H, J = 8.4 Hz), 6.68 (d, 1 H, J = 8.4 Hz), 5.52 (qq, 1 H, J = 6.9, 1.2 Hz), 3.96 (s, 6 H), 
2.11 (d, 3 H, J = 0.6 Hz), 1.86 (d, 3 H, J = 6.6 Hz); 13C NMR ? 192.8, 150.6, 148.9, 144.3, 
134.3, 131.6, 128.4, 127.3, 125.1, 124.4, 121.9, 106.4, 103.4, 55.7, 55.6, 18.9, 14.2; MS (EI) m/z 
(rel intensity) 270(M+, 60), 255 (100), 237 (50), 227 (55), 139 (55); HRMS (EI) Calcd for 
C17H18O3 270.1255, found 270.1260. 
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(E)-(3-Bromo-4-(1-(triisopropylsilyloxy)allyl)thiophen-2-yl)(3-(but-2-en-2-yl)-5,8-
dimethoxynaphthalen-2-yl)methanone (281). To a solution of 64 mg (0.63 mmol) of 
diisopropylamine and 0.11 g (0.63 mmol) of HMPA in 3.0 mL of THF at 0 °C as added 0.40 mL 
(0.63 mmol) of a 1.6 M solution n-BuLi in hexanes. The resulting pale yellow solution was 
stirred for 30 min and then a solution of 0.12 g (0.31 mmol) of 260 in 1.0 mL of THF was added. 
The resulting red solution was stirred for 1 h.  Then, a solution of 0.10 g (0.37 mmol) of 280 in 
1.0 mL of THF was added. The reaction mixture was stirred for 2 h, quenched with a saturated 
aqueous solution of NH4Cl, and extracted with Et2O (3x).  The combined organic layers were 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by chromatography on SiO2 (0?5% EtOAc/hexanes) to yield 0.10 g (49%) of the alcohol as a 
yellow oil. To a solution of 0.10 g (0.15 mmol) of the alcohol in 2.0 mL of DCM was added 
0.080 g (0.18 mmol) of Dess-Martin periodinane at room temperature. The reaction mixture was 
stirred for 30 min, and quenched with a 1:1 solution of saturated aqueous NaHCO3/Na2S2O3. The 
aqueous layer was extracted with DCM (3x), and the combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo. The residue was purified by chromatography on 
SiO2 (0?5% EtOAc/hexanes) to yield 29 mg (29%) of 281 as a yellow oil: IR (film) 2941, 2865, 
1657, 1626, 1589, 1462 cm-1; 1H NMR ? 8.35 (s, 1 H), 8.09 (s, 1 H), 7.59 (s, 1 H), 6.78 (d, 1 H, J 
= 8.4 Hz), 6.70 (d, 1 H, J = 8.4 Hz), 5.89 (ddd, 1 H, J = 17.1, 10.2, 5.7 Hz), 5.54 (qq, 1 H, J = 
6.9, 1.5 Hz), 5.40 (d, 1 H, J = 5.7 Hz), 5.31 (ddd, 1 H, J = 17.1, 1.2 Hz), 5.09 (d, 1 H, J = 10.2 
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Hz), 3.98 (s, 3 H), 3.94 (s, 3 H), 1.94 (s, 3 H), 1.60 (dd, 3 H, J = 6.6, 0.6 Hz), 1.17-1.08 (m, 3 H), 
1.05 (d, 9 H, J = 7.2 Hz), 1.03 (d, 9 H, J = 6.6 Hz); 13C NMR ? 190.5, 150.0, 149.1, 146.2, 
141.6, 139.1, 138.8, 137.2, 135.2, 127.5, 127.3, 127.1, 124.2, 123.4, 120.8, 114.1, 113.6, 105.1, 
103.4, 71.6, 55.67, 55.65, 17.92, 17.89, 17.6, 14.3, 12.1; MS (ES) m/z (rel intensity) 667 (100), 
665 ([M+23Na]+, 65); HRMS (ES) Calcd for C33H43O4NaSiSBr 665.1732, found 665.1715. 
 
S
MeO
OMe
OHO
 
3-(1-Hydroxyallyl)-6,9-dimethoxy-4-methyl-4-vinylanthra[2,3-b]thiophen-11(4H)-one (282). 
To a solution of 29 mg (0.045 mmol) of 281 in 0.50 mL of NMP in a microwave reaction vessel 
was added 9.0 mg (0.085 mmol) of Pd(Ph3P)4 and 0.13 mL (of Et3N.  The solution was heated at 
220 °C for 5 min under microwave irradiation, and filtered through a plug of celite, which was 
washed with Et2O.  The filtrate was washed with brine (2x), and the organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. The residue was purified by chromatography on 
SiO2 (0?3% EtOAc/hexanes) to give 18 mg of the alcohol as a yellow oil. To a solution of 18 
mg (0.031 mmol) of the alcohol in 0.50 mL of THF at 0 °C was added 0.10 mL (0.10 mmol) of a 
1 M solution of TBAF in THF.  The solution was stirred for 15 min, quenched with a saturated 
aqueous solution of NH4Cl, diluted with H2O and, extracted with Et2O (3x).  The combined 
organic layers were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by chromatography on SiO2 (0?20% EtOAc/hexanes) to yield 11 mg 
(60%) of 282 as a yellow, oily 2.1:1 mixture of diastereomers: IR (film) 3428, 2928, 1649, 1622, 
1468, 1434, 1396 cm-1; 1H NMR ? 9.25 (s, 1 H), 8.34 (s, 1 H), 7.81 (s, 1 H), 6.80 (d, 1 H, J = 8.4 
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Hz), 6.70 (d, 1 H, J = 8.4 Hz), 6.21-6.07 (m, 2 H), 5.78 (bs, 1 H), 5.65 (d, 1 H, J = 12.6 Hz), 5.56 
(d, 1 H, J = 9.6 Hz), 5.48-5.39 (m, 1 H), 5.27 (d, 1 H, J = 10.2 Hz), 4.00 (s, 3 H), 3.98 (s, 3 H), 
1.99 (s, 3 H); characteristic signals for minor isomer: 1H NMR ? 8.32 (s, 1 H), 7.87 (s, 1 H), 6.29 
(dd, 1 H, J = 17.1, 10.2 Hz), 1.84 (s, 3 H); 13C NMR ? 178.8, 151.1, 150.8, 150.6, 148.8, 144.8, 
144.5, 144.4, 143.2, 142.9, 139.5, 139.3, 138.2, 134.3, 134.2, 128.5, 128.46, 127.4, 125.03, 
125.00, 123.0, 122.9, 121.9, 115.7, 114.8, 114.7, 114.5, 105.93, 105.89, 103.4, 103.3, 67.8, 67.7, 
55.8, 55.7, 46.3, 46.1, 29.4, 29.1; MS (ES) m/z (rel intensity) 429 ([M+23Na]+, 100); HRMS (ES) 
Calcd for C24H22O4NaS 429.1137, found 429.1134. 
 
Convertion of 282 to 224.  To a solution of 11 mg (0.027 mmol) of 282 in 11 mL of DCM was 
added 3.4 mg (0.0054 mmol) of 223.  The reaction mixture was heated at reflux for 2 h, cooled 
filtered through florisil, which was washed with EtOAc and the combined filtrates were 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0?40% 
EtOAc/hexanes) to give 9 mg (87%) of 224 as a 3.5:1 yellow, glassy mixture of diastereomers. 
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 182 
Table A1. Crystal data and structure refinement for bw0407t. 
Identification code  bw0407t  
Empirical formula  C16 H23 N O3 S 
Formula weight  309.41  
Temperature  150(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P2(1)  
Unit cell dimensions a = 7.4576(7) Å a= 90°. 
 b = 13.6267(12) Å b= 108.086(2)°. 
 c = 8.6904(8) Å g = 90°. 
Volume 839.51(13) Å3 
Z 2  
Density (calculated) 1.224 Mg/m3 
Absorption coefficient 0.202 mm-1  
F(000) 332  
Crystal size 0.27 x 0.20 x 0.20 mm3 
Theta range for data collection 2.47 to 30.00°. 
Index ranges -10<=h<=10, -19<=k<=18, -12<=l<=12 
Reflections collected 9774  
Independent reflections 4740 [R(int) = 0.0416] 
Completeness to theta = 30.00° 99.80%  
Absorption correction None  
Max. and min. transmission 0.9607 and 0.9475 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4740 / 1 / 191 
Goodness-of-fit on F2 0.956  
Final R indices [I>2sigma(I)] R1 = 0.0579, wR2 = 0.1207 
R indices (all data) R1 = 0.0898, wR2 = 0.1328 
Absolute structure parameter 0.07(8)  
Largest diff. peak and hole 0.280 and -0.149 e.Å-3 
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Table A2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters   
(Å2x 103) for bw0407t.  U(eq) is defined as one third of the trace of the orthogonalized   
Uij tensor. 
 
 x y z U(eq) 
S 1064(1) 3901(1) 9130(1) 47(1) 
N 1364(3) 5038(2) 10073(3) 47(1) 
O(1) 399(3) 3521(2) 12086(3) 58(1) 
C(1) 558(4) 5202(2) 11429(3) 45(1) 
O(2) -1925(3) 4494(2) 12230(3) 71(1) 
C(2) 2648(4) 5110(2) 11757(3) 47(1) 
O(3) -963(3) 3869(2) 8249(3) 68(1) 
C(3) 3971(4) 5983(2) 12096(4) 57(1) 
C(4) 4553(4) 6313(2) 13834(4) 49(1) 
C(5) 5841(4) 5777(2) 15037(4) 58(1) 
C(6) 6434(4) 6081(3) 16606(4) 69(1) 
C(7) 5744(5) 6940(3) 17026(4) 70(1) 
C(8) 4496(4) 7488(2) 15881(4) 63(1) 
C(9) 3884(4) 7183(2) 14285(4) 55(1) 
C(10) -464(4) 4375(2) 11955(3) 46(1) 
C(11) -627(5) 2672(2) 12332(5) 72(1) 
C(12) -396(5) 6171(3) 11364(4) 63(1) 
C(13) 2315(4) 4195(2) 7665(3) 50(1) 
C(14) 1526(5) 5095(3) 6679(4) 75(1) 
C(15) 4382(4) 4292(3) 8641(5) 79(1) 
C(16) 2001(6) 3277(3) 6610(5) 81(1) 
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Table A3. Bond lengths [Å] and angles [°] for bw0407t. 
S-O(3) 1.468(2) C(10)-O(1)-C(11) 117.1(2) 
S-N 1.734(2) C(12)-C(1)-N 113.9(2) 
S-C(13) 1.841(3) C(12)-C(1)-C(2) 122.4(3) 
N-C(2) 1.483(3) N-C(1)-C(2) 59.34(16) 
N-C(1) 1.496(3) C(12)-C(1)-C(10) 113.1(2) 
O(1)-C(10) 1.318(3) N-C(1)-C(10) 119.5(2) 
O(1)-C(11) 1.439(4) C(2)-C(1)-C(10) 118.2(2) 
C(1)-C(12) 1.493(4) N-C(2)-C(1) 60.22(16) 
C(1)-C(2) 1.499(4) N-C(2)-C(3) 115.2(2) 
C(1)-C(10) 1.508(4) C(1)-C(2)-C(3) 123.2(3) 
O(2)-C(10) 1.196(3) C(4)-C(3)-C(2) 113.4(2) 
C(2)-C(3) 1.514(4) C(5)-C(4)-C(9) 117.6(3) 
C(3)-C(4) 1.505(4) C(5)-C(4)-C(3) 121.0(3) 
C(4)-C(5) 1.388(4) C(9)-C(4)-C(3) 121.4(3) 
C(4)-C(9) 1.388(4) C(6)-C(5)-C(4) 121.9(3) 
C(5)-C(6) 1.361(5) C(5)-C(6)-C(7) 119.6(3) 
C(6)-C(7) 1.374(5) C(8)-C(7)-C(6) 120.2(3) 
C(7)-C(8) 1.356(5) C(7)-C(8)-C(9) 120.6(3) 
C(8)-C(9) 1.383(5) C(8)-C(9)-C(4) 120.3(3) 
C(13)-C(14) 1.506(4) O(2)-C(10)-O(1) 123.5(3) 
C(13)-C(15) 1.517(4) O(2)-C(10)-C(1) 122.5(3) 
C(13)-C(16) 1.526(4) O(1)-C(10)-C(1) 114.0(2) 
O(3)-S-N 103.55(12) C(14)-C(13)-C(15) 113.4(3) 
O(3)-S-C(13) 107.85(13) C(14)-C(13)-C(16) 111.4(3) 
N-S-C(13) 96.53(12) C(15)-C(13)-C(16) 110.3(3) 
C(2)-N-C(1) 60.44(16) C(14)-C(13)-S 112.2(2) 
C(2)-N-S 118.33(18) C(15)-C(13)-S 106.1(2) 
C(1)-N-S 118.74(18) C(16)-C(13)-S 102.7(2) 
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Table A4. Anisotropic displacement parmeters (Å2x 103) for bw0407t.  The anisotropic 
 displacement factor exponent take the form: -2p2[h2 a*2U33 + … + 2 h k a* b* U12 ] 
 
 U11 U22 U33 U23 U13 U12 
S 53(1) 41(1) 52(1) -6(1) 24(1) -3(1) 
N 50(1) 47(1) 43(1) -9(1) 14(1) -2(1) 
O(1) 53(1) 52(1) 78(1) 10(1) 34(1) 4(1) 
C(1) 46(1) 45(2) 42(1) -5(1) 12(1) 4(1) 
O(2) 52(1) 77(2) 96(2) -8(1) 38(1) 2(1) 
C(2) 45(1) 47(1) 49(1) -3(1) 17(1) -6(1) 
O(3) 54(1) 76(1) 78(1) -29(1) 26(1) -17(1) 
C(3) 58(2) 57(2) 56(2) -3(1) 17(1) -15(1) 
C(4) 39(1) 49(2) 62(2) -5(1) 17(1) -13(1) 
C(5) 43(2) 51(2) 74(2) -4(2) 12(2) -2(1) 
C(6) 49(2) 78(2) 71(2) 3(2) 6(2) 1(2) 
C(7) 62(2) 84(3) 62(2) -14(2) 17(2) -20(2) 
C(8) 54(2) 55(2) 83(2) -16(2) 26(2) -7(2) 
C(9) 48(2) 49(2) 67(2) 0(1) 17(1) -3(1) 
C(10) 43(1) 55(2) 41(1) -7(1) 13(1) -3(1) 
C(11) 78(2) 58(2) 91(2) 0(2) 43(2) -15(2) 
C(12) 67(2) 55(2) 67(2) -6(1) 19(2) 13(2) 
C(13) 52(2) 51(2) 52(2) 2(1) 23(1) 3(1) 
C(14) 91(3) 72(2) 70(2) 20(2) 35(2) 16(2) 
C(15) 51(2) 107(3) 84(2) 7(2) 28(2) -4(2) 
C(16) 105(3) 72(2) 88(2) -20(2) 62(2) -7(2) 
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Table A5. Hydrogen coordinates (x 104) and isotropic displacement parameters   
(Å2x 103) for bw0407t. 
 
 x y z U(eq) 
H(2A) 3217 4477 12259 56 
H(3B) 5114 5809 11806 68 
H(3C) 3345 6536 11395 68 
H(5A) 6321 5180 14757 69 
H(6A) 7321 5701 17406 83 
H(7A) 6142 7151 18122 84 
H(8A) 4038 8086 16177 75 
H(9A) 3003 7569 13493 66 
H(11A) 154 2085 12406 108 
H(11B) -1788 2604 11419 108 
H(11C) -946 2749 13337 108 
H(12A) 329 6678 11018 95 
H(12B) -471 6335 12440 95 
H(12C) -1670 6137 10592 95 
H(14A) 2232 5224 5919 113 
H(14B) 1638 5659 7401 113 
H(14C) 194 4985 6074 113 
H(15A) 5117 4451 7914 118 
H(15B) 4831 3671 9195 118 
H(15C) 4533 4816 9443 118 
H(16A) 2618 3358 5774 122 
H(16B) 645 3176 6096 122 
H(16C) 2537 2707 7283 122 
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X-RAY CRYSTAL DATA FOR 114 
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Table B1. Crystal data and structure refinement for bw929s. 
Identification code  bw929s  
Empirical formula  C22 H35 N O4 S 
Formula weight  409.57  
Temperature  228(2) K  
Wavelength  0.71073 Å  
Crystal system  Tetragonal  
Space group  P4(1)  
Unit cell dimensions a = 12.8025(4) Å ?= 90°. 
 b = 12.8025(4) Å ?= 90°. 
 c = 14.9383(11) Å ? = 90°. 
Volume 2448.4(2) Å3 
Z 4  
Density (calculated) 1.111 Mg/m3  
Absorption coefficient 0.156 mm-1  
F(000) 888  
Crystal size 0.29 x 0.27 x 0.21 mm3 
Theta range for data collection 1.59 to 32.50°. 
Index ranges -19<=h<=19, -19<=k<=19, -22<=l<=22 
Reflections collected 32521  
Independent reflections 8717 [R(int) = 0.0327] 
Completeness to theta = 32.50° 99.10%  
Absorption correction Sadabs  
Max. and min. transmission 0.9679 and 0.9561 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8717 / 1 / 258 
Goodness-of-fit on F2 0.966  
Final R indices [I>2sigma(I)] R1 = 0.0551, wR2 = 0.1312 
R indices (all data) R1 = 0.0900, wR2 = 0.1518 
Absolute structure parameter 0.00(6)  
Largest diff. peak and hole 0.307 and -0.125 e.Å-3 
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Table B2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters   
(Å2x 103) for bw929s.  U(eq) is defined as one third of the trace of the orthogonalized   
Uij tensor. 
 
 x y z U(eq) 
S 8355(1) 2599(1) 2051(1) 49(1) 
O(1) 8369(2) 2044(1) 2886(1) 76(1) 
O(2) 7500(1) 2445(1) 1443(1) 64(1) 
O(3) 10946(2) 5566(2) -855(1) 94(1) 
O(4) 11307(1) 5317(2) 566(1) 72(1) 
N 8409(2) 3818(1) 2305(1) 49(1) 
C(1) 9545(2) 2257(2) 1457(1) 53(1) 
C(2) 9566(2) 2777(2) 560(2) 59(1) 
C(3) 9514(4) 1073(2) 1338(3) 122(2) 
C(4) 10462(2) 2607(4) 2020(2) 122(2) 
C(5) 7982(1) 4659(1) 1748(1) 41(1) 
C(6) 7027(2) 5155(2) 2211(1) 51(1) 
C(7) 6462(2) 5923(2) 1619(1) 52(1) 
C(8) 5886(2) 5572(2) 889(2) 77(1) 
C(9) 5374(3) 6269(3) 338(2) 95(1) 
C(10) 5434(3) 7331(3) 502(2) 90(1) 
C(11) 5994(2) 7676(2) 1219(2) 72(1) 
C(12) 6509(2) 6983(2) 1766(2) 58(1) 
C(13) 8821(1) 5443(1) 1506(1) 41(1) 
C(14) 9035(1) 5605(1) 652(1) 40(1) 
C(15) 9828(2) 6348(1) 257(1) 45(1) 
C(16) 10752(2) 5721(2) -96(1) 49(1) 
C(17) 12196(2) 4676(3) 325(2) 92(1) 
C(18) 9332(2) 6989(2) -497(2) 61(1) 
C(19) 8401(2) 7633(2) -190(2) 76(1) 
C(20) 8732(4) 8484(3) 473(4) 135(2) 
C(21) 7816(4) 8062(4) -1007(3) 146(2) 
C(22) 9360(2) 5983(2) 2275(2) 64(1) 
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Table B3. Bond lengths [Å] and angles [°] for bw929s. 
 
S-O(2) 1.4367(18) C(18)-H(18A) 0.98 
S-O(1) 1.4361(17) C(18)-H(18B) 0.98 
S-N 1.6075(18) C(19)-C(21) 1.533(5) 
S-C(1) 1.816(2) C(19)-C(20) 1.531(6) 
O(3)-C(16) 1.177(3) C(19)-H(19A) 0.99 
O(4)-C(16) 1.323(3) C(20)-H(20A) 0.97 
O(4)-C(17) 1.449(3) C(20)-H(20B) 0.97 
N-C(5) 1.465(2) C(20)-H(20C) 0.97 
N-H(1N) 0.82(3) C(21)-H(21A) 0.97 
C(1)-C(2) 1.496(3) C(21)-H(21B) 0.97 
C(1)-C(4) 1.512(4) C(21)-H(21C) 0.97 
C(1)-C(3) 1.527(4) C(22)-H(22A) 0.97 
C(2)-H(2A) 0.97 C(22)-H(22B) 0.97 
C(2)-H(2B) 0.97 C(22)-H(22C) 0.97 
C(2)-H(2C) 0.97 O(2)-S-O(1) 119.41(11) 
C(3)-H(3A) 0.97 O(2)-S-N 108.36(10) 
C(3)-H(3B) 0.97 O(1)-S-N 105.97(11) 
C(3)-H(3C) 0.97 O(2)-S-C(1) 107.31(10) 
C(4)-H(4A) 0.97 O(1)-S-C(1) 107.12(10) 
C(4)-H(4B) 0.97 N-S-C(1) 108.26(10) 
C(4)-H(4C) 0.97 C(16)-O(4)-C(17) 117.2(2) 
C(5)-C(13) 1.514(2) C(5)-N-S 124.31(14) 
C(5)-C(6) 1.542(3) C(5)-N-H(1N) 118.3(17) 
C(5)-H(5A) 0.99 S-N-H(1N) 115.6(17) 
C(6)-C(7) 1.507(3) C(2)-C(1)-C(4) 110.6(2) 
C(6)-H(6A) 0.98 C(2)-C(1)-C(3) 109.7(2) 
C(6)-H(6B) 0.98 C(4)-C(1)-C(3) 112.3(3) 
C(7)-C(12) 1.375(3) C(2)-C(1)-S 110.19(14) 
C(7)-C(8) 1.391(3) C(4)-C(1)-S 107.93(16) 
C(8)-C(9) 1.380(4) C(3)-C(1)-S 105.94(19) 
C(8)-H(8A) 0.94 C(1)-C(2)-H(2A) 109.5 
C(9)-C(10) 1.384(5) C(1)-C(2)-H(2B) 109.5 
C(9)-H(9A) 0.94 H(2A)-C(2)-H(2B) 109.5 
C(10)-C(11) 1.362(4) C(1)-C(2)-H(2C) 109.5 
C(10)-H(10A) 0.94 H(2A)-C(2)-H(2C) 109.5 
C(11)-C(12) 1.375(4) H(2B)-C(2)-H(2C) 109.5 
C(11)-H(11A) 0.94 C(1)-C(3)-H(3A) 109.5 
C(12)-H(12A) 0.94 C(1)-C(3)-H(3B) 109.5 
C(13)-C(14) 1.321(2) H(3A)-C(3)-H(3B) 109.5 
C(13)-C(22) 1.507(3) C(1)-C(3)-H(3C) 109.5 
C(14)-C(15) 1.511(2) H(3A)-C(3)-H(3C) 109.5 
C(14)-H(14A) 0.94 H(3B)-C(3)-H(3C) 109.5 
C(15)-C(16) 1.523(3) C(1)-C(4)-H(4A) 109.5 
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Table B3. Cont’d 
C(15)-C(18) 1.531(3) C(1)-C(4)-H(4B) 109.5 
C(15)-H(15A) 0.99 H(4A)-C(4)-H(4B) 109.5 
C(17)-H(17A) 0.97 C(1)-C(4)-H(4C) 109.5 
C(17)-H(17B) 0.97 H(4A)-C(4)-H(4C) 109.5 
C(17)-H(17C) 0.97 H(4B)-C(4)-H(4C) 109.5 
C(18)-C(19) 1.521(3) N-C(5)-C(13) 111.00(15) 
N-C(5)-C(6) 110.15(15) C(18)-C(15)-H(15A) 109 
C(13)-C(5)-C(6) 113.34(15) O(3)-C(16)-O(4) 122.7(2) 
N-C(5)-H(5A) 107.4 O(3)-C(16)-C(15) 125.8(2) 
C(13)-C(5)-H(5A) 107.4 O(4)-C(16)-C(15) 111.39(17) 
C(6)-C(5)-H(5A) 107.4 O(4)-C(17)-H(17A) 109.5 
C(7)-C(6)-C(5) 112.76(16) O(4)-C(17)-H(17B) 109.5 
C(7)-C(6)-H(6A) 109 H(17A)-C(17)-H(17B) 109.5 
C(5)-C(6)-H(6A) 109 O(4)-C(17)-H(17C) 109.5 
C(7)-C(6)-H(6B) 109 H(17A)-C(17)-H(17C) 109.5 
C(5)-C(6)-H(6B) 109 H(17B)-C(17)-H(17C) 109.5 
H(6A)-C(6)-H(6B) 107.8 C(19)-C(18)-C(15) 113.22(18) 
C(12)-C(7)-C(8) 117.8(2) C(19)-C(18)-H(18A) 108.9 
C(12)-C(7)-C(6) 121.9(2) C(15)-C(18)-H(18A) 108.9 
C(8)-C(7)-C(6) 120.2(2) C(19)-C(18)-H(18B) 108.9 
C(7)-C(8)-C(9) 120.7(3) C(15)-C(18)-H(18B) 108.9 
C(7)-C(8)-H(8A) 119.7 H(18A)-C(18)-H(18B) 107.7 
C(9)-C(8)-H(8A) 119.7 C(21)-C(19)-C(18) 109.7(2) 
C(10)-C(9)-C(8) 120.2(3) C(21)-C(19)-C(20) 113.3(3) 
C(10)-C(9)-H(9A) 119.9 C(18)-C(19)-C(20) 111.3(3) 
C(8)-C(9)-H(9A) 119.9 C(21)-C(19)-H(19A) 107.5 
C(9)-C(10)-C(11) 119.1(3) C(18)-C(19)-H(19A) 107.4 
C(9)-C(10)-H(10A) 120.4 C(20)-C(19)-H(19A) 107.5 
C(11)-C(10)-H(10A) 120.4 C(19)-C(20)-H(20A) 109.5 
C(12)-C(11)-C(10) 120.7(3) C(19)-C(20)-H(20B) 109.5 
C(12)-C(11)-H(11A) 119.6 H(20A)-C(20)-H(20B) 109.5 
C(10)-C(11)-H(11A) 119.6 C(19)-C(20)-H(20C) 109.5 
C(11)-C(12)-C(7) 121.4(2) H(20A)-C(20)-H(20C) 109.5 
C(11)-C(12)-H(12A) 119.3 H(20B)-C(20)-H(20C) 109.5 
C(7)-C(12)-H(12A) 119.3 C(19)-C(21)-H(21A) 109.5 
C(14)-C(13)-C(5) 118.83(15) C(19)-C(21)-H(21B) 109.5 
C(14)-C(13)-C(22) 124.64(17) H(21A)-C(21)-H(21B) 109.5 
C(5)-C(13)-C(22) 116.53(16) C(19)-C(21)-H(21C) 109.5 
C(13)-C(14)-C(15) 128.01(16) H(21A)-C(21)-H(21C) 109.5 
C(13)-C(14)-H(14A) 116 H(21B)-C(21)-H(21C) 109.5 
C(15)-C(14)-H(14A) 116 C(13)-C(22)-H(22A) 109.5 
C(14)-C(15)-C(16) 108.98(15) C(13)-C(22)-H(22B) 109.5 
C(14)-C(15)-C(18) 110.30(17) H(22A)-C(22)-H(22B) 109.5 
C(16)-C(15)-C(18) 110.52(16) C(13)-C(22)-H(22C) 109.5 
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Table B3. Cont’d 
C(14)-C(15)-H(15A) 109 H(22A)-C(22)-H(22C) 109.5 
C(16)-C(15)-H(15A) 109 H(22B)-C(22)-H(22C) 109.5 
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Table B4. Anisotropic displacement parmeters (Å2x 103) for bw929s.  The anisotropic 
 displacement factor exponent take the form: -2?2[h2 a*2U33 + … + 2 h k a* b* U12 ]. 
 
 U11 U22 U33 U23 U13 U12 
S 54(1) 44(1) 48(1) 6(1) 13(1) -4(1) 
O(1) 103(1) 61(1) 64(1) 22(1) 29(1) 4(1) 
O(2) 55(1) 62(1) 77(1) -6(1) 7(1) -17(1) 
O(3) 134(2) 102(2) 46(1) 6(1) 29(1) 49(1) 
O(4) 67(1) 91(1) 56(1) -12(1) -3(1) 24(1) 
N 66(1) 49(1) 34(1) 0(1) 3(1) -2(1) 
C(1) 57(1) 60(1) 43(1) 2(1) 6(1) 11(1) 
C(2) 60(1) 69(1) 48(1) 5(1) 14(1) 12(1) 
C(3) 183(4) 56(2) 127(3) 20(2) 85(3) 40(2) 
C(4) 53(1) 252(5) 63(2) -47(2) -9(1) 33(2) 
C(5) 46(1) 42(1) 33(1) -3(1) 5(1) -1(1) 
C(6) 53(1) 53(1) 47(1) -4(1) 14(1) -3(1) 
C(7) 47(1) 57(1) 51(1) -10(1) 10(1) 3(1) 
C(8) 75(2) 72(2) 84(2) -26(1) -18(1) 6(1) 
C(9) 86(2) 114(2) 85(2) -28(2) -32(2) 23(2) 
C(10) 92(2) 99(2) 79(2) -1(2) -8(2) 41(2) 
C(11) 83(2) 66(1) 68(2) -5(1) 14(1) 16(1) 
C(12) 64(1) 58(1) 51(1) -13(1) 9(1) 6(1) 
C(13) 48(1) 40(1) 35(1) -3(1) 3(1) -2(1) 
C(14) 46(1) 38(1) 34(1) -3(1) 2(1) 0(1) 
C(15) 54(1) 42(1) 38(1) 0(1) 9(1) -2(1) 
C(16) 61(1) 44(1) 43(1) -1(1) 12(1) -3(1) 
C(17) 70(2) 110(2) 95(2) -8(2) 4(2) 31(2) 
C(18) 72(1) 55(1) 57(1) 18(1) 18(1) 10(1) 
C(19) 86(2) 64(1) 79(2) 23(1) 24(1) 23(1) 
C(20) 126(3) 69(2) 209(5) -36(3) 49(3) 14(2) 
C(21) 145(4) 177(4) 115(3) 69(3) 33(3) 103(3) 
C(22) 77(2) 78(1) 37(1) -11(1) 3(1) -29(1) 
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Table B5. Hydrogen coordinates (x 104) and isotropic displacement parameters   
(Å2x 103) for bw929s. 
 
 x y z U(eq) 
H(1N) 8551(17) 3948(18) 2826(17) 50(6) 
H(2A) 10205 2590 250 89 
H(2B) 9538 3528 638 89 
H(2C) 8969 2549 211 89 
H(3A) 10134 846 1019 183 
H(3B) 8897 881 999 183 
H(3C) 9492 739 1921 183 
H(4A) 11108 2436 1715 183 
H(4B) 10442 2254 2594 183 
H(4C) 10424 3356 2113 183 
H(5A) 7734 4338 1184 49 
H(6A) 6541 4601 2389 61 
H(6B) 7258 5514 2756 61 
H(8A) 5844 4852 771 92 
H(9A) 4984 6021 -151 114 
H(10A) 5093 7809 123 108 
H(11A) 6028 8395 1340 87 
H(12A) 6901 7238 2250 69 
H(14A) 8646 5210 240 48 
H(15A) 10075 6827 731 53 
H(17A) 12531 4418 864 138 
H(17B) 12690 5090 -16 138 
H(17C) 11962 4090 -35 138 
H(18A) 9861 7459 -747 73 
H(18B) 9107 6515 -974 73 
H(19A) 7919 7156 129 91 
H(20A) 9093 8166 975 202 
H(20B) 8118 8850 687 202 
H(20C) 9194 8974 176 202 
H(21A) 7637 7491 -1405 219 
H(21B) 8259 8555 -1321 219 
H(21C) 7184 8411 -812 219 
H(22A) 9882 6461 2043 96 
H(22B) 9694 5467 2653 96 
H(22C) 8849 6370 2622 96 
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APPENDIX C 
X-RAY CRYSTAL DATA FOR 116 
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 Table C1. Crystal data and structure refinement for bw0419s. 
Identification code  bw0419s  
Empirical formula  C18 H29 N O3 S 
Formula weight  339.48  
Temperature  295(2) K  
Wavelength  0.71073 Å  
Crystal system  Triclinic  
Space group  P1  
Unit cell dimensions a = 6.3998(8) Å a= 70.719(3)°. 
 b = 8.4297(11) Å b= 88.743(3)°. 
 
c = 10.0584(13) 
Å g = 75.346(3)°. 
Volume 494.41(11) Å3 
Z 1  
Density (calculated) 1.140 Mg/m3  
Absorption coefficient 0.177 mm-1  
F(000) 184  
Crystal size 0.28 x 0.14 x 0.09 mm3 
Theta range for data collection 2.15 to 25.00°. 
Index ranges 
-7<=h<=7, -10<=k<=10, -
11<=l<=11 
Reflections collected 3974  
Independent reflections 3284 [R(int) = 0.0224] 
Completeness to theta = 25.00° 99.90%  
Absorption correction Multi-scan (Sadabs) 
Max. and min. transmission 0.9843 and 0.9522 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3284 / 3 / 222 
Goodness-of-fit on F2 0.915  
Final R indices [I>2sigma(I)] R1 = 0.0602, wR2 = 0.1385 
R indices (all data) R1 = 0.0766, wR2 = 0.1492 
Absolute structure parameter 0.22(12)  
Largest diff. peak and hole 0.230 and -0.190 e.Å-3 
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Table C2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters   
(Å2x 103) for bw0419s.  U(eq) is defined as one third of the trace of the orthogonalized   
Uij tensor. 
 x y z U(eq) 
S -1254(1) 5796(1) 4359(1) 50(1) 
N -1980(6) 4580(5) 5777(4) 54(1) 
O(1) -2594(6) 7521(4) 4046(4) 78(1) 
O(2) 1050(5) 5533(5) 4520(3) 73(1) 
O(3) 3628(6) -3817(4) 6364(4) 62(1) 
C(5) -494(6) 3263(5) 6944(4) 43(1) 
C(1) -1150(11) 6251(9) 1606(6) 94(2) 
C(2) -4153(9) 5091(9) 2879(6) 89(2) 
C(3) -351(10) 3180(7) 3288(6) 90(2) 
C(4) -1740(8) 5007(6) 2951(5) 64(1) 
C(6) -401(6) 1433(5) 7038(4) 47(1) 
C(7) -2493(8) 923(7) 7120(7) 76(2) 
C(8) 1536(6) 326(5) 7143(4) 48(1) 
C(9) 2093(7) -1591(5) 7410(5) 52(1) 
C(10) 3687(11) -2530(6) 8707(6) 86(2) 
C(11) 3089(8) -1995(6) 6152(5) 64(1) 
C(12) -1154(7) 3593(6) 8328(4) 57(1) 
C(13) 445(7) 2483(5) 9545(4) 50(1) 
C(14) 2299(8) 2912(7) 9693(5) 69(1) 
C(15) 3826(9) 1920(9) 10794(6) 86(2) 
C(16) 3496(11) 452(9) 11751(6) 89(2) 
C(17) 1678(11) -34(7) 11613(6) 81(2) 
C(18) 128(9) 965(6) 10510(5) 68(1) 
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Table C3. Bond lengths [Å] and angles [°] for bw0419s. 
S-O(1) 1.423(3) C(8)-C(6)-C(5) 118.2(3) 
S-O(2) 1.439(3) C(7)-C(6)-C(5) 117.8(4) 
S-N 1.596(4) C(6)-C(8)-C(9) 129.1(4) 
S-C(4) 1.815(5) C(8)-C(9)-C(11) 110.4(3) 
N-C(5) 1.472(5) C(8)-C(9)-C(10) 109.3(4) 
O(3)-C(11) 1.430(5) C(11)-C(9)-C(10) 109.6(4) 
C(5)-C(6) 1.500(6) O(3)-C(11)-C(9) 112.0(4) 
C(5)-C(12) 1.537(6) C(13)-C(12)-C(5) 112.7(3) 
C(1)-C(4) 1.521(7) C(14)-C(13)-C(18) 118.2(4) 
C(2)-C(4) 1.530(7) C(14)-C(13)-C(12) 119.9(4) 
C(3)-C(4) 1.501(7) C(18)-C(13)-C(12) 121.8(4) 
C(6)-C(8) 1.332(5) C(13)-C(14)-C(15) 121.9(5) 
C(6)-C(7) 1.499(6) C(16)-C(15)-C(14) 119.8(6) 
C(8)-C(9) 1.495(5) C(17)-C(16)-C(15) 119.7(5) 
C(9)-C(11) 1.504(6) C(16)-C(17)-C(18) 120.8(5) 
C(9)-C(10) 1.529(7) C(17)-C(18)-C(13) 119.6(5) 
C(12)-C(13) 1.495(6)   
C(13)-C(14) 1.349(7)   
C(13)-C(18) 1.387(6)   
C(14)-C(15) 1.380(7)   
C(15)-C(16) 1.357(9)   
C(16)-C(17) 1.351(9)   
C(17)-C(18) 1.391(7)   
O(1)-S-O(2) 118.0(2)   
O(1)-S-N 108.5(2)   
O(2)-S-N 107.7(2)   
O(1)-S-C(4) 108.2(2)   
O(2)-S-C(4) 106.7(2)   
N-S-C(4) 107.3(2)   
C(5)-N-S 125.1(3)   
N-C(5)-C(6) 113.0(3)   
N-C(5)-C(12) 108.7(3)   
C(6)-C(5)-C(12) 111.7(3)   
C(3)-C(4)-C(1) 112.3(5)   
C(3)-C(4)-C(2) 111.9(5)   
C(1)-C(4)-C(2) 110.8(4)   
C(3)-C(4)-S 108.3(3)   
C(1)-C(4)-S 106.0(4)   
C(2)-C(4)-S 107.2(3)   
C(8)-C(6)-C(7) 123.8(4)   
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Table C4. Anisotropic displacement parmeters (Å2x 103) for bw0419s.  The anisotropic 
 displacement factor exponent take the form: -2?2[h2 a*2U33 + … + 2 h k a* b* U12 ]. 
 
 U11 U22 U33 U23 U13 U12 
S 54(1) 46(1) 44(1) -16(1) -5(1) -4(1) 
N 40(2) 57(2) 54(2) -22(2) 2(2) 8(2) 
O(1) 104(3) 53(2) 61(2) -18(2) -9(2) 5(2) 
O(2) 63(2) 98(3) 58(2) -17(2) 0(2) -33(2) 
O(3) 63(2) 46(2) 76(2) -32(2) -12(2) 3(2) 
C(5) 39(2) 39(2) 42(2) -10(2) -4(2) 2(2) 
C(1) 118(5) 105(5) 57(4) -22(3) 7(3) -31(4) 
C(2) 84(4) 116(5) 81(4) -50(4) -11(3) -23(4) 
C(3) 114(5) 75(4) 75(4) -45(3) -3(3) 10(3) 
C(4) 72(3) 69(3) 51(3) -29(2) 4(2) -10(3) 
C(6) 43(2) 48(2) 51(2) -19(2) 5(2) -11(2) 
C(7) 55(3) 68(3) 110(5) -36(3) 13(3) -18(3) 
C(8) 46(2) 44(2) 58(3) -23(2) 9(2) -14(2) 
C(9) 53(3) 39(2) 61(3) -18(2) 6(2) -7(2) 
C(10) 126(5) 48(3) 72(4) -17(3) -23(3) -5(3) 
C(11) 78(3) 47(3) 65(3) -25(2) 5(2) -4(2) 
C(12) 65(3) 49(3) 49(3) -18(2) -2(2) 3(2) 
C(13) 59(3) 45(2) 42(2) -21(2) 2(2) 3(2) 
C(14) 72(3) 77(3) 56(3) -22(3) 5(2) -15(3) 
C(15) 59(3) 117(5) 80(4) -44(4) -7(3) -1(3) 
C(16) 93(5) 84(4) 65(4) -31(3) -21(3) 33(4) 
C(17) 119(5) 48(3) 56(3) -9(2) 0(3) 3(3) 
C(18) 85(4) 62(3) 61(3) -24(3) 10(3) -18(3) 
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Table C5. Hydrogen coordinates (x 104) and isotropic displacement parameters   
(Å2x 103) for bw0419s. 
 
 
 x y z U(eq) 
H(1N) -3010(60) 4960(50) 5950(40) 21(10) 
H(3) 2820(80) -4050(70) 5900(60) 72(18) 
H(5A) 961 3431 6776 52 
H(1A) -1421 5913 817 141 
H(1B) 355 6213 1687 141 
H(1C) -2012 7413 1465 141 
H(2A) -4987 6273 2683 134 
H(2B) -4517 4374 3766 134 
H(2C) -4469 4680 2143 134 
H(3A) -528 2763 2528 135 
H(3B) -776 2443 4143 135 
H(3C) 1138 3165 3408 135 
H(7A) -2462 189 6562 114 
H(7B) -3671 1950 6766 114 
H(7C) -2687 304 8084 114 
H(8) 2707 814 7035 57 
H(9) 772 -1994 7588 62 
H(10A) 5026 -2208 8511 128 
H(10B) 3947 -3765 8932 128 
H(10C) 3089 -2206 9492 128 
H(11A) 2082 -1377 5329 77 
H(11B) 4389 -1585 5969 77 
H(12A) -1296 4808 8200 68 
H(12B) -2556 3364 8544 68 
H(14) 2555 3905 9034 83 
H(15) 5079 2256 10879 104 
H(16) 4515 -217 12500 107 
H(17) 1461 -1049 12264 98 
H(18) -1114 617 10419 82 
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APPENDIX D 
X-RAY CRYSTAL DATA FOR 118C 
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Table D1. Crystal data and structure refinement for bw927s. 
Identification code  bw927s  
Empirical formula  C31 H44 N2 O5 S 
Formula weight  556.74  
Temperature  200(2) K  
Wavelength  0.71073 Å  
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 9.9411(4) Å a= 90°. 
 b = 24.7469(10) Å b= 90°. 
 c = 25.9473(11) Å g = 90°. 
Volume 6383.3(5) Å3 
Z 8  
Density (calculated) 1.159 Mg/m3 
Absorption coefficient 0.140 mm-1  
F(000) 2400  
Crystal size 0.30 x 0.22 x 0.20 mm3 
Theta range for data collection 1.57 to 32.58°. 
Index ranges -15<=h<=15, -36<=k<=37, -38<=l<=39 
Reflections collected 85322  
Independent reflections 22718 [R(int) = 0.0657] 
Completeness to theta = 32.58° 99.20%  
Absorption correction None  
Max. and min. transmission 0.9725 and 0.9592 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 22718 / 0 / 720 
Goodness-of-fit on F2 1.02  
Final R indices [I>2sigma(I)] R1 = 0.0724, wR2 = 0.1376 
R indices (all data) R1 = 0.1279, wR2 = 0.1594 
Absolute structure parameter 0.02(5)  
Largest diff. peak and hole 0.481 and -0.259 e.Å-3 
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Table D2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters   
(Å2x 103) for bw927s.  U(eq) is defined as one third of the trace of the orthogonalized   
Uij tensor. 
 
 x y z U(eq) 
S(1) 4507(1) 7866(1) 2907(1) 31(1) 
C(1) 8473(3) 7026(1) 2675(1) 55(1) 
N(1) 6106(2) 7951(1) 2861(1) 32(1) 
O(1) 3871(2) 8147(1) 2488(1) 47(1) 
C(2) 8554(4) 6471(1) 2640(1) 77(1) 
N(2) 3458(2) 8803(1) 4247(1) 39(1) 
O(2) 4100(2) 7990(1) 3427(1) 40(1) 
S(2) 7270(1) 9662(1) -39(1) 39(1) 
C(3) 8636(4) 6162(1) 3078(1) 80(1) 
N(3) 8885(2) 9692(1) -4(1) 35(1) 
O(3) 4714(2) 9344(1) 4733(1) 49(1) 
C(4) 8663(4) 6409(1) 3553(1) 70(1) 
N(4) 6484(2) 8851(1) 1354(1) 42(1) 
O(4) 2337(2) 8557(1) 5202(1) 69(1) 
C(5) 8598(3) 6964(1) 3589(1) 51(1) 
O(5) 1101(2) 9306(1) 5155(1) 77(1) 
C(6) 8510(2) 7282(1) 3152(1) 40(1) 
O(6) 6735(2) 9477(1) 438(1) 67(1) 
C(7) 8408(2) 7886(1) 3190(1) 42(1) 
O(7) 6809(2) 10173(1) -227(1) 62(1) 
C(8) 6978(2) 8093(1) 3302(1) 31(1) 
O(8) 7335(2) 8239(1) 1904(1) 46(1) 
C(9) 6998(2) 8693(1) 3412(1) 34(1) 
O(9) 3120(2) 8551(1) 1067(1) 91(1) 
C(10) 6547(2) 8908(1) 3847(1) 37(1) 
O(10) 4938(2) 8050(1) 1019(1) 82(1) 
C(11) 5855(2) 8617(1) 4286(1) 35(1) 
C(12) 4642(2) 8954(1) 4444(1) 34(1) 
C(13) 2228(2) 9061(1) 4406(1) 39(1) 
C(14) 1039(3) 8887(1) 4066(1) 46(1) 
C(15) 1087(2) 9135(1) 3535(1) 42(1) 
C(16) 1454(2) 8840(1) 3105(1) 45(1) 
C(17) 1484(3) 9073(1) 2623(1) 58(1) 
C(18) 1145(3) 9604(1) 2562(1) 66(1) 
C(19) 787(4) 9905(1) 2981(2) 75(1) 
C(20) 761(3) 9673(1) 3465(1) 62(1) 
C(21) 4174(3) 7156(1) 2810(1) 40(1) 
C(22) 2659(3) 7087(1) 2856(1) 57(1) 
C(23) 4674(4) 7001(1) 2272(1) 65(1) 
C(24) 4902(3) 6831(1) 3230(1) 55(1) 
C(25) 7598(3) 9048(1) 2999(1) 44(1) 
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Table D2. Cont’d 
 
C(26) 6781(3) 8524(1) 4749(1) 48(1) 
C(27) 6122(3) 8217(1) 5195(1) 65(1) 
C(28) 7102(5) 8199(3) 5651(2) 131(2) 
C(29) 5656(6) 7663(2) 5039(2) 108(2) 
C(30) 1922(3) 8932(1) 4966(1) 46(1) 
C(31) 581(5) 9212(2) 5666(1) 103(2) 
C(32) 11441(3) 9370(1) -785(1) 50(1) 
C(33) 11697(3) 9084(2) -1238(1) 70(1) 
C(34) 11947(3) 8542(2) -1214(1) 68(1) 
C(35) 11976(3) 8283(1) -747(1) 69(1) 
C(36) 11735(3) 8567(1) -303(1) 53(1) 
C(37) 11458(2) 9114(1) -314(1) 38(1) 
C(38) 11190(2) 9411(1) 183(1) 38(1) 
C(39) 9707(2) 9374(1) 363(1) 32(1) 
C(40) 9565(2) 9553(1) 918(1) 37(1) 
C(41) 9217(2) 9218(1) 1297(1) 35(1) 
C(42) 8818(2) 8634(1) 1264(1) 30(1) 
C(43) 7477(2) 8549(1) 1542(1) 30(1) 
C(44) 5103(2) 8839(1) 1520(1) 45(1) 
C(45) 4508(3) 9412(1) 1537(1) 58(1) 
C(46) 5246(3) 9786(1) 1893(1) 62(1) 
C(47) 4875(4) 9836(2) 2407(1) 89(1) 
C(48) 5584(6) 10194(2) 2731(2) 103(2) 
C(49) 6634(5) 10479(2) 2547(2) 93(1) 
C(50) 7015(5) 10433(1) 2048(2) 87(1) 
C(51) 6318(4) 10094(1) 1720(1) 67(1) 
C(52) 6848(3) 9173(1) -524(1) 56(1) 
C(53) 5315(3) 9127(1) -517(2) 76(1) 
C(54) 7354(4) 9370(2) -1037(1) 93(1) 
C(55) 7480(4) 8625(1) -368(2) 96(2) 
C(56) 9902(4) 10134(1) 1024(1) 61(1) 
C(57) 9902(2) 8247(1) 1466(1) 39(1) 
C(58) 9736(3) 7664(1) 1300(1) 44(1) 
C(59) 9936(4) 7593(1) 717(1) 61(1) 
C(60) 10733(3) 7299(2) 1582(1) 73(1) 
C(61) 4263(3) 8471(1) 1182(1) 55(1) 
C(62) 4209(4) 7674(2) 698(2) 104(2) 
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Table D3. Bond lengths [Å] and angles [°] for bw927s. 
 
S(1)-O(1) 1.4372(18) C(9)-C(10) 1.325(3) 
S(1)-O(2) 1.4417(16) C(9)-C(25) 1.509(3) 
S(1)-N(1) 1.608(2) O(9)-C(61) 1.191(3) 
S(1)-C(21) 1.807(2) C(10)-C(11) 1.513(3) 
C(1)-C(2) 1.377(4) C(10)-H(10A) 0.95 
C(1)-C(6) 1.392(4) O(10)-C(61) 1.310(4) 
C(1)-H(1A) 0.95 O(10)-C(62) 1.444(4) 
N(1)-C(8) 1.477(3) C(11)-C(12) 1.521(3) 
N(1)-H(1N) 0.77(2) C(11)-C(26) 1.531(3) 
C(2)-C(3) 1.372(5) C(11)-H(11A) 1 
C(2)-H(2A) 0.95 C(13)-C(30) 1.519(4) 
N(2)-C(12) 1.336(3) C(13)-C(14) 1.537(3) 
N(2)-C(13) 1.440(3) C(13)-H(13A) 1 
N(2)-H(2N) 0.85(3) C(14)-C(15) 1.510(4) 
S(2)-O(6) 1.4224(19) C(14)-H(14A) 0.99 
S(2)-O(7) 1.430(2) C(14)-H(14B) 0.99 
S(2)-N(3) 1.6101(19) C(15)-C(20) 1.381(4) 
S(2)-C(52) 1.796(3) C(15)-C(16) 1.381(4) 
C(3)-C(4) 1.376(4) C(16)-C(17) 1.378(4) 
C(3)-H(3A) 0.95 C(16)-H(16A) 0.95 
N(3)-C(39) 1.479(3) C(17)-C(18) 1.366(5) 
N(3)-H(3N) 0.85(2) C(17)-H(17A) 0.95 
O(3)-C(12) 1.226(3) C(18)-C(19) 1.365(5) 
C(4)-C(5) 1.378(4) C(18)-H(18A) 0.95 
C(4)-H(4A) 0.95 C(19)-C(20) 1.381(5) 
N(4)-C(43) 1.331(3) C(19)-H(19A) 0.95 
N(4)-C(44) 1.439(3) C(20)-H(20A) 0.95 
N(4)-H(4N) 0.82(3) C(21)-C(22) 1.520(4) 
O(4)-C(30) 1.187(3) C(21)-C(23) 1.529(3) 
C(5)-C(6) 1.386(4) C(21)-C(24) 1.535(4) 
C(5)-H(5A) 0.95 C(22)-H(22A) 0.98 
O(5)-C(30) 1.326(3) C(22)-H(22B) 0.98 
O(5)-C(31) 1.444(4) C(22)-H(22C) 0.98 
C(6)-C(7) 1.502(3) C(23)-H(23A) 0.98 
C(7)-C(8) 1.538(3) C(23)-H(23B) 0.98 
C(7)-H(7A) 0.99 C(23)-H(23C) 0.98 
C(7)-H(7B) 0.99 C(24)-H(24A) 0.98 
C(8)-C(9) 1.512(3) C(24)-H(24B) 0.98 
C(8)-H(8A) 1 C(24)-H(24C) 0.98 
O(8)-C(43) 1.221(3) C(25)-H(25A) 0.98 
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Table D3.  Cont’d 
C(25)-H(25B) 0.98 C(42)-H(42A) 1 
C(25)-H(25C) 0.98 C(44)-C(61) 1.515(4) 
C(26)-C(27) 1.532(4) C(44)-C(45) 1.537(4) 
C(26)-H(26A) 0.99 C(44)-H(44A) 1 
C(26)-H(26B) 0.99 C(45)-C(46) 1.502(5) 
C(27)-C(29) 1.501(6) C(45)-H(45A) 0.99 
C(27)-C(28) 1.533(5) C(45)-H(45B) 0.99 
C(27)-H(27A) 1 C(46)-C(51) 1.384(5) 
C(28)-H(28A) 0.98 C(46)-C(47) 1.390(5) 
C(28)-H(28B) 0.98 C(47)-C(48) 1.410(7) 
C(28)-H(28C) 0.98 C(47)-H(47A) 0.95 
C(29)-H(29A) 0.98 C(48)-C(49) 1.347(7) 
C(29)-H(29B) 0.98 C(48)-H(48A) 0.95 
C(29)-H(29C) 0.98 C(49)-C(50) 1.354(6) 
C(31)-H(31A) 0.98 C(49)-H(49A) 0.95 
C(31)-H(31B) 0.98 C(50)-C(51) 1.381(5) 
C(31)-H(31C) 0.98 C(50)-H(50A) 0.95 
C(32)-C(37) 1.378(3) C(51)-H(51A) 0.95 
C(32)-C(33) 1.394(4) C(52)-C(54) 1.504(5) 
C(32)-H(32A) 0.95 C(52)-C(53) 1.528(4) 
C(33)-C(34) 1.365(5) C(52)-C(55) 1.548(5) 
C(33)-H(33A) 0.95 C(53)-H(53A) 0.98 
C(34)-C(35) 1.373(5) C(53)-H(53B) 0.98 
C(34)-H(34A) 0.95 C(53)-H(53C) 0.98 
C(35)-C(36) 1.371(4) C(54)-H(54A) 0.98 
C(35)-H(35A) 0.95 C(54)-H(54B) 0.98 
C(36)-C(37) 1.382(4) C(54)-H(54C) 0.98 
C(36)-H(36A) 0.95 C(55)-H(55A) 0.98 
C(37)-C(38) 1.507(3) C(55)-H(55B) 0.98 
C(38)-C(39) 1.549(3) C(55)-H(55C) 0.98 
C(38)-H(38A) 0.99 C(56)-H(56A) 0.98 
C(38)-H(38B) 0.99 C(56)-H(56B) 0.98 
C(39)-C(40) 1.515(3) C(56)-H(56C) 0.98 
C(39)-H(39A) 1 C(57)-C(58) 1.513(4) 
C(40)-C(41) 1.332(3) C(57)-H(57A) 0.99 
C(40)-C(56) 1.500(3) C(57)-H(57B) 0.99 
C(41)-C(42) 1.502(3) C(58)-C(60) 1.528(4) 
C(41)-H(41A) 0.95 C(58)-C(59) 1.535(4) 
C(42)-C(43) 1.530(3) C(58)-H(58A) 1 
C(42)-C(57) 1.534(3) C(59)-H(59A) 0.98 
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Table D3.  Cont’d 
C(59)-H(59B) 0.98 C(5)-C(4)-H(4A) 119.9 
C(59)-H(59C) 0.98 C(43)-N(4)-C(44) 125.8(2) 
C(60)-H(60A) 0.98 C(43)-N(4)-H(4N) 118.2(19) 
C(60)-H(60B) 0.98 C(44)-N(4)-H(4N) 115.1(19) 
C(60)-H(60C) 0.98 C(4)-C(5)-C(6) 120.9(3) 
C(62)-H(62A) 0.98 C(4)-C(5)-H(5A) 119.5 
C(62)-H(62B) 0.98 C(6)-C(5)-H(5A) 119.5 
C(62)-H(62C) 0.98 C(30)-O(5)-C(31) 116.6(3) 
O(1)-S(1)-O(2) 118.84(11) C(5)-C(6)-C(1) 118.1(2) 
O(1)-S(1)-N(1) 108.37(11) C(5)-C(6)-C(7) 121.1(2) 
O(2)-S(1)-N(1) 108.56(10) C(1)-C(6)-C(7) 120.8(2) 
O(1)-S(1)-C(21) 106.49(11) C(6)-C(7)-C(8) 114.0(2) 
O(2)-S(1)-C(21) 106.67(10) C(6)-C(7)-H(7A) 108.7 
N(1)-S(1)-C(21) 107.37(11) C(8)-C(7)-H(7A) 108.7 
C(2)-C(1)-C(6) 120.7(3) C(6)-C(7)-H(7B) 108.7 
C(2)-C(1)-H(1A) 119.7 C(8)-C(7)-H(7B) 108.7 
C(6)-C(1)-H(1A) 119.7 H(7A)-C(7)-H(7B) 107.6 
C(8)-N(1)-S(1) 123.67(15) N(1)-C(8)-C(9) 112.83(18) 
C(8)-N(1)-H(1N) 118.5(19) N(1)-C(8)-C(7) 108.48(18) 
S(1)-N(1)-H(1N) 110.3(19) C(9)-C(8)-C(7) 110.53(18) 
C(3)-C(2)-C(1) 120.4(3) N(1)-C(8)-H(8A) 108.3 
C(3)-C(2)-H(2A) 119.8 C(9)-C(8)-H(8A) 108.3 
C(1)-C(2)-H(2A) 119.8 C(7)-C(8)-H(8A) 108.3 
C(12)-N(2)-C(13) 121.0(2) C(10)-C(9)-C(25) 120.4(2) 
C(12)-N(2)-H(2N) 114.3(19) C(10)-C(9)-C(8) 123.4(2) 
C(13)-N(2)-H(2N) 124.6(19) C(25)-C(9)-C(8) 116.2(2) 
O(6)-S(2)-O(7) 117.51(14) C(9)-C(10)-C(11) 127.2(2) 
O(6)-S(2)-N(3) 109.76(11) C(9)-C(10)-H(10A) 116.4 
O(7)-S(2)-N(3) 107.37(11) C(11)-C(10)-H(10A) 116.4 
O(6)-S(2)-C(52) 107.76(15) C(61)-O(10)-C(62) 116.2(3) 
O(7)-S(2)-C(52) 106.40(13) C(10)-C(11)-C(12) 107.59(18) 
N(3)-S(2)-C(52) 107.62(12) C(10)-C(11)-C(26) 112.9(2) 
C(2)-C(3)-C(4) 119.6(3) C(12)-C(11)-C(26) 110.42(19) 
C(2)-C(3)-H(3A) 120.2 C(10)-C(11)-H(11A) 108.6 
C(4)-C(3)-H(3A) 120.2 C(12)-C(11)-H(11A) 108.6 
C(39)-N(3)-S(2) 124.27(15) C(26)-C(11)-H(11A) 108.6 
C(39)-N(3)-H(3N) 118.7(16) O(3)-C(12)-N(2) 120.4(2) 
S(2)-N(3)-H(3N) 108.7(16) O(3)-C(12)-C(11) 123.3(2) 
C(3)-C(4)-C(5) 120.2(3) N(2)-C(12)-C(11) 116.30(19) 
C(3)-C(4)-H(4A) 119.9 N(2)-C(13)-C(30) 110.5(2) 
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N(2)-C(13)-C(14) 111.38(19) H(22B)-C(22)-H(22C) 109.5 
C(30)-C(13)-C(14) 109.7(2) C(21)-C(23)-H(23A) 109.5 
N(2)-C(13)-H(13A) 108.4 C(21)-C(23)-H(23B) 109.5 
C(30)-C(13)-H(13A) 108.4 H(23A)-C(23)-H(23B) 109.5 
C(14)-C(13)-H(13A) 108.4 C(21)-C(23)-H(23C) 109.5 
C(15)-C(14)-C(13) 112.7(2) H(23A)-C(23)-H(23C) 109.5 
C(15)-C(14)-H(14A) 109.1 H(23B)-C(23)-H(23C) 109.5 
C(13)-C(14)-H(14A) 109.1 C(21)-C(24)-H(24A) 109.5 
C(15)-C(14)-H(14B) 109.1 C(21)-C(24)-H(24B) 109.5 
C(13)-C(14)-H(14B) 109.1 H(24A)-C(24)-H(24B) 109.5 
H(14A)-C(14)-H(14B) 107.8 C(21)-C(24)-H(24C) 109.5 
C(20)-C(15)-C(16) 117.8(3) H(24A)-C(24)-H(24C) 109.5 
C(20)-C(15)-C(14) 120.3(2) H(24B)-C(24)-H(24C) 109.5 
C(16)-C(15)-C(14) 121.9(2) C(9)-C(25)-H(25A) 109.5 
C(17)-C(16)-C(15) 121.2(3) C(9)-C(25)-H(25B) 109.5 
C(17)-C(16)-H(16A) 119.4 H(25A)-C(25)-H(25B) 109.5 
C(15)-C(16)-H(16A) 119.4 C(9)-C(25)-H(25C) 109.5 
C(18)-C(17)-C(16) 120.1(3) H(25A)-C(25)-H(25C) 109.5 
C(18)-C(17)-H(17A) 120 H(25B)-C(25)-H(25C) 109.5 
C(16)-C(17)-H(17A) 120 C(27)-C(26)-C(11) 114.2(2) 
C(19)-C(18)-C(17) 119.8(3) C(27)-C(26)-H(26A) 108.7 
C(19)-C(18)-H(18A) 120.1 C(11)-C(26)-H(26A) 108.7 
C(17)-C(18)-H(18A) 120.1 C(27)-C(26)-H(26B) 108.7 
C(18)-C(19)-C(20) 120.2(3) C(11)-C(26)-H(26B) 108.7 
C(18)-C(19)-H(19A) 119.9 H(26A)-C(26)-H(26B) 107.6 
C(20)-C(19)-H(19A) 119.9 C(29)-C(27)-C(26) 112.3(3) 
C(15)-C(20)-C(19) 120.9(3) C(29)-C(27)-C(28) 112.2(4) 
C(15)-C(20)-H(20A) 119.5 C(26)-C(27)-C(28) 109.0(3) 
C(19)-C(20)-H(20A) 119.5 C(29)-C(27)-H(27A) 107.7 
C(22)-C(21)-C(23) 111.4(2) C(26)-C(27)-H(27A) 107.7 
C(22)-C(21)-C(24) 110.7(2) C(28)-C(27)-H(27A) 107.7 
C(23)-C(21)-C(24) 111.3(2) C(27)-C(28)-H(28A) 109.5 
C(22)-C(21)-S(1) 106.2(2) C(27)-C(28)-H(28B) 109.5 
C(23)-C(21)-S(1) 108.16(18) H(28A)-C(28)-H(28B) 109.5 
C(24)-C(21)-S(1) 108.86(17) C(27)-C(28)-H(28C) 109.5 
C(21)-C(22)-H(22A) 109.5 H(28A)-C(28)-H(28C) 109.5 
C(21)-C(22)-H(22B) 109.5 H(28B)-C(28)-H(28C) 109.5 
H(22A)-C(22)-H(22B) 109.5 C(27)-C(29)-H(29A) 109.5 
C(21)-C(22)-H(22C) 109.5 C(27)-C(29)-H(29B) 109.5 
H(22A)-C(22)-H(22C) 109.5 H(29A)-C(29)-H(29B) 109.5 
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C(27)-C(29)-H(29C) 109.5 C(40)-C(39)-H(39A) 108.1 
H(29A)-C(29)-H(29C) 109.5 C(38)-C(39)-H(39A) 108.1 
H(29B)-C(29)-H(29C) 109.5 C(41)-C(40)-C(56) 121.3(2) 
O(4)-C(30)-O(5) 124.7(3) C(41)-C(40)-C(39) 123.0(2) 
O(4)-C(30)-C(13) 126.1(2) C(56)-C(40)-C(39) 115.7(2) 
O(5)-C(30)-C(13) 109.3(2) C(40)-C(41)-C(42) 128.7(2) 
O(5)-C(31)-H(31A) 109.5 C(40)-C(41)-H(41A) 115.7 
O(5)-C(31)-H(31B) 109.5 C(42)-C(41)-H(41A) 115.7 
H(31A)-C(31)-H(31B) 109.5 C(41)-C(42)-C(43) 109.53(18) 
O(5)-C(31)-H(31C) 109.5 C(41)-C(42)-C(57) 113.27(18) 
H(31A)-C(31)-H(31C) 109.5 C(43)-C(42)-C(57) 111.43(18) 
H(31B)-C(31)-H(31C) 109.5 C(41)-C(42)-H(42A) 107.4 
C(37)-C(32)-C(33) 120.8(3) C(43)-C(42)-H(42A) 107.4 
C(37)-C(32)-H(32A) 119.6 C(57)-C(42)-H(42A) 107.4 
C(33)-C(32)-H(32A) 119.6 O(8)-C(43)-N(4) 123.4(2) 
C(34)-C(33)-C(32) 119.7(3) O(8)-C(43)-C(42) 123.31(19) 
C(34)-C(33)-H(33A) 120.2 N(4)-C(43)-C(42) 113.34(18) 
C(32)-C(33)-H(33A) 120.2 N(4)-C(44)-C(61) 111.4(2) 
C(33)-C(34)-C(35) 120.1(3) N(4)-C(44)-C(45) 110.9(2) 
C(33)-C(34)-H(34A) 120 C(61)-C(44)-C(45) 111.0(2) 
C(35)-C(34)-H(34A) 120 N(4)-C(44)-H(44A) 107.8 
C(36)-C(35)-C(34) 120.0(3) C(61)-C(44)-H(44A) 107.8 
C(36)-C(35)-H(35A) 120 C(45)-C(44)-H(44A) 107.8 
C(34)-C(35)-H(35A) 120 C(46)-C(45)-C(44) 113.5(2) 
C(35)-C(36)-C(37) 121.3(3) C(46)-C(45)-H(45A) 108.9 
C(35)-C(36)-H(36A) 119.4 C(44)-C(45)-H(45A) 108.9 
C(37)-C(36)-H(36A) 119.4 C(46)-C(45)-H(45B) 108.9 
C(32)-C(37)-C(36) 118.2(3) C(44)-C(45)-H(45B) 108.9 
C(32)-C(37)-C(38) 122.2(2) H(45A)-C(45)-H(45B) 107.7 
C(36)-C(37)-C(38) 119.6(2) C(51)-C(46)-C(47) 117.8(4) 
C(37)-C(38)-C(39) 113.37(19) C(51)-C(46)-C(45) 121.2(3) 
C(37)-C(38)-H(38A) 108.9 C(47)-C(46)-C(45) 121.0(3) 
C(39)-C(38)-H(38A) 108.9 C(46)-C(47)-C(48) 119.6(4) 
C(37)-C(38)-H(38B) 108.9 C(46)-C(47)-H(47A) 120.2 
C(39)-C(38)-H(38B) 108.9 C(48)-C(47)-H(47A) 120.2 
H(38A)-C(38)-H(38B) 107.7 C(49)-C(48)-C(47) 120.5(4) 
N(3)-C(39)-C(40) 113.82(19) C(49)-C(48)-H(48A) 119.8 
N(3)-C(39)-C(38) 107.54(17) C(47)-C(48)-H(48A) 119.8 
C(40)-C(39)-C(38) 110.93(18) C(48)-C(49)-C(50) 120.7(5) 
N(3)-C(39)-H(39A) 108.1 C(48)-C(49)-H(49A) 119.7 
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C(50)-C(49)-H(49A) 119.7 C(58)-C(57)-H(57B) 108.6 
C(49)-C(50)-C(51) 120.0(5) C(42)-C(57)-H(57B) 108.6 
C(49)-C(50)-H(50A) 120 H(57A)-C(57)-H(57B) 107.5 
C(51)-C(50)-H(50A) 120 C(57)-C(58)-C(60) 110.8(2) 
C(50)-C(51)-C(46) 121.5(4) C(57)-C(58)-C(59) 112.1(2) 
C(50)-C(51)-H(51A) 119.3 C(60)-C(58)-C(59) 108.7(2) 
C(46)-C(51)-H(51A) 119.3 C(57)-C(58)-H(58A) 108.4 
C(54)-C(52)-C(53) 111.6(3) C(60)-C(58)-H(58A) 108.4 
C(54)-C(52)-C(55) 112.2(3) C(59)-C(58)-H(58A) 108.4 
C(53)-C(52)-C(55) 109.6(3) C(58)-C(59)-H(59A) 109.5 
C(54)-C(52)-S(2) 108.9(2) C(58)-C(59)-H(59B) 109.5 
C(53)-C(52)-S(2) 106.0(2) H(59A)-C(59)-H(59B) 109.5 
C(55)-C(52)-S(2) 108.3(2) C(58)-C(59)-H(59C) 109.5 
C(52)-C(53)-H(53A) 109.5 H(59A)-C(59)-H(59C) 109.5 
C(52)-C(53)-H(53B) 109.5 H(59B)-C(59)-H(59C) 109.5 
H(53A)-C(53)-H(53B) 109.5 C(58)-C(60)-H(60A) 109.5 
C(52)-C(53)-H(53C) 109.5 C(58)-C(60)-H(60B) 109.5 
H(53A)-C(53)-H(53C) 109.5 H(60A)-C(60)-H(60B) 109.5 
H(53B)-C(53)-H(53C) 109.5 C(58)-C(60)-H(60C) 109.5 
C(52)-C(54)-H(54A) 109.5 H(60A)-C(60)-H(60C) 109.5 
C(52)-C(54)-H(54B) 109.5 H(60B)-C(60)-H(60C) 109.5 
H(54A)-C(54)-H(54B) 109.5 O(9)-C(61)-O(10) 122.7(3) 
C(52)-C(54)-H(54C) 109.5 O(9)-C(61)-C(44) 124.8(3) 
H(54A)-C(54)-H(54C) 109.5 O(10)-C(61)-C(44) 112.5(2) 
H(54B)-C(54)-H(54C) 109.5 O(10)-C(62)-H(62A) 109.5 
C(52)-C(55)-H(55A) 109.5 O(10)-C(62)-H(62B) 109.5 
C(52)-C(55)-H(55B) 109.5 H(62A)-C(62)-H(62B) 109.5 
H(55A)-C(55)-H(55B) 109.5 O(10)-C(62)-H(62C) 109.5 
C(52)-C(55)-H(55C) 109.5 H(62A)-C(62)-H(62C) 109.5 
H(55A)-C(55)-H(55C) 109.5 H(62B)-C(62)-H(62C) 109.5 
H(55B)-C(55)-H(55C) 109.5   
C(40)-C(56)-H(56A) 109.5   
C(40)-C(56)-H(56B) 109.5   
H(56A)-C(56)-H(56B) 109.5   
C(40)-C(56)-H(56C) 109.5   
H(56A)-C(56)-H(56C) 109.5   
H(56B)-C(56)-H(56C) 109.5   
C(58)-C(57)-C(42) 114.86(19)   
C(58)-C(57)-H(57A) 108.6   
C(42)-C(57)-H(57A) 108.6   
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Table D4. Anisotropic displacement parmeters (Å2x 103) for bw927s.  The anisotropic 
 displacement factor exponent take the form: -2?2[h2 a*2U33 + … + 2 h k a* b* U12 ]. 
 
 U11 U22 U33 U23 U13 U12 
S(1) 32(1) 34(1) 26(1) 1(1) 2(1) -2(1) 
C(1) 69(2) 58(2) 38(1) 5(1) 4(1) 24(2) 
N(1) 34(1) 36(1) 26(1) 2(1) 4(1) -4(1) 
O(1) 42(1) 56(1) 43(1) 12(1) -1(1) 1(1) 
C(2) 116(3) 66(2) 48(2) -14(2) -10(2) 42(2) 
N(2) 38(1) 41(1) 37(1) -12(1) -5(1) 0(1) 
O(2) 36(1) 49(1) 36(1) -10(1) 6(1) -7(1) 
S(2) 31(1) 49(1) 38(1) 11(1) 1(1) -4(1) 
C(3) 129(3) 45(2) 66(2) -5(2) -19(2) 34(2) 
N(3) 34(1) 33(1) 38(1) 9(1) 1(1) -5(1) 
O(3) 41(1) 42(1) 64(1) -24(1) -9(1) 1(1) 
C(4) 108(3) 52(2) 49(2) 12(1) -12(2) 28(2) 
N(4) 34(1) 50(1) 41(1) 19(1) 11(1) 8(1) 
O(4) 88(2) 67(1) 51(1) 9(1) 10(1) 13(1) 
C(5) 64(2) 52(2) 39(1) 1(1) -8(1) 17(1) 
O(5) 78(2) 96(2) 59(1) -6(1) 14(1) 36(1) 
C(6) 39(1) 41(1) 40(1) 1(1) 0(1) 10(1) 
O(6) 38(1) 112(2) 50(1) 27(1) 1(1) -11(1) 
C(7) 31(1) 45(1) 48(1) 5(1) 2(1) 4(1) 
O(7) 47(1) 51(1) 89(2) 11(1) -3(1) 7(1) 
C(8) 29(1) 34(1) 31(1) 4(1) 2(1) 0(1) 
O(8) 42(1) 59(1) 36(1) 17(1) 10(1) 10(1) 
C(9) 27(1) 34(1) 42(1) 5(1) -5(1) -4(1) 
O(9) 33(1) 99(2) 140(2) 1(2) -14(1) 8(1) 
C(10) 37(1) 28(1) 47(1) -2(1) -6(1) -5(1) 
O(10) 45(1) 95(2) 104(2) -33(1) -16(1) 18(1) 
C(11) 37(1) 34(1) 35(1) -5(1) -5(1) -1(1) 
C(12) 37(1) 33(1) 33(1) -3(1) -1(1) -2(1) 
C(13) 36(1) 43(1) 40(1) -7(1) -2(1) 0(1) 
C(14) 39(1) 53(2) 46(1) -2(1) -5(1) -4(1) 
C(15) 32(1) 47(1) 47(1) -4(1) -10(1) 0(1) 
C(16) 35(1) 50(2) 50(2) -1(1) -6(1) 0(1) 
C(17) 49(2) 74(2) 51(2) -4(2) -5(1) -3(2) 
C(18) 62(2) 73(2) 63(2) 16(2) -20(2) -14(2) 
C(19) 88(3) 46(2) 91(3) 10(2) -29(2) 2(2) 
C(20) 72(2) 54(2) 59(2) -11(2) -16(2) 9(2) 
C(21) 47(1) 37(1) 36(1) -6(1) 2(1) -12(1) 
C(22) 51(2) 65(2) 55(2) 0(1) -3(1) -22(1) 
C(23) 84(2) 60(2) 50(2) -25(1) 12(2) -17(2) 
C(24) 62(2) 38(1) 64(2) 9(1) -1(1) -9(1) 
 
 212 
Table D4. Cont’d. 
C(25) 43(1) 34(1) 55(2) 9(1) 4(1) -7(1) 
C(26) 39(1) 58(2) 48(1) -8(1) -7(1) 12(1) 
C(27) 68(2) 85(2) 41(2) 8(2) -7(1) 20(2) 
C(28) 106(4) 231(6) 56(2) 29(3) -21(2) 39(4) 
C(29) 165(5) 66(2) 92(3) 30(2) 25(3) -1(3) 
C(30) 43(1) 54(2) 42(1) -10(1) 0(1) 2(1) 
C(31) 102(3) 149(4) 59(2) -10(2) 32(2) 35(3) 
C(32) 49(2) 58(2) 45(2) 9(1) 2(1) 2(1) 
C(33) 59(2) 110(3) 41(2) 2(2) 3(1) 8(2) 
C(34) 54(2) 88(3) 63(2) -27(2) 7(2) 4(2) 
C(35) 62(2) 55(2) 89(2) -12(2) 28(2) 4(2) 
C(36) 50(2) 51(2) 57(2) 10(1) 14(1) 5(1) 
C(37) 26(1) 47(1) 41(1) 1(1) 3(1) -1(1) 
C(38) 33(1) 44(1) 37(1) 2(1) -3(1) -5(1) 
C(39) 31(1) 34(1) 31(1) 2(1) -3(1) -7(1) 
C(40) 38(1) 38(1) 35(1) -5(1) -1(1) -10(1) 
C(41) 37(1) 43(1) 26(1) -8(1) -2(1) -7(1) 
C(42) 28(1) 38(1) 23(1) -1(1) 1(1) -2(1) 
C(43) 32(1) 36(1) 23(1) -2(1) 2(1) 0(1) 
C(44) 35(1) 59(2) 41(1) 17(1) 11(1) 12(1) 
C(45) 46(2) 72(2) 56(2) 17(2) 12(1) 26(2) 
C(46) 62(2) 68(2) 56(2) 3(2) 1(2) 38(2) 
C(47) 74(2) 129(3) 63(2) -2(2) 9(2) 48(2) 
C(48) 114(4) 139(4) 57(2) -25(2) -6(2) 74(3) 
C(49) 112(4) 81(3) 88(3) -22(2) -20(3) 52(3) 
C(50) 115(3) 49(2) 96(3) -10(2) -16(3) 24(2) 
C(51) 86(2) 50(2) 64(2) -2(2) -3(2) 21(2) 
C(52) 47(2) 57(2) 66(2) 0(1) -23(1) -5(1) 
C(53) 52(2) 76(2) 99(3) 22(2) -37(2) -16(2) 
C(54) 75(2) 155(4) 48(2) -14(2) -13(2) -5(3) 
C(55) 84(3) 50(2) 152(4) -25(2) -64(3) 3(2) 
C(56) 87(2) 43(2) 52(2) -11(1) 3(2) -21(2) 
C(57) 26(1) 54(1) 37(1) 5(1) 0(1) 3(1) 
C(58) 42(1) 45(1) 45(1) 12(1) 5(1) 11(1) 
C(59) 80(2) 51(2) 53(2) -1(1) 12(2) 18(2) 
C(60) 64(2) 84(2) 71(2) 26(2) 7(2) 33(2) 
C(61) 33(1) 71(2) 60(2) 21(2) 10(1) 3(1) 
C(62) 61(2) 124(4) 125(4) -51(3) -20(2) 3(2) 
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(Å2x 103) for bw927s. 
 
 x y z U(eq) 
H(1A) 8391 7235 2369 66 
H(1N) 6290(30) 8062(10) 2592(10) 31(7) 
H(2A) 8553 6302 2312 92 
H(2N) 3500(30) 8543(11) 4036(11) 44(7) 
H(3A) 8674 5779 3053 96 
H(3N) 9140(20) 10011(10) -80(9) 30(6) 
H(4A) 8727 6196 3857 84 
H(4N) 6620(30) 9022(10) 1090(10) 41(7) 
H(5A) 8614 7130 3919 62 
H(7A) 8724 8047 2863 50 
H(7B) 9015 8013 3467 50 
H(8A) 6632 7903 3615 38 
H(10A) 6672 9286 3888 45 
H(11A) 5531 8259 4159 42 
H(13A) 2344 9461 4372 47 
H(14A) 1043 8488 4033 55 
H(14B) 188 8993 4236 55 
H(16A) 1691 8471 3143 54 
H(17A) 1740 8863 2332 70 
H(18A) 1158 9763 2229 79 
H(19A) 555 10274 2939 90 
H(20A) 516 9887 3754 74 
H(22A) 2423 6707 2804 85 
H(22B) 2211 7309 2593 85 
H(22C) 2366 7202 3199 85 
H(23A) 4503 6616 2212 97 
H(23B) 5642 7072 2248 97 
H(23C) 4197 7216 2013 97 
H(24A) 4732 6445 3179 82 
H(24B) 4568 6941 3569 82 
H(24C) 5871 6900 3209 82 
H(25A) 7564 9426 3110 66 
H(25B) 7085 9005 2679 66 
H(25C) 8536 8943 2939 66 
H(26A) 7581 8319 4633 58 
H(26B) 7097 8878 4878 58 
H(27A) 5313 8427 5306 78 
H(28A) 6683 8006 5939 196 
H(28B) 7323 8568 5758 196 
H(28C) 7925 8011 5547 196 
H(29A) 5232 7485 5334 161 
H(29B) 6429 7450 4923 161 
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H(29C) 5003 7695 4758 161 
H(31A) 9 9516 5769 155 
H(31B) 1331 9178 5909 155 
H(31C) 51 8878 5669 155 
H(32A) 11252 9746 -802 60 
H(33A) 11697 9265 -1560 84 
H(34A) 12101 8344 -1522 82 
H(35A) 12163 7907 -731 82 
H(36A) 11760 8384 19 63 
H(38A) 11432 9796 137 45 
H(38B) 11777 9260 456 45 
H(39A) 9419 8987 339 39 
H(41A) 9222 9369 1634 42 
H(42A) 8671 8547 891 36 
H(44A) 5082 8690 1878 54 
H(45A) 4522 9566 1184 69 
H(45B) 3557 9389 1647 69 
H(47A) 4147 9630 2540 106 
H(48A) 5319 10235 3080 124 
H(49A) 7113 10715 2771 112 
H(50A) 7762 10634 1923 104 
H(51A) 6579 10072 1369 80 
H(53A) 5027 8864 -777 113 
H(53B) 4917 9480 -594 113 
H(53C) 5018 9007 -175 113 
H(54A) 7129 9105 -1304 139 
H(54B) 8333 9416 -1021 139 
H(54C) 6931 9717 -1119 139 
H(55A) 7264 8353 -629 144 
H(55B) 7119 8511 -34 144 
H(55C) 8459 8665 -343 144 
H(56A) 9780 10209 1392 91 
H(56B) 9306 10368 822 91 
H(56C) 10839 10203 927 91 
H(57A) 10791 8377 1347 47 
H(57B) 9899 8261 1847 47 
H(58A) 8804 7545 1389 53 
H(59A) 9293 7822 531 92 
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Table D5. Cont’d. 
H(59B) 9788 7214 624 92 
H(59C) 10855 7698 624 92 
H(60A) 10614 7341 1955 110 
H(60B) 11653 7401 1487 110 
H(60C) 10571 6922 1485 110 
H(62A) 4808 7379 594 155 
H(62B) 3878 7861 390 155 
H(62C) 3446 7526 891 155 
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Table E1. Crystal data and structure refinement for bw612s. 
Identification code  bww612s  
Empirical formula  C16 H10 O2 S 
Formula weight  266.3  
Temperature  173(2) K  
Wavelength  0.71073 Å  
Crystal system  Triclinic  
Space group  P-1  
Unit cell dimensions a = 7.3598(9) Å a= 100.717(2)°. 
 b = 7.9274(10) Å b= 96.314(2)°. 
 c = 11.2447(14) Å g = 108.545(2)°. 
Volume 600.99(13) Å3 
Z 2  
Density (calculated) 1.472 Mg/m3 
Absorption coefficient 0.262 mm-1  
F(000) 276  
Crystal size ? x ? x ? mm3 
Theta range for data collection 1.87 to 32.60°. 
Index ranges -10<=h<=11, -11<=k<=11, -16<=l<=17 
Reflections collected 7843  
Independent reflections 4090 [R(int) = 0.0169] 
Completeness to theta = 32.60° 93.40%  
Absorption correction None  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4090 / 0 / 213 
Goodness-of-fit on F2 1.176  
Final R indices [I>2sigma(I)] R1 = 0.0448, wR2 = 0.1238 
R indices (all data) R1 = 0.0529, wR2 = 0.1321 
Extinction coefficient 0.000(4)  
Largest diff. peak and hole 0.496 and -0.267 e.Å-3 
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Table E2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters   
(Å2x 103) for bww612s.  U(eq) is defined as one third of the trace of the orthogonalized   
Uij tensor. 
 
 x y z U(eq) 
S(1) -1313(1) -11762(1) -1364(1) 28(1) 
C(1) 30(2) -10139(2) -2060(1) 22(1) 
O(1) 1981(2) -11720(1) -2938(1) 35(1) 
O(2) -4831(1) -7809(1) -961(1) 32(1) 
C(2) 1398(2) -10417(2) -2855(1) 24(1) 
C(3) 1901(2) -9071(2) -3644(1) 22(1) 
C(4) 2928(2) -9432(2) -4581(1) 26(1) 
C(5) 3420(2) -8264(2) -5358(1) 29(1) 
C(6) 2915(2) -6699(2) -5193(1) 28(1) 
C(7) 1904(2) -6319(2) -4267(1) 25(1) 
C(8) 1345(2) -7512(2) -3498(1) 20(1) 
C(9) 265(2) -7060(2) -2467(1) 20(1) 
C(10) -1281(2) -6267(2) -2816(1) 24(1) 
C(11) -2923(2) -6555(2) -2356(1) 25(1) 
C(12) -3472(2) -7773(2) -1505(1) 23(1) 
C(13) -2304(2) -8960(2) -1424(1) 22(1) 
C(14) -2807(2) -10562(2) -1022(1) 28(1) 
C(15) -645(2) -8710(2) -1995(1) 20(1) 
C(16) 1799(2) -5566(2) -1403(1) 27(1) 
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Table E3. Bond lengths [Å] and angles [°] for bww612s. 
S(1)-C(14) 1.6986(14) C(4)-C(3)-C(2) 117.42(11) 
S(1)-C(1) 1.7261(12) C(8)-C(3)-C(2) 122.81(10) 
C(1)-C(15) 1.3682(15) C(5)-C(4)-C(3) 120.75(12) 
C(1)-C(2) 1.4590(17) C(5)-C(4)-H(4) 121.9(11) 
O(1)-C(2) 1.2308(15) C(3)-C(4)-H(4) 117.2(11) 
O(2)-C(12) 1.2240(15) C(4)-C(5)-C(6) 119.44(12) 
C(2)-C(3) 1.4951(17) C(4)-C(5)-H(5) 120.8(11) 
C(3)-C(4) 1.4021(16) C(6)-C(5)-H(5) 119.7(11) 
C(3)-C(8) 1.4074(16) C(7)-C(6)-C(5) 120.54(12) 
C(4)-C(5) 1.3814(19) C(7)-C(6)-H(6) 118.4(13) 
C(4)-H(4) 0.936(18) C(5)-C(6)-H(6) 121.1(13) 
C(5)-C(6) 1.3906(19) C(6)-C(7)-C(8) 120.68(12) 
C(5)-H(5) 0.960(18) C(6)-C(7)-H(7) 119.8(10) 
C(6)-C(7) 1.3885(18) C(8)-C(7)-H(7) 119.6(10) 
C(6)-H(6) 0.92(2) C(7)-C(8)-C(3) 118.78(11) 
C(7)-C(8) 1.3947(16) C(7)-C(8)-C(9) 120.14(10) 
C(7)-H(7) 1.014(18) C(3)-C(8)-C(9) 120.96(10) 
C(8)-C(9) 1.5283(15) C(15)-C(9)-C(10) 108.80(9) 
C(9)-C(15) 1.4900(15) C(15)-C(9)-C(8) 110.64(9) 
C(9)-C(10) 1.5134(16) C(10)-C(9)-C(8) 114.67(10) 
C(9)-C(16) 1.5600(17) C(15)-C(9)-C(16) 108.86(9) 
C(10)-C(11) 1.3366(17) C(10)-C(9)-C(16) 106.30(9) 
C(10)-H(10) 0.921(18) C(8)-C(9)-C(16) 107.34(9) 
C(11)-C(12) 1.4795(17) C(11)-C(10)-C(9) 123.72(11) 
C(11)-H(11) 0.95(2) C(11)-C(10)-H(10) 116.7(11) 
C(12)-C(13) 1.4712(17) C(9)-C(10)-H(10) 119.5(11) 
C(13)-C(14) 1.3801(17) C(10)-C(11)-C(12) 123.34(11) 
C(13)-C(15) 1.4166(16) C(10)-C(11)-H(11) 122.7(12) 
C(14)-H(14) 0.98(2) C(12)-C(11)-H(11) 113.9(12) 
C(16)-H(16A) 0.988(17) O(2)-C(12)-C(13) 124.05(11) 
C(16)-H(16B) 0.978(19) O(2)-C(12)-C(11) 121.79(11) 
C(16)-H(16C) 0.94(2) C(13)-C(12)-C(11) 114.10(10) 
C(14)-S(1)-C(1) 92.01(6) C(14)-C(13)-C(15) 112.06(11) 
C(15)-C(1)-C(2) 122.71(11) C(14)-C(13)-C(12) 126.79(11) 
C(15)-C(1)-S(1) 111.20(9) C(15)-C(13)-C(12) 120.16(10) 
C(2)-C(1)-S(1) 124.69(9) C(13)-C(14)-S(1) 111.96(9) 
O(1)-C(2)-C(1) 123.11(12) C(13)-C(14)-H(14) 124.7(12) 
O(1)-C(2)-C(3) 122.61(12) S(1)-C(14)-H(14) 122.9(12) 
C(1)-C(2)-C(3) 114.09(10) C(1)-C(15)-C(13) 112.72(10) 
C(4)-C(3)-C(8) 119.75(11) C(1)-C(15)-C(9) 123.85(10) 
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Table E3. Cont’d. 
C(13)-C(15)-C(9) 123.43(10) 
C(9)-C(16)-H(16A) 109.5(10) 
C(9)-C(16)-H(16B) 114.2(11) 
H(16A)-C(16)-H(16B) 106.8(14) 
C(9)-C(16)-H(16C) 110.1(11) 
H(16A)-C(16)-H(16C) 108.0(15) 
H(16B)-C(16)-H(16C) 108.0(16) 
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Table E4. Anisotropic displacement parmeters (Å2x 103) for bww612s.  The anisotropic 
 displacement factor exponent take the form: -2?2[h2 a*2U33 + … + 2 h k a* b* U12 ]. 
 
 U11 U22 U33 U23 U13 U12 
S(1) 38(1) 21(1) 30(1) 11(1) 10(1) 12(1) 
C(1) 27(1) 20(1) 23(1) 7(1) 5(1) 10(1) 
O(1) 44(1) 30(1) 44(1) 13(1) 14(1) 25(1) 
O(2) 30(1) 38(1) 36(1) 12(1) 15(1) 16(1) 
C(2) 26(1) 21(1) 26(1) 4(1) 2(1) 11(1) 
C(3) 19(1) 23(1) 22(1) 3(1) 2(1) 8(1) 
C(4) 23(1) 30(1) 26(1) 3(1) 5(1) 12(1) 
C(5) 24(1) 39(1) 24(1) 5(1) 6(1) 11(1) 
C(6) 24(1) 35(1) 26(1) 12(1) 6(1) 9(1) 
C(7) 24(1) 26(1) 28(1) 11(1) 6(1) 9(1) 
C(8) 18(1) 21(1) 21(1) 5(1) 4(1) 7(1) 
C(9) 21(1) 18(1) 24(1) 7(1) 6(1) 8(1) 
C(10) 26(1) 23(1) 29(1) 11(1) 8(1) 12(1) 
C(11) 25(1) 24(1) 31(1) 10(1) 7(1) 13(1) 
C(12) 22(1) 23(1) 24(1) 5(1) 6(1) 7(1) 
C(13) 24(1) 21(1) 21(1) 5(1) 6(1) 8(1) 
C(14) 33(1) 26(1) 26(1) 10(1) 11(1) 9(1) 
C(15) 21(1) 19(1) 19(1) 4(1) 3(1) 8(1) 
C(16) 26(1) 22(1) 29(1) 1(1) 4(1) 7(1) 
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Table E5. Hydrogen coordinates (x 104) and isotropic displacement parameters   
(Å2x 103) for bww612s. 
 x y z U(eq) 
H(4) 3190(20) -10530(20) -4689(16) 32(4) 
H(5) 4130(30) -8500(20) -5996(16) 41(5) 
H(6) 3260(30) -5880(30) -5683(18) 50(5) 
H(7) 1570(30) -5160(20) -4143(16) 38(4) 
H(10) -1070(20) -5480(20) -3337(15) 33(4) 
H(11) -3870(30) -6030(30) -2573(17) 48(5) 
H(14) -3980(30) -11050(30) -682(18) 49(5) 
H(16A) 1180(30) -5330(20) -686(15) 31(4) 
H(16B) 2370(30) -4390(30) -1611(16) 40(5) 
H(16C) 2810(30) -5980(20) -1158(17) 43(5) 
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Table F1. Crystal data and structure refinement for bw31308. 
Identification code  bw31308  
Empirical formula  C37 H30 O2 S  
Formula weight  538.67  
Temperature  173(2) K  
Wavelength  0.71073 Å  
Crystal system  Orthorhombic  
Space group  Pna2(1)  
Unit cell dimensions a = 14.0848(8) Å a= 90°. 
 b = 12.0300(7) Å b= 90°. 
 c = 33.068(2) Å g = 90°. 
Volume 5603.0(6) Å3 
Z 8  
Density (calculated) 1.277 Mg/m3  
Absorption coefficient 0.149 mm-1  
F(000) 2272  
Crystal size 0.38 x 0.35 x 0.18 mm3 
Theta range for data collection 1.80 to 32.63°. 
Index ranges 
-21<=h<=21, -17<=k<=18, -
50<=l<=49 
Reflections collected 70149  
Independent reflections 19605 [R(int) = 0.0681] 
Completeness to theta = 32.63° 98.20%  
Absorption correction Multi-scan (Sadabs) 
Max. and min. transmission 0.9737 and 0.9457 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 19605 / 1 / 778 
Goodness-of-fit on F2 1.01  
Final R indices [I>2sigma(I)] R1 = 0.0681, wR2 = 0.1432 
R indices (all data) R1 = 0.1202, wR2 = 0.1704 
Absolute structure parameter 0.55(8)  
Largest diff. peak and hole 0.605 and -0.226 e.Å-3 
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Table F2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters   
(Å2x 103) for bw31308.  U(eq) is defined as one third of the trace of the orthogonalized   
Uij tensor. 
 
 x y z U(eq) 
S(1) 3896(1) -747(1) 2346(1) 37(1) 
S(2) 3591(1) 4265(1) 2560(1) 36(1) 
O(1) 5016(2) 944(2) 1862(1) 51(1) 
O(2) 2901(1) -600(2) 3609(1) 25(1) 
O(3) 2467(2) 5953(2) 3039(1) 49(1) 
O(4) 4601(1) 4430(2) 1297(1) 25(1) 
C(1) 4633(2) 293(2) 2512(1) 29(1) 
C(2) 5129(2) 1001(3) 2230(1) 35(1) 
C(3) 5788(2) 1807(3) 2418(1) 33(1) 
C(4) 6387(5) 2433(3) 2161(2) 40(2) 
C(5) 7003(3) 3203(3) 2326(1) 51(1) 
C(6) 7018(3) 3377(3) 2738(1) 49(1) 
C(7) 6438(3) 2764(4) 2991(1) 41(1) 
C(8) 5821(2) 1958(2) 2838(1) 30(1) 
C(9) 5188(2) 1312(2) 3135(1) 26(1) 
C(10) 4659(2) 365(2) 2928(1) 25(1) 
C(11) 4069(2) -446(2) 3113(1) 25(1) 
C(12) 3627(2) -1097(3) 2829(1) 32(1) 
C(13) 5824(2) 855(2) 3469(1) 29(1) 
C(14) 5879(2) 1234(3) 3841(1) 36(1) 
C(15) 4438(2) 2117(3) 3303(1) 32(1) 
C(16) 3917(2) -648(2) 3559(1) 23(1) 
C(17) 4341(2) -1756(2) 3673(1) 29(1) 
C(18) 5058(2) -1879(3) 3922(1) 36(1) 
C(19) 2503(2) -533(2) 4013(1) 24(1) 
C(20) 2647(2) 1517(2) 4189(1) 31(1) 
C(21) 3099(5) 2414(3) 4371(2) 37(1) 
C(22) 3895(3) 2246(4) 4603(1) 42(1) 
C(23) 4237(2) 1180(3) 4653(1) 37(1) 
C(24) 3790(2) 282(3) 4475(1) 29(1) 
C(25) 2981(2) 434(2) 4240(1) 24(1) 
C(26) 2590(3) -1793(4) 4642(1) 35(1) 
C(27) 2541(3) -2833(4) 4818(1) 41(1) 
C(28) 2459(3) -3777(3) 4577(1) 43(1) 
C(29) 2388(3) -3657(3) 4162(2) 39(1) 
C(30) 2425(4) -2610(3) 3970(2) 28(1) 
C(31) 2542(2) -1672(3) 4226(1) 26(1) 
C(32) 850(2) -154(3) 4278(1) 33(1) 
C(33) -112(2) 12(3) 4227(1) 40(1) 
C(34) -505(2) 46(3) 3845(1) 38(1) 
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Table F2. Cont’d. 
C(35) 78(2) -92(3) 3515(1) 36(1) 
C(36) 1044(2) -269(3) 3562(1) 31(1) 
C(37) 1443(2) -299(2) 3944(1) 25(1) 
C(38) 2857(2) 5301(2) 2391(1) 28(1) 
C(39) 2352(2) 6018(3) 2672(1) 34(1) 
C(40) 1695(2) 6820(3) 2483(1) 34(1) 
C(41) 1087(5) 7443(3) 2730(2) 46(2) 
C(42) 484(3) 8215(3) 2570(1) 52(1) 
C(43) 469(3) 8381(3) 2157(1) 48(1) 
C(44) 1047(3) 7755(4) 1908(1) 39(1) 
C(45) 1665(2) 6961(2) 2062(1) 31(1) 
C(46) 2301(2) 6312(2) 1766(1) 25(1) 
C(47) 2833(2) 5382(2) 1977(1) 22(1) 
C(48) 3427(2) 4563(2) 1791(1) 25(1) 
C(49) 3870(2) 3917(3) 2075(1) 32(1) 
C(50) 1663(2) 5849(2) 1434(1) 29(1) 
C(51) 1616(3) 6220(3) 1061(1) 38(1) 
C(52) 3059(2) 7120(3) 1596(1) 31(1) 
C(53) 3583(2) 4360(2) 1346(1) 24(1) 
C(54) 3170(2) 3244(2) 1232(1) 29(1) 
C(55) 2462(2) 3121(3) 975(1) 37(1) 
C(56) 4999(2) 4486(2) 895(1) 24(1) 
C(57) 3706(2) 5251(3) 432(1) 31(1) 
C(58) 3238(2) 6131(3) 244(1) 38(1) 
C(59) 3572(3) 7204(4) 289(1) 42(1) 
C(60) 4358(5) 7400(3) 525(3) 43(2) 
C(61) 4838(2) 6514(2) 709(1) 34(1) 
C(62) 4519(2) 5425(2) 659(1) 27(1) 
C(63) 6643(2) 4890(3) 629(1) 36(1) 
C(64) 7611(2) 5060(3) 675(1) 41(1) 
C(65) 8002(2) 5078(3) 1059(1) 41(1) 
C(66) 7432(2) 4919(3) 1389(1) 39(1) 
C(67) 6458(2) 4737(2) 1343(1) 31(1) 
C(68) 6057(2) 4733(2) 962(1) 26(1) 
C(69) 4936(3) 3190(3) 276(1) 35(1) 
C(70) 4965(3) 2110(5) 115(2) 50(1) 
C(71) 5054(3) 1209(3) 358(2) 52(1) 
C(72) 5116(3) 1347(3) 766(1) 39(1) 
C(73) 5084(4) 2405(3) 915(2) 33(1) 
C(74) 4970(3) 3339(3) 693(1) 26(1) 
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Table F3. Bond lengths [Å] and angles [°] for bww31308. 
S(1)-C(12) 1.697(3) C(17)-C(18) 1.312(4) 
S(1)-C(1) 1.717(3) C(17)-H(17) 1.01(3) 
S(2)-C(49) 1.706(3) C(18)-H(18A) 0.93(3) 
S(2)-C(38) 1.713(3) C(18)-H(18B) 0.95(3) 
O(1)-C(2) 1.229(4) C(19)-C(37) 1.537(4) 
O(2)-C(16) 1.442(3) C(19)-C(25) 1.539(4) 
O(2)-C(19) 1.451(3) C(19)-C(31) 1.542(4) 
O(3)-C(39) 1.228(3) C(20)-C(21) 1.389(6) 
O(4)-C(56) 1.444(3) C(20)-C(25) 1.396(4) 
O(4)-C(53) 1.445(3) C(20)-H(20A) 0.95 
C(1)-C(10) 1.380(4) C(21)-C(22) 1.374(8) 
C(1)-C(2) 1.442(4) C(21)-H(21A) 0.95 
C(2)-C(3) 1.480(5) C(22)-C(23) 1.381(5) 
C(3)-C(8) 1.401(4) C(22)-H(22A) 0.95 
C(3)-C(4) 1.416(6) C(23)-C(24) 1.382(4) 
C(4)-C(5) 1.381(7) C(23)-H(23A) 0.95 
C(4)-H(4A) 0.95 C(24)-C(25) 1.390(4) 
C(5)-C(6) 1.376(5) C(24)-H(24A) 0.95 
C(5)-H(5A) 0.95 C(26)-C(27) 1.380(5) 
C(6)-C(7) 1.384(5) C(26)-C(31) 1.387(5) 
C(6)-H(6A) 0.95 C(26)-H(26A) 0.95 
C(7)-C(8) 1.396(5) C(27)-C(28) 1.392(6) 
C(7)-H(7A) 0.95 C(27)-H(27A) 0.95 
C(8)-C(9) 1.537(4) C(28)-C(29) 1.385(6) 
C(9)-C(10) 1.524(4) C(28)-H(28A) 0.95 
C(9)-C(13) 1.524(4) C(29)-C(30) 1.411(6) 
C(9)-C(15) 1.538(4) C(29)-H(29A) 0.95 
C(10)-C(11) 1.421(4) C(30)-C(31) 1.420(6) 
C(11)-C(12) 1.372(4) C(30)-H(30A) 0.95 
C(11)-C(16) 1.510(4) C(32)-C(33) 1.379(4) 
C(12)-H(12) 0.88(3) C(32)-C(37) 1.396(4) 
C(13)-C(14) 1.313(4) C(32)-H(32A) 0.95 
C(13)-H(13) 1.00(3) C(33)-C(34) 1.381(5) 
C(14)-H(14A) 0.98(3) C(33)-H(33A) 0.95 
C(14)-H(14B) 1.04(4) C(34)-C(35) 1.377(5) 
C(15)-H(15A) 0.98 C(34)-H(34A) 0.95 
C(15)-H(15B) 0.98 C(35)-C(36) 1.386(4) 
C(15)-H(15C) 0.98 C(35)-H(35A) 0.95 
C(16)-C(17) 1.508(4) C(36)-C(37) 1.383(4) 
C(16)-H(16A) 1 C(36)-H(36A) 0.95 
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Table F3. Cont’d. 
C(38)-C(47) 1.373(4) C(58)-C(59) 1.382(6) 
C(38)-C(39) 1.453(4) C(58)-H(58A) 0.95 
C(39)-C(40) 1.475(5) C(59)-C(60) 1.374(9) 
C(40)-C(41) 1.401(7) C(59)-H(59A) 0.95 
C(40)-C(45) 1.403(4) C(60)-C(61) 1.400(6) 
C(41)-C(42) 1.366(8) C(60)-H(60A) 0.95 
C(41)-H(41A) 0.95 C(61)-C(62) 1.394(4) 
C(42)-C(43) 1.381(5) C(61)-H(61A) 0.95 
C(42)-H(42A) 0.95 C(63)-C(64) 1.387(4) 
C(43)-C(44) 1.381(5) C(63)-C(68) 1.388(4) 
C(43)-H(43A) 0.95 C(63)-H(63A) 0.95 
C(44)-C(45) 1.390(5) C(64)-C(65) 1.384(5) 
C(44)-H(44A) 0.95 C(64)-H(64A) 0.95 
C(45)-C(46) 1.540(4) C(65)-C(66) 1.370(5) 
C(46)-C(47) 1.517(4) C(65)-H(65A) 0.95 
C(46)-C(50) 1.523(4) C(66)-C(67) 1.398(4) 
C(46)-C(52) 1.548(4) C(66)-H(66A) 0.95 
C(47)-C(48) 1.431(4) C(67)-C(68) 1.380(4) 
C(48)-C(49) 1.369(4) C(67)-H(67A) 0.95 
C(48)-C(53) 1.509(4) C(69)-C(74) 1.394(5) 
C(49)-H(49) 0.99(3) C(69)-C(70) 1.405(5) 
C(50)-C(51) 1.315(4) C(69)-H(69A) 0.95 
C(50)-H(50) 0.95(3) C(70)-C(71) 1.356(7) 
C(51)-H(51A) 0.99(4) C(70)-H(70A) 0.95 
C(51)-H(51B) 1.00(4) C(71)-C(72) 1.361(6) 
C(52)-H(52A) 0.98 C(71)-H(71A) 0.95 
C(52)-H(52B) 0.98 C(72)-C(73) 1.366(5) 
C(52)-H(52C) 0.98 C(72)-H(72A) 0.95 
C(53)-C(54) 1.511(4) C(73)-C(74) 1.351(6) 
C(53)-H(53A) 1 C(73)-H(73A) 0.95 
C(54)-C(55) 1.317(5)   
C(54)-H(54) 1.04(4)   
C(55)-H(55A) 1.02(3)   
C(55)-H(55B) 1.00(3)   
C(56)-C(62) 1.530(4)   
C(56)-C(74) 1.533(4)   
C(56)-C(68) 1.536(4)   
C(57)-C(62) 1.387(4)   
C(57)-C(58) 1.393(4)   
C(57)-H(57A) 0.95   
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Table F4. Anisotropic displacement parmeters (Å2x 103) for bw31308.  The anisotropic 
 displacement factor exponent take the form: -2?2[h2 a*2U33 + … + 2 h k a* b* U12 ]. 
 
 U11 U22 U33 U23 U13 U12 
S(1) 49(1) 37(1) 25(1) -6(1) -6(1) -2(1) 
S(2) 48(1) 37(1) 25(1) 6(1) -5(1) 1(1) 
O(1) 71(2) 60(2) 23(1) 6(1) 3(1) -2(1) 
O(2) 21(1) 31(1) 24(1) 1(1) 1(1) 2(1) 
O(3) 65(2) 58(2) 25(1) -6(1) 1(1) 2(1) 
O(4) 24(1) 30(1) 21(1) 1(1) 1(1) 0(1) 
C(1) 34(2) 28(1) 24(1) -1(1) 0(1) 5(1) 
C(2) 41(2) 39(2) 24(1) 4(1) 5(1) 9(1) 
C(3) 32(2) 34(2) 31(2) 11(1) 4(1) 5(1) 
C(4) 37(3) 50(3) 33(3) 16(2) 15(3) 1(1) 
C(5) 44(2) 59(2) 51(2) 23(2) 12(2) -11(2) 
C(6) 42(2) 41(2) 65(2) 11(2) 5(2) -13(2) 
C(7) 45(2) 40(2) 39(2) 8(2) 5(2) -10(2) 
C(8) 32(2) 29(1) 30(2) 7(1) 5(1) 2(1) 
C(9) 29(1) 24(1) 24(1) 3(1) 3(1) -1(1) 
C(10) 25(1) 24(1) 25(1) -3(1) 0(1) 3(1) 
C(11) 27(1) 23(1) 26(1) 0(1) 0(1) 4(1) 
C(12) 36(2) 30(2) 30(2) -4(1) -3(1) -5(1) 
C(13) 30(2) 26(1) 31(2) 2(1) -3(1) -3(1) 
C(14) 40(2) 37(2) 31(2) 1(1) -4(1) -4(1) 
C(15) 37(2) 23(2) 37(2) 0(1) 4(1) 2(1) 
C(16) 22(1) 23(1) 25(1) 2(1) -2(1) -4(1) 
C(17) 26(1) 26(1) 35(2) 4(1) 6(1) 2(1) 
C(18) 29(2) 34(2) 45(2) 9(1) -1(1) 4(1) 
C(19) 22(1) 28(1) 21(1) 0(1) -1(1) -1(1) 
C(20) 35(2) 27(1) 30(2) 3(1) -1(1) 2(1) 
C(21) 42(3) 28(2) 39(3) 4(1) 1(2) -1(1) 
C(22) 57(3) 33(2) 37(2) 0(2) -4(2) -13(2) 
C(23) 41(2) 40(2) 31(2) 2(1) -7(1) -9(1) 
C(24) 33(2) 30(2) 24(1) 0(1) -1(1) 1(1) 
C(25) 26(1) 27(1) 20(1) 1(1) 0(1) -3(1) 
C(26) 34(2) 38(2) 33(2) 1(2) 2(2) 5(2) 
C(27) 45(2) 41(2) 39(2) 13(2) -1(2) 0(2) 
C(28) 37(2) 31(2) 60(2) 14(2) 3(2) 2(1) 
C(29) 26(2) 30(2) 61(3) 2(2) 1(2) -1(1) 
C(30) 24(2) 30(2) 30(2) -10(1) 4(2) -3(1) 
C(31) 23(2) 23(2) 32(2) 6(1) 0(1) 1(1) 
C(32) 30(2) 38(2) 31(2) -1(1) 4(1) 0(1) 
C(33) 32(2) 41(2) 47(2) 3(2) 12(2) 7(1) 
C(34) 25(1) 36(2) 54(2) 0(2) 1(1) 6(1) 
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Table F4. Cont’d. 
C(35) 35(2) 34(2) 40(2) -1(1) -10(1) 4(1) 
C(36) 31(2) 31(1) 31(2) 0(1) -2(1) 3(1) 
C(37) 25(1) 24(1) 26(1) -1(1) 1(1) -1(1) 
C(38) 35(2) 26(1) 23(1) 0(1) 2(1) -3(1) 
C(39) 41(2) 38(2) 23(1) -3(1) 3(1) -7(1) 
C(40) 35(2) 32(2) 33(2) -8(1) 7(1) -5(1) 
C(41) 53(4) 49(3) 37(3) -18(2) 3(3) -5(2) 
C(42) 47(2) 50(2) 58(2) -25(2) 8(2) 8(2) 
C(43) 42(2) 46(2) 58(2) -12(2) 1(2) 15(2) 
C(44) 36(2) 39(2) 41(2) -4(2) 1(2) 9(2) 
C(45) 30(2) 28(1) 35(2) -5(1) 2(1) 0(1) 
C(46) 28(1) 22(1) 25(1) -1(1) 1(1) -2(1) 
C(47) 23(1) 21(1) 23(1) -1(1) 1(1) -3(1) 
C(48) 27(1) 24(1) 24(1) 2(1) -1(1) -2(1) 
C(49) 39(2) 31(2) 26(2) 2(1) 2(1) 1(1) 
C(50) 28(2) 29(1) 31(2) -4(1) 0(1) 2(1) 
C(51) 39(2) 40(2) 33(2) -1(1) -5(1) 6(2) 
C(52) 36(2) 22(2) 35(2) 0(1) 4(1) -3(1) 
C(53) 22(1) 26(1) 23(1) -1(1) 2(1) 0(1) 
C(54) 26(1) 26(2) 34(2) -2(1) 5(1) 1(1) 
C(55) 32(2) 36(2) 45(2) -8(2) 2(1) -5(1) 
C(56) 27(1) 23(1) 20(1) -3(1) 0(1) -2(1) 
C(57) 34(2) 29(2) 29(2) -3(1) -2(1) 3(1) 
C(58) 40(2) 45(2) 29(2) -1(1) -9(1) 5(1) 
C(59) 50(2) 42(2) 33(2) 9(2) -5(2) 14(2) 
C(60) 59(4) 25(2) 44(3) 8(2) -2(3) 2(2) 
C(61) 37(2) 32(2) 33(2) -1(1) 0(1) -1(1) 
C(62) 29(1) 29(1) 22(1) 1(1) 3(1) 2(1) 
C(63) 34(2) 41(2) 31(2) -4(1) 2(1) -3(1) 
C(64) 32(2) 40(2) 50(2) -8(2) 13(2) -4(1) 
C(65) 26(2) 34(2) 63(2) -8(2) -2(2) -2(1) 
C(66) 35(2) 35(2) 46(2) 0(1) -13(2) -5(1) 
C(67) 29(2) 30(1) 33(2) -1(1) -4(1) -4(1) 
C(68) 25(1) 21(1) 32(1) -3(1) 0(1) 2(1) 
C(69) 38(2) 35(2) 32(2) -9(2) -3(2) 5(2) 
C(70) 46(2) 58(3) 46(2) -31(2) 2(2) 0(2) 
C(71) 42(2) 38(2) 76(3) -26(2) 7(2) -2(2) 
C(72) 29(2) 29(2) 59(3) -4(2) 12(2) 2(1) 
C(73) 19(2) 33(2) 47(3) -10(1) 2(2) 1(1) 
C(74) 22(2) 33(2) 24(1) -3(1) 1(1) 3(1) 
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Table F5. Hydrogen coordinates (x 104) and isotropic displacement parameters   
(Å2x 103) for bw31308. 
 x y z U(eq) 
H(4A) 6366 2324 1877 48 
H(5A) 7416 3613 2156 62 
H(6A) 7431 3923 2848 59 
H(7A) 6459 2893 3274 49 
H(12) 3210(20) -1630(30) 2872(10) 34(9) 
H(13) 6210(20) 210(30) 3374(10) 36(9) 
H(14A) 5500(20) 1880(30) 3928(10) 35(9) 
H(14B) 6340(30) 860(30) 4049(11) 41(9) 
H(15A) 4043 2394 3081 48 
H(15B) 4755 2743 3436 48 
H(15C) 4037 1727 3500 48 
H(16A) 4225 -42 3720 28 
H(17) 4170(30) -2430(30) 3507(12) 28(11) 
H(18A) 5270(30) -2610(30) 3935(12) 24(11) 
H(18B) 5340(20) -1240(30) 4039(10) 34(9) 
H(20A) 2102 1644 4026 37 
H(21A) 2856 3144 4335 44 
H(22A) 4207 2858 4727 50 
H(23A) 4789 1061 4812 45 
H(24A) 4038 -445 4513 35 
H(26A) 2656 -1154 4809 42 
H(27A) 2564 -2904 5104 50 
H(28A) 2451 -4495 4696 51 
H(29A) 2312 -4303 4000 47 
H(30A) 2373 -2537 3685 33 
H(32A) 1111 -170 4542 40 
H(33A) -507 104 4457 48 
H(34A) -1167 162 3810 46 
H(35A) -185 -64 3250 44 
H(36A) 1435 -370 3330 37 
H(41A) 1094 7326 3015 56 
H(42A) 79 8636 2741 62 
H(43A) 59 8926 2044 58 
H(44A) 1021 7871 1624 47 
H(49) 4320(20) 3300(30) 2015(10) 34(9) 
H(50) 1250(20) 5260(30) 1514(10) 32(9) 
H(51A) 2040(30) 6820(30) 960(10) 39(9) 
H(51B) 1160(30) 5910(30) 859(11) 48(10) 
H(52A) 3470 6722 1406 46 
H(52B) 3442 7413 1819 46 
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Table F5. Cont’d. 
H(52C) 2743 7736 1456 46 
H(53A) 3269 4960 1185 29 
H(54) 3530(30) 2550(30) 1336(13) 42(14) 
H(55A) 2120(30) 2410(30) 894(12) 30(12) 
H(55B) 2180(20) 3730(30) 806(10) 36(9) 
H(57A) 3463 4518 404 37 
H(58A) 2689 5994 85 46 
H(59A) 3260 7803 158 50 
H(60A) 4576 8140 564 51 
H(61A) 5385 6656 868 41 
H(63A) 6376 4880 365 43 
H(64A) 8003 5163 444 49 
H(65A) 8664 5200 1093 49 
H(66A) 7701 4933 1653 46 
H(67A) 6071 4615 1574 37 
H(69A) 4893 3814 101 42 
H(70A) 4922 2009 -170 60 
H(71A) 5073 484 245 63 
H(72A) 5180 727 941 47 
H(73A) 5147 2492 1199 39 
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APPENDIX G 
X-RAY CRYSTAL DATA FOR 268 
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Table G1. Crystal data and structure refinement for bw32608s. 
Identification code  bw32608s  
Empirical formula  C23 H15 N O5 S 
Formula weight  417.42  
Temperature  173(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P2(1)/c  
Unit cell dimensions a = 6.8826(11) Å a= 90°. 
 b = 23.289(4) Å b= 105.618(3)°. 
 c = 12.400(2) Å g = 90°. 
Volume 1914.2(5) Å3 
Z 4  
Density (calculated) 1.448 Mg/m3 
Absorption coefficient 0.206 mm-1  
F(000) 864  
Crystal size 0.34 x 0.25 x 0.25 mm3 
Theta range for data collection 3.54 to 30.70°. 
Index ranges -9<=h<=9, -33<=k<=32, -17<=l<=17 
Reflections collected 19064  
Independent reflections 5624 [R(int) = 0.0619] 
Completeness to theta = 30.70° 94.90%  
Absorption correction None  
Max. and min. transmission 0.9502 and 0.9331 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5624 / 0 / 331 
Goodness-of-fit on F2 1.008  
Final R indices [I>2sigma(I)] R1 = 0.0659, wR2 = 0.1415 
R indices (all data) R1 = 0.1225, wR2 = 0.1701 
Largest diff. peak and hole 0.406 and -0.279 e.Å-3 
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Table G2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters   
(Å2x 103) for bw32608s.  U(eq) is defined as one third of the trace of the orthogonalized   
Uij tensor. 
 
 x y z U(eq) 
S 353(1) 2603(1) 5985(1) 54(1) 
O(1) 2140(3) 1737(1) 4568(2) 62(1) 
O(2) 2328(2) 4408(1) 6974(1) 34(1) 
O(3) 1894(3) 5340(1) 6478(1) 37(1) 
O(4) 2793(3) 5000(1) 12399(1) 59(1) 
O(5) 2046(3) 5883(1) 11994(2) 53(1) 
N 2437(3) 5402(1) 11740(2) 37(1) 
C(1) 1813(4) 2700(1) 5068(2) 34(1) 
C(2) 2606(4) 2243(1) 4515(2) 39(1) 
C(3) 4097(4) 2432(1) 3912(2) 34(1) 
C(4) 4976(4) 2014(1) 3381(3) 52(1) 
C(5) 6334(5) 2164(1) 2800(3) 72(1) 
C(6) 6880(5) 2730(1) 2764(4) 75(1) 
C(7) 6036(4) 3151(1) 3279(3) 54(1) 
C(8) 4613(3) 3013(1) 3847(2) 34(1) 
C(9) 3468(3) 3489(1) 4238(2) 27(1) 
C(10) 4706(4) 3993(1) 4827(2) 34(1) 
C(11) 4060(4) 4333(1) 5510(2) 34(1) 
C(12) 2118(4) 4243(1) 5809(2) 31(1) 
C(13) 1537(3) 3623(1) 5709(2) 31(1) 
C(14) 445(4) 3321(1) 6286(2) 46(1) 
C(15) 2294(3) 3262(1) 4999(2) 27(1) 
C(16) 1936(4) 3721(1) 3171(2) 37(1) 
C(17) 2155(3) 4968(1) 7181(2) 28(1) 
C(18) 2515(3) 4620(1) 9145(2) 28(1) 
C(19) 2601(3) 4728(1) 10251(2) 30(1) 
C(20) 2437(3) 5290(1) 10575(2) 29(1) 
C(21) 2223(3) 5749(1) 9844(2) 31(1) 
C(22) 2179(3) 5634(1) 8746(2) 30(1) 
C(23) 2302(3) 5071(1) 8389(2) 26(1) 
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Table G3. Bond lengths [Å] and angles [°] for bww32608s. 
S-C(14) 1.711(3) C(18)-C(23) 1.390(3) 
S-C(1) 1.723(2) C(18)-H(18) 0.97(2) 
O(1)-C(2) 1.227(3) C(19)-C(20) 1.382(3) 
O(2)-C(17) 1.340(2) C(19)-H(19) 0.98(2) 
O(2)-C(12) 1.464(3) C(20)-C(21) 1.383(3) 
O(3)-C(17) 1.208(2) C(21)-C(22) 1.380(3) 
O(4)-N 1.222(2) C(21)-H(21) 0.94(2) 
O(5)-N 1.214(2) C(22)-C(23) 1.393(3) 
N-C(20) 1.468(3) C(22)-H(22) 0.97(2) 
C(1)-C(15) 1.360(3) C(14)-S-C(1) 91.26(12) 
C(1)-C(2) 1.450(3) C(17)-O(2)-C(12) 117.12(16) 
C(2)-C(3) 1.490(3) O(5)-N-O(4) 123.5(2) 
C(3)-C(4) 1.399(3) O(5)-N-C(20) 118.5(2) 
C(3)-C(8) 1.406(3) O(4)-N-C(20) 118.0(2) 
C(4)-C(5) 1.370(4) C(15)-C(1)-C(2) 123.3(2) 
C(4)-H(4) 0.96(3) C(15)-C(1)-S 111.30(16) 
C(5)-C(6) 1.375(4) C(2)-C(1)-S 125.17(17) 
C(5)-H(5) 0.91(4) O(1)-C(2)-C(1) 122.9(2) 
C(6)-C(7) 1.380(4) O(1)-C(2)-C(3) 122.4(2) 
C(6)-H(6) 0.89(4) C(1)-C(2)-C(3) 114.70(19) 
C(7)-C(8) 1.390(3) C(4)-C(3)-C(8) 119.6(2) 
C(7)-H(7) 0.95(3) C(4)-C(3)-C(2) 118.3(2) 
C(8)-C(9) 1.514(3) C(8)-C(3)-C(2) 122.1(2) 
C(9)-C(15) 1.494(3) C(5)-C(4)-C(3) 120.9(3) 
C(9)-C(10) 1.516(3) C(5)-C(4)-H(4) 120.9(16) 
C(9)-C(16) 1.551(3) C(3)-C(4)-H(4) 118.2(16) 
C(10)-C(11) 1.321(3) C(4)-C(5)-C(6) 119.5(3) 
C(10)-H(10) 0.94(2) C(4)-C(5)-H(5) 121(2) 
C(11)-C(12) 1.495(3) C(6)-C(5)-H(5) 120(2) 
C(11)-H(11) 0.96(2) C(5)-C(6)-C(7) 120.9(3) 
C(12)-C(13) 1.494(3) C(5)-C(6)-H(6) 123(2) 
C(12)-H(12) 0.97(2) C(7)-C(6)-H(6) 116(2) 
C(13)-C(14) 1.365(3) C(6)-C(7)-C(8) 120.8(3) 
C(13)-C(15) 1.413(3) C(6)-C(7)-H(7) 117.4(16) 
C(14)-H(14) 0.95(3) C(8)-C(7)-H(7) 121.8(16) 
C(16)-H(15A) 0.99(3) C(7)-C(8)-C(3) 118.4(2) 
C(16)-H(16B) 0.98(2) C(7)-C(8)-C(9) 119.4(2) 
C(16)-H(16C) 0.95(3) C(3)-C(8)-C(9) 121.70(19) 
C(17)-C(23) 1.492(3) C(15)-C(9)-C(8) 111.09(17) 
C(18)-C(19) 1.381(3) C(15)-C(9)-C(10) 107.37(17) 
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Table G3. Cont’d. 
C(8)-C(9)-C(10) 116.60(18) C(9)-C(16)-H(16B) 111.0(13) 
C(15)-C(9)-C(16) 107.63(19) H(15A)-C(16)-H(16B) 107.4(19) 
C(8)-C(9)-C(16) 105.96(18) C(9)-C(16)-H(16C) 110.2(15) 
C(10)-C(9)-C(16) 107.82(18) H(15A)-C(16)-H(16C) 110(2) 
C(11)-C(10)-C(9) 122.0(2) H(16B)-C(16)-H(16C) 107(2) 
C(11)-C(10)-H(10) 118.6(14) O(3)-C(17)-O(2) 124.2(2) 
C(9)-C(10)-H(10) 119.3(14) O(3)-C(17)-C(23) 124.45(19) 
C(10)-C(11)-C(12) 123.5(2) O(2)-C(17)-C(23) 111.35(17) 
C(10)-C(11)-H(11) 122.4(15) C(19)-C(18)-C(23) 120.0(2) 
C(12)-C(11)-H(11) 114.1(15) C(19)-C(18)-H(18) 120.4(13) 
O(2)-C(12)-C(13) 106.86(16) C(23)-C(18)-H(18) 119.5(13) 
O(2)-C(12)-C(11) 110.48(19) C(18)-C(19)-C(20) 118.5(2) 
C(13)-C(12)-C(11) 110.63(19) C(18)-C(19)-H(19) 120.8(13) 
O(2)-C(12)-H(12) 107.1(13) C(20)-C(19)-H(19) 120.6(13) 
C(13)-C(12)-H(12) 111.7(13) C(19)-C(20)-C(21) 122.9(2) 
C(11)-C(12)-H(12) 110.0(13) C(19)-C(20)-N 118.33(19) 
C(14)-C(13)-C(15) 111.6(2) C(21)-C(20)-N 118.7(2) 
C(14)-C(13)-C(12) 128.8(2) C(22)-C(21)-C(20) 117.8(2) 
C(15)-C(13)-C(12) 119.39(19) C(22)-C(21)-H(21) 122.9(15) 
C(13)-C(14)-S 112.47(19) C(20)-C(21)-H(21) 119.3(15) 
C(13)-C(14)-H(14) 125.4(18) C(21)-C(22)-C(23) 120.7(2) 
S-C(14)-H(14) 122.1(18) C(21)-C(22)-H(22) 119.8(14) 
C(1)-C(15)-C(13) 113.36(19) C(23)-C(22)-H(22) 119.4(14) 
C(1)-C(15)-C(9) 124.22(19) C(18)-C(23)-C(22) 120.1(2) 
C(13)-C(15)-C(9) 122.41(18) C(18)-C(23)-C(17) 121.39(19) 
C(9)-C(16)-H(15A) 111.1(14) C(22)-C(23)-C(17) 118.51(18) 
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Table G4. Anisotropic displacement parmeters (Å2x 103) for bw32608s.  The anisotropic 
 displacement factor exponent take the form: -2?2[h2 a*2U33 + … + 2 h k a* b* U12 ]. 
 U11 U22 U33 U23 U13 U12 
S 83(1) 36(1) 59(1) -7(1) 47(1) -22(1) 
O(1) 96(2) 22(1) 84(2) -5(1) 50(1) -10(1) 
O(2) 49(1) 24(1) 30(1) -2(1) 14(1) 2(1) 
O(3) 52(1) 28(1) 35(1) 5(1) 16(1) 7(1) 
O(4) 96(2) 45(1) 31(1) 2(1) 10(1) -17(1) 
O(5) 69(1) 50(1) 41(1) -13(1) 19(1) 0(1) 
N 38(1) 40(1) 32(1) -6(1) 8(1) -9(1) 
C(1) 44(1) 26(1) 37(1) 0(1) 20(1) -7(1) 
C(2) 50(2) 22(1) 45(1) 1(1) 15(1) -2(1) 
C(3) 36(1) 24(1) 45(1) 3(1) 14(1) 4(1) 
C(4) 52(2) 26(1) 84(2) -4(1) 32(2) 7(1) 
C(5) 70(2) 41(2) 126(3) -19(2) 62(2) 6(2) 
C(6) 75(2) 52(2) 128(3) -18(2) 78(2) -6(2) 
C(7) 56(2) 37(2) 84(2) -8(1) 46(2) -7(1) 
C(8) 31(1) 28(1) 46(1) -2(1) 17(1) 2(1) 
C(9) 31(1) 20(1) 34(1) 0(1) 15(1) 0(1) 
C(10) 37(1) 28(1) 40(1) 0(1) 16(1) -8(1) 
C(11) 43(1) 26(1) 34(1) 0(1) 13(1) -8(1) 
C(12) 42(1) 26(1) 26(1) 0(1) 11(1) 0(1) 
C(13) 37(1) 26(1) 33(1) -2(1) 14(1) -5(1) 
C(14) 62(2) 36(1) 50(2) -11(1) 34(1) -13(1) 
C(15) 30(1) 24(1) 31(1) 1(1) 11(1) -3(1) 
C(16) 53(2) 28(1) 31(1) 3(1) 11(1) 8(1) 
C(17) 27(1) 25(1) 36(1) -2(1) 12(1) 1(1) 
C(18) 27(1) 22(1) 37(1) 0(1) 10(1) 1(1) 
C(19) 28(1) 28(1) 35(1) 4(1) 8(1) -3(1) 
C(20) 24(1) 34(1) 28(1) -3(1) 5(1) -4(1) 
C(21) 32(1) 26(1) 35(1) -3(1) 7(1) 1(1) 
C(22) 32(1) 24(1) 32(1) 2(1) 7(1) 2(1) 
C(23) 23(1) 25(1) 31(1) 1(1) 7(1) 0(1) 
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Table G5. Hydrogen coordinates (x 104) and isotropic displacement parameters   
(Å2x 103) for bw32608s. 
 x y z U(eq) 
H(4) 4580(40) 1623(12) 3420(20) 49(7) 
H(5) 6820(60) 1894(16) 2410(30) 98(12) 
H(6) 7660(60) 2855(16) 2340(30) 100(13) 
H(7) 6430(40) 3535(11) 3210(20) 48(7) 
H(10) 5950(40) 4078(9) 4677(18) 34(6) 
H(11) 4790(40) 4665(11) 5850(20) 41(7) 
H(12) 1070(40) 4485(10) 5342(19) 32(6) 
H(14) -150(50) 3477(12) 6830(20) 66(9) 
H(15A) 1050(40) 3409(11) 2760(20) 43(7) 
H(16B) 1060(30) 4015(10) 3361(19) 37(6) 
H(16C) 2630(40) 3898(11) 2690(20) 50(8) 
H(18) 2530(30) 4229(9) 8881(18) 27(6) 
H(19) 2710(30) 4412(10) 10791(19) 35(6) 
H(21) 2120(30) 6121(10) 10110(20) 39(7) 
H(22) 2120(30) 5948(10) 8225(19) 36(6) 
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